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SUMMARY	  
The	  field	  of	  cancer	  vaccines	  has	  been	  investigated	  for	  decades,	  but	  it	  is	  still	  in	  the	  early	  
stages	  of	  development.	  The	  slow	  progress	  can	  be	  partly	  attributed	  to	  shortcomings	  in	  
vaccine	   design,	   which	   induced	   ineffective	   anti-­‐tumour	   cytotoxic	   responses.	   An	  
increasing	   number	   of	   adjuvants	   are	   currently	   being	   researched	   to	   overcome	   these	  
shortcomings,	  but	  effective	  adjuvants	  are	  in	  most	  cases,	  unsafe	  and	  not	  well-­‐tolerated.	  
In	  fact	  the	  number	  of	  licensed	  adjuvants	  for	  human	  use	  are	  few.	  
The	  adjuvant	  of	  interest	  in	  this	  work	  was	  CD40mAb,	  which	  stimulates	  CD40	  mimicking	  
T	  cell	  help	   in	  the	  CD40-­‐CD154	  co-­‐stimulatory	  pathway.	  Previous	  publications	  showed	  
that	  conjugation	  of	  CD40mAb	  to	  antigen	  enhanced	  the	  immunogenicity	  of	  the	  antigen	  
by	   up	   to	   a	   1000-­‐fold.	   The	   primary	   finding	   in	   this	   thesis	   showed	   that	   a	   low	   average	  
molecular	   weight	   conjugate	   maximised	   the	   adjuvant	   potential	   of	   CD40mAb,	   and	   a	  
strong	  trend	  of	  enhanced	  overall	  and	  median	  survival	  in	  a	  murine	  tumour	  model	  when	  
administered	  as	  a	  prophylactic	  vaccine	  was	  observed.	  
Cancer	  vaccines	  that	  progressed	  to	  Phase	  III	  clinical	  trials	  include	  the	  B	  cell	  lymphoma	  
therapeutic	   vaccines.	   Most	   B	   cell	   lymphoma	   patients	   are	   routinely	   treated	   with	  
rituximab	  that	  depletes	  B	  cells.	  Thus,	  another	  aim	  was	  to	  identify	  if	  B	  cells	  or	  DCs	  are	  
the	   primary	   target	   of	   the	   CD40mAb	   as	   an	   adjuvant.	   This	   would	   give	   valuable	  
information	  in	  defining	  the	  optimal	  timing	  of	  the	  CD40mAb-­‐Id	  therapy	  relative	  to	  other	  
therapies	  such	  as	  rituximab.	  The	  work	  presented	  shows	  that	  CD40mAb	  conjugated	  to	  
antigen	   targeted	   and	   activated	   both	   B	   cells	   and	   DCs	   in	   vitro.	   In	   addition,	   CD40mAb	  
enhanced	  cross-­‐presentation	  by	  both	  B	  cells	  and	  DCs	  in	  vitro.	  	  
A	  central	  finding	  of	  this	  thesis	  is	  that	  CD40mAb-­‐adjuvanted	  vaccines	  directly	  enhanced	  
CD8+	  cytotoxic	  T	  cell	  responses	  against	  the	  conjugated	  antigen	  in	  a	  murine	  system.	  The	  
aforementioned	  results	   together	  with	   the	  knowledge	  that	  CD40mAb	   immunotherapy	  
in	  human	  cancer	   trials	   is	  well-­‐tolerated	  shows	  the	  great	  potential	  of	  CD40mAb	  as	  an	  
adjuvant	  in	  therapeutic	  and	  prophylactic	  vaccines.	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   Rig-­‐I-­‐like	  helicases	  
ROS	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   Transporter-­‐associated	  with	  antigen	  processing	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TH	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  1	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   T-­‐cell	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  2	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   Inflammatory	  DC	  
TLR	   	   	   	   Toll-­‐like	  receptor	  
TNF-­‐α	   	   	   	   Tumour	  necrosis	  factor-­‐α	  
TNFRSF	   	   	   Tumour	  necrosis	  factor	  receptor	  superfamily	  
TRAF	   	   	   	   TNFR-­‐associated	  factors	  
Treg	   	   	   	   Regulatory	  T	  cell	  
VLP	   	   	   	   Virus-­‐like	  particle	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1.1. Basic	  concepts	  of	  the	  immune	  response	  
The	  primary	   lines	  of	  defence	  against	  pathogens	  are	   the	  physical	  barriers	  of	   the	  host	  
body,	   for	   example	   the	   skin,	   ciliated	   epithelia	   and	   mucous	   membranes.	   The	   first	  
immune	  cells	  that	  pathogens	  come	  into	  contact	  with	  once	  they	  break	  the	  first	  line	  of	  
defence	   are	   the	   phagocytic	   white	   blood	   cells	   like	   macrophages,	   which	   reside	   in	  
different	   tissues	   and	   neutrophils	   that	   patrol	   the	   lymph	   and	   blood	   circulation.	   Both	  
macrophages	   and	   neutrophils	   are	   able	   to	   rapidly	   and	   non-­‐specifically	   phagocytose	  
pathogens.	   Phagocytosis	   is	   the	   process	   by	   which	   pathogens	   are	   internalised	   into	  
phagosomes	  where	  they	  are	  killed	  by	  the	  production	  of	  toxic	  compounds	  like	  hydrogen	  
peroxide	   (H2O2)	   and	   superoxide	   anion	   (O2-­‐).	   Tissue	   macrophages	   also	   release	  
chemokines	   and	   cytokines	   upon	   pathogen	   encounter	   that	   lead	   to	   an	   inflammatory	  
response.	  Another	   tissue-­‐residing	   cell	   type,	   the	  dendritic	   cell	   (DC)	   is	   also	   efficient	   at	  
antigen-­‐uptake	  at	  the	  site	  of	  infection	  (Murphy	  et	  al.,	  2008).	  Immune	  cells	  are	  able	  to	  
identify	   self	   from	   non-­‐self	   by	   certain	   structures	   expressed	   by	   pathogens	   or	  
transformed	   cells,	   and	   become	   activated.	   Activation	   of	   tissue-­‐residing	   macrophages	  
and	  DCs	  as	  well	  as	  mobile	  cells	  like	  neutrophils,	  natural	  killer	  (NK)	  cells	  and	  eosinophils	  
lead	  to	  the	  release	  of	  cytokines	  like	  interleukins	  (IL)	  and	  tumour	  necrosis	  factor	  (TNF-­‐
α),	   and	   the	   rapid	   recruitment	   of	   more	   cells	   to	   the	   site	   of	   infection	   by	   means	   of	  
enhanced	   permeability	   of	   vessels	   leading	   to	   inflammation	   (Moser	   and	   Leo,	   2010).	  
Inflammation	  could	  also	  be	  triggered	  by	  activation	  of	  the	  complement	  system,	  which	  
activates	   phagocytes	   and	   mast	   cells	   to	   release	   granules	   containing	   histamine.	   The	  
complement	  system	  consists	  of	  a	  number	  of	  plasma	  proteins	  that	  work	  collectively	  to	  
opsonise	  pathogens	  to	  aid	  in	  the	  internalisation	  by	  phagocytes	  (Murphy	  et	  al.,	  2008).	  
In	  anti-­‐tumour	  immunity,	  DCs	  at	  the	  tumour	  site	  sample	  tumour	  antigens,	  which	  could	  
be	   (i)	   mutated	   protein	   typical	   of	   tumours,	   (ii)	   the	   products	   of	   non-­‐mutated	   genes	  
preferentially	   expressed	   by	   tumour	   cells,	   or	   (iii)	   differentiation	   antigen	   linked	   with	  
tumour	  origin.	  DC	  activation,	  a	  step	  crucial	  to	  promote	  immunity,	  is	  supplied	  by	  signals	  
from	  necrotic	   tumour	  cells	   (Sauter	  et	  al.,	  2000,	  Brusa	  et	  al.,	  2008).	  Tumour	  cells	  also	  
express	   endoplasmic	   reticulum	   (ER)	   proteins	   like	   calreticulin	   on	   their	   plasma	  
membrane	   that	   promote	   tumour	   cell	   phagocytosis	   (Mellman	   et	   al.,	   2011).	   Innate	  
recognition	  of	  tumours	  is	  mediated	  by	  type	  I	  interferon	  (IFN),	  which	  is	  predominantly	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secreted	  by	  a	  subset	  of	  DC	  at	  the	  site	  of	  the	  tumour	  (Cella	  et	  al.,	  1999).	  NK	  cells	  are	  
activated	   by	   IFNs	   and	   target	   certain	   ligands	   expressed	   by	   malignantly	   transformed	  
cells.	   NK	   cells	   also	   target	   cells	   that	   have	   lost	   surface	   molecules	   like	   major	  
histocompatibility	   complex	   (MHC),	   making	   them	   crucial	   for	   early	   defence	   against	  
tumours	  (Mocikat	  et	  al.,	  2003).	  NK	  cells	  mediate	  tumour-­‐directed	  killing	  by	  binding	  to	  
malignant	   cells	   and	   releasing	   cytotoxic	   granules	   and	   effector	   proteins	   that	   induce	  
programmed	  cell	  death	  (Hayakawa	  et	  al.,	  2002,	  Murphy	  et	  al.,	  2008).	  
If	   the	   innate	   immune	  mechanisms	  are	   inefficient	   in	  clearing	   the	   tumour	  or	   infection,	  
the	  second	  line	  of	  defence	  is	  induced,	  which	  directs	  a	  specific	  and	  long-­‐lasting	  immune	  
response	  against	  the	  pathogens	  or	  malignant	  cells.	  The	  adaptive	   immune	  response	   is	  
not	   exclusively	   induced	   against	   antigens	   that	   escape	   the	   innate	   immune	   response.	  
Vaccine	  antigens	  presented	  by	  migratory	  DCs	   (De	  Vries	  et	  al.,	  2003a,	  De	  Vries	  et	  al.,	  
2003b,	  Lesterhuis	  et	  al.,	  2011,	  Mellman	  et	  al.,	  2011),	  also	  induce	  adaptive	  immunity.	  
The	  cellular	  backbones	  of	  the	  adaptive	  immune	  response	  are	  the	  B	  and	  T	  lymphocytes.	  
Mature	   naive	   lymphocytes	   develop	   in	   the	   primary	   lymphoid	   organs,	   and	   are	   found	  
circulating	   in	   the	   lymph	   and	   the	   blood	   as	   well	   as	   within	   the	   secondary	   lymphoid	  
organs,	  such	  as	  the	  lymph	  nodes	  and	  spleen	  where	  the	  adaptive	  immune	  response	  is	  
initiated.	  Both	  B	  and	  T	   lymphocytes	  become	  activated	  by	  engagement	  of	   their	  B	  cell	  
(BCR)	   or	   T	   cell	   receptors	   (TCR)	   (respectively)	   to	   specific	   antigens	   (Moser	   and	   Leo,	  
2010).	   Antigen-­‐specific	   naive	   CD4+	   (helper)	   T	   cells	   and	   CD8+	   (cytotoxic)	   T	   cells	   are	  
found	   in	   low	   frequencies	   in	   the	   absence	   of	   antigen,	   but	   once	   encountering	   foreign	  
antigen	   predominantly	   presented	   by	   migrating	   DCs,	   they	   undergo	   clonal	   expansion	  
leading	  to	  the	  formation	  of	  effector	  and	  memory	  T	  cells.	  Antigen	  can	  also	  be	  presented	  
to	   T	   cells	   by	   other	   antigen	   presenting	   cells	   (APCs)	   namely	   B	   cells	   or	   macrophages	  
resident	   in	   the	   secondary	   lymphoid	   organs.	   Following	   activation,	   B	   cells	   undergo	  
proliferation	  and	  differentiate	  into	  antibody-­‐producing	  plasma	  cells	  as	  well	  as	  memory	  
cells.	   These	   B	   and	   T	  memory	   cells	   together	   with	   antibody	   responses	   constitute	   the	  
basis	   for	   protection	   against	   disease	   and	   infection.	   Immune	  memory	   is	   an	   important	  
property	   of	   the	   adaptive	   immune	   response,	   and	   allows	   a	   rapid	   and	   more	   robust	  
response	  once	  the	  host	  re-­‐encounters	  the	  same	  pathogen	  (Moser	  and	  Leo,	  2010).	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1.1.1. Pattern	  recognition	  receptors	  of	  the	  innate	  immune	  system	  
DCs,	  macrophages	  and	  B	  cells	  have	  pattern	  recognition	  receptors	  (PRRs)	  that	  are	  able	  
to	   identify	   a	   series	   of	   conserved	   molecular	   structures	   expressed	   by	   pathogens	   or	  
malignant	   cells.	   The	   conserved	  molecular	   structures	   can	  be	  divided	   into	   two	  groups.	  
The	   first	   group	   is	   the	   pathogen-­‐associated	  molecular	   patterns	   (PAMPs)	   that	   include	  
flagella	   and	   lipoproteins,	   and	   the	   second	   group	   is	   the	   damage-­‐associated	  molecular	  
patterns	   (DAMPs)	   that	   include	  heat	  shock	  proteins	  and	  extracellular	  ATP	   (Moser	  and	  
Leo,	  2010).	  Whilst	  PAMPs	  are	  molecules	  of	  exogenous	  nature	   found	   selectively	  on	  a	  
group	   of	   microbes,	   DAMPs	   are	  molecules	   of	   endogenous	   nature	   released	   on	   tissue	  
damage	  or	  cell	  lysis	  due	  to	  infection	  or	  tumour.	  	  
The	  cells	  of	  the	  innate	  immune	  system	  can	  therefore	  directly	  identify	  pathogens	  in	  an	  
infectious	   event,	   a	   mechanism	   first	   described	   by	   Janeway	   and	   referred	   to	   as	   the	  
Pattern	   Recognition	   Theory	   (Janeway,	   1989b).	   Cell	   damage	   or	   stress	   resulting	   from	  
infection	   or	   tumour	   can	   also	   be	   directly	   identified.	   The	   latter	   mechanism	   was	  
described	  by	  Matzinger	  and	  referred	  to	  as	  the	  Danger	  Theory	  (Matzinger,	  1994).	  The	  
signals	  released	  from	  PAMPs	  or	  DAMPs	  are	  known	  as	  ‘danger	  signals’	  characterised	  by	  
the	  release	  of	  chemokines	  and	  cytokines	  from	  the	  cells	  of	  the	  innate	  immune	  system.	  
The	   most	   well-­‐characterised	   PRRs	   include	   the	   membrane	   bound	   Toll-­‐Like	   receptors	  
(TLRs).	   Ten	   types	   have	   been	   recently	   discovered	   in	   humans	   and	   these	   have	   been	  
classified	  according	  to	  the	  type	  of	  PAMPs	  they	  recognise	  and	  where	  they	  are	  localised	  
(Table	   1.1.)	   (Moser	   and	   Leo,	   2010).	   TLRs	   also	   respond	   to	   some	   DAMP	   signalling	  
(Sollinger	   et	   al.,	   2014).	   The	   activation	   of	   TLRs	   leads	   to	   the	   production	   of	  
proinflammatory	  cytokines	  such	  as	  IL-­‐6	  and	  TNF-­‐α,	  as	  well	  as	  to	  APC	  activation	  linking	  
the	  innate	  response	  to	  the	  adaptive	  immune	  response.	  	  
Microbes	   express	   multiple	   PAMPs	   that	   lead	   to	   different	   TLRs	   being	   activated	  
simultaneously.	  Since	  different	  TLRs	  respond	  to	  different	  adaptor	  proteins,	  the	  nature	  
of	  the	  TLR	  being	  activated	  shapes	  the	  immune	  response.	  Different	  signalling	  pathways	  
are	   induced	   depending	   on	   the	   PAMP	   stimulated,	   leading	   to	   the	   activation	   of	  
transcription	   factors	   including	   activation	   protein	   	   (AP)-­‐1,	   nuclear	   factor	   (NF)-­‐ΚΒ	   and	  
interferon-­‐regulatory	  factor	  (IRF)-­‐3	  (Krishnaswamy	  et	  al.,	  2013).	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Stimulation	  of	  TLRs	   leads	  to	  the	  release	  of	  danger	  signals	   in	  response	  to	  microbes	  or	  
altered	   endogenous	   molecules	   presented	   on	   the	   cell	   surface	   or	   in	   endosomal	  
compartments.	   In	  contrast	  to	  TLR	  family	  members,	  two	  other	  families	  of	  PRRs,	  RIG-­‐I-­‐
like	  helicases	  (RIHs)	  and	  Nod-­‐like	  receptors	  (NLRs),	  recognise	  and	  respond	  to	  microbial	  
components	  that	  escaped	  into	  the	  cytosol	  (Maisonneuve	  et	  al.,	  2014).	  	  
The	   innate	   immune	   response	   is	   not	   specific	   and	   does	   not	   provide	   immunological	  
memory,	  which	  together	  with	  the	  lack	  of	  knowledge	  about	  PRRs	  were	  reasons	  why	  the	  
innate	   immune	  response	  was	  taken	  for	  granted	  for	  vaccine	  development	   in	  the	  past.	  
However,	   due	   to	   recent	   progress	   in	   immunology,	   the	   innate	   immune	   system	   is	   also	  
considered	  a	  target	  of	  interest	  in	  vaccine	  design.	  
TLRs	  expressed	  on	  the	  cell	  surface	  
TLR	   PAMP	   DAMP	  
1	   lipopeptides,	  peptidoglycan	   -­‐	  
2	   lipopeptides,	  zymosan,	  glycolipids,	  
lipoteichoic	  acid	  
-­‐	  
4	   lipopolysaccharide,	  virus	  envelope	  
protein,	  respiratory	  syncytial	  virus	  
fusion	  protein,	  mouse	  mammary	  
tumour,	  phosphorylcholine	  
defensin	  2,	  hyaluronic	  acid,	  fibrinogen,	  
heat	  shock	  protein,	  high-­‐mobility	  group	  1	  
protein	  
5	   flagellin	   -­‐	  
6	   lipopeptides	   -­‐	  
TLRs	  expressed	  in	  endosomal	  compartments	  
TLR	   PAMP	   DAMP	  
3	   small	  interfering	  RNA,	  double-­‐
stranded	  RNA	  
messenger	  RNA	  
7/8	   imidaqzoquinoline,	  imiquidmod,	  
resiquimod,	  single-­‐stranded	  RNA	  
Autoantigens-­‐containing	  immune	  
complexes,	  U1	  small	  nuclear	  RNA	  
9	   CpG	  DNA	   Chromatin	  complex	  
10	   Unknown	  –	  but	  has	  been	  implicated	  in	  viral	  infections	  
Table	   1.1.	   Ten	   types	  of	   TLRs	   and	   their	   respective	  PAMPs	  and	  DAMPs	  which	   are	   expressed	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1.1.2. Dendritic	  cells	  connect	  the	  innate	  and	  adaptive	  immune	  response	  
DCs	   patrol	   peripheral	   organs	   in	   an	   antigen-­‐sampling	   state	   characterised	   by	   high	  
endocytic	  and	  phagocytic	  potential	   in	   the	   immature	  state.	  DCs	   take	  up	  pathogen-­‐	  or	  
tumour-­‐derived	   antigens	   in	   the	   peripheral	   organs	   through	   pinocytosis,	   phagocytosis	  
and	   receptor-­‐mediated	   endocytosis	   (Reis	   e	   Sousa	   et	   al.,	   1993,	   Jiang	   et	   al.,	   1995,	  
Sallusto	   et	   al.,	   1995).	   Upon	   uptake	   of	   antigen,	   DCs	   migrate	   to	   areas	   of	   secondary	  
lymphoid	  organs	   that	   are	   T	   cell	   rich	   and	  mature	   into	   an	   antigen-­‐presenting	   state	  by	  
upregulating	  expression	  of	  MHC	  and	  co-­‐stimulatory	  molecules	  such	  as	  CD40,	  CD80	  and	  
CD86	   and	   adhesion	   molecules	   such	   as	   intracellular	   adhesion	   molecule	   (ICAM)-­‐1	  
(Sallusto	  et	  al.,	  1995,	  Cella	  et	  al.,	  1997,	  Vermaelen	  et	  al.,	  2001,	  Henri	  et	  al.,	  2001).	  This	  
mechanism	  is	  known	  as	  the	  Langerhans	  cell	  paradigm.	  The	  enhanced	  surface	  antigen	  
expression	  make	  DCs	  better	  equipped	  to	  activate	  naive	  T	  helper	   (TH)	  cells	   residing	   in	  
the	   lymph	   node	   (Cella	   et	   al.,	   1996).	   The	   ability	   of	   DCs	   to	  migrate	   to	   the	   secondary	  
lymphoid	  organs	  and	  differentiate	  marks	  a	  very	  important	  difference	  to	  macrophages	  
that	   typically	   remain	   at	   the	   site	   of	   antigen-­‐uptake.	   Macrophages	   are	   very	   efficient	  
phagocytes	   of	   cellular	   debris,	   pathogens	   and	   dead	   cells,	   and	   rapidly	   break	   down	  
internalised	  antigens	  into	  amino	  acids.	  In	  contrast,	  DCs	  retain	  internalised	  antigens	  in	  
phagosomes	  for	  extended	  time	  periods	  and	  can	  still	  efficiently	  present	  the	  peptides	  to	  
T	  cells	  (Turley	  et	  al.,	  2000).	  	  
1.1.2.1. DC	  subsets	  	  
DCs	   make	   up	   a	   heterogeneous	   group	   of	   efficient	   APCs	   that	   are	   phenotypically	   and	  
functionally	  diverse.	  In	  spite	  of	  the	  great	  advances	  made	  in	  understanding	  DC	  subsets,	  
deciphering	  between	  the	  different	  DC	  types	   is	   still	  a	  challenging	   task.	  DCs	  present	   in	  
peripheral	   tissues	   and	   lymphoid	   organs	   are	   constantly	   being	   replenished	   from	  
hematopoietic	  stem	  cells	  (HSCs)	  in	  the	  bone	  marrow	  (Liu	  et	  al.,	  2007).	  HSCs	  give	  rise	  to	  
either	   lymphoid	   (LP)	   or	   myeloid	   (MP)	   committed	   progenitors.	   DCs	   could	   arise	   from	  
either	  LP	  or	  MP	  origin,	  but	  a	  fate-­‐mapping	  study	  showed	  that	  only	  a	  small	  proportion	  
of	  DCs	  arise	  from	  LP	  progenitors	  (Schlenner	  et	  al.,	  2010).	  MPs	  lead	  to	  the	  generation	  of	  
precursors	   of	   macrophages,	   monocytes	   and	   DCs	   (MDPs),	   which	   in	   turn	   generate	  
common	  DC	  precursors	   (CDPs),	  monocytes	  and	  some	  subsets	  of	  macrophages.	  MDPs	  
and	  CDPs	  are	  only	  found	  in	  the	  bone	  marrow	  (Liu	  et	  al.,	  2009).	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CDPs	  can	  give	  rise	  to	  all	  subsets	  of	  DCs.	  DC	  subsets	  migrating	  to	  the	  spleen	  only	  do	  so	  
via	  the	  blood,	  whilst	  DC	  subsets	  migrating	  to	  the	  lymph	  nodes	  do	  so	  via	  the	  blood	  as	  
well	   as	   the	   lymphatic	   system	   (Jakubzick	   et	   al.,	   2008).	   DC	   subsets	   residing	   in	   the	  
secondary	  lymphoid	  organs	  are	  classical	  or	  conventional	  DCs	  (cDCs),	  plasmacytoid	  DCs	  
(pDCs)	  and	  DCs	  subsets	  arising	  from	  monocytes	  (Liu	  et	  al.,	  2007).	  	  
1.1.2.1.1. cDCs	  	  
The	  CDPs	   in	  the	  bone	  marrow	  develop	   into	  pre-­‐cDCs	  that	  migrate	  through	  the	  blood	  
stream	  to	  the	  secondary	  lymphoid	  organs	  where	  they	  further	  divide	  and	  differentiate	  
(Liu	  et	  al.,	  2007,	  Liu	  et	  al.,	  2009).	  Therefore,	  in	  contrast	  to	  pDCs	  and	  monocytes,	  cDCs	  
that	  are	  resident	  in	  the	  lymphoid	  tissues	  migrate	  out	  of	  the	  bone	  marrow	  as	  immature	  
cells.	   Different	   cDCs	   are	   categorised	   according	   to	   their	   function,	   location	   and	  
phenotypic	  surface	  markers.	  
There	   are	   two	  main	   types	   of	   cDC	   subsets	   in	   secondary	   lymphoid	   organs,	   namely	   (i)	  
CD8+DEC205+	  and	  (ii)	  CD8-­‐33D1+	   (Dudziak	  et	  al.,	  2007).	   In	   the	  spleen,	   the	  cDC	  subset	  
CD8+DEC205+	   can	   be	   found	   in	   the	   T	   cell	   zone	   and	   are	   specialised	   for	   uptake	   from	  
apoptotic	   cells	   and	   cross-­‐presenting	   the	   antigens	   to	   CD8+	   T	   cells	   (den	   Haan	   et	   al.,	  
2000).	  In	  contrast,	  cDC	  subset	  CD8-­‐33D1+	  can	  be	  found	  in	  the	  pulp	  and	  marginal	  zone	  
of	  the	  spleen	  and	  is	  specialized	  for	  presentation	  of	  antigen	  to	  CD4+	  T	  cells	  (Dudziak	  et	  
al.,	  2007).	  Both	  CD8+	  and	  CD8-­‐	  cDC	  subsets	  have	  a	  short	  half-­‐life	  and	  are	  continuously	  
replaced	  from	  the	  bone	  marrow	  precursors	  via	  a	  FMS-­‐related	  tyrosine	  kinase	  3	  ligand	  
(Flt3L)-­‐dependent	  mechanism	  (Waskow	  et	  al.,	  2008).	  	  
Another	  two	  subsets	  of	  cDCs	  can	  be	  found	  in	  non-­‐lymphoid	  tissues	  including	  the	  skin,	  
lung	  and	  liver.	  These	  include	  CD103+CD11blow	  and	  CD103-­‐CD11bhigh	  DCs	  (Ginhoux	  et	  al.,	  
2009).	   In	   the	   skin,	   CD103+	   cDCs	  are	   very	   similar	   to	  CD8+	   cDCs,	   and	  also	   specialize	   in	  
cross-­‐presentation	  of	  antigens	  (Bedoui	  et	  al.,	  2009).	  In	  a	  steady	  state	  skin-­‐derived	  cDCs	  
account	  for	  20%	  of	  DCs	  in	  the	  lymph	  nodes	  (Jakubzick	  et	  al.,	  2008),	  a	  percentage	  which	  
rises	  dramatically	  in	  the	  presence	  of	  inflammation	  (Jakubzick	  et	  al.,	  2008),	  mechanical	  
or	  chemical	  stress	  (Tomura	  et	  al.,	  2014).	  	  
It	   is	   worthy	   to	   mention	   that	   the	   maturation	   status	   of	   the	   cDC	   subsets	   residing	   in	  
lymphoid	  and	  non-­‐lymphoid	  tissues	  is	  variable.	  cDCs	  residing	  in	  the	  peripheral	  organs	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are	  phenotypically	  immature	  which	  mature	  prior	  to	  migration	  to	  the	  lymphoid	  organs	  
conforming	  with	  the	  Langerhans	  cell	  paradigm.	  However,	  in	  contrast	  to	  the	  paradigm	  
cDCs	   in	   the	   secondary	   lymphoid	   organs	   were	   also	   found	   to	   be	   relatively	   immature	  
(Wilson	  et	  al.,	  2003,	  Wilson	  et	  al.,	  2004,	  Dudziak	  et	  al.,	  2007).	  
1.1.2.1.2. pDCs	  
The	   pDC	   subset	   in	   contrast	   to	   the	   cDC	   subset,	   matures	   in	   the	   bone	   marrow	   and	  
migrates	   to	   the	   secondary	   lymphoid	   organs	   also	   via	   the	   bloodstream.	   pDCs	   are	   a	  
CD11cloCD11b−CD45RAhi	  population	  (O'Keeffe	  et	  al.,	  2003)	  that	  could	  be	  distinguished	  
from	   cDCs	   by	   their	   characteristic	   spherical	   appearance	   similar	   to	   antibody-­‐bearing	  
plasma	   cells	   (Cella	   et	   al.,	   1999).	   In	   addition,	   pDCs	   also	   express	   the	   surface	  markers;	  
bone	  marrow	  stromal	  cell	  Ag	  2	  (BST2)	  (Blasius	  et	  al.,	  2006)	  and	  Siglec-­‐H	  (Zhang	  et	  al.,	  
2006)	   in	  murine	   systems	   and	   BDCA2	   (Dzionek	   et	   al.,	   2001)	   in	   human	   systems.	   pDCs	  
respond	   to	   oligonucleotides	   containing	   CpG	  motifs	   in	   culture	   (O'Keeffe	   et	   al.,	   2003)	  
and	   viral	   infection	   (Cella	   et	   al.,	   1999)	   by	   producing	   type	   I	   IFN,	   which	   maintains	   a	  
prolonged	  T	  cell	  response	  and	  crucial	  anti-­‐viral	  and	  anti-­‐tumour	  immunity.	  
1.1.2.1.3. Monocyte-­‐derived	  DCs	  
Monocytes	   are	   blood	  mononuclear	   cells	   that	   express	   F4/80	   and	   CD11b	   in	  mice	   and	  
CD11c,	  CD11b	  and	  CD14	  in	  humans	  (Geissmann	  et	  al.,	  2003).	  Murine	  monocytes	  in	  the	  
blood	  derived	   from	  MDPs	   in	   the	  bone	  marrow,	  do	  not	  differentiate	   to	  cDCs	  or	  pDCs	  
(Liu	  et	  al.,	  2007)	  but	  into	  Gr1+CX3CR1lowCCR2+	  monocytes	  that	  in	  turn	  give	  rise	  to	  DCs	  	  
during	  inflammation	  caused	  by	  infection	  (Serbina	  et	  al.,	  2003,	  Geissmann	  et	  al.,	  2003).	  
The	  inflammatory	  DC	  subset	  is	  called	  TipDCs	  that	  produce	  mediators	  of	  inflammation	  
like	  iNOS,	  TNF	  and	  reactive	  oxygen	  species	  (Serbina	  et	  al.,	  2003).	  The	  TipDC	  subset	   is	  
only	  present	  in	  the	  spleen	  following	  systemic	  infection.	  The	  human	  equivalents	  of	  the	  
inflammatory	  monocyte	  subset	  are	  of	  the	  phenotype	  CD14lowCD16+	  (Geissmann	  et	  al.,	  
2003).	  
In	   vitro,	   murine	   and	   human	   DCs	   can	   be	   generated	   from	   bone	   marrow-­‐derived	  
monocytes	  in	  culture	  using	  the	  cytokines	  GM-­‐CSF	  and	  other	  cytokines	  for	  example	  IL-­‐4	  
(Sallusto	  and	  Lanzavecchia,	  1994,	  Son	  et	  al.,	  2002,	  Galea-­‐Lauri	  et	  al.,	  2004).	  Similar	  to	  
cDCs,	  DCs	  generated	   in	  vitro	  display	  an	  immature	  phenotype	  after	  a	  specified	  time	  in	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culture	   that	   develop	   a	   mature	   phenotype	   after	   stimulation.	   However,	   the	  
corresponding	  in	  vivo	  DC	  subset	  is	  still	  unclear.	  	  
	  
1.1.3. CD4+	  T	  lymphocytes	  	  
Naive	   T	   helper	   lymphocytes	   (TH	   cells)	   express	   CD4	   surface	  marker	   and	   only	   become	  
activated	   to	   form	  cytokine-­‐producing	  effector	   cells,	  when	   they	   recognise	   antigens	   in	  
the	  form	  of	  particular	  peptides	  on	  the	  surface	  of	  the	  MHC	  class	  II	  harboured	  by	  APCs	  
(Interactions	   between	   T	   cells	   and	  APCs,	   see	   Section	   1.1.6.).	   Effector	   lymphocytes	   do	  
not	  circulate	  in	  the	  blood	  or	  lymph	  like	  naive	  lymphocytes,	  instead	  they	  either	  migrate	  
to	   the	  site	  of	   infection	  via	   the	  blood	  or	   remain	   in	   the	  secondary	   lymphoid	  organs.	  A	  
sign	  of	  TH	  cell	  activation	  is	  IL-­‐2	  production	  (Morgan	  et	  al.,	  1976,	  Taniguchi	  et	  al.,	  1983).	  
A	  defining	  characteristic	  of	  antigen-­‐specific	  TH	  cells	   is	  that	  post-­‐activation,	  effector	  TH	  
cells	  can	  develop	  into	  different	  subsets	  including	  TH1,	  TH2,	  TH17	  and	  regulatory	  T	  cells	  
(Treg),	   shaping	   the	   immune	   response	   according	   to	   the	   invading	   pathogen	   or	  
transformed	  cells.	  	  
The	   T	   cell	   subtypes,	   TH1	   and	   TH2,	   were	   first	   discovered	   in	   mice	   by	   Mossman	   and	  
Coffman	   in	  1986	   (Mosmann	  et	  al.,	   1986).	  TH	   cell	  polarisation	   into	   the	  TH1	   subtype	   is	  
induced	   by	   intracellular	   pathogens	   and	   driven	   by	   the	   cytokine	   IL-­‐12	   (Seder	   et	   al.,	  
1992).	   TH1	   cells	   produce	   IFN-­‐γ	   that	   leads	   to	   (i)	   inflammation	   and	   macrophage	  
activation	  (Nathan	  et	  al.,	  1983),	  as	  well	  as	  (ii)	  CD8+	  T	  cell-­‐directed	  killing	  (Whitmire	  et	  
al.,	   2005),	   for	   an	   anti-­‐bacterial,	   anti-­‐viral	   and	   anti-­‐tumour	   response.	   TH1	   cells	   are	  
therefore	   specialised	   for	   cell-­‐mediated	   responses	   and	   phagocyte-­‐dependent	  
inflammation	   for	   clearance	  of	   intracellular	  pathogens.	   The	  TH2	   response	   is	   driven	  by	  
the	  cytokine	  IL-­‐4	  (Seder	  et	  al.,	  1992)	  and	  is	  characterised	  by	  the	  cytokines	  IL-­‐4,	  IL-­‐5	  and	  
IL-­‐13	  that	  promote	  the	  humoral	  immune	  response.	  TH2	  cells	  are	  the	  main	  TH	  cells	  that	  
provide	   help	   for	   the	   production	   of	   isotype	   class-­‐switched	   antibodies	   by	   B	   cells,	  
especially	  IgG1	  (Vitetta	  et	  al.,	  1985)	  and	  IgE	  (Kaplan	  et	  al.,	  1996,	  Coffman	  et	  al.,	  1986),	  
and	  are	  important	  for	  the	  clearance	  of	  parasites	  (Collins	  et	  al.,	  1995).	  Due	  to	  induction	  
of	   proinflammatory	   IgE	   isotype-­‐class	   switch,	   TH2	   cells	   also	   contribute	   to	   the	  
pathological	  response	  in	  asthma	  (Wong	  et	  al.,	  2001).	  Once	  naïve	  TH	  cells	  commit	  to	  a	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particular	   TH	   subset	   lineage,	   cytokines	   produced	   by	   one	   pathway	   inhibit	   cytokines	  
produced	   by	   another	   pathway.	   For	   example,	   IFN-­‐γ	   production	   blocks	   TH2	  
differentiation	   (Whitmire	   et	   al.,	   2005).	   The	   TH17	   subset	   is	   characterised	   by	   the	  
production	   of	   IL-­‐17	   and	   IL-­‐22,	   important	   for	   the	   protection	   against	   extracellular	  
bacterial	   and	   fungal	  diseases	   (Aujla	  et	   al.,	   2008,	  Hernández-­‐Santos	  et	   al.,	   2013).	   The	  
cytokines	   IL-­‐17	   and	   IL-­‐22	   can	   however,	   also	   play	   a	   pathogenic	   role	   in	   autoimmune	  
disease	   (Nakae	   et	   al.,	   2003).	   The	   development	   of	   TH17	   is	   driven	   by	  mainly	   tumour-­‐
growth	  factor	  (TGF)-­‐β	  (Veldhoen	  et	  al.,	  2006)	  as	  well	  as	  IL-­‐6	  (Bettelli	  et	  al.,	  2006),	  and	  
maintained	  by	  maintained	  by	  IL-­‐23	  (Park	  et	  al.,	  2005).	  The	  Treg	  subset,	  as	  their	  name	  
implies	  are	  regulatory	  T	  cells	  with	  a	   lead	  role	   in	   immune	  and	   inflammatory	  response	  
suppression,	   maintenance	   of	   self-­‐tolerance	   and	   prevention	   of	   autoimmunity.	   Tregs	  
produce	  TGF-­‐β	  and	  IL-­‐10,	  which	  induce	  isotype-­‐switching	  to	  IgG4	  and	  IgA	  and	  suppress	  
IgE	  production	  (respectively)	  (Taylor	  et	  al.,	  2006).	  
	  
1.1.3.1. DC	  influence	  on	  T	  cell	  differentiation	  
Mice	   with	   depleted	   DCs	   fail	   to	   mount	   an	   appropriate	   adaptive	   response	   (Phythian-­‐
Adams	  et	  al.,	  2010),	  indicating	  that	  DCs	  are	  fundamental	  in	  CD4+	  T	  cell	  priming.	  DCs	  of	  
the	   innate	   immune	  response	  could	  be	  regarded	  as	  a	  converter	  station	  that	   identifies	  
and	  translates	  pathogen	  input	  signals	  into	  output	  signals	  that	  have	  a	  direct	  effect	  on	  TH	  
cell	   polarisation.	   An	   example	   of	   an	   input	   signal	   is	   PRR	   stimulation.	   The	   output	   DC	  
signals	   are	   (i)	   co-­‐stimulatory	   molecule	   expression,	   (ii)	   antigen	   presentation	   and	   (iii)	  
cytokine	  production	  (Walsh	  and	  Mills,	  2013).	  
DCs	  expressing	  high	   levels	  of	   co-­‐stimulatory	  molecules	   tend	   to	  activate	  TH1,	  TH2	  and	  
TH17	   subsets,	   whilst	   Tregs	   only	   become	   activated	   by	   immature	   or	   partially	   mature	  
human	  DCs	  (Jonuleit	  et	  al.,	  2000).	  Tregs	  upregulate	  negative	  regulator	  molecules	  such	  
as	  for	  example	  cytotoxic	  T	  lymphocyte–associated	  molecule	  4	  (CTLA-­‐4)	  which	  binds	  to	  
the	   CD80	   and	   CD86	  molecules	   instead	   of	   CD28.	   This	   inhibits	   T	   cell	   stimulation	   that	  
leads	   to	   immunosuppression.	   Therefore,	   DCs	   presenting	   peptide	   in	   a	   steady	   state	  
promote	  tolerance	  by	  driving	  Treg	  differentiation.	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The	  extent	  of	  peptide	  presented	  by	  the	  DCs	  as	  well	  as	  the	  strength	  of	  the	  TCR	  binding	  
to	   the	   peptide	   influences	   the	   functional	   differentiation	   of	   TH	   subsets.	   A	   low	  
concentration	  of	  peptide	  presented	  and	  a	  weak	  affinity	  to	  TCR	  tends	  to	  skew	  towards	  
a	  TH2	  phenotype	  whilst	  a	  high	  concentration	  of	  peptide	  presented	  and	  a	  strong	  affinity	  
to	  TCR	  skews	  towards	  a	  TH1	  phenotype	  (Constant	  et	  al.,	  1995,	  Tao	  et	  al.,	  1997).	  
TLRs	  play	  an	  important	  role	  in	  DC	  driven	  TH	  differentiation.	  As	  summarised	  in	  Table	  1.1,	  
different	  TLRs	  expressed	  by	  different	  cells,	  respond	  to	  different	  adaptor	  proteins.	  This	  
means	   the	   nature	   of	   the	   TLR	   activated,	   shapes	   the	   immune	   response,	   which	   is	  
influenced	   by	   cytokine	   production.	   For	   example,	   TLR4	   stimulation	   by	  
lipopolysaccharide	   (LPS)	   leads	   to	   IL-­‐12	   production	   which	   predominantly	   induces	   the	  
TH1	  response	  (Krummen	  et	  al.,	  2010).	  Furthermore,	  TLR4	  stimulation	  also	  leads	  to	  IL-­‐23	  
production	  which	  maintains	  TH17	  differentation	  (Abdollahi-­‐Roodsaz	  et	  al.,	  2008).	  TLR2	  
knockout	   mice	   show	   impaired	   IL-­‐10	   production	   and	   reduced	   Treg	   numbers,	   which	  
means	  that	  TLR2	  stimulation	  has	  a	  role	  in	  the	  induction	  of	  Treg	  subsets	  (Netea	  et	  al.,	  
2004).	  	  
Specific	  DC	  subsets	  also	  have	  a	  role	  in	  influencing	  the	  TH	  polarisation	  (Figure	  1.1).	  The	  
lymphoid	   CD8+	   DC	   subsets	   have	   been	   reported	   to	   have	   the	   highest	   potential	   to	  
produce	   IFN-­‐y	  when	  stimulated	  with	   IL-­‐12	   (Ohteki	  et	  al.,	  1999).	  The	  CD103+CD11blow	  
(see	   Section	   1.1.2.1.1.)	   subset	   being	   the	   migratory	   non-­‐lymphoid	   complementary	  
subset	  of	  CD8+	  DCs	  also	  demonstrates	  a	   role	   in	  driving	  TH1	   responses,	  however	   they	  
have	   been	   reported	   to	   also	   produce	   IL-­‐17,	   the	   characteristic	   cytokine	   of	   the	   TH17	  
response	   (King	   et	   al.,	   2010).	   Conversely,	   CD103-­‐CD11bhigh	   (see	   Section	   1.1.2.1.1.)	  
induced	   TH2	   responses	   that	   in	   turn	   were	   an	   important	   mediator	   of	   allergic	  
inflammation	   caused	   by	   the	   dust	   mite	   antigen	   (Plantinga	   et	   al.,	   2013,	   Zhou	   et	   al.,	  
2014).	  The	  TNF-­‐α	  and	  nitric	  oxide	  producing	  TipDCs	  have	  been	  shown	  to	  have	  a	  role	  in	  
early	  innate	  immune	  responses	  at	  the	  site	  of	  infection	  (Serbina	  et	  al.,	  2003)	  however,	  
TipDCs	   have	   been	   also	   implicated	   in	   TH1	   responses	   in	   a	   Leishmania	   experimental	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Figure	  1.1.	  The	  influence	  of	  DC	  subsets	  on	  priming	  T	  cell	  responses	  and	  shaping	  the	  immune	  
response.	  Different	   DC	   subsets	   influence	   TH	   cell	   polarisation	   into	   TH1,	   TH2	   or	   TH17	   amongst	  
others.	  TH	  cell	   subsets	  produce	  cytokines	   that	   lead	  to	  specific	   immune	  responses	  against	   the	  
foreign	  antigens	  through	  other	  cells	  of	  the	  innate	  and	  adaptive	  immune	  response.	  
CTL	  =	  Cytotoxic	  T	  lymphocyte;	  TH	  =	  T	  helper	  lymphocyte;	  pDC	  =	  Plasmacytoid	  dendritic	  cell;	  cDC	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The	   described	   involvement	   of	   DCs	   in	   linking	   the	   innate	   and	   the	   adaptive	   immune	  
response	   shows	   that	   DC	   subsets	   and	   their	   PRRs	   are	   an	   important	   target	   for	   more	  
defined	  vaccine	  development.	  
	  
1.1.4. CD8+	  T	  lymphocytes	  
Cytotoxic	  T	  cells	  express	  the	  CD8	  surface	  marker	  (CD8+	  T	  cells)	  and	  are	  known	  as	  killer	  
cells	  because	  of	  their	  effector	  functions.	  CD8+	  T	  cells	  carry	  out	  this	  effector	  function	  by	  
releasing	   cytolytic	   proteins,	   like	   perforin	   that	   cause	   the	   release	   of	   the	   intracellular	  
proteases	  or	  granzymes	  which	   causes	   the	   cell	   to	  become	  apoptotic	   (Chowdhury	  and	  
Lieberman,	  2008).	  TCR	  recognition	  of	  endogenous	  peptide	  on	  the	  MHC	  class	  I	  complex	  
leads	  to	  the	  death	  of	  the	  malignant	  or	  infected	  cells.	  Exogenous	  antigens	  could	  also	  be	  
presented	   to	  CD8+	  T	   cell	   in	   context	  of	   the	  MHC	  class	   I	   complex	  of	  professional	  APCs	  
(see	  Section	  1.1.6.).	  Similar	  to	  CD4+	  T	  cells,	  naive	  antigen-­‐specific	  CD8+	  T	  cells	  undergo	  
proliferation	   and	   differentiation	   upon	   antigen	   encounter,	   however	   the	   efficiency	   of	  
this	   process	   is	   different	   for	   the	   two	   lymphocytes.	   CD8+	   T	   cells	   tend	   to	   proliferate	  
sooner	  and	  at	  a	  faster	  rate	  than	  their	  CD4+	  expressing	  counterpart	  (Seder	  and	  Ahmed,	  
2003).	  	  
	  
1.1.5. B	  Lymphocytes	  
B	   lymphocytes	   are	   APCs	   that	   are	   able	   to	   produce	   antibodies	   that	   neutralise	   the	  
pathogen	   effects	   directly,	   or	   indirectly	   through	   opsonisation	   of	   the	   microorganism	  
promoting	   efficient	   complement-­‐mediated	   killing	   or	   phagocytosis.	   Antibody	  
production	   is	   inarguably	   the	   most	   crucial	   effector	   function	   of	   B	   lymphocytes.	   The	  
concept	   of	   the	   ability	   of	   certain	   B	   cell	   subsets	   to	   drive	   TH1,	   TH2	   or	   Treg	   cell	  
differentiation	  is	  still	  relatively	  new	  and	  controversial	  (Lund	  and	  Randall,	  2010).	  
1.1.5.1. Antibody	  types	  
Antibodies	   are	   proteins	   composed	   of	   two	   light	   chains	   and	   two	   heavy	   chains	   linked	  
together	  by	  disulphide	  bonds	  (Amzel	  and	  Poljak,	  1979),	  which	  are	  secreted	  by	  effector	  
B	   lymphocytes	  known	  as	  plasma	  cells.	  Each	  chain	   is	  composed	  of	  a	  variable	   region	  –	  
CHAPTER	  1	  
	   14	  
important	   for	   binding	   antigen	   and	   a	   constant	   region	   –	   important	   for	   the	   effector	  
function	  involved	  in	  the	  elimination	  of	  bound	  antigen.	  There	  are	  five	  kinds	  of	  antibody	  
isotypes	  that	  are	  determined	  by	  their	  heavy	  chains	  μ	  –	   IgM,	  δ	  –	   IgD,	  γ	  –	   IgG,	  α	  –	   IgA	  
and	  ε	  –	  IgE.	  Each	  antibody	  isotype	  has	  a	  particular	  function	  (Murphy	  et	  al.,	  2008).	  
As	   the	   B	   cells	   develop	   in	   the	   bone	   marrow,	   the	   BCR	   normally	   consists	   of	   the	   IgM	  
isotype.	  However,	  once	   the	  B	   cells	   leave	   the	  bone	  marrow	   they	   start	   to	  express	   IgD	  
(Pernis	  et	  al.,	  1966,	  Geisberger	  et	  al.,	  2006).	  IgM	  antibodies	  are	  the	  first	  secreted	  in	  the	  
primary	   immune	   response	   on	   first	   encounter	  with	   foreign	   antigen	   because	   they	   are	  
produced	  without	   class-­‐switching.	   IgG	   is	   the	   principal	   antibody	   isotype	   found	   in	   the	  
extracellular	   fluid	  and	  blood,	  and	  have	  four	  subclasses	  named	   in	  order	  of	  abundance	  
called	   IgG1,	   IgG2,	   IgG3	   and	   IgG4.	   IgG	   antibodies	   are	   secreted	   in	   large	   quantities	   on	  
second	   encounter	   of	   foreign	   antigen	   in	   the	   secondary	   humoral	   response.	   IgA	  
antibodies	   can	   form	   dimers	   and	   are	   the	   principal	   antibody	   isotype	   found	   in	   body	  
secretions	  like	  saliva,	  milk	  and	  tears.	  IgA	  antibodies	  are	  divided	  in	  two	  subclasses,	  IgA1	  
and	   IgA2.	   IgE	   antibodies	   are	  present	   in	   low	   levels	   in	   the	  extracellular	   fluid	  or	   blood.	  
Secreted	   IgE	  antibodies	  bind	   to	   the	  surface	  of	  mast	  cells	  and	  basophils,	  by	  means	  of	  
their	  constant	  regions	  (Fc	  portions)	  (Murphy	  et	  al.,	  2008).	  
1.1.5.2. B	  cell	  response	  to	  antigen	  
B	   cells	   residing	   in	   the	   secondary	   lymphoid	   organs	   encounter	   antigens	   in	   two	   ways.	  
Naive	   B	   cells	   residing	   in	   the	   B	   cell	   follicles	   could	   directly	   encounter	   antigens	   of	   low	  
molecular	  weight	  (<70kDa)	  that	  drain	  to	  the	  lymph	  nodes	  or	  the	  spleen	  (in	  the	  case	  of	  
systemic	  infection)	  (Pape	  et	  al.,	  2007,	  Roozendaal	  et	  al.,	  2009).	  Otherwise,	  antigens	  are	  
delivered	   on	   the	   surface	   of	   subcapsular	   sinus	   macrophages	   (Junt	   et	   al.,	   2007),	  
peripheral	  DCs	  that	  have	  migrated	  to	  the	  secondary	  lymphoid	  organs	  (Bergtold	  et	  al.,	  
2005)	  or	  stromal	  cells	  called	  follicular	  DCs	  that	  as	  their	  name	  implies	  reside	  within	  the	  
follicles	  were	  they	  are	  specialised	  to	  trap-­‐antigen	  (Suzuki	  et	  al.,	  2009).	  
Once	   activated,	   B	   cells	   differentiate	   into	   plasmablasts	   located	   outside	   the	   B-­‐cell	  
follicles,	  which	  secrete	  IgM	  antibodies.	  This	  occurs	  2-­‐12	  days	  after	  antigen	  encounter.	  
Isotype	  switching	  to	  IgG	  and	  affinity	  maturation	  occurs	  within	  9-­‐20	  days	  after	  antigen	  
encounter	  in	  specialised	  anatomical	  structures	  namely	  germinal	  centres.	  Finally,	  B	  cells	  
residing	   in	   the	   germinal	   centres	   differentiate	   into	   plasma	   cells	   and	   memory	   cells	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harbouring	  high-­‐affinity	   Igs	  on	  their	   surface.	  Memory	  cells	  have	  a	   long	   life	  span,	  and	  
become	  plasma	   cells	   upon	   antigen	   re-­‐encounter.	  However,	   plasma	   cells	   only	   have	   a	  
short	  life	  span	  ranging	  from	  a	  few	  days	  up	  to	  a	  few	  months	  (Jacob	  et	  al.,	  1991,	  Jacob	  
and	  Kelsoe,	   1992,	   Elgueta	  et	   al.,	   2009).	   Some	  plasma	   cells	   remain	   in	   the	   spleen	  and	  
lymph	  nodes,	  but	  most	  migrate	   to	  and	  reside	   in	   the	  bone	  marrow,	   from	  where	   they	  
secrete	  antibodies	  into	  the	  blood	  (Murphy	  et	  al.,	  2008).	  
B	   cells	   could	   be	   directly	   activated	   by	   T-­‐cell	   independent	   (TI)	   antigens,	   such	   as	  
polysaccharide	  antigens,	  by	  extensive	  cross-­‐linking	  of	  antibodies	  on	  the	  cell	  surface,	  in	  
absence	   of	   CD4+	   T	   cell	   help.	   However,	   for	   this	   type	   of	   immune	   response	   no	   class-­‐
switching	  occurs	  and	  the	  predominant	  antibody	  secreted	  is	  IgM	  type,	  and	  no	  memory	  
cells	   are	   produced.	   This	  means	   that	   on	   second	   encounter	   of	   the	   same	   antigen,	   the	  
secondary	   immune	   response	   to	   a	   TI	   antigen	   would	   be	   poor,	   whilst	   an	   immune	  
response	   to	   a	   T-­‐cell	   dependent	   (TD)	   antigen	   would	   be	   fast-­‐developing	   and	   mostly	  
made	  up	  of	  IgG	  antibodies	  (Moser	  and	  Leo,	  2010).	  
	  
1.1.6. Interactions	  between	  APCs	  and	  T	  lymphocytes	  
Macrophages,	  DCs	   and	  B	   cells	   are	   able	   to	   identify	   pathogens	   and	  malignant	   cells	   by	  
means	   of	   PRRs,	   and	   uptake	   antigens	   by	   different	  mechanisms.	   Internalised	   antigens	  
are	  cleaved	  into	  peptides	  by	  proteases	  in	  different	  cellular	  compartments.	  Proteins	  are	  
broken	  down	  into	  a	  myriad	  of	  different	  epitopes	  capable	  of	  binding	  to	  MHC	  molecules,	  
but	   T	   cells	   only	   respond	   to	   a	   limited	   number	   of	   these	   epitopes,	   called	   the	  
immunodominant	   epitopes	   (Sercarz	   et	   al.,	   1993).	   The	   peptide-­‐MHC	   complex	   is	  
trafficked	  to	  the	  cell	  surface.	  Prior	  to	  interaction	  with	  T	  cells,	  APCs	  upregulate	  surface	  
co-­‐stimulatory	  molecules	  ready	  for	  interaction	  with	  T	  cells.	  	  
1.1.6.1. Antigen	  uptake	  by	  APCs	  
DCs	  patrol	   the	  peripheral	   tissues	  as	  well	   as	   the	   secondary	   lymphoid	  organs,	  and	  can	  
internalise	  antigen	  non-­‐specifically	  at	  each	  location.	  Naive	  B	  cells	  are	  circulating	  in	  the	  
blood	  and	  lymphatic	  system,	  and	  are	  also	  found	  in	  the	  follicles	  of	  secondary	  lymphoid	  
organs.	  Due	   to	   their	   anatomical	   locations,	  DCs	   are	  more	   efficient	  APCs.	   Both	  B	   cells	  
and	   DCs	   are	   able	   to	   internalize	   antigen	   non-­‐specifically	   by	   three	   distinct	   pathways,	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namely	   clathrin-­‐mediated	   endocytosis,	   phagocytosis	   and	   macropinocytosis	   (Parra	   et	  
al.,	   2012,	  Gao	  et	  al.,	   2012,	  Blum	  et	  al.,	   2013).	  However,	  B	   cells	   are	  most	  efficient	  at	  
antigen-­‐specific	  uptake,	  and	   the	  major	  pathway	   for	  B	  cell	  uptake	   is	   through	   the	  BCR	  
(Avalos	   and	   Ploegh,	   2014).	   In	   fact,	   antigen	   recognition	   and	   uptake	   through	   BCR	  
enhances	  their	  CD4+	  T	  cell	  stimulatory	  capacity	  by	  103-­‐104	  fold	  (Lanzavecchia,	  1985).	  In	  
addition,	   B	   cells	   become	   increasingly	   better	   APCs	   when	   the	   amount	   of	   soluble	   or	  
particulate	   antigen	   is	   low	   (Malynn	  et	   al.,	   1985).	   Published	  work	   shows	   that	   in	  B	   cell	  
depleted	   mice,	   B	   cells	   are	   dispensable	   APCs	   when	   the	   antigen	   load	   is	   high	   but	  
necessary	  when	  the	  amount	  of	  antigen	  is	  limited	  (Bouaziz	  et	  al.,	  2007).	  
Clathrin-­‐mediated	  endocytosis	  mediates	   the	   internalisation	  of	   clusters	  of	   cell	   surface	  
receptor-­‐ligand	   complexes,	   soluble	   macromolecules	   and	   membrane	   proteins	   into	  
endosomes.	   This	   pathway	   allows	   capture	   of	   antigens	   by	   means	   of	   cell-­‐surface	  
receptors	  that	  include	  BCR,	  Fc	  receptor,	  C-­‐type	  lectin	  receptor	  DEC205	  as	  well	  as	  CD40	  
co-­‐stimulatory	  molecule	  (Davidson	  et	  al.,	  1990,	  Bonifaz	  et	  al.,	  2004,	  Chatterjee	  et	  al.,	  
2012).	   In	   fact	   some	   of	   these	   receptors	   (DEC205,	   CD40)	   were	   targeted	   in	   vaccine	  
development	  studies	  (Bonifaz	  et	  al.,	  2004).	  The	  CD40	  receptor	  was	  found	  less	  efficient	  
at	  internalisation	  compared	  to	  the	  DEC205	  receptor,	  however,	  it	  was	  the	  most	  efficient	  
at	   presenting	   antigen	   to	   CD8+	   T	   cells	   (Chatterjee	   et	   al.,	   2012).	   Once	   internalised,	  
antigens	   are	   trafficked	   into	   early	   endosomes	   (weakly	   acidic,	   pH	   6.8-­‐5.9),	   late	  
endosomes	   (pH	   6.0–4.8)	   and	   lysosomes	   (pH	   4.5)	   harbouring	   microenvironments	   of	  
decreasing	   pH	   (Murphy	   et	   al.,	   1984,	   Maxfield	   and	   Yamashiro,	   1987).	   Concentrated	  
amounts	  of	  MHC	  class	  II	  molecules	  (Harding	  et	  al.,	  1990),	  but	  limited	  amounts	  of	  MHC	  
class	   I	   molecules	   are	   detected	   in	   the	   late	   endosomes	   (Peters	   et	   al.,	   1991),	   where	  
peptide	  loading	  occurs.	  
Phagocytosis	  is	  the	  process	  by	  which	  whole	  pathogens	  as	  well	  as	  apoptotic	  or	  necrotic	  
cells	  are	  engulfed,	  usually	  mediated	  by	  opsonisation	  with	  the	  complement	  system.	  This	  
mechanism	   is	   mediated	   by	   surface	   receptors.	   Phagocytosed	   antigens	   are	   trafficked	  
into	   a	   phagosome	   containing	   proteases,	   reactive	   oxygen	   species	   (ROS)	   and	   anti-­‐
microbial	  agents	  to	   increase	  the	  efficiency	  of	  pathogen	  removal	  (Ramachandra	  et	  al.,	  
2009).	   Phagosomes	   containing	   phagocytosed	   antigens	   fuse	   with	   lysosomes	   to	   form	  
phagolysosomes.	  Phagolysosomes	  also	  have	  a	   low	  pH	  ranging	  from	  4	  to	  4.5,	  which	   is	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the	   environment	   at	   which	   the	   proteases	   called	   cathepsins	   work	   at	   their	   optimum.	  
Published	   work	   shows	   that	   phagosomes	   contain	   both	  MHC	   class	   I	   and	   II	   molecules	  
(Harding	  and	  Geuze,	  1992,	  Harding,	  1995,	  Ackerman	  et	  al.,	  2003).	  	  
Macropinocytosis	   is	   the	   capture	   of	   large	   quantities	   of	   extracellular	   materials	   into	  
vesicles	   called	   pinosomes,	   not	   by	   surface	   receptors	   in	   this	   case,	   but	   by	   means	   of	  
membrane	   folding	   (Hewlett	   et	   al.,	   1994).	   Innate	   immune	   stimuli,	   for	   example	   TLR	  
stimulation	  in	  DCs	  promotes	  rapid	  macropinocytosis	  stimulating	  antigen	  presentation	  
preferentially	  to	  either	  MHC	  class	  I	  or	  II	  molecules	  (West	  et	  al.,	  2004).	  	  
	  
1.1.6.2. Antigen	  processing	  and	  presentation	  of	  peptide-­‐MHC	  complexes	  
The	   MHC	   is	   polygenic	   and	   is	   located	   on	   chromosome	   6	   or	   17,	   in	   humans	   or	   mice	  
respectively.	  MHC	  genes	  are	   called	  human	   leucocyte	  antigen	   (HLA)	  genes	   in	  humans	  
and	   H-­‐2	   genes	   in	   mouse	   (Murphy	   et	   al.,	   2008).	   Structurally	   MHC	   class	   I	   and	   II	  
molecules	   possess	   a	   similar	   antigen-­‐presenting	   groove	  made	  up	  of	   two	  domains,	   α1	  
and	   α2	   or	   α1	   and	   β1	   respectively	   (Bjorkman	   et	   al.,	   1987,	   Fremont	   et	   al.,	   1992).	  
However,	  certain	  unique	  structural	  features	  lead	  to	  each	  molecule	  binding	  peptides	  of	  
different	  lengths.	  	  
Peptides	   presented	   by	  MHC	   class	   I	   are	   8-­‐9	   amino	   acids	   long	   (Falk	   et	   al.,	   1991).	   The	  
peptide-­‐binding	  groove	  stabilises	  the	  peptide	  at	  both	  ends	  by	  hydrogen	  bonding	  with	  
residues	   on	   the	   amino	   and	   carboxyl	   ends	   of	   the	   peptide	   known	   as	   anchor	   residues.	  
Longer	   peptides	   can	   bind	   to	   the	   MHC	   class	   I	   however,	   they	   are	   cleaved	   by	  
exopeptidases	  in	  the	  ER,	  which	  is	  the	  location	  were	  the	  peptide	  binds	  to	  the	  peptide-­‐
binding	  groove	   (Murphy	  et	  al.,	  2008,	  Blum	  et	  al.,	  2013).	  Peptides	  presented	  by	  MHC	  
class	  II	  are	  more	  heterogeneous	  in	  size	  with	  15	  amino	  acids	  being	  the	  average	  peptide	  
length	   (Hunt	   et	   al.,	   1992,	   Chicz	   et	   al.,	   1992).	   In	   contrast	   to	   MHC	   class	   I	   binding,	  
peptides	  are	  not	  bound	  via	  their	  N-­‐	  or	  C-­‐	  termini,	  but	  by	  interactions	  along	  the	  length	  
of	  the	  peptide	  (Murphy	  et	  al.,	  2008,	  Blum	  et	  al.,	  2013).	  
Generally,	  peptides	  presented	  by	  MHC	  class	  I	  molecules	  are	  derived	  from	  endogenous	  
antigens	   like	   viruses	   or	   transformed	   cells	   and	   degraded	   by	   a	   large,	   multicatalytic	  
proteinase	   complex,	   the	   proteasome.	   The	   generated	   peptides	   are	   translocated	   into	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the	   ER	   by	  means	   of	   a	   transporter	   associated	  with	   antigen	   processing	   (TAP)	   and	   are	  
bound	   to	  MHC	   class	   I	   molecules	   (Oancea	   et	   al.,	   2009).	   Peptide-­‐binding	   is	   essential,	  
otherwise	   the	  MHC	   class	   I	  molecule	   and/or	   unbound	   peptide	   are	   translocated	   back	  
into	   the	   cytosol	   from	   the	   ER	   and	   are	   degraded	   by	   the	   proteasome.	   Only	   stable	  
peptide:MHC	   complexes	   are	   transported	   to	   the	   cell	   surface	   (Grommé	   and	   Neefjes,	  
2002).	   In	   some	   cases,	   exogenous	   antigens	   are	   also	   presented	   on	   MHC	   class	   I	  
molecules,	  by	  a	  mechanism	  known	  as	  cross-­‐presentation,	  and	  it	  allows	  APCs	  to	  directly	  
prime	  naive	  CD8+	  T	  cells	   (Moore	  et	  al.,	  1988,	  Kurts	  et	  al.,	  1996).	  Exogenous	  antigens	  
can	   escape	   from	   endosomes	   or	   phagolysosomes	   into	   the	   cytosol	   were	   they	   are	  
degraded	   by	   proteasome	   and	   bound	   to	   newly	   synthesised	   MHC	   class	   I	   in	   the	   ER	  
(Grommé	  and	  Neefjes,	  2002).	  
Internalised	  exogenous	  antigens	  are	  generally	  presented	  on	  MHC	  class	  II	  molecules	  by	  
APCs	  (Chicz	  et	  al.,	  1992,	  Hunt	  et	  al.,	  1992).	  MHC	  class	  II	  molecules	  are	  synthesised	  in	  
the	  ER,	  but	  full	  functional	  maturation	  occurs	  in	  the	  endosomal	  vesicles,	  which	  contain	  
fragmented	   peptides	   (Villadangos,	   2001).	   It	   is	   noteworthy	   that	   exogenous	   peptides	  
need	   to	   compete	   for	  MHC	   class	   II	   binding	  with	   endogenous	   peptides	   present	   in	   the	  
endosomal/lysosomal	   compartments	   being	   trafficked	   to	   the	   lysosomes	   to	   be	  
degraded.	  Therefore,	  to	  ensure	  that	  exogenous	  peptides	  are	  presented,	  the	  MHC	  class	  
II	  molecules	  are	  designed	  to	  accommodate	  diverse	  lengths	  and	  sequences	  of	  peptides.	  
In	  this	  way,	  APCs	  present	  a	  huge	  variety	  of	  peptides,	  increasing	  the	  chance	  for	  one	  to	  
be	  detected	  by	  T	  cells	  (Villadangos,	  2001).	  Endogenous	  proteins	  get	  trafficked	  intro	  the	  
different	   cellular	   compartments	   explained	   in	   Section	   1.1.6.1.	   Vesicles	   of	   low	   pH	  
containing	   peptide	   fragments	   fuse	   with	   newly	   synthesised	   MHC	   class	   II-­‐containing	  
vesicles.	   Endogenous	   peptides	   can	   also	   be	   presented	   on	   MHC	   class	   II	   molecules	  
(Nuchtern	  et	  al.,	  1990).	  
	  
1.1.6.3. Mechanism	  of	  co-­‐stimulation	  
For	   an	   efficient	   immune	   response	   to	   be	  mounted	   APCs	   and	   T	   lymphocytes	   need	   to	  
receive	  two	  signals.	  The	  first	  signal	  is	  termed	  as	  antigen	  specific	  and	  is	  delivered	  by	  the	  
antigen	  itself	  when	  it	  binds	  to	  the	  receptor	  on	  the	  surface	  of	  the	  cell;	  TCR	  on	  T	  cells,	  
BCR	   on	   B	   cells.	   The	   second	   signal	   is	   termed	   as	   co-­‐stimulation,	   and	   is	   not	   antigen	  
CHAPTER	  1	  
	   19	  
specific.	  It	  is	  delivered	  by	  activated	  APCs	  to	  T	  cells,	  or	  by	  TH	  cells	  for	  the	  activation	  of	  
APCs	  (Huet	  et	  al.,	  1987,	  Schwartz,	  1990,	  Barr	  et	  al.,	  2006).	  The	  TCR	  must	  engage	  both	  
the	  presented	  peptide	  antigen	  and	  the	  co-­‐stimulatory	  molecules	  on	  the	  same	  APCs.	  In	  
the	   absence	   of	   either	   stimulus	   the	   naive	   T	   lymphocyte	   will	   enter	   a	   state	   of	   anergy	  
(Murphy	  et	  al.,	  2008).	  Co-­‐stimulation	   is	  crucial	   for	  an	  efficient	   immune	  response	  and	  
for	   tolerance	   of	   self-­‐antigens.	   There	   are	   multiple	   co-­‐stimulatory	   molecules	   and	   the	  
principal	  ones	  are	  illustrated	  in	  Figure	  1.2.	  	  
The	   TCR	   is	   composed	  of	   a	   complex	  of	  membrane	  proteins	   and	   is	   also	   known	  as	   the	  
TCR-­‐CD3	   complex.	   The	   TCR-­‐CD3	   complex	   is	   composed	   of	   the	   three	   CD3	   signalling	  
molecules,	  namely	  γε,	  δε,	  and	  ζζ	  and,	  ligand-­‐sensing	  subunits	  that	  determine	  affinity	  
for	   the	   antigens	   (Garboczi	   et	   al.,	   1996,	   Call	   et	   al.,	   2002).	   The	   TCR-­‐CD3	   complexes	  
cluster	  on	  the	  T	  cell	  surface	  in	  order	  to	  be	  in	  close	  proximity	  with	  the	  MHC	  molecules	  
on	   APC	   upon	   antigen	   presentation.	   Simultaneously,	   the	   co-­‐receptors	   CD4	   and	   CD8	  
bind	   to	   either	   MHC	   class	   II	   or	   MHC	   class	   I	   respectively,	   resulting	   in	   a	   stable	   MHC-­‐
antigen-­‐TCR	  structure	  (Maroun	  and	  Julius,	  1994).	  Furthermore,	  the	  adhesion	  molecule	  
(ICAM-­‐1)	   is	   another	   crucial	   molecule	   for	   the	   interaction	   of	   APCs	   and	   naive	   T	  
lymphocytes.	   Activated	   T	   cells	   binds	   to	   the	   adhesion	   molecule	   ICAM-­‐1	   that	   is	  
upregulated	  on	  activated	  APCs,	  through	  LFA-­‐1	  (Dustin	  and	  Springer,	  1989).	  
The	  most	  important	  co-­‐stimulatory	  molecules	  for	  the	  work	  conducted	  in	  this	  thesis	  are	  
CD40	   and	   its	   cognate	   ligand	   CD154.	   The	   cell	   surface	   molecule	   CD40	   is	   a	   48kDa	  
phosphorylated	   transmembrane	   glycoprotein	   (previously	   known	   as	   Bp50),	   first	  
identified	   in	   1985	   (Clark	   and	   Ledbetter,	   1986).	   CD40	   is	   a	   member	   of	   the	   tumour	  
necrosis	   factor	   receptor	   (TNF-­‐R)	   superfamily	   and	   is	   expressed	   by	   DCs,	  macrophages	  
and	   B	   cells.	   However,	   the	   CD40	   receptor	   is	   also	   expressed	   on	   hematopoietic	  
progenitors,	  endothelial	  cells	  and	  epithelial	  cells	  (van	  Kooten	  and	  Banchereau,	  2000).	  
The	  CD154	  (CD40L,	  gp39,	  T-­‐BAM	  or	  TRAP)	  molecule	  belonging	  to	  the	  TNF	  family,	  was	  
first	  discovered	   in	  1992	  by	  the	   Immunex	  group	   in	  Seattle	  and	   is	  mainly	  expressed	  on	  
activated	  CD4+	  T	  cells	   (Armitage	  et	  al.,	  1992).	  However,	   it	   is	  also	  expressed	  on	  other	  
cell	   types	   for	   example	   CD8+	   T	   cells,	   human	   basophils,	   mast	   cells	   and	   eosinophils	  
(Gauchat	   et	   al.,	   1993).	   CD4+	   T	   cells	   only	   upregulate	   their	   CD154	   expression	   after	  
antigen-­‐TCR	  ligation	  binding.	  CD154	  expression	  on	  activated	  T	  cells	  is	  tightly	  regulated	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and	  occurs	  in	  two	  phases.	  First,	  the	  CD4+	  T	  cells	  are	  activated	  within	  five	  minutes	  of	  the	  
interaction	   between	   CD40	   and	   their	   CD154	   ligand,	  which	   lasts	   for	   two	   hours	   and	   is	  
then	   down-­‐regulated.	   At	   this	   stage	   the	   second	   phase	   of	   expression	   occurs,	  were	  de	  
novo	   synthesis	   of	   the	   ligand	   is	   seen	   in	  CD4+	   T	   cells.	   This	   expression	  peaks	  within	   six	  
hours	   and	   is	   sustained	   for	  more	   than	   twenty	  hours	   (Casamayor-­‐Palleja	   et	   al.,	   1995).	  
Activated	  T	  cells	  do	  not	  only	  express	  cell-­‐membrane	  associated	  CD154	  but	  also	  soluble	  
forms	   of	   the	   ligand,	   which	   can	   also	   potentially	   bind	   to	   CD40,	   and	   deliver	   biological	  
signals	  (Graf	  et	  al.,	  1995).	  	  
Other	  APC	  co-­‐stimulatory	  molecules	  are	  CD80	  (B7-­‐1)	  and	  CD86	  (B7-­‐2),	  which	  belong	  to	  
the	  B7/CD28	  family	  and	  have	  a	  role	  in	  both	  T	  cell	  activation	  and	  inhibition.	  The	  two	  T	  
cell	  molecules,	  CD28	   (Linsley	  et	  al.,	   1991a)	  and	  CTLA-­‐4	   (Linsley	  et	  al.,	   1991b)	  bind	   to	  
the	  B7	  ligands.	  In	  contrast	  to	  CD28	  that	  is	  expressed	  on	  50%	  of	  the	  CD8+	  T	  cells	  and	  the	  
majority	  of	  CD4+	   T	   cells	   (Linsley	  et	   al.,	   1991a,	   Lenschow	  et	   al.,	   1996),	   CTLA-­‐4	   is	   only	  
expressed	   on	   activated	   CD4+	   T	   cells	   (Linsley	   et	   al.,	   1991b).	   CD28	   binding	   provides	  
positive	  signals	  and	  leads	  to	  T	  cell	  proliferation,	  cytokine	  production	  (in	  particular	  IL-­‐2)	  
and	  enhanced	  survival.	  In	  contrast,	  CTLA-­‐4	  binding	  dampens	  T	  cell-­‐responses	  in	  order	  
to	  guard	  against	  autoproliferative	  and	  autoimmune	  disease.	  In	  fact,	  CTLA-­‐4	  binds	  to	  B7	  
ligands	   with	   a	   higher	   affinity	   than	   CD28,	   and	   has	   a	   role	   in	   a	   negative	   feedback	  
mechanism	  by	  blocking	  CD28	  ligation,	  and	  limiting	  physical	  contact	  between	  APCs	  and	  
T	  cells	  (Linsley	  et	  al.,	  1991b,	  Linsley	  et	  al.,	  1991a,	  Rudd	  et	  al.,	  2009).	  
Other	  members	  of	  the	  B7	  family	  called	  programmed	  death	  (PD)-­‐L1	  (B7-­‐H1)	  and	  PD-­‐L2	  
(B7-­‐DC)	   also	   have	   a	   role	   in	   T	   cell	   fate	   by	   binding	   to	   the	   PD-­‐1	   expressed	   by	   T	   cells.	  
Whilst	  PD-­‐L2	  is	  only	  expressed	  by	  APCs,	  many	  different	  cell	  kinds	  express	  PD-­‐L1.	  Both	  
PD-­‐L2	  and	  PD-­‐L1	  binding	   to	  PD-­‐1	  block	  T	  cell	  proliferation	  by	   inhibiting	   the	  cell	   cycle	  
(Latchman	  et	  al.,	  2001).	  PD-­‐1	  is	  a	  powerful	  modulator	  in	  blocking	  T	  cell	  activation	  and	  
proliferation	   when	   the	   immune	   response	   is	   ineffective.	   The	   PD-­‐L1	   molecule	   is	   also	  
expressed	   by	   tumour	   cells	   (Dong	   et	   al.,	   2002).	   Agonistic	   antibodies	   against	   PD-­‐1	  
blocking	  the	  binding	  to	  PD-­‐L1,	  enhance	  T	  cell	  response	  against	  the	  tumour	  cells	  (Iwai	  et	  










Figure	  1.2.	  Cross-­‐talk	  between	  APCs	  and	  T	  cells	  illustrating	  the	  principal	  contributing	  
co-­‐stimulatory	   molecules.	   The	   first	   signal	   to	   the	   B	   cell	   is	   released	   on	   antigen	  
internalisation.	  The	  first	  signal	  to	  the	  T	  cell	  is	  released	  on	  TCR-­‐CD3	  complex	  recognition	  
of	   MHC-­‐peptide	   complex	   on	   APC.	   The	   second	   signal	   is	   released	   leading	   to	   T	   cell	  
proliferation	   once	   the	   CD154,	   CD28	   and	   LFA-­‐1	   on	   the	   T	   cell	   surface	   bind	   to	   CD40,	  
CD80/CD86	   and	   ICAM-­‐1	   (respectively)	   on	   the	   APC	   surface.	   T	   cell	   proliferation	   is	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1.1.7. CD40-­‐CD154	  co-­‐stimulatory	  pathway	  
The	  CD40-­‐CD154	  pathway	  is	  crucial	  for	  the	  generation	  of	  an	  effective	  adaptive	  immune	  
response.	   The	   importance	   of	   the	   CD40-­‐CD154	   interaction	   in	   T-­‐cell	   dependent	   B	   cell	  
responses	  has	  been	  demonstrated	  by	  a	  condition	  characterised	  by	  a	  mutation	   in	   the	  
CD154	   gene	   called	   X-­‐linked	   hyper	   IgM	   syndrome	   (H1GM1).	   The	   CD154	   impairment	  
leads	   to	   (i)	   autoimmunity,	   (ii)	  neutropenia,	   (iii)	  normal	  or	  elevated	   levels	  of	   IgM,	   (iv)	  
low	   or	   absent	   IgG,	   IgA	   and	   IgE,	   (v)	   normal	   numbers	   of	   recirculating	   B	   cells	   and	   (vi)	  
susceptibility	  to	  bacterial	  and	  opportunistic	  infections	  (Ramesh	  et	  al.,	  1994,	  Callard	  et	  
al.,	  1993).	  In	  other	  words,	  the	  immune	  response	  resulted	  in	  poor	  isotype-­‐switching	  and	  
no	  B	  cell	  memory.	  Similar	  phenotypes	  to	  patients	  with	  X-­‐linked	  hyper	   IgM	  syndrome	  
were	  observed	  in	  mice	  deficient	  of	  the	  CD154	  ligand	  (Xu	  et	  al.,	  1994).	  Mice	  immunised	  
with	  CD40	  monoclonal	  antibody	  (CD40mAb,	  rat	  IgG2a	  antibody)	  were	  able	  to	  enhance	  
primary	  antibody	  responses	  against	  the	  Fc	  part	  of	  the	  CD40mAb,	  enhance	  ex	  vivo	  T	  cell	  
proliferation	  to	  rat	  IgG2a	  and	  also	  delayed-­‐type	  hypersensitivity	  responses	  (Carlring	  et	  
al.,	  2004).	  	  
CD40	   ligation	  also	  plays	  a	   significant	   role	   in	   the	  CD8+	  CTL	   response.	  This	   can	  also	  be	  
observed	   in	  patients	  with	  X-­‐linked	  hyper-­‐IgM	   syndrome,	  who	  have	   an	   increased	   risk	  
for	   malignancies	   (particularly	   lymphomas)	   and	   carcinomas	   (Schneider,	   2000).	   In	  
addition,	  CD40-­‐deficient	  mice	  have	  an	  increased	  tumour	  susceptibility	  when	  compared	  
to	  healthy	  mice	  (Mackey	  et	  al.,	  1997).	  
	  
1.1.7.1. CD40	  function	  on	  B	  cells	  	  
CD40-­‐CD154	   engagement	   on	   B	   cells	   leads	   to	   activation,	   sustained	   antigen-­‐specific	   B	  
cell	   proliferation	   (Clark	   and	   Ledbetter,	   1986),	   affinity	   maturation,	   germinal	   centre	  
formation	   and	   progression	   (Foy	   et	   al.,	   1994),	   isotype	   switching	   as	   well	   as	   the	  
generation	   of	   memory	   B	   cells	   and	   plasma	   cells	   (Foy	   et	   al.,	   1994)	   which	   are	   the	  
characteristic	   hallmarks	   of	   the	   adaptive	   humoral	   immune	   response.	   CD40	   signalling	  
has	  an	  effect	  on	  each	  aforementioned	  stage	  of	  B	  cell	  development.	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The	  use	  of	  an	  agonistic	  murine	  anti-­‐CD40	  antibody	  directed	  against	  B	  cells	  showed	  that	  
the	  CD40	  signal	  leads	  to	  B	  cell	  activation.	  This	  is	  marked	  by	  upregulation	  of	  MHC	  II,	  co-­‐
stimulatory	   molecules	   such	   as,	   CD23	   and	   CD86	   as	   well	   as	   adhesion	   molecules	   like	  
ICAM-­‐1	  (Hasbold	  et	  al.,	  1994,	  Heath	  et	  al.,	  1994)	  and	  increase	  in	  cell	  volume	  (Vallé	  et	  
al.,	  1989).	  The	  use	  of	  human	  or	  murine	  CD40mAb	  also	  showed	  the	  importance	  of	  the	  
CD40	   signalling	   in	  B	   cell	   proliferation	   (Heath	  et	   al.,	   1994),	  which	   is	   enhanced	  by	   the	  
addition	  of	   IL-­‐4	  cytokines	   (Vallé	  et	  al.,	  1989).	   It	   is	  of	  great	   interest	   that	  amongst	   the	  
two	   clones	  of	  CD40mAb	   (1C10	  and	  4F11)	  used	   in	   a	   study	   conducted	  by	  Heath	  et	   al.	  
(1994),	   only	   1C10	   induced	   B	   cell	   proliferation.	   This	   suggested	   that	   the	   two	   mAbs	  
bound	   to	  different	   functional	  epitopes,	   and	  1C10	  bound	  epitopes	  within	   the	  binding	  
site	   of	   CD154	   which	   was	   confirmed	   by	   a	   later	   study	   (Barr	   and	   Heath,	   2001).	  
Furthermore,	  CD40mAb	  require	  co-­‐engagement	  of	  their	  Fc	  domain	  with	  the	  inhibitory	  
FcγRIIB	  receptor	  for	   immune	  co-­‐stimulatory	  and	  anti-­‐tumour	  activity	  (Li	  and	  Ravetch,	  
2011).	  The	   ligation	  of	  CD40	  by	  activated	  T	  cell	   inhibits	  programmed	  cell	  death	  (PCD).	  
PCD	  is	  a	  protective	  response	  that	  prevents	  B	  cell	  activation	  in	  response	  to	  TD	  antigens	  
in	  the	  absence	  of	  T	  cell	  help	  and	  sentences	  the	  cells	  to	  apoptotic	  death	  (Sarma	  et	  al.,	  
1995,	  Garrone	  et	  al.,	  1995).	  
CD40	   signalling	   plays	   a	   critical	   role	   in	   different	   stages	   of	   B	   cell	   differentiation.	   On	  
encounter	  of	  TD	  antigens,	  animal	  systems	  with	  defective	  CD40	  receptor	  or	  the	  CD154	  
receptor	   are	   not	   capable	   of	   forming	   germinal	   centres	   or	   producing	   class-­‐switched	  
antibodies	   after	   immunisation	   (Xu	   et	   al.,	   1994,	   Castigli	   et	   al.,	   1994,	   Kawabe	   et	   al.,	  
1994).	   In	  contrast	   there	  was	  no	  difference	   in	   the	   immune	  response	   to	  TI	  antigens	   in	  
the	  absence	  of	  CD40	  signalling,	  indicating	  the	  necessity	  of	  the	  CD40-­‐CD154	  interaction	  
in	  response	  to	  TD	  antigens	  for	  the	  differentiation	  into	  plasmablasts.	  	  
Even	   though	   antibody	   class	   switching	   is	   initiated	   by	   CD40-­‐CD154	   engagement,	  
cytokines	  have	  the	  main	  role	  in	  the	  determination	  of	  the	  specificity	  of	  the	  isotype.	  For	  
example,	   whilst	   the	   use	   of	   human	   recombinant	   CD154	   in	   vitro	   demonstrated	   B	   cell	  
proliferation	   and	   antibody	   secretion,	   IL-­‐2	   and	   IL-­‐10	   were	   specifically	   required	   to	  
enhance	  IgG1,	  IgA	  and	  IgM	  production,	  and	  IL-­‐4	  was	  required	  for	  the	  production	  of	  IgE	  
and	  IgG4	  (Armitage	  et	  al.,	  1993).	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B	   cells	   localised	   in	   the	   germinal	   centres	   differentiate	   into	   either	   antigen	   specific	  
antibody-­‐producing	   plasma	   cells	   or	   long-­‐lasting	   memory	   cells.	   CD40	   signal	   drives	  
differentiation	   of	   B	   cells	   into	   memory	   cells,	   but	   actively	   prevents	   formation	   of	  
antibody-­‐producing	   plasma	   cells	   (Arpin	   et	   al.,	   1995,	   Randall	   et	   al.,	   1998).	   However,	  
upon	   disruption	   of	   the	   CD40-­‐CD154	   interaction	   the	   antibody-­‐producing	   function	   is	  
retrieved	  (Randall	  et	  al.,	  1998).	  Randal	  et	  al.	  (1998)	  also	  show	  that	  the	  use	  of	  CD154-­‐
transfected	   cells	   inhibited	   B	   cell	   differentiation,	   however	   monoclonal	   or	   polyclonal	  
CD40	  antibodies	  did	  not,	  showing	  that	  the	  type	  of	  trigger	  of	  the	  CD40	  receptor	  has	  an	  
effect	  on	   the	  CD40	  signal	  produced.	  B	  cell	   fate	   is	  also	  determined	  by	   the	  amount	  of	  
CD154	  expressed	  on	  the	  CD4+	  T	  cell	  and	  therefore	  the	  strength	  of	  the	  CD40	  signal.	  The	  
use	  of	  transgenic	  mice	  showed	  that	  high	  CD154	  expression	  on	  activated	  T	  cells	  induced	  
higher	  antibody	  IgG	  titres	  of	  high	  affinity,	  compared	  to	  the	  wild	  type	  controls	  (Pérez-­‐
Melgosa	  et	  al.,	  1999).	  
	  
1.1.7.2. CD40	  function	  on	  DC	  
The	  initial	  studies	  carried	  out	  on	  the	  CD40-­‐CD154	  pathway	  were	  conducted	  on	  B	  cells,	  
and	   it	  was	  only	  after	  a	  decade	  of	   research	   that	  attention	  shifted	   towards	  other	  cells	  
expressing	  the	  CD40	  receptor,	   like	  DCs,	  due	  to	  their	   important	  function	  in	  linking	  the	  
innate	  and	  adaptive	  immune	  response.	  
The	  CD40	   signal	   leads	   to	  DC	  maturation	  by	  upregulation	  of	   accessory	  molecules	   like	  
CD54	  (ICAM-­‐1),	  CD58	  (LFA-­‐3),	  CD80,	  CD86	  and	  MHC	  class	   II	   (Caux	  et	  al.,	  1994).	  CD40	  
ligation	  also	  supports	  DC	  survival	   (Björck	  et	  al.,	  1997),	  and	  secretion	  of	  macrophage-­‐
inflammatory	   protein	   1-­‐α,	   TNF-­‐α	   IL-­‐1,	   IL-­‐6,	   IL-­‐8	   and	   IL-­‐12	   (Mutini	   et	   al.,	   1999).	   Even	  
though	   similar	   to	   B	   cells,	   CD40-­‐CD154	   engagement	   leads	   to	   DC	   activation,	   it	   is	  
noteworthy	  that	  different	  cell	  types	  respond	  in	  different	  ways	  to	  the	  CD40	  signal.	  For	  
example,	   high	   levels	   of	   IL-­‐12	  were	  produced	  by	   the	  DCs	   after	   stimulation	   via	   CD154	  
(Cella	  et	  al.,	  1996),	   therefore	   showing	   the	  ability	   to	   skew	  the	   immune	   response	   to	  a	  
TH1	   response.	   Therefore,	   CD40	   cross-­‐linking	   on	   DCs	   drives	   these	   cells	   to	   perform	  
functions	  that	  B	  cells	  are	  not	  able	  to	  do	  as	  efficiently.	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1.2. History	  of	  vaccine	  development	  
In	   the	  past	  century,	  vaccination	  has	  been	  a	  very	  useful	   tool	   to	   reduce	  morbidity	  and	  
mortality	   caused	  by	   infectious	   disease.	   Vaccination	   has	   led	   to	   the	   control	   of	   various	  
threatening	   diseases	   including	   tetanus,	   pertussis,	   yellow	   fever,	   diphtheria,	   measles,	  
mumps,	   rubella,	   rabies,	   typhoid	   and	   Haemophilus	   influenzae	   type	   b	   (Plotkin	   and	  
Plotkin,	  2008).	  Smallpox	  is	  the	  only	  human	  disease	  that	  has	  been	  certified	  eradicated	  
(Breman	  and	  Arita,	  1980,	  Fenner	  et	  al.,	  1988),	  however,	  poliomyelitis	  cases	  have	  fallen	  
by	  99%,	  and	  in	  2014	  the	  only	  countries	  that	  remain	  polio-­‐endemic	  are	  Nigeria,	  Pakistan	  
and	  Afghanistan	  (WHO,	  2014).	  
The	  first	  vaccine	  developed	  was	  for	  smallpox	  and	  this	  was	  produced	  by	  Edward	  Jenner	  
in	  1796	  (Jenner,	  1798).	  During	  Jenner’s	  time,	  pathogens	  were	  only	  thought	  to	  result	  as	  
a	   consequence	   of	   death,	   but	   not	   to	   cause	   it.	   It	  was	   almost	   100	   years	   after	   Jenner’s	  
discovery,	   in	   1876,	   that	   Robert	   Koch	  made	   the	   connection	   between	   pathogens	   and	  
disease	  due	  to	  his	   research	  on	  anthrax	  bacilli.	  This	   information	   led	  to	  the	  concept	  of	  
pathogens	   rendered	   non-­‐pathogenic	   as	   prophylactic	   vaccines,	   which	   are	   called	   live-­‐
attenuated	  vaccines	  today	  was	  postulated	  by	  Louis	  Pasteur	  in	  1881.	  He	  found	  that	  on	  
prolonged	  culture	  of	  Pasteurella	  multocida	  (Plotkin,	  2005)	  the	  cause	  of	  chicken	  cholera	  
in	  non-­‐human	  cells	  lose	  their	  pathogenicity	  in	  human	  cells.	  Pasteur	  hypothesized	  that	  
this	   loss	   in	   pathogenicity	   was	   due	   to	   environmental	   factors	   like	   high	   temperature,	  
chemicals	   and	   oxygen	   and	   described	   the	   vaccine	   as	   “live	   atmosphere-­‐attenuated”	  
(Pasteur,	   1880).	   He	   proved	   this	   hypothesis	   by	   his	   ensuing	   work	   on	   anthrax,	   and	  
developed	   an	   anthrax	   vaccine	   using	   a	   high	   temperature	   of	   42-­‐43°C	   (Pasteur,	   1881).	  
Pasteur	   developed	   the	   first	   therapeutic	   vaccine	   produced,	   using	   a	   new	   attenuation	  
method	  involving	  the	  use	  of	  chemically	  dried	  nervous	  tissue	  (Pasteur,	  1885).	  This	  was	  
developed	   for	   the	   simple	   reason	   that	   the	   attenuation	   technique	   used	   for	   cholera,	  
which	   is	   caused	  by	  bacteria,	  was	  not	   effective	   for	   rabies	   as	   it	   is	   a	   viral	   disease.	   This	  
vaccination	  strategy	  was	  used	  for	  ten	  years	  (Smith,	  2012).	  Between	  1930	  and	  1980	  a	  
number	  of	  live-­‐attenuated	  vaccines	  for	  viral	  diseases	  were	  developed	  because	  the	  cell	  
culture	  technique	  was	  optimised	  for	  viruses	  (Plotkin,	  2005).	  It	  is	  worth	  noting	  however,	  
that	  certain	  pathogens	  are	  difficult	  to	  culture	  in	  vitro	  and	  therefore	  alternative	  vaccine	  
strategies	  are	  required.	  For	  example	  it	  is	  only	  recently	  that	  the	  technique	  for	  hepatitis	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C	  (HCV)	  (Wakita	  et	  al.,	  2005)	  and	  human	  papilloma	  virus	  (HPV)	  (Aaltonen	  et	  al.,	  1998)	  
growth	   in	   culture	   have	   been	   developed	   and	   therefore,	   the	   use	   of	   a	   live-­‐attenuated	  
vaccine	  for	  these	  pathogens	  has	  not	  yet	  been	  evaluated.	  
Live-­‐attenuated	   vaccines	   administered	   by	   different	   routes	   (nasal,	   oral	   or	  
intramuscular)	  cause	  a	  long-­‐lasting	  and	  durable	  immune	  response	  similar	  to	  a	  natural	  
infection	   that	   leads	   to	   both	   humoral	   and	   cell-­‐mediated	   responses	   against	   the	  
pathogen	  without	   the	  need	   for	  multiple	  boosters.	   Some	  examples	  of	   live-­‐attenuated	  
vaccines	   include	   the	   Bacille	   Calmette-­‐Guérin	   (BCG)	   tuberculosis	   vaccine	   (Calmette,	  
1931),	  oral	  polio	  vaccine	   (OPV)	   (Sabin	  et	  al.,	  1954)	  as	  well	  as	   the	  measles	   (Schwartz,	  
1990),	   mumps	   (Hilleman	   et	   al.,	   1968)	   and	   rubella	   vaccines	   (Plotkin	   et	   al.,	   1969).	  
Despite	   all	   the	   advantages	   of	   live-­‐attenuated	   vaccines,	   they	   have	   the	   disadvantage	  
that	   the	   virus	  might	   revert	   to	   a	  more	   virulent	   strain,	   as	  was	   the	   case	  with	   the	  OPV	  
(Guillot	  et	  al.,	  1994)	  and	  the	  live	  flavivirus	  vaccines	  (Seligman	  and	  Gould,	  2004).	  Due	  to	  
the	   risk	   of	   disease,	   live-­‐attenuated	   vaccine	   administration	   is	   restricted	   to	   healthy	  
individuals.	  	  
The	  next	  breakthrough	  in	  vaccine	  development	  was	  the	  use	  of	  whole-­‐killed	  pathogen	  
based	  vaccines.	  The	  whole-­‐killed	  pathogens	  were	  killed	  through	  denaturation	  by	  heat	  
or	  by	  chemical	  treatment.	  The	  first	  whole-­‐killed	  vaccines	  developed	  were	  for	  typhoid	  
(Wright	   and	   Semple,	   1897)	   and	   cholera	   (Kolle,	   1896)	   in	   the	   1890s,	   followed	   by	   the	  
development	   of	   hepatitis	   A	   (Wiedermann	   et	   al.,	   1990,	   Iino	   et	   al.,	   1992),	   and	   the	  
inactivated	   polio	   (Salk	   type)	   vaccine	   (Salk,	   1955,	   Salk	   et	   al.,	   1981)	   in	   the	   twentieth	  
century.	   Toxoid	   vaccines	  made	   up	   of	   inactivated	   toxins,	  were	   also	   developed	   in	   the	  
1920s	  against	  extracellular	   toxins	  produced	  by	  bacteria	  as	   in	  the	  case	  diphtheria	  and	  
tetanus	   diseases	   (Plotkin,	   2005).	   Whole-­‐killed	   vaccines	   have	   inherent	   immune-­‐
potentiating	  properties	  due	   to	   the	  bacterial	  or	  viral	   components	  and	   impurities	   they	  
contain.	  However	  as	  they	  are	  incapable	  of	  replication,	  multiple	  large	  doses	  have	  to	  be	  
administered,	  leading	  to	  the	  problem	  of	  reactogenicity.	  	  
Over	   the	   years,	   vaccine	   design	   has	   been	   further	   refined,	   and	   the	   use	   of	   well-­‐
characterised	  antigens,	  rather	  than	  whole-­‐killed	  or	  attenuated	  pathogens,	  has	  gained	  
in	  popularity.	  Vaccines	  developed	  using	  only	  specific	  components	  from	  the	  pathogen,	  
are	   known	   as	   subunit	   vaccines	   and	   include	   (i)	   protein-­‐based	   vaccines	   such	   as	   HBV	  
vaccine	  (Dupont	  et	  al.,	  2006),	  (ii)	  polysaccharide-­‐based	  vaccines	  such	  as	  Haemophilus	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influenzae	  type	  b	  (Hib)	  vaccine	  (WHO.,	  2013)	  or	  (iii)	  peptide/T-­‐cell	  epitope	  based	  such	  
as	   malaria	   vaccines	   (Vreden	   et	   al.,	   1991)	   or	   cancer	   vaccine	   (Nestle	   et	   al.,	   1998)	  
respectively.	  The	  subunit	  vaccine	  approach,	  (i)	  significantly	  enhances	  vaccine	  safety,	  (ii)	  
improves	   lot-­‐to-­‐lot	   consistency,	   (iii)	   targets	   the	   immune	   response	   to	   particular	  
epitopes	  and	  (iv)	  allows	  non-­‐refrigerated	  storage	  and	  transport	  as	  the	  vaccines	  can	  be	  
freeze-­‐dried	  (Moyle	  and	  Toth,	  2013).	  The	  challenge	  with	  these	  vaccines	  is	  that	  they	  are	  
less	  immunogenic	  than	  traditional	  vaccines.	  In	  addition	  they	  need	  to	  achieve	  immunity	  
in	  an	  immunogenetically	  heterogeneous	  population.	  In	  the	  case	  of	  traditional	  vaccines	  
this	  is	  realised	  by	  the	  broad	  range	  of	  diverse	  epitopes	  of	  the	  pathogen	  in	  the	  vaccine.	  
On	  utilising	  better-­‐characterised	  subunit	  vaccines	  like	  synthetic	  peptide-­‐	  and	  epitope-­‐
based	   vaccines,	   the	   benefit	   of	   increased	   specificity	   towards	   the	   disease	   might	   not	  
always	  outweigh	  the	  cost.	  That	  is,	  that	  subunit	  vaccines	  might	  not	  induce	  a	  protective	  
vaccine-­‐associated	   immune	   response	   in	   every	   individual	   (Zepp,	   2010).	   The	   subunit	  
vaccine	   approach	   therefore	   requires	   the	   incorporation	   of	   immunostimulatory	  
components	  like	  adjuvants	  to	  shift	  the	  balance	  to	  a	  beneficial	  one.	  
	  
1.3. Overcoming	  limitations	  of	  Novel	  Vaccines	  
The	  slow	  progress	  in	  subunit	  vaccine	  development	  demonstrates	  that	  this	  is	  a	  difficult	  
process.	   However,	   some	   subunit	   vaccines	   for	   example	   Engerix-­‐B®	   (GlaxoSmithKline,	  
2012)	   and	   Recombivax®	   (Merck,	   2011b)	   targeting	   HBV	   as	   well	   as	   Cervarix-­‐B®	  
(GlaxoSmithKline,	  2011),	  and	  Gardasil®	  (Merck,	  2011a)	  targeting	  HPV	  are	   licensed	  for	  
human	  use,	   showing	   that	   this	   approach	   is	   not	   fruitless.	  However,	   it	   is	   interesting	   to	  
note	   that	   all	   aforementioned	   vaccines	   are	   based	   on	   virus-­‐like	   particles	   (VLP),	   which	  
due	   to	   their	   repetitive	   structures	   and	   size	   are	   more	   immunogenic	   compared	   to	  
peptides	  or	  soluble	  antigens.	  A	  substantial	  amount	  of	  effort	  has	  been	  directed	  against	  
diseases	  like,	  HIV	  and	  malaria	  (Rappuoli	  and	  Aderem,	  2011),	  but	  still	  no	  vaccines	  have	  
yet	  been	   licensed	   for	  human	  use	  against	   these	  diseases,	   because	  novel	   vaccines	   are	  
unable	  to	  develop	  a	  long-­‐lasting,	  sustained	  TH1	  response,	  which	  to	  date	  has	  only	  been	  
realised	  with	  live	  attenuated	  vaccines	  (Seder	  and	  Ahmed,	  2003).	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Vaccines	   against	   non-­‐infectious	   diseases	   like	   cancer	   are	   gaining	   in	   popularity.	  
However,	  while	  immunotherapies	  like	  rituximab	  have	  shown	  great	  success	  for	  decades	  
(Miller	   et	   al.,	   1982,	   Kwak	   et	   al.,	   1992),	  most	   cancer	   vaccines	   do	   not	   advance	   out	   of	  
Phase	   III	   clinical	   trials.	   In	  most	   cases	   this	   is	   due	   to	   the	   induction	   of	   ineffective	   anti-­‐
tumour	  cytotoxic	  responses.	  In	  fact	  the	  only	  two	  effective	  prophylactic	  cancer	  vaccines	  
include	  the	  HBV	  vaccine	  in	  prevention	  of	  HBV-­‐associated	  hepatocarcinoma	  (Lim	  et	  al.,	  
2009),	   and	   the	   HPV	   vaccine	   in	   prevention	   of	   HPV-­‐associated	   cervical	   carcinoma	  
(Wright	   et	   al.,	   2006).	   Not	   considering	   therapeutic	   immunotherapies	   involving	  
monoclonal	   antibody	   drugs	   like	   rituximab,	   the	   only	   therapeutic	   vaccine	   licensed	   for	  
human	   use	   is	   sipuleucel-­‐T	   (ProvengeTM,	   Dendreon),	   against	   advanced	   metastatic	  
prostate	  cancer	   (Higano	  et	  al.,	  2009).	  Dendreon’s	  ProvengeTM	   is	  a	   cell-­‐based	   therapy	  
that	  is	  time-­‐consuming	  and	  expensive	  to	  produce	  (Buonaguro	  et	  al.,	  2013).	  
For	  the	  unmet	  requirements	  of	  vaccines	  to	  be	  fulfilled	  three	  important	  factors	  need	  to	  
be	   considered	   (i)	   conjugation	   chemistry,	   (ii)	   the	   roles	   of,	   and	   (iii)	   the	  mechanism	   of	  
action	  of	  traditional	  and	  novel	  adjuvants	  in	  vaccine	  formulations.	  
	  
1.3.1. Refining	  vaccine	  formulations	  by	  bioconjugation	  
One	   feature	  of	  bioconjugation	   is	   to	   improve	   immunogenicity	  of	  antigens	  by	  covalent	  
coupling	  of	  the	  antigens	  with	  highly	  immunogenic	  foreign	  carrier	  molecules,	  a	  strategy	  
first	  adopted	  for	  Haemophilus	  influenzae	  type	  b	  (Hib)	  in	  the	  1980s	  (Schneerson	  et	  al.,	  
1980),	   using	   diphtheria	   toxoid	   as	   a	   carrier.	   The	   polysaccharide	   capsule	   found	   in	  
bacterial	   organisms	   like	   H.	   influenzae,	   leads	   to	   a	   T-­‐independent	   immune	   response	  
when	  administered	  alone.	  However,	   covalent	   coupling	  of	   the	  polysaccharide	   capsule	  
to	   highly	   immunogenic	   foreign	   carrier	   molecules	   alters	   the	   poor	   T-­‐independent	  
response	   to	  a	   strong	  T-­‐dependent	   immune	  response	   (Schneerson	  et	  al.,	  1980).	  Since	  
the	   1980s,	   advances	   in	   bioconjugation	   led	   to	   production	   of	   three	   other	   licensed	  
vaccines	  for	  this	  disease.	  These	  include	  the	  conjugation	  of	  the	  capsular	  polysaccharide	  
of	  Hib	  namely	  polyribosylribitol	  phosphate	  (PRP)	  to	  tetanus	  toxoid	  (PRP-­‐T)	  (Schneerson	  
et	  al.,	  1980,	  Schneerson	  et	  al.,	  1986),	  mutant	  non-­‐toxic	  diphtheria	  toxin	  CRM197	  (HbOC)	  
(Anderson,	  1983)	  or	  the	  outer	  membrane	  protein	  from	  a	  Neisseria	  meningitides	  group	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B	   strain	   (PRP-­‐OMP)	   (Vella	   et	   al.,	   1992).	   The	   four	   vaccines	   differed	   in	   the	   (i)	   type	   of	  
carrier	  protein,	   (ii)	   conjugation	  chemistry	  and	   (iii)	   size	  of	  PRP	  the	  carrier	  protein	  was	  
conjugated	  to.	  The	  vaccine	  composition	  affected	  the	  immunogenicity	  of	  each	  vaccine	  
all	   requiring	   different	   doses	   and	   frequency	   of	   doses	   to	   be	   effective.	   The	   PRP-­‐OMP	  
vaccine	  stimulates	  higher	  antibody	  production	  after	  two	  doses	  compared	  to	  the	  other	  
vaccines	   (Decker	   et	   al.,	   1992).	   In	   contrast,	   PRP-­‐T	   and	   HbOC	   vaccines	   are	   more	  
immunogenic	  after	   the	   third	  dose	   than	   the	  PRP-­‐OMP	  vaccine.	  Conjugation	  strategies	  
are	  getting	  more	  refined,	  causing	  vaccines	  deemed	  successful	   in	  the	  past,	  to	  become	  
obsolete.	   In	  fact,	   in	  spite	  of	   its	  success	   in	  the	  beginning,	  the	  vaccine	  using	  diphtheria	  
toxoid	  carrier,	  was	  recently	  removed	  from	  the	  market	  (WHO,	  2006).	  	  
The	   protein	   carriers	   CRM197	   or	   OMP,	   used	   for	   H.	   influenzae	   vaccines,	   have	   been	  
successful	  in	  enhancing	  the	  humoral	  immune	  response.	  CD8+	  T	  cell	  as	  well	  as	  antibody	  
responses	  are	  crucial	  anti-­‐tumour	  effectors	  that	  should	  be	  targeted	  by	  cancer	  vaccines.	  
This	   is	   the	   reason	   why	   keyhole	   limpet	   hemocyanin	   (KLH),	   a	   protein	   carrier	   of	   high	  
molecular	  mass	  obtained	  from	  the	  giant	  keyhole	   limpet	  Megathura	  crenulata	  marine	  
mollusc	  which	  has	   the	  ability	   to	   induce	  both	   types	  of	   immune	   responses	   (Harris	  and	  
Markl,	  1999),	  is	  the	  protein	  carrier	  of	  choice	  for	  cancer	  vaccines.	  Keeping	  this	  in	  mind,	  
the	  immunogenicity	  and	  efficacy	  of	  the	  vaccine	  does	  not	  just	  rely	  on	  the	  carrier	  protein	  
or	  adjuvant,	  the	  method	  of	  conjugation	  also	  plays	  a	  very	  significant	  role.	  The	  research	  
currently	  being	  conducted	  on	  therapeutic	  cancer	  vaccines	  against	  B	  cell	  lymphomas	  is	  
a	   recent	  example	  of	   the	   fact	   that	   the	  optimal	   conjugation	   strategy	   is	   the	  product	  of	  
exhaustive	  experimental	  validation.	  	  
Conjugation	   of	   KLH	   to	   specific	   peptides	   or	   antigens	   has	   shown	   promise	   in	   tumours	  
including	  metastatic	  breast	  cancer	  (Theratope®	  vaccine)	  (Miles	  et	  al.,	  2011,	  Ibrahim	  et	  
al.,	  2013)	  and	  lymphoma	  (Kwak	  et	  al.,	  1992,	  Bendandi	  et	  al.,	  1999,	  Betting	  et	  al.,	  2008,	  
Kafi	   et	   al.,	   2009).	   Malignant	   B	   cell	   lymphomas	   express	   a	   unique	   immunoglobulin	  
idiotype	  (Id),	  which	  when	  used	  alone	  is	  poorly	  immunogenic,	  and	  so	  it	  is	  conjugated	  to	  
KLH	  to	  enhance	  its	  immunogenicity.	  Conjugation	  of	  the	  lymphoma-­‐Id	  to	  KLH	  (KLH-­‐Id)	  is	  
traditionally	   performed	   using	   glutaraldehyde,	   and	   showed	   encouraging	   results	   in	  
murine	  models	   (Campbell	   et	   al.,	   1987,	   Kaminski	   et	   al.,	   1987,	   Campbell	   et	   al.,	   1988).	  
Successful	  Phase	  I/II	  clinical	  trials,	  led	  this	  vaccine	  to	  be	  investigated	  in	  three	  Phase	  III	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clinical	   trials	   in	  patients	  with	   follicular	   lymphoma	  (Levy	  et	  al.,	  2008,	  Freedman	  et	  al.,	  
2009,	  Schuster	  et	  al.,	  2009).	  One	  trial	  in	  which	  the	  vaccine	  was	  given	  only	  to	  patients	  
that	  had	  received	  cytotoxic	  chemotherapy	  showed	  statistically	   improved	  disease-­‐free	  
survival.	  The	  other	  two	  Phase	  III	  clinical	  trials	  failed	  to	  reach	  their	  primary	  endpoints.	  
Bendandi	  (2009)	  discussed	  that	  the	  failure	  of	  KLH-­‐Id	  vaccination	  could	  have	  been	  due	  
to	   the	   design	   of	   the	   clinical	   trials.	   However,	   Timmerman	   (2009)	   suggested	   that	  
alternative	  strategies,	  involving	  different	  conjugation	  techniques	  could	  be	  the	  ‘missing	  
link’	  required	  to	  improve	  the	  humoral	  and	  cell-­‐mediated	  immune	  responses	  necessary	  
to	  protect	  against	  tumours.	  	  
KLH	  was	   therefore	   conjugated	   to	   Id	   using	  maleimide	   coupling	   instead	   of	   traditional	  
methods	   using	   glutaraldehyde	   treatment.	   In	   a	   murine	   setting	   the	   novel	   method	  
showed	   increased	   efficacy	   when	   compared	   to	   glutaraldehyde	   conjugated	   vaccines	  
(Betting	   et	   al.,	   2008,	   Kafi	   et	   al.,	   2009).	   The	   authors	   proposed	   that	   this	   occurred	  
because	   the	   reaction	   is	   limited	   to	   reduced	   cysteine	   sulphydryl	   groups.	   Alternatively,	  
glutaraldehyde	   treatment	   causes	   extensive	   cross-­‐linking	   potentially	   destroying	  
valuable	  epitopes.	  Further	  refining	  of	  the	  lymphoma	  Id	  vaccine	  involved	  conjugation	  of	  
Id	   to	   the	   adjuvant	   CD40mAb	   that	   also	   demonstrated	   enhanced	  median	   and	   overall	  
survival	  in	  an	  A20	  murine	  model	  compared	  to	  the	  KLH-­‐Id	  lymphoma	  vaccines	  made	  by	  
traditional	  methods	  (Carlring	  et	  al.,	  2012).	  
	  
1.3.2. Adjuvants	  and	  their	  roles	  
An	   adjuvant	   can	   be	   described	   as	   any	   substance	   which,	   when	   administered	   with	   an	  
antigen,	  enhances	  or	  modifies	  the	  immune	  response	  to	  that	  antigen.	  The	  late	  Charles	  
Janeway	  Jr	  (Janeway,	  1989b)	  described	  adjuvants	  as	  ‘immunology’s	  dirty	  little	  secret’.	  
Adjuvants	   were	   described	   as	   ‘dirty’	   because	   the	   addition	   of	   crude	   extracts	   like	  
mycobacteria,	  aluminium	  hydroxide	  and	  mineral	  oil	  was	  required	  to	  allow	  the	  antigen	  
to	   be	   of	   sufficient	   immunogenicity.	   Other	   technologies	   for	   example	   live	   vector	  
technology	   (Galen	   et	   al.,	   2010,	   Wang	   et	   al.,	   2013)	   have	   been	   utilised	   instead	   of	  
adjuvants,	  however	  for	  the	  purpose	  of	  this	  thesis	  the	  focus	  will	  be	  on	  adjuvants.	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The	  most	  widely	  used	  adjuvants	  are	  aluminium	  salts	  or	  alum,	  which	  were	  discovered	  in	  
the	  early	  1920s	  by	  Glenny	  and	  colleagues	  whilst	  the	  group	  was	  investigating	  diphtheria	  
toxin	  (Glenny	  et	  al.,	  1923).	  They	  were	  the	  only	  adjuvants	  used	  in	  humans	  for	  80	  years.	  
It	  is	  only	  recently	  that	  other	  adjuvants	  have	  been	  introduced	  in	  vaccine	  formulations.	  
This	   slow	  development	   could	  be	  attributed	   to	   the	  empirical	   approach	  carried	  out	  by	  
researchers.	  In	  the	  mid-­‐1950s,	  Freund	  tested	  different	  parts	  of	  the	  mycobacterial	  cell	  
walls	  for	  adjuvant	  activity	  (Freund,	  1956)	  and	  this	  is	  how	  Freund’s	  complete	  adjuvant	  
(FCA),	  which	  is	  a	  mixture	  of	  inactivated	  bacteria	  and	  mineral	  oil,	  was	  identified.	  FCA	  is	  
very	   potent	   and	   used	   in	   animal	   models,	   however	   it	   causes	   serious	   side-­‐effects	   like	  
pain,	  swelling	  and	  fever,	  due	  to	   its	  reactogenicity	  and	   is	   therefore	  considered	  unsafe	  
for	  use	  in	  humans.	  Smaller	  bacterial	  cell	  wall	  compounds	  were	  subsequently	  made	  for	  
example	  muramyl	  dipeptide	  (MDP)	  (Ellouz	  et	  al.,	  1974).	  Lipopolysaccharide	  (LPS)	  was	  
found	   to	   be	   an	   adjuvant	   with	   potent	   activity,	   but	   because	   of	   its	   toxicity	   it	   was	  
dismissed	  for	  use	  as	  a	  vaccine	  adjuvant	  (Johnson	  et	  al.,	  1956).	  The	  cause	  of	  the	  toxicity	  
and	  adjuvant	  properties	  was	   the	   lipid	  A	  portion	  of	   LPS	   (Galanos	  et	  al.,	   1985,	  Takada	  
and	   Kotani,	   1989).	   However,	   on	   removal	   of	   a	   residue	   from	   the	   phosphate	   group	  
residing	  in	  the	  lipid	  A	  portion	  of	  LPS,	  the	  molecule	  became	  100-­‐to	  1000-­‐fold	  less	  toxic	  
without	  losing	  its	  adjuvant	  properties	  (Takayama	  et	  al.,	  1981,	  Takayama	  et	  al.,	  1984).	  
This	  derivative	  was	  later	  further	  refined	  and	  was	  called	  monophosphoryl	  lipid	  A	  (MPL)	  
(Myers	  et	  al.,	  1990),	  which	  is	  one	  of	  the	  most	  successful	  adjuvants	  recently	  licensed	  for	  
human	  use.	  
In	   the	   past	   the	   antibody	   responses	   were	   considered	   the	   predominant	   means	   to	  
develop	  an	  immune	  response,	  and	  in	  fact	  vaccination	  successes	  were	  mediated	  by	  the	  
production	  of	  protective	  antibodies	  (Plotkin,	  2010).	  Diseases	  like	  cancer	  also	  require	  a	  
cell-­‐mediated	   response	   to	   achieve	   an	   effective	   vaccine-­‐mediated	   immune	   response	  
against	   the	   inoculated	   antigen.	   Therefore,	   traditional	   adjuvants	   like	   alum	   are	   not	  
useful	  as	  they	  preferentially	  promote	  an	  antibody-­‐based	  immune	  response	  (Brewer	  et	  
al.,	  1999).	  Furthermore,	  cells	  of	  the	  innate	  immune	  response	  that	  behave	  as	  vessels	  by	  
which	  the	  pathogenic	  or	  dangerous	  self-­‐antigens	  like	  tumour	  antigens	  get	  transported	  
to	  the	  secondary	  lymphoid	  organs	  need	  to	  be	  targeted	  and	  activated.	  	  In	  fact,	  a	  reason	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behind	   ineffective	   cancer	   vaccines	   in	   the	   past	   decade	   is	   the	   lack	   of	   a	   DC-­‐activating	  
adjuvant.	  	  
Peptides	   immunised	   alone	   tend	   to	   be	   cleared	   by	   the	   immune	   system	  prior	   to	   being	  
internalised	  or	   loaded	  onto	  DCs.	   In	  addition,	   targeting	  DCs	   is	  not	  enough,	  because	   if	  
DCs	  are	  not	  activated,	  peptide-­‐loaded	  DCs	  will	  remain	   in	  a	  steady	  state	  and	  promote	  
tolerance	   (De	   Vries	   et	   al.,	   2003a,	   De	   Vries	   et	   al.,	   2003b,	   Lesterhuis	   et	   al.,	   2011,	  
Kastenmüller	   et	   al.,	   2014).	   The	   immune	   stimulant	   IL-­‐2	  was	   recently	   co-­‐administered	  
with	  a	  short	  peptide	   in	  advanced	  melanoma	  patients,	  and	  resulted	   in	  enhanced	  anti-­‐
tumour	   responses	   and	   prolonged	   tumour	   progression-­‐free	   survival	   in	   certain	  
conditions	  when	  compared	  with	  the	  use	  of	  IL-­‐2	  alone	  (Schwartzentruber	  et	  al.,	  2011).	  	  
The	  use	  of	  peptide	  vaccines	  has	  potential	  in	  improving	  therapeutic	  efficiency	  if	  applied	  
in	   the	   right	   way.	   This	   is	   the	   reason	   why	   novel	   adjuvant	   development	   is	   no	   longer	  
empirical.	  In	  fact,	  novel	  vaccine	  formulations	  include	  adjuvants	  with	  particular	  roles	  to	  
achieve	  the	  appropriate	  vaccine-­‐mediated	   immune	  response	  against	  vaccine	  antigen.	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Adjuvant	  Role	   	   	   Example	   Reference	  
To	  enhance	  effector	  T	  
cell	  responses	  
MPL:	  
Enhanced	   TH1	   response	   when	   co-­‐delivered	   with	  
hepatitis	  B	  virus	  core	  antigen	  in	  PLGA	  nanoparticle	  
compared	  to	  non-­‐adjuvanted	  vaccine	  
(Chong	  et	  al.,	  
2005)	  
To	  enhance	  duration	  
of	  response	  –	  	  
induce	  generation	  of	  
memory	  cells	  
AS04	  adjuvant:	  
Generated	   protective	   memory	   CD8+	   T	   cell	  
responses	  against	  influenza	  A	  challenge	  
(MacLeod	  et	  
al.,	  2011)	  
To	  enhance	  rapidity	  of	  
immune	  response	  	  
AS04	  adjuvant:	  
Reduced	   dose-­‐regimen	   from	   3	   doses	   to	   2	   in	  
combination	  with	  recombinant	  hepatitis	  B	  antigen	  
(Levie	  et	  al.,	  
2002)	  
To	  broaden	  the	  
immune	  response	  
TLR4	  and	  TLR7	  encapsulated	  in	  synthetic	  
nanoparticles:	  
Displayed	   higher	   neutralisation	   titres	   as	   well	   as	  
antibodies	  with	  high	  avidity	  to	  the	  vaccine-­‐antigen	  
compared	  to	  in	  the	  absence	  of	  the	  nanoparticles	  
(Kasturi	  et	  al.,	  
2011)	  




Higher	   numbers	   of	   activated	   antigen-­‐presenting	  
DCs	   in	   the	   draining	   LN	   were	   observed	   after	  
injection	  with	   AS01-­‐adjuvanted	   vaccine	   compared	  
to	  injection	  with	  antigen	  alone	  	  
(Didierlaurent	  
et	  al.,	  2014)	  
Antigen	  dose-­‐sparing	   CAF01	  (composed	  of	  cationic	  liposomes):	  
Allowed	  for	  a	  10	  times	  dose	  sparing	  when	  used	  in	  
formulation	  with	  IPV	  
(Dietrich	  et	  
al.,	  2014)	  
Table	  1.2.	  Roles	  of	  adjuvants.	  	  
PLGA	  =	   Poly(d,l-­‐lactic-­‐co-­‐glycolic	   acid)	   polymer,	  AS04	  =	   adjuvant	   system	   containing	  MPL	   and	  
alum,	  AS01	  =	  adjuvant	  system	  containing	  Quillaja	  saponaria	  (QS)-­‐21,	  MPL	  and	  liposomes.	  
	  
Due	   to	   the	   knowledge	   of	   the	   importance	   of	   DCs	   in	   the	   immune	   response	   and	   their	  
effect	  on	  T	  cell	  responses,	  current	  vaccines	  are	  now	  designed	  differently.	  In	  fact	  early	  
stage	   trials	   have	   been	   investigating	   the	   targeting	   of	   DC	   receptors	   like	   DEC-­‐205	   by	  
monoclonal	   antibodies	   coupled	   to	   peptides	   in	   the	   presence	   of	   adjuvants.	   In	   a	   study	  
comparing	   receptor	   targeting	   of	   DEC205,	   CD11c,	   mannose	   receptor	   1	   and	   CD40	  
molecule	  using	  LPS	  as	  an	  adjuvant,	  targeting	  of	  the	  CD40	  molecule	   led	  to	  best	  cross-­‐
presentation	  to	  CD8+	  T	  cells	  (Chatterjee	  et	  al.,	  2012).	  Other	  receptors	  on	  DCs	  that	  have	  
been	  targeted	  extensively	  are	  the	  TLRs	   (Cho	  et	  al.,	  2000).	  One	  reason	  for	   this	   is	   that	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TLRs	   recognise	   specific	   pathogen	   sequences	   and	   sequentially	   tailor	   the	   immune	  
response	  according	  to	  the	  invading	  pathogen.	  	  
Novel	  adjuvants	   like	  TLR-­‐agonists	  and	  vaccine	  antigens	  were	   later	  conjugated	  aiming	  
to	  co-­‐deliver	  the	  adjuvant	  and	  the	  vaccine	  antigen	  to	  the	  same	  APC,	  and	  reducing	  side-­‐
effects	   like	   induction	   of	   tolerance,	   autoimmune	   responses	   or	   undesired	   cytokine	  
release.	  The	  success	  of	  conjugation	  of	  a	  TLR-­‐agonist	  adjuvant	  to	  a	  vaccine	  antigen	  was	  
first	   demonstrated	  with	   the	  use	  of	   TLR9-­‐agonist	   CpG	   linked	   to	   ovalbumin	   antigen	   in	  
mouse	  studies	  (Cho	  et	  al.,	  2000),	  which	  demonstrated	  CD8+	  T	  cell	  activity	  and	  TH1-­‐bias,	  
compared	  to	  a	  vaccine	  consisting	  of	  the	  uncoupled	  counterparts.	   It	   is	  worthy	  to	  note	  
that	   B	   cells	   also	   express	   TLRs,	   which	   means	   that	   TLR-­‐agonists	   could	   also	   be	   acting	  
directly	  on	  B	  cells	  especially	  if	  conjugated	  to	  antigen	  (Shirota	  et	  al.,	  2002).	  The	  work	  in	  
our	   group	   in	   fact	   aims	   to	   target	   CD40	   molecules	   on	   APCs	   by	   coupling	   of	   agonistic	  
monoclonal	  antibodies	  to	  the	  vaccine	  peptides	  or	  antigen	  (Barr	  et	  al.,	  2003,	  Hatzifoti	  
and	  Heath,	  2007,	  Carlring	  et	  al.,	  2012).	  	  
Several	  vaccine	  conjugates	  of	  TLR-­‐agonists	  with	  vaccine	  antigens	  were	  tested	  in	  vivo	  in	  
mice	  in	  the	  context	  of	  different	  disease	  settings	  like	  tumour,	  allergy	  and	  infection	  (Cho	  
et	  al.,	  2000,	  Tighe	  et	  al.,	  2000,	  Jackson	  et	  al.,	  2004).	  All	  conjugates	  produced	  a	  stronger	  
immune	   response	   than	   the	  mixtures	   of	   the	   vaccine	   antigen	   and	   adjuvant.	   However,	  
only	  one	  of	  these	  thus	  far	  proceeded	  to	  studies	   in	  non-­‐human	  primates	  (Wille-­‐Reece	  
et	  al.,	  2005).	  
	  
1.3.3. Mode	  of	  action	  of	  traditional	  and	  novel	  adjuvants	  
Novel	   and	   traditional	   adjuvants	   can	   be	   broadly	   classed	   in	   three	   groups	   according	   to	  
their	   mode	   of	   action	   namely	   (i)	   immunopotentiators	   -­‐	   direct	   activation	   of	   certain	  
receptors	   of	   the	   innate	   immune	   system	   (for	   example	   TLR-­‐agonists),	   (ii)	   delivery	  
systems	  -­‐	  delivery	  of	  antigen	  of	   interest	   leading	  to	  enhanced	  antigen	  presentation	  to	  
the	  immune	  system	  (for	  example	  emulsions),	  or	  (iii)	  a	  combination	  of	  both	  (i)	  and	  (ii)	  
(for	  example	  adjuvant	  system	  04	  or	  AS04)	  (Reed	  et	  al.,	  2013).	  	  
Alum	  adjuvants	  are	  the	  most	  widely	  used	  and	  are	  incorporated	  in	  tetanus,	  diphtheria,	  
pertussis,	   HAV	   and	   HBV	   vaccines	   (Leroux-­‐Roels,	   2010).	   However,	   alum	   adjuvants	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preferentially	   induce	   a	   TH2	   response,	   and	   has	   minimal	   or	   no	   effect	   on	   TH1	   and	  
cytotoxic	   cell	   responses	   (Grun	  and	  Maurer,	   1989,	  Brewer	  et	   al.,	   1996,	  Brewer	  et	   al.,	  
1999).	   Despite	   the	   years	   of	   research	   only	   a	   few	   adjuvants	   have	   been	   licensed	   for	  
human	  use	  in	  Europe	  and/or	  the	  US.	  	  These	  include	  oil-­‐in-­‐water	  emulsions;	  MF59	  and	  
AS03	   (Vesikari	   et	   al.,	   2009,	   Andrews	   et	   al.,	   2011),	   AS04	   (MPL	   co-­‐administered	   with	  
alum)	   (Levie	  et	  al.,	  2002)	  and	  virosomes	   (Moser	  et	  al.,	  2007,	  Bovier,	  2008,	  Herzog	  et	  
al.,	  2009).	  The	  previously	  mentioned	   licensed	  adjuvants	  as	  well	  as	  some	  examples	  of	  
other	  adjuvants	  in	  pre-­‐clinical	  and	  clinical	  development	  are	  listed	  in	  Table	  1.3.	  
The	   putative	   mode	   of	   action	   of	   mounting	   an	   adjuvant-­‐mediated	   immune	   response	  
requires	   activation	   of	   TH	   cells	   with	   the	   help	   of	   components	   of	   the	   innate	   immune	  
response.	  Four	  signals	  are	  required	  to	  mount	  an	  immune	  response;	  signal	  0	  -­‐	  activation	  
of	  innate	  immune	  cell	  by	  for	  example	  TLR	  stimulation,	  signal	  1	  -­‐	  antigen-­‐presentation,	  
signal	   2	   -­‐	   co-­‐stimulation	   and	   signal	   3	   -­‐	   immune	   modulation	   by	   cytokine	   release	  
(Janeway,	  1989a).	  This	  is	  another	  way	  to	  classify	  adjuvants.	  	  
Understanding	  which	  of	  these	  signals	  adjuvants	  provide	  or	  enhance	  will	  give	  a	  better	  
way	   to	   cleverly	   tailor	   vaccines	   to	   mount	   a	   specific	   immune	   responses	   and	   target	  
particular	  pathways.	  Some	  examples	  are	  illustrated	  in	  Figure	  1.3.	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Lipid	  A	  analogues	  	  
(MPL*)	  





Allergy	   (Richards	  et	  al.,	  
1998,	  Ismaili	  et	  al.,	  
2002,	  Johansen	  et	  
al.,	  2003,	  Baldrick	  
et	  al.,	  2007)	  
Imidazoquinolines	  	  
(imiquimod*)	  
TLR7	  and	  TLR8	   Ab,	  TH1,	  CD8+	  
T	  cells	  (when	  
conjugated)	  
AldaraTM	   HPV,	  HIV	  
(pre-­‐
clinical)	  
(Owens	  et	  al.,	  
1998,	  Wenzel	  et	  
al.,	  2005,	  Wille-­‐
Reece	  et	  al.,	  2005)	  








HBV	   (Shirota	  et	  al.,	  
2000,	  Miconnet	  et	  
al.,	  2002,	  Shirota	  
et	  al.,	  2002,	  Eng	  et	  
al.,	  2013)	  
Particulate	  formulation	  or	  delivery	  systems	  










(Vesikari	  et	  al.,	  
2009,	  Andrews	  et	  
al.,	  2011,	  Moris	  et	  
al.,	  2011,	  Calabro	  
et	  al.,	  2011)	  









(Grun	  and	  Maurer,	  
1989,	  Brewer	  et	  
al.,	  1996,	  Brewer	  
et	  al.,	  1999,	  
Leroux-­‐Roels,	  
2010,	  Kool	  et	  al.,	  
2008)	  	  
Virosomes	   Antigen	  
delivery	  




(Bungener	  et	  al.,	  
2002,	  Bovier,	  
2008,	  Herzog	  et	  
al.,	  2009)	  
Adjuvant	  systems	  (a	  combination	  of	  immunopotentiators	  and	  particulate	  formulation)	  
AS01	  contains	  	  
QS21,	   MPL,	  
liposomes	  





Malaria	   (Agnandji	  et	  al.,	  





aluminium	   salt,	  
MPL	  





HPV,	  HBV	   (Levie	  et	  al.,	  2002,	  




Table	  1.3	  Licensed	  and	  late-­‐stage	  tested	  adjuvants	  classified	  as	  immunopotentiators,	  
particulate	  formulations	  or	  delivery	  systems,	  or	  adjuvant	  systems	  	  
*licensed	  for	  human	  use.	  ODN	  -­‐	  oligodeoxynucleotides	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Figure	   1.3.	   Mechanisms	   of	   action	   of	   adjuvants.	   Signal	   0	   and	   signal	   1	   are	   signals	   to	   APCs.	  
Signals	  1,	  2	  and	  3	  are	  signals	  to	  T	  cells.	  Adapted	  by	  permission	  from	  Macmillan	  Publishers	  Ltd:	  
Nature	  (Reed	  et	  al.,	  2013),	  copyright	  2013.	  
Immunopotentiators	   or	   immunodulatory	   molecules	   directly	   activate	   APCs	   by	   means	   of	  
surface	  receptors.	  This	  could	  occur	  via	  mimicking	  a	  PAMP	  recognised	  by	  a	  pattern	  recognition	  
receptor	  (PRR)	  such	  as	  a	  TLR	  on	  the	  APC.	  Recognition	  leads	  to	  the	  release	  of	  so-­‐called	  ‘danger	  
signals’	   which	   the	   immune	   system	   can	   quickly	   respond	   to.	   Examples	   of	   these	   include	   TLR-­‐
agonists	   like	   MPL,	   Immunostimulatory	   sequences	   (ISS)	   of	   microbial	   DNA	   (CpG-­‐rich	   motifs),	  
Imidazoquinolines	  and	  heat	  shock	  proteins.	  Otherwise,	  co-­‐stimulatory	  agonists	   like	  CD40mAb	  
target	  co-­‐stimulatory	  molecules.	  Immunodulatory	  molecules	  also	  activate	  the	  inflammasome	  
complex	  via	  NLRP3	  protein	  for	  example	  aluminium	  salts.	  
Delivery	   systems	   recruit	   immune	   cells	   and	   target	   antigen	  presentation	   via	  MHC	   to	   the	   TCR.	  
Examples	   include	  aluminium	  hydroxide,	   liposomes	  and	  oil	  emulsions.	  Delivery	   systems	  could	  
also	  direct	  the	  adjuvant	  and	  the	  vaccine	  antigen	  to	  the	  same	  cell.	  Examples	  include	  some	  TLR-­‐
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1.3.3.1. Delivery	  systems	  
The	   purpose	   of	   delivery	   systems,	   as	   their	   name	   suggests,	   is	   to	   deliver	   the	   vaccine	  
antigen,	   immunomodulatory	   molecule	   or	   both	   to	   the	   APC.	   This	   class	   of	   adjuvants	  
normally	  enhance	  persistence	  of	  vaccine	  antigen	  at	   the	  site	  of	  vaccine	   inoculation,	  a	  
theory	  coined	  by	  Glenny	  and	  his	  colleague	  in	  the	  1920s,	  known	  as	  depot	  formulation	  
(Glenny	   and	   Pope,	   1925).	   Furthermore,	   due	   to	   the	   fact	   that	   these	   adjuvants	   are	   in	  
particulate	  form,	  they	  enhance	  APC	  uptake	  leading	  to	  enhanced	  presentation	  by	  these	  
cells	  (Ott	  et	  al.,	  1995,	  Dupuis	  et	  al.,	  1998,	  Calabro	  et	  al.,	  2011),	  and	  thus	  prolong	  signal	  
1.	  An	  example	  of	  a	  delivery	  system	  adjuvant	  licensed	  for	  use	  is	  the	  influenza	  vaccine,	  
InflexalTM,	   introduced	   in	   the	   Swiss	  market	   in	  1997	   (Crucell,	   http://www.crucell.com).	  
Virosomes	   (approximately	   150nm	   in	   diameter)	   are	   able	   to	   induce	   B	   and	   T	   cell	  
responses	   as	   they	  present	   vaccine	   antigen	   in	   the	   context	   of	   both	  MHC	   class	   I	   and	   II	  
(Bungener	   et	   al.,	   2002).	   The	   adjuvant	   function	   of	   this	   vaccine	   is	   mediated	   via	   the	  
haemagglutinin	   portion	   of	   the	   envelope	   binding	   to	   the	   cell	   receptors	   leading	   to	   pH-­‐
dependent	  fusion	  and	  stimulation	  of	  the	  cell	  (Wilschut,	  2009).	  Another	  delivery-­‐based	  
adjuvant	  licensed	  for	  human	  use	  is	  the	  oil-­‐in-­‐water	  emulsion	  MF59,	  used	  in	  the	  vaccine	  
FluadTM	  (also	  an	  influenza	  vaccine).	  This	  adjuvant	  has	  been	  found	  efficacious	  and	  safe	  
even	  in	  young	  children	  (Vesikari	  et	  al.,	  2009).	  It	  has	  been	  compared	  to	  alum,	  and	  is	  a	  
more	  effective	  adjuvant,	  as	   it	   (i)	   induces	  more	  potent	  antibody	   responses,	   (ii)	  allows	  
antigen	   dose-­‐sparing	   and	   fewer	   immunisations,	   (iii)	   generates	  memory	   cells	   and	   (iv)	  
drives	  the	  immune	  response	  to	  a	  mixed	  TH1	  and	  TH2	  phenotype	  (Ott	  et	  al.,	  1995).	  This	  
increased	  efficacy	  could	  be	  due	  to	  the	  fact	  that	  MF59	  has	  a	  direct	  effect	  on	   immune	  
cells	   and	   promotes	   recruitment	   of	   granulocytes,	   DCs,	   as	   well	   as	   differentiation	   of	  
monocytes	  into	  DCs	  (Seubert	  et	  al.,	  2008,	  Calabro	  et	  al.,	  2011),	  in	  addition	  to	  enhanced	  
antigen	  uptake	  by	  DCs	  (Dupuis	  et	  al.,	  1998).	  
Alum	   is	   still	   one	   of	   the	   commonly	   used	   adjuvants	   in	   humans.	   This	   adjuvant	   has	   a	  
delivery	   role,	   due	   to	   its	   particulate	   nature.	   Alum	   adjuvant	   is	   made	   up	   of	   vaccine	  
antigen	   adsorbed	   to	   precipitates	   of	   aluminium	   phosphate	   or	   aluminium	   hydroxide	  
(Glenny	  et	  al.,	  1923,	  Glenny	  and	  Pope,	  1925).	  Alum	  induces	  antibody	  responses	  in	  the	  
absence	  of	  TLR-­‐signalling	  (Gavin	  et	  al.,	  2006),	  and	  enhances	  the	  TH2	  pathway	  (Brewer	  
et	  al.,	  1999).	  For	  years,	  alum	  was	   thought	   to	   just	  create	  a	  depot	  effect	  and	  enhance	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uptake	   by	   APCs.	   However,	   it	   is	   now	   known	   that	   antigen	   depot	   is	   not	   required	   for	  
adjuvanticity	  (Hutchison	  et	  al.,	  2012).	  It	  is	  apparent	  that	  alum	  is	  able	  to	  recruit	  immune	  
cells	  to	  the	  site	  of	  infection	  (Calabro	  et	  al.,	  2011)	  and	  stimulate	  the	  cells	  of	  the	  immune	  
response,	  leading	  to	  enhanced	  antigen-­‐presentation	  (Ghimire	  et	  al.,	  2012).	  The	  NLRP3	  
inflammasome,	  has	  been	  shown	   to	  have	  a	   role	   in	   this	  mechanism	   (Kool	  et	  al.,	   2008,	  
Franchi	  and	  Núñez,	  2008,	  Wang	  et	  al.,	  2012).	  Alum	  might	  be	  inducing	  antigen	  uptake	  
after	  interaction	  with	  DCs	  by	  means	  of	  cell	  membrane	  lipid	  reordering.	  However,	  alum	  
is	  not	  taken	  up	  by	  the	  DCs	  (Flach	  et	  al.,	  2011).	  Studies	  show	  that	  alum	  induces	  danger	  
signals	  via	  necrotic	  cell	  DNA	  release	  (Marichal	  et	  al.,	  2011),	  uric	  acid	  production	  (Kool	  
et	  al.,	  2008)	  or	  heat	  shock	  protein	  70	  (Wang	  et	  al.,	  2012).	  Franchi	  et	  al.	  (2008)	  shows	  in	  
NLRP3	  deficient	  mice	  that	  the	  IgG	  antibody	  response	  is	  still	  enhanced	  in	  the	  presence	  
of	  alum	  adjuvant.	  This	  demonstrates	  that	  the	  NLRP3	  inflammasome	  has	  a	  role	  and	   is	  
not	  indispensible	  for	  the	  IgG	  adjuvant	  activity.	  	  
	  
1.3.3.2. Immunomodulatory	  molecules	  
The	  immunopotentiators	  encompass	  a	  broad	  class	  of	  adjuvants,	  for	  example	  saponins	  
like	  QS-­‐21	   (mechanism	  unknown)	   (Skene	  and	  Sutton,	  2006),	   co-­‐stimulatory	  molecule	  
agonists	  (CD40mAb)	  as	  well	  as	  ligands	  of	  the	  innate	  immune	  response	  including	  NLRs,	  
C-­‐type	  lectins,	  TLRs	  and	  RIG-­‐I-­‐like	  receptors	  (Maisonneuve	  et	  al.,	  2014).	  As	  illustrated	  
in	   Figure	   1.3,	   immunomodulatory	  molecules	   have	   a	   direct	   effect	   on	   APCs	   (signal	   0).	  
There	   are	  many	   immunomodulatory	  molecule-­‐based	   adjuvants	   that	   are	   licensed	   for	  
human	  use	  or	  have	  proceeded	  to	  late-­‐stage	  clinical	  trials	  (Table	  1.3).	  One	  of	  these	  has	  
recently	  completed	  Phase	  III	  clinical	  trial	  is	  the	  TLR-­‐agonist	  (TLR-­‐9)	  CPG	  ODN	  used	  in	  a	  
HBV	   vaccine	   (HepislavTM)	   (Eng	  et	   al.,	   2013).	  Another	   TLR-­‐agonist,	   based	  on	   the	   TLR4	  
ligand,	  MPL	  is	  currently	  tested	  in	  multiple	  clinical	  trials	  for	  different	  applications,	  and	  is	  
used	   in	   two	   licensed	   vaccines	   CervarixTM	   (Didierlaurent	   et	   al.,	   2009)	   and	   FendrixTM	  
(Kundi,	   2007,	   Didierlaurent	   et	   al.,	   2009)	   together	   in	   a	   formulation	   with	   alum.	   The	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1.3.3.3. Combination	  systems	  
Most	  novel	  vaccines	  contain	  a	  combination	  of	  delivery	  as	  well	  as	   immunostimulatory	  
adjuvants.	   In	  fact,	  certain	  adjuvants	  are	  physically	  adsorbed	  or	  chemically	  conjugated	  
to	  the	  vaccine	  antigen	  in	  order	  to	  co-­‐deliver	  the	  stimulation	  and	  antigen	  to	  the	  same	  
target	  cell	  (Demento	  et	  al.,	  2011).	  The	  TLR-­‐agonist	  CpG	  adjuvant	  was	  found	  to	  enhance	  
both	  B	   cell	   (Shirota	  et	  al.,	   2002)	  and	  DC	  driven	   (Shirota	  et	  al.,	   2002)	  antigen-­‐specific	  
TH1	   responses	  when	  conjugated	   to	   the	  antigen	  compared	   to	   the	  unconjugated	   form.	  
Furthermore,	   using	   a	   formulation	   of	   CpG	   and	   antigen	   encapsulated	   into	   a	   delivery	  
system	   enhanced	   CD8+	   T	   cell	   responses	   compared	   to	   the	   CpG	   and	   antigen	   alone	  
(Beaudette	  et	  al.,	  2009).	  	  
The	   licensed	   HBV	   vaccine,	   used	   to	   consist	   of	   only	   recombinant	   hepatitis	   B	   surface	  
antigen	   (HBsAg)	   adsorbed	   to	   aluminium	   salts.	  However	   the	   addition	  of	   the	   adjuvant	  
AS04,	  consisting	  of	  the	  MPL	  (together	  with	  alum)	  enhanced	  protective	  antibody	  levels	  
and	   made	   the	   new	   vaccine	   (FendrixTM,	   GlaxosmithKline)	   effective	   in	   2	   doses	   rather	  
than	   the	   3	   doses	   required	  with	   the	   original	   vaccine	   (Levie	   et	   al.,	   2002,	   Kundi,	   2007,	  
Didierlaurent	   et	   al.,	   2009).	   The	   adjuvant	   AS04	   was	   also	   used	   in	   the	   HPV	   vaccine	  
(CervarixTM,	   GlaxosmithKline)	   that	   also	   showed	   significantly	   enhanced	   anti-­‐HPV	  
antibody	   titres	  compared	   to	   the	  use	  of	  aluminium	  salts	  alone	   (Giannini	  et	  al.,	  2006).	  
Alum	  adjuvants	  are	  delivery	  systems	  able	  to	  generate	  antibody	  and	  TH2-­‐type	  helper	  T	  
cell	   responses	   but	   these	   are	   not	   enough	   to	   achieve	   a	   protective	   and	   long-­‐lasting	  
immune	  response.	  Upon	  addition	  of	  the	  TLR4	  agonist,	  the	  required	  TH1-­‐type	  of	  helper	  
T	   cell	   response	   is	   also	   enhanced	   achieving	   the	   desirable	   effect	   (Didierlaurent	   et	   al.,	  
2009).	   Therefore,	   the	   use	   of	   MPL	   and	   alum	   as	   an	   adjuvant	   system	   is	   the	   perfect	  
example	  of	   filling	  an	  unmet	  vaccine	   requirement	  due	   to	  better	  understanding	  of	   the	  
adjuvants’	  roles	  and	  the	  type	  of	  immune	  response	  initiated.	  	  
In	   theory,	   certain	   combinations	   of	   adjuvants	   or	   different	   formulations	   should	   work	  
together	   to	   achieve	   vaccine	   protection.	   However,	   the	   aim	   is	   not	   always	   fulfilled.	   An	  
example	   of	   this	   is	   the	   RTS,S	   malaria	   vaccine	   candidate.	   Immunisation	   with	   RTS,S	  
vaccine	   formulated	  with	  AS02	   (MPL,	  QS-­‐21	   and	   emulsions),	   AS03	   (emulsion	   only)	   or	  
AS04	  (alum	  and	  MPL)	  together	  with	  the	  same	  circumsporozoite	  protein	  fused	  to	  HBsAg	  
gave	   largely	   variable	   results.	   The	   use	   of	   AS02	   formulation	   protected	   6	   out	   of	   7	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individuals,	  whilst	  the	  use	  of	  AS03	  and	  AS04	  led	  to	  7	  from	  8	  and	  5	  from	  8	  to	  become	  
infected	  by	  malaria	  (Stoute	  et	  al.,	  1997).	  Even	  though	  in	  the	  aforementioned	  study	  the	  
primary	   dose	   was	   well	   tolerated,	   the	   second	   dose	   with	   AS03	   and	   AS04	   produced	  
adverse	   reactions,	   with	   four	   individuals	   demonstrating	   pain,	   malaise,	   headache,	  
myalgias	   and	   fever.	   To	   further	   improve	   the	   effectiveness	   of	   the	   vaccine,	   the	  
formulation	  AS02	  was	   switched	   to	  AS01,	  which	  contained	   the	  same	  adjuvants	  but	   in	  
liposomes	  not	  emulsions.	  The	  difference	   in	  adjuvant	   in	   the	  AS01	   formulation	  greatly	  
enhanced	  immunogenicity	  of	  RTS,S	  vaccine	  (Stewart	  et	  al.,	  2006).	  Both	  of	  the	  previous	  
formulations	  were	  well	  tolerated.	  
	  
1.3.4. Effective	  versus	  successful	  adjuvants	  	  
There	   are	  multiple	   effective	   novel	   adjuvants	   in	   pre-­‐clinical	   and	   clinical	   development	  
(Table	   1.3)	   that	   can	   induce	   cell-­‐mediated	   responses,	   humoral	   responses	   as	   well	   as	  
target	  and	  activate	  DCs.	  O'Hagan	  and	  De	  Gregorio	  (2009),	  define	  successful	  adjuvants	  
as	   ones	   that	   have	   been	   included	   in	   a	   licensed	   vaccine	   product.	  With	   this	   definition,	  
many	   novel	   adjuvants	   are	   unsuccessful	   as	   approval	   of	   adjuvants	   for	   human	   use	   has	  
been	  slow.	  
The	   reasons	   why	   adjuvants	   are	   unsuccessful	   are	   several	   fold,	   (i)	   complex	   synthetic	  
pathway,	   meaning	   that	   they	   are	   difficult	   to	   scale-­‐up,	   (ii)	   difficulty	   to	   obtain	   raw	  
materials	  due	  to	  expense	  or	  purity,	  (iii)	  non-­‐biodegradable,	  which	  poses	  a	  problem	  at	  
the	  site	  of	  administration	  (iv)	  vaccine	  formulation	  not	  optimal	  and	  (v)	   incompatibility	  
with	   different	   antigens,	   which	   makes	   conjugation	   and	   use	   in	   adjuvant	   systems	  
problematic	   (O'Hagan	   and	   De	   Gregorio,	   2009).	   However,	   the	   crucial	   reason	   why	  
certain	   adjuvants	   are	   unsuccessful	   is	   safety,	   tolerability	   and	   the	   risk	   of	   triggering	  
autoimmune	  diseases,	  due	  to	  the	  direct	  stimulation	  of	  receptors	  of	  cells	  of	  the	  innate	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1.4. CD40mAb	  co-­‐administered	  with	  antigen	  as	  an	  adjuvant.	  
Current	  experimental	  progress.	  
CD40	  stimulation	  plays	  an	  important	  role	  in	  T	  cell	  immunity	  both	  via	  B	  cells	  and	  DCs	  in	  
humoral	   (Ramesh	  et	   al.,	   1993,	  Xu	  et	   al.,	   1994)	  and	   cell-­‐mediated	   immune	   responses	  
(Mackey	   et	   al.,	   1997,	   Schneider,	   2000).	   This	   is	   a	   critical	   point	   for	   adjuvanticity.	  
Stimulation	  via	  the	  co-­‐stimulatory	  molecule	  CD40	  could:	  (1)	  employ	  signal	  1	  or	  signal	  2	  
by-­‐passing	  TLRs	  and	  associated	  side-­‐effects	  and	  (2)	  initiate	  both	  TH1	  and	  TH2	  immune	  
responses	  which	  is	  not	  the	  case	  for	  traditional	  adjuvants.	  Certain	  novel	  adjuvants	  fail	  
Phase	   III	   clinical	   trials	  due	   to	   safety	   reasons.	  To	  date,	   four	  different	  CD40mAbs	  have	  
been	   explored	   as	   immunotherapy	   in	   human	   cancer	   clinical	   trials:	   lucatumumab	  
(Novartis)	   (Fanale	   et	   al.,	   2014),	   CP-­‐870,	   893	   (Pfizer	   and	   VLST)	   (Vonderheide	   et	   al.,	  
2007),	   dacetuzumab	   (Seattle	   Genetics)	   (Khubchandani	   et	   al.,	   2009)	   and	   Chi	   Lob	   7/4	  
(University	   of	   Southampton,	   Southampton,	   UK)	   (Johnson	   et	   al.,	   2010).	   The	   different	  
CD40mAbs	   are	   heterogeneous	   and	   show	   a	   variety	   of	   activities	   ranging	   from	  
antagonism	   (lucatumumab)	   to	   agonism	   (CP-­‐870,893).	   CD40mAb	   treatments	   have	   all	  
been	  well	  tolerated	  in	  clinic	  with	  only	  mild	  to	  moderate	  cytokine	  release	  syndrome	  as	  
side-­‐effects,	  showing	  that	  the	  use	  of	  this	  treatment	  is	  a	  step	  in	  the	  right	  direction.	  	  
CD40mAb	  has	  been	  studied	  by	  members	  of	  the	  Heath	  laboratory	  not	  for	  its	  application	  
alone	   in	   immunotherapy,	  but	   for	   its	  potential	   to	  boost	  the	   immune	  response	  against	  
co-­‐administered	  antigens	  in	  therapeutic	  and	  prophylactic	  vaccines.	  
	  
1.4.1. CD40mAb	  co-­‐administered	  with	  TI	  antigens	  
The	   effectiveness	   of	   CD40mAb	   as	   an	   adjuvant	   was	   first	   investigated	   in	   a	   study	  
conducted	  by	  Dullforce	  et	  al.	  (1998).	  When	  CD40mAb	  was	  co-­‐administered	  with	  a	  TI-­‐2	  
antigen	  (type	  3	  pneumococcal	  capsular	  polysaccharide,	  PS3)	  in	  vivo,	  an	  enhanced	  IgG-­‐
type	  isotype	  switched	  antibody	  responses,	  that	  were	  protective	  against	  Streptococcus	  
pneumonia	  (Dullforce	  et	  al.,	  1998)	  were	  generated.	  This	  is	  not	  normally	  observed	  with	  
TI-­‐2	  antigens.	  The	  authors	  came	  up	  with	  the	  hypothesis	  that	  CD40mAb	  is	  working	  by	  
direct	   CD40	   receptor	   stimulation,	   bypassing	   T	   cell	   help,	  which	   is	   not	   initiated	   by	   TI-­‐
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antigens.	   However,	   it	   is	   noteworthy	   that	   the	   doses	   of	   antibodies	   used	   in	   the	  
aforementioned	   study	  were	  as	  high	  as	   500µg,	  which	  was	   shown	  by	  other	   studies	   to	  
stimulate	  CD8+	  T	  cell	  responses	  in	  the	  absence	  of	  T	  cell	  help	  (French	  et	  al.,	  1999,	  Tutt	  
et	   al.,	   2002).	   This	   response	   was	   probably	   due	   to	   overstimulation	   of	   CD40	   receptor	  
bearing	  APCs	  (Bennett	  et	  al.,	  1998,	  Schoenberger	  et	  al.,	  1998),	  which	  is	  the	  very	  reason	  
high	  doses	  are	  very	  impractical	  for	  vaccination	  (Barr	  et	  al.,	  2005).	  
In	   a	   subsequent	   study,	   co-­‐administration	   of	   CD40mAb	  with	   LPS,	   a	   TI-­‐1	   antigen,	  was	  
investigated	  in	  a	  Salmonella	  infection	  model	  (Barr	  and	  Heath,	  1999).	  TI-­‐2	  antigens	  have	  
multiple	   highly	   repetitive	   epitopes	   and	   only	   activate	   B	   lymphocytes,	   unlike	   TI-­‐1	  
antigens	  that	  activate	  B	  lymphocytes	  through	  TLR	  signalling	  (Dintzis	  et	  al.,	  1983,	  Mond	  
et	   al.,	   1995).	   Enhanced	   production	   of	   protective	   antibodies	   against	   the	   antigen	  was	  
again	   observed,	   further	   demonstrating	   the	   effectiveness	   of	   the	   CD40mAb	   adjuvant.	  
The	   same	  mode	   of	   action	  was	   again	   proposed.	   Another	   group	   that	   investigated	   the	  
antibody	   responses	   on	   co-­‐administration	  of	   CD40mAb	  and	   TI-­‐1	   antigen	   showed	   that	  
IgG3-­‐type	   antibodies	   were	   predominant	   (Garcia	   de	   Vinuesa	   et	   al.,	   1999),	   which	   is	  
characteristic	  of	  a	  TI-­‐2	  response	  together	  with	  the	  absence	  of	  memory	  B	  cells	  or	  GC.	  
Due	  to	  their	  results,	  they	  disagreed	  that	  CD40mAb	  works	  by	  replacing	  T-­‐cell	  help	  but	  
rather	  mimicking	  T	  cell	  help,	  and	  proposed	  that	  CD40mAb	  works	  via	  APC	  stimulation.	  
	  
1.4.2. CD40mAb	  co-­‐administered	  with	  TD	  antigens	  
CD40mAb	   targeting	  CD40	   receptor	  has	   also	  been	   shown	   to	   lead	   to	   the	   formation	  of	  
memory	   T	   cells,	   as	   well	   as	   enhanced	   T	   cell	   responses	   when	   immunised	   in	   mice.	  
However,	   in	   this	   case	   the	   adjuvant	   effect	  was	   achieved	   against	   the	   Fc	   region	   of	   the	  
CD40mAb	   itself,	   considered	  as	  a	  TD	  antigen	   (Carlring	  et	  al.,	  2004).	  Barr	  et	  al.	   (2005),	  
showed	  that	  CD40mAb	  does	  not	  work	  by	  replacing	  T-­‐cell	  help,	  as	  in	  CD4	  depleted	  mice	  
antibody	  responses	  against	   the	  Fc	  region	  were	  not	  enhanced	  when	  compared	  to	   the	  
isotype	  control,	  even	  on	   the	  simultaneous	  administration	  of	   recombinant	   IL-­‐4.	  These	  
results	  conform	  to	  the	  previous	  study	  by	  Carlring	  et	  al.	  (2004)	  that	  demonstrated	  that	  
T	   cells	   are	   as	   important	   as	   B	   cells	   for	   the	   adjuvant	   effect.	   Interestingly,	   in	   CD154	  
deficient	  mice,	  CD40mAb	  immunised	  mice	  enhanced	  antibody	  responses	  compared	  to	  
the	  isotype	  control,	  showing	  that	  the	  CD40mAb	  replaces	  the	  CD154	  stimulus	  to	  B	  cells	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which	   is	   absent	   (Barr	   et	   al.,	   2005).	   The	   previous	   two	   studies	   therefore	   show	   that	  
CD40mAb	   could	   directly	   stimulate	   antigen-­‐specific	   B	   cells,	   in	   addition	   to	   enhancing	  
antigen-­‐presentation	   to	   T	   cells,	   leading	   to	   improved	   T-­‐cell	   help.	   It	   is	   however	  
noteworthy	  that	  CD40	  receptor	  is	  expressed	  by	  other	  APCs	  including	  macrophages	  and	  
DCs	  and	  these	  cell	  types	  could	  have	  a	  role	  in	  the	  mode	  of	  action	  of	  CD40mAb.	  
CD40mAb	   admixed	   with	   inﬂuenza	   A	   virus	   nucleoprotein	   CTL	   epitope	   (NP-­‐366-­‐374)	  
encapsulated	   in	   liposomes	   administered	   prophylactically	   in	   virus	   challenged	   mice,	  
induced	  protective	  CD8+	  cytotoxic	  T	  cell	  immunity	  (Ninomiya	  et	  al.,	  2002).	  To	  confirm	  
the	   requirement	   of	   CD8+	   cytotoxic	   T	   cell	   immunity,	   MHC	   class	   I,	   or	   MHC	   class	   II	  
deficient	   mice	   prophylactically	   immunised	   with	   the	   adjuvant	   formulation	   were	   also	  
infected	  with	  influenza.	  Results	  showed	  that	  there	  was	  no	  protection	  from	  the	  disease	  
in	  either	  group	  of	  mice,	  demonstrating	  that	  both	  CD8+	  and	  CD4+	  T	  cells	  are	  important	  
for	   clearing	   the	   virus.	   The	   fact	   that	   protection	   was	   achieved	   when	   the	   adjuvant	  
formulation	   was	   administered	   intranasally	   but	   not	   subcutaneously	   showed	   that	   the	  
route	   of	   administration	   is	   a	   factor	   to	   consider.	  Other	   studies	   have	   shown	   enhanced	  
CD8+	  cytotoxic	  T	  cell	  responses	  with	  the	  use	  of	  liposomal	  peptide	  co-­‐administered	  with	  
CD40mAb	  (Ito	  et	  al.,	  2000a,	   Ito	  et	  al.,	  2000b,	  Hatzifoti	  et	  al.,	  2008).	   Interestingly,	  the	  
CD40mAb	   and	   the	   CTL	   peptide	   alone	   do	   not	   induce	   a	   cytotoxic	   response	   in	   the	  
absence	  of	  liposomes	  (Ito	  et	  al.,	  2000b).	  This	  indicates	  that	  co-­‐delivery	  of	  the	  antigen	  
and	   the	   CD40mAb	   is	   essential	   for	   an	   optimal	   vaccine	   efficacy.	   Heat-­‐killed	   Listeria	  
monocytogenes	   (HKL)-­‐based	   vaccines	   are	   ineffective	   and	   very	   poorly	   immunogenic.	  
However,	  immunisation	  together	  with	  CD40mAb	  induced	  TH1	  and	  CD8+	  CTL	  responses	  
which	   led	   the	   mice	   to	   survive	   a	   normally	   lethal	   dose	   of	   the	   pathogen	   (Rolph	   and	  
Kaufmann,	  2001).	  	  
The	  combination	  of	  CD40mAb	  with	  TLR-­‐agonists	  co-­‐administered	  with	  antigen	  has	  also	  
shown	  success	  in	  vitro	  (Ahonen	  et	  al.,	  2004).	  The	  use	  of	  these	  two	  adjuvants	  together	  
aimed	  to	  target	  two	  separate	  pathways	  and	  would	  exemplify	  filling	  the	  unmet	  need	  of	  
a	   vaccine	   as	   TLR	   stimulation	   was	   found	   important	   for	   improving	   CD40-­‐induced	  
responses.	  In	  fact,	  the	  use	  of	  CD40mAb	  and	  TLR	  agonists	  co-­‐administered	  with	  tumour	  
antigen	   showed	   promise	   for	   both	   therapeutic	   and	   prophylactic	   vaccines	   in	   murine	  
studies	  (Llopiz	  et	  al.,	  2008).	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1.5. CD40mAb	   conjugated	   to	   antigen	   as	   an	   adjuvant.	   Current	  
experimental	  progress.	  
Since	  CD40	   receptor	   is	  widely	   expressed,	   it	   is	   likely	   that	   administration	  of	  CD40mAb	  
adjuvant	   could	   result	   in	   activation	   of	   non-­‐antigen	   specific	   cells,	   or	  more	   alarmingly,	  
self-­‐reactive	   B	   cells.	   In	   fact	   high	   doses	   of	   the	   antibody	   induced	   widespread	   APC	  
activation	   giving	   rise	   to	   side-­‐effects	   like	   splenomegaly	   and	   polyclonal	   antibody	  
production.	  This	  problem	  was	  elegantly	  by-­‐passed	  by	  conjugation	  of	  CD40mAb	  to	  the	  
vaccine	  antigen	  (Barr	  et	  al.,	  2003).	  
CD40mAb	   chemically	   conjugated	   to	   vaccine	   antigen	   (TD	   antigen)	   showed	  between	  a	  
100-­‐fold	  to	  a	  1000-­‐fold	  increase	  in	  antibody	  responses	  against	  the	  conjugated	  antigen	  
compared	   to	   the	   CD40mAb/antigen	  mixture	   (Barr	   et	   al.,	   2005).	   This	   adjuvant	   effect	  
was	   achieved	   even	   at	   the	   very	   low	   dose	   of	   1μg.	   Thus,	   the	   problem	   of	   toxicity	   was	  
overcome	   (Barr	   et	   al.,	   2003).	   An	   antibody	   response	   could	   be	   observed	  within	   just	   7	  
days	   of	   immunisation	   (Bhagawati-­‐Prasad	   et	   al.,	   2010).	   Liposomal	   encapsulation	  with	  
CD40mAb	  also	  showed	  success	  and	  gave	  another	  potential	  route	  for	  the	  production	  of	  
a	  more	  immunogenic	  multivalent	  vaccine	  (Hatzifoti	  et	  al.,	  2008).	  	  
CD40mAb	  was	  conjugated	   to	   three	   influenza	  vaccine	  antigens	   to	  produce	   (i)	  B	  and	  T	  
cell	   epitope	   (from	   virus	   haemagglutinin)-­‐based	   vaccine	   (subunit	   vaccine),	   (ii)	   whole-­‐
killed	  influenza	  virus	  vaccine	  and	  (iii)	  detergent	  split	  virus	  vaccine.	  Immunogenicity	  of	  
all	   three	   vaccines	   was	   enhanced	   when	   compared	   to	   the	   respective	   isotype	   control	  
conjugates.	  Interestingly,	  the	  different	  vaccine	  antigens	  enhanced	  antibody	  production	  
to	   different	   degrees,	   with	   the	   weakest	   vaccine	   antigen	   being	   the	   epitope-­‐based	  
vaccine	  (Hatzifoti	  and	  Heath,	  2007).	  Furthermore,	  the	  detergent	  split	  virus	  vaccine	  was	  
found	  to	  enhance	  splenic	  lymphocyte	  proliferation	  ex	  vivo	  against	  the	  vaccine	  antigen.	  
A	   CD40mAb	   conjugated	   to	   lymphoma	   Id	   vaccine	  was	   evaluated	   for	   therapeutic	   and	  
prophylactic	   anti-­‐tumour	   efficacy	   in	   a	  murine	   tumour	  model.	   A	   conjugation	   strategy	  
(based	  on	  sulphydryl-­‐thiol	  chemistry)	  used	  by	  our	  lab	  for	  the	  past	  decade	  was	  used	  to	  
link	   the	   CD40mAb	   and	   the	   antigen.	   Prophylactic	   immunisation	   with	   the	   CD40mAb	  
conjugate	   vaccine	   enhanced	   median	   and	   overall	   survival	   of	   mice	   compared	   to	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lymphoma	   Id	   conjugated	   to	   KLH	   carrier	   protein,	   made	   by	   traditional	   techniques	  
(Carlring	  et	  al.,	  2012).	  	  
Murine	   survival	   was	   further	   enhanced	   in	   a	   prophylactic	   setting	   and	   tumour	  
progression	  was	  retarded	  in	  a	  therapeutic	  setting,	  on	  co-­‐administration	  of	   lymphoma	  
Id-­‐CD40mAb	  vaccine	  with	  the	  TLR-­‐agonist	  MPL,	  confirming	  the	  assumptions	  of	  possible	  
synergy	  between	  CD40mAb	  co-­‐stimulatory	  molecules	  and	  TLR-­‐agonists.	  CD8+	  and	  CD4+	  
depletion	  studies	  on	  A20-­‐CD40mAb+MPL	   immunised	  mice	  demonstrated	  that	  CD8+	  T	  
cells	  were	  the	  major	  effector	  cells	   in	  inhibiting	  tumour	  growth,	  however,	  CD4+	  T	  cells	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1.5.1. Mode	  of	  action	  of	  CD40mAb-­‐adjuvanted	  conjugates	  	  
THESIS	  RATIONALE	  
	  
The	   precise	   mode	   of	   action	   of	   CD40mAb-­‐adjuvanted	   conjugate	   vaccines	   remains	  
unknown.	   One	   of	   the	   main	   aims	   of	   this	   project	   was	   to	   evaluate	   CD40mAb	   as	   an	  
adjuvant	   for	   T	   cell	   responses	   against	   conjugated	   antigen,	   which	   is	   hypothesised	   to	  
work	  by:	  
1. Enhanced	   delivery	   of	   antigen	   to	   APCs	   (B	   cells	   or	   DC)	   leading	   to	   increased	  
antigen	  on	  MHC	  class	  II,	  or	  class	  I	  
2. Enhanced	  activation	  of	  APCs	  (B	  cells	  or	  DC)	  leading	  to	  better	  co-­‐stimulation	  	  
3. Both	  of	  the	  above	  
	  
The	  work	  in	  this	  thesis	  presents	  first	  a	  novel	  conjugation	  strategy	  aiming	  to	  refine	  the	  
conjugation	   technique	   to	   maximise	   the	   potential	   of	   CD40mAb	   as	   an	   adjuvant,	   in	  
CD40mAb-­‐adjuvanted	  conjugates	  (Chapter	  3).	  
The	   experimental	   work	   shown	   in	   Chapter	   4	   and	   Chapter	   5	   is	   heavily	   focused	   on	  
identifying	  whether	  B	  cells	  or	  DCs	  (or	  both)	  are	  involved	  in	  the	  mechanism	  of	  action	  of	  
CD40-­‐mAb-­‐adjuvanted	   conjugate	   vaccines.	   The	   latter	   was	   also	   investigated	   in	   the	  
context	   of	   downstream	   CD4+	   and	   CD8+	   T	   cell	   responses.	   A	   summary	   of	   the	  
hypothesised	  mechanisms	   of	   how	  CD40mAb	  possibly	  works	   as	   an	   adjuvant	   for	   CD4+	  
and	  CD8+	  T	  cell	   responses	  against	  conjugated	  antigen	   (investigated	   in	   this	   thesis)	  are	  
illustrated	  in	  Figure	  1.4.	  	  
The	  knowledge	  of	  which	  APC	  is	  crucial	  in	  the	  mechanism	  of	  action,	  and	  also	  the	  type	  of	  
immune	  response	  elicited	  will	  allow	  better	  prophylactic	  application	  of	  the	  vaccine,	  or	  











Figure	   1.4.	   Hypothesised	   mechanism	   of	   action	   of	   CD40mAb	   as	   an	   adjuvant	   for	   T	   cell	  
responses	   against	   conjugated	   antigen,	   investigated	   in	   this	   work.	   	   CD40mAb-­‐antigen	  
conjugates	  could	  work	  by	  delivery	  of	  antigen	  to	  B	  cells	  and/or	  DCs,	  or	  both,	   leading	  to	  more	  
peptide	   loading	  on	  MHC	  class	   I	  and/or	   II.	  CD40mAb-­‐antigen	  conjugates	  could	  activate	  B	  cells	  
and/or	   DC	   leading	   to	   enhanced	   co-­‐stimulatory	   molecule	   expression,	   possibly	   enhancing	  
antigen	   presentation	   to	   naive	   CD4+	   and/or	   CD8+T	   cells.	   CD40mAb-­‐antigen	   conjugates	   could	  
enhance	   CD4+	   T	   cell	   proliferation	   against	   conjugated	   antigen.	   CD40mAb-­‐antigen	   conjugates	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2.1. Materials	  
2.1.1. General	  Materials	  
Ultrapure	  or	  de-­‐ionised	  Water	  (dH2O)	  
A	   Millipore	   deionising	   unit	   was	   used	   to	   de-­‐ionise	   water.	   De-­‐ionised	   water	   was	  
autoclaved	  at	  121°C	  for	  15	  minutes	  before	  use.	  
Phosphate	  Buffered	  Saline	  (PBS)	  
PBS	   (supplied	   by	   Oxoid,	   Basingstoke,	   UK)	   was	   prepared	   by	   dissolving	   1	   tablet	   in	  
100ml	  dH2O.	  PBS	  was	  autoclaved	  at	  121°C	  for	  15	  minutes	  before	  use.	  
Buffers	  
The	   buffers	   used	   for	   click	   chemistry	   conjugation,	   sodium	   dodecyl	   sulphate	  
polyacrylamide	  gel	  electrophoresis	  (SDS	  PAGE)	  and	  Western	  blotting	  were	  prepared	  
as	   follows.	   The	   pH	   of	   each	   buffer	   was	   adjusted.	   Each	   buffer	   was	   autoclaved	   (as	  
above)	  and	  stored	  at	  room	  temperature	  (RT)	  unless	  stated	  otherwise.	  
Tris	  (1.5M)	  buffer	  pH	  8.8	  
Tris	  Base	  (Fisher	  Scientific,	  Loughborough,	  UK)	   	   18.2g	  
dH2O	  volume	  up	  to:	   	   	   	   	   	   100ml	   	   	  
Tris	  (1.0M)	  pH	  6.8	  (for	  SDS	  PAGE)	  and	  pH	  8.0	  (for	  conjugation)	  
Tris	  HCl	  (Melford	  Laboratories	  Ltd.,	  Suffolk,	  UK)	   	   15.76g	  
dH2O	  volume	  up	  to:	   	   	   	   	   	   130ml	   	   	  
10%	  Sodium	  dodecyl	  sulphate	  (SDS)	  
Electrophoresis	  grade	  SDS	  (BDH	  Biochemical,	  Poole,	  UK)	   10g	  
dH2O	  volume	  up	  to:	   	   	   	   	   	   100ml	  
10X	  Erythrocyte	   lysis	  buffer,	  pH	  7.3	  (all	  chemicals	  purchased	  from	  Sigma-­‐Aldrich),	  
stored	  at	  4°C	  
Ammonium	  chloride	   	   	   	   	   	   89.9g	  
Potassium	  Hydrogen	  Carbonate	   	   	   	   10g	  
Tetrasodium	  EDTA	   	   	   	   	   	   370mg	  
dH2O	  volume	  up	  to:	   	   	   	   	   	   1000ml	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2X	  Loading	  buffer,	  pH	  6.8,	  stored	  at	  -­‐4°C	  
Tris-­‐HCl	   	   	   	   	   	   	   12g	  
SDS	   	   	   	   	   	   	   	   2g	  
Dithiothreitol	  (DTT,	  Sigma-­‐Aldrich)	   	   	   	   5g	  
Glycerol	  (BDH	  Laboratory	  supplies)	  	   	   	   	   15g	  
Bromophenol	  blue	  (Biorad)	  	   	   	   	   	   0.04g	  
dH2O	  volume	  up	  to:	  	   	   	   	   	   	   100ml	  
	  
SDS-­‐PAGE	  Running	  buffer	  and	  WB	  transfer	  buffer	  compositions	  
	   Company	   Running	  (1X)	   Transfer	  (1X)	  
Tris-­‐base	  	   Fisher	  Scientific	   1.515g	   1.515g	  
Glycine	   Sigma-­‐Aldrich	   9.5g	   9.5g	  
SDS	  	   BDH	  Biochemical	   1g	   -­‐-­‐	  
Methanol	   VWR	  international	  Ltd.	   -­‐-­‐	   100ml	  
dH2O	  volume	  up	  to:	   -­‐-­‐	   500ml	   500ml	  
pH	   -­‐-­‐	   8.8	   8.8	  
Table	   2.1.	   Preparation	   of	   1X	   running	   and	   transfer	   buffer	   for	   SDS	   PAGE	   and	   Western	  
blotting	  respectively	  
	  
Preparation	  of	  SDS	  PAGE	  gel	  
	   Resolving	  gel	  (10ml)	   Stacking	  gel	  (4ml)	  
6%	   10%	   15%	   5%	  
dH2O	   	   5.3ml	   4.0ml	   2.3ml	   2.7ml	  
30%	  Acrylamide	  mix*	  	   	   2.0ml	   3.3ml	   5.0ml	   0.67ml	  
1.5M	  Tris	  (pH	  8.8)	   	   	   2.5ml	   2.5ml	   2.5ml	   -­‐-­‐	  
1.0M	  Tris	  (pH	  6.8)	   	   	   -­‐-­‐	   -­‐-­‐	   -­‐-­‐	   0.5ml	  
10%	  SDS	  	   	   	   	   0.1ml	   0.1ml	   0.1ml	   0.04ml	  
10%	  ammonium	  
persulphate**	  
0.1ml	   0.1ml	   0.1ml	   0.04ml	  
TEMED**	   	   	   	   0.008ml	   0.004ml	   0.004ml	   0.004ml	  
Table	  2.2.	  Preparation	  of	  SDS	  PAGE	  resolving	  and	  stacking	  gel.	  *purchased	  from	  Geneflow	  
Ltd.,	  Lichfield,	  UK	  	  **purchased	  from	  Sigma-­‐Aldrich	  
	  
Western	  blotting	  buffers	  
Wash	  buffer	  
0.1%	  Tween-­‐20	  (Fisher	  Scientific,	  UK)	   	   	   0.5	  ml	   	   	  
PBS	  volume	  up	  to:	   	   	   	   	   	   500	  ml	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Blocking	  buffer	  	  
Non-­‐fat	  milk	  powder	   	   	   	   	   	   3g	  
Wash	  buffer	  volume	  up	  to:	   	   	   	   	   100ml	  
	  
ELISA	  buffers	  	  
ELISA	   plates	   were	   washed	   after	   each	   incubation	   step	   with	   the	   following	   wash	  
buffer:	  
0.05%	  Tween-­‐20	   	   	   	   	   	   5	  ml	   	   	  
PBS	  volume	  up	  to:	   	   	   	   	   	   10,000	  ml	  
ELISA	  plates	  are	  blocked	  either	  with	  the	  western	  blotting	  blocking	  buffer	  or:	  	  
5%	  bovine	  serum	  albumin	  (First	  Link	  Ltd.,	  UK)	   	   5	  ml	   	   	  
PBS	  volume	  up	  to:	   	   	   	   	   	   100	  ml	  
The	  blocking	  buffer	  used	  is	  indicated	  in	  the	  methods	  section.	  
	  
Protein	  quantification	  assay	  
Protein	   quantification	   was	   carried	   out	   using	   the	   bicinchoninic	   acid	   (BCA)	   Protein	  
Assay	  kit	  purchased	  from	  Pierce,	  IL,	  USA.	  
	  
Endotoxin	  assay	  
The	  Chromogenic	  Limulus	  Amebocyte	  Lysate	  (LAL)	  kit	  purchased	  from	  Biowhittaker,	  
Lonza,	  UK,	  was	  used	  to	  test	  for	  endotoxin	  contamination.	  
	  
General	  non-­‐reusable	  materials	  
Product	   Company	  
10ml,	  25ml	  Stripette	  pipettes	   Corning	  incorporated,	  Pittsburgh,	  USA	  
20,	  50ml	  Universal	  Tubes	   Sarstedt,	  Nümbrecht,	  Germany	  
1ml,	  5ml	  and	  60ml	  syringes	   BD	  PlastipakTM,	  Oxford,	  UK	  
21-­‐gauge	  needle	   BD	  Microlance	  3,	  Fraga,	  Spain	  
Sterile	  Petri	  Dishes	  	   Bibby	  Sterilin,	  Nottingham,	  UK	  
0.1%	  Trypan	  Blue	  	   Sigma-­‐Aldrich,	  Steinheim,	  Germany	  
Trypsin-­‐Versene®	   Biowhittaker,	  Lonza,	  UK	  
Table	  2.3.	  General	  non-­‐reusable	  materials	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2.1.2. Monoclonal	   antibodies,	   reagents	   and	   materials	   used	   for	  
conjugation	  
Product	   Company	  
General	  Materials	  
30kDa	  and	  100kDa	  molecular-­‐weight	  cut-­‐off	  
(MWCO)	  centrifugal	  filter	  units	  
Amicon®	  Ultra-­‐4,	  EMD	  Millipore,	  
Billerica,	  MA,	  USA	  
MACSMix	  tube	  rotator	  	   Miltenyi	  Biotec	  GmbH,	  Germany	  
Dimethylsulphoxide	  (DMSO)	  Hybri-­‐Max™	   Sigma-­‐Aldrich,	  Steinheim,	  Germany	  
Dimethylformamide	  (DMF)	   Pierce,	  IL,	  USA	  	  
Sodium	  azide	   Sigma-­‐Aldrich,	  Steinheim,	  Germany	  
Sulphydryl-­‐maleimide	  coupling	  (Standard	  method)	  
N-­‐ethylmaleimide	  (NEM)	   Sigma-­‐Aldrich,	  Steinheim,	  Germany	  
N-­‐Succinimidyl	  S-­‐acetylthioacetate	  (SATA)	   Pierce,	  IL,	  USA	  
Sulfosuccinimidyl-­‐4-­‐(N-­‐maleimidomethyl)	  
cyclohexane-­‐1-­‐carboxylate	  (SMCC)	  
Pierce,	  IL,	  USA	  
Hydroxylamine	  hydrochloride	  	   BDH	  Laboratory	  supplies,	  Poole,	  
England	  
L-­‐cysteine	  hydrochloride	   Sigma-­‐Aldrich,	  Steinheim,	  Germany	  
Click	  chemistry	  coupling	  (CLICK	  method)	  
Dibenzylcyclooctyne-­‐NHS	   ester	   (DBCO)	  
linker	  
Jena	  Bioscience,	  GmbH,	  Germany	  
15-­‐Azido-­‐4,7,10,13-­‐tetraoxa-­‐pentadecanoic	  
acid	   succinimidyl	   ester	   (NHS-­‐PEG4-­‐Azide)	  
linker	  
Jena	  Bioscience,	  GmbH,	  Germany	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Product	   Company	  
Chicken	  Egg	  Albumin	  (OVA)	  	   Sigma-­‐Aldrich,	   Steinheim,	  
Germany	  
ImjectTM	  Maleimide-­‐activated	  OVA	   Pierce,	  IL,	  USA	  
A20-­‐Idiotype	  (A20	  antibody)	  (mouse	  IgG2a)	   Antibody	   resource	   centre	  
(ARC).	   University	   of	   Sheffield,	  
UK.	  
CD40mAb;	  clone	  1C10	  (rat	  IgG2a)*	   Antibody	   resource	   centre.	  
University	  of	  Sheffield,	  UK.	  
Isotype	  mAb;	  GL117mAb*	  
(rat	   IgG2a,	   which	   recognises	   E.coli	   β-­‐
galactosidase).	  
Antibody	  resource	  centre.	  
University	  of	  Sheffield,	  UK.	  
CD40mAb;	  clone	  10C8	  (rat	  IgG1)*	   Antibody	  resource	  centre.	  
University	  of	  Sheffield,	  UK.	  
Isotype	  mAb;	  20C2	  mAb*	  
(rat	   IgG1	   which	   recognises	   human	   IL-­‐12,	   CRL-­‐
2382™,	  ATCC)	  
Antibody	  resource	  centre.	  
University	  of	  Sheffield,	  UK.	  
SIINFEKLC	  peptide	  (>95%	  purity)	  	   Genecust,	  Dudelange	  
Luxembourg	  




EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	  	   Pierce,	  IL,	  USA	  
NHS-­‐Fluorescein	  	   Pierce,	  IL,	  USA	  
DyLight	  650	  NHS	  Ester	  	   Pierce,	  IL,	  USA	  
Table	  2.5	  Monoclonal	  antibodies	  and	  OVA	  used	  for	  conjugation	  
Hybridomas	  were	  grown	  in	  bioreactors	  and	  antibodies	  were	  purified	  from	  tissue	  culture	  supernatants	  
(Heath	  et	  al.,	  1994,	  Presky	  et	  al.,	  1996,	  Barr	  and	  Heath,	  2001),	  by	  protein	  G	  affinity	  
	  
	  
2.1.3. ELISA	  and	  Western	  blotting	  reagents	  and	  antibodies	  
2.1.3.1. ELISA	  reagents	  and	  antibodies	  
ELISA	  antibodies	   shown	   in	  Table	  2.6	  were	  diluted	   in	  PBS	  and	  added	   to	   the	  96-­‐well	  
plate	  in	  a	  volume	  of	  100μl,	  unless	  suggested	  otherwise.	  The	  ELISA	  experiments	  were	  
carried	  out	  in	  96-­‐well	  flat-­‐bottomed	  plates	  (without	  lid)	  and	  purchased	  from	  Corning	  
inc.	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Murine	  recombinant	  IL-­‐2	  purchased	  from	  eBioscience	  was	  used	  as	  a	  standard	  in	  the	  
IL-­‐2	   detecting	   ELISA.	   A20-­‐Id	   Fab	   fragments	   used	   for	   the	   CD40-­‐specific	   ELISA	   were	  
generated	  in-­‐house	  and	  used	  at	  a	  concentration	  of	  2.5µg/ml.	  A20-­‐Id	  Fab	  fragments	  





Type	   Application	  
and	  WD	  
Source	  
OVA-­‐specific	  ELISA	  or	  Western	  blot	  
Rat	  IgG	  	   none	   Polyclonal	  goat	  anti-­‐rat	  
IgG	  (mouse	  adsorbed)	  
ELISA:	  1/500	   Serotec	  














A20-­‐Id-­‐specific	  ELISA	  or	  Western	  blot	  
Rat	  IgG	  	   none	   Polyclonal	  goat	  anti-­‐rat	  
IgG	  (mouse	  adsorbed)	  
ELISA:	  1/500	   Serotec	  
Mouse	  Ig	   HRP	   Polyclonal	  goat	  anti-­‐
mouse	  (multiple	  
adsorbed)	  
ELISA	  and	  WB:	  
1/2000	  
Pharmingen	  
CD40-­‐specific	  ELISA	  or	  WB	  
Human	  IgG	  (Fc	  
specific)	  
none	   Goat	  anti-­‐human	  (mouse	  
and	  rat	  adsorbed)	  IgG	  
ELISA:	  1/200	   Sigma-­‐
Aldrich	  
Mouse	  CD40	   none	   Recombinant	  mouse	  
fusion	  protein	  between	  
mouse	  CD40	  and	  human	  
IgG1	  Fc	  (CD40/Fc	  chimera)	  
ELISA:	  1/1000	   R&D	  Systems	  
Mouse	  Ig	   HRP	   Polyclonal	  goat	  anti-­‐
mouse	  (multiple	  
adsorbed)	  
ELISA	  and	  WB:	  
1/2000	  
Pharmingen	  
Rat	  IgG	  (mAb)-­‐specific	  WB	  
Rat	  IgG	   HRP	   Polyclonal	  goat	  anti-­‐rat	  
(H+L)	  IgG	  
WB:	  1/1000	   Biosource	  
Biotinylated	  conjugate	  by	  WB	  
Biotin	   HRP	   HRP-­‐labelled	  Streptavidin	   WB:	  1/2000	   Vector	  Labs	  
Antibodies	  used	  for	  detection	  of	  IL-­‐2	  by	  ELISA	  
Mouse	  IL-­‐2	   none	   Purified	  rat	  anti-­‐mouse	  
IgG2	  
ELISA:	  1/250	   eBioscience	  
Mouse	  IL-­‐2	   none	   Biotinylated	  rat	  anti-­‐
mouse	  IgG2b	  
ELISA:	  1/500	   eBioscience	  
Biotin	   HRP	   HRP-­‐labelled	  Streptavidin	   ELISA:	  1/2000	   Vector	  Labs	  
Figure	  2.6.	  The	  antibodies	  used	  for	  ELISA	  and/or	  Western	  blotting	  experiments.	  
WD-­‐	  working	  dilution;	  WB	  –	  Western	  Blot;	  HRP	  –	  Horseradish	  Peroxidase	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The	   ELISA	   substrate	   used	   was	   SIGMAFAST™	  OPD	   (o-­‐Phenylenediamine	  
dihydrochloride)	   purchased	   from	   Sigma-­‐Aldrich.	   This	   consisted	   of	   two	   tablets;	   one	  
OPD	   tablet	   and	   one	   urea	   hydrogen	   peroxide/buffer	   tablet.	   The	   two	   tablets	   were	  
dissolved	  in	  20ml	  of	  dH2O	  obtaining	  a	  ready-­‐to-­‐use	  substrate.	  	  
	  
2.1.3.2. Western	  Blotting	  reagents	  and	  antibodies	  
ECL	  Western	  blotting	  substrate	  purchased	  from	  Pierce	  (IL,	  USA)	  was	  used.	  Detection	  
reagents	  1	  and	  2	  were	  mixed	  at	  a	  1:1	  ratio,	  added	  to	  the	  GE	  Healthcare	  Amersham™	  
Protran™	   Premium	   NC	   Nitrocellulose	   Membrane	   (Pittsburgh,	   USA)	   of	   pore	   size	  
0.45µm	  and	  incubated	  for	  1	  minute	  in	  the	  dark.	  The	  excess	  reagent	  was	  drained.	  The	  
membrane	  was	  either	  exposed	  to	  an	  X-­‐ray	  film,	  placed	  in	  developer	  solution	  (Ilford	  
Phenisol,	  Harman	  technology	  Ltd,	  Cheshire,	  UK)	  for	  few	  minutes	  and	  then	  dipped	  in	  
fixer	   solution	   (Ilford	   Hypam	   Rapid	   Fixer,	   Harman	   technology	   Ltd,	   Cheshire,	   UK),	  
otherwise	   the	  membrane	  was	   imaged	  using	   the	  ChemiDoc™	  XRS+	  System	  (Biorad),	  
using	  the	  Image	  LabTM	  acquisition	  and	  analysis	  software	  (Biorad).	  
	  
2.1.4. Flow	  cytometry	  instrument,	  reagents	  and	  antibodies	  
2.1.4.1. Flow	  cytometry	  instrument	  
All	   samples	   for	   this	   thesis	   were	   analysed	   on	   an	   LSRIITM	   flow	   cytometer,	   (BD	  
Biosciences).	  The	  BD	  LSRIITM	  has	  4	  lasers,	  as	  shown	  in	  Table	  2.4.	  Table	  2.4	  also	  shows	  
the	   settings	   at	   the	   BD	   LSRIITM	   Core	   Flow	   Cytometry	   facility	   at	   the	   University	   of	  
Sheffield.	   BD	   FACSDivaTM	   (BD	   Biosciences)	   and/or	   FlowJoTM	   (Tree	   Star,	   San	   Carlos,	  
California)	   software	   were	   used	   to	   analyse	   results	   (overlaid	   histograms	   were	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Laser	   Excitation	  channel	  (nm)	   Filters	  
Red	   633	   780/60	  
730/45	  
660/20	  






Violet	   405	   525/50	  
450/50	  
UV	   355	   530/30	  
450/50	  
Figure	  2.7.	  The	  four	  laser	  settings	  of	  the	  BD	  LSRIITM	  cytometer	  	  
	  
2.1.4.2. Flow	  cytometry	  buffers,	  reagents	  and	  antibodies	  
FACS	  buffer	  was	  made	  using	  sterile	  PBS	  containing	  0.1%	  BSA.	  This	  was	  refrigerated	  at	  
4°C	  and	  kept	  on	   ice	  during	  sample	  preparation.	  Paraformaldehyde	  purchased	   from	  
Sigma-­‐Aldrich,	  was	  frozen	  at	  a	  stock	  solution	  of	  4%	  in	  sterile	  PBS	  buffer.	  	  
A	   cell	   viability	   dye	   LIVE/DEAD®	   Fixable	   Blue	   Dead	   Cell	   Stain	   control	   (Molecular	  
Probes,	   Invitrogen,	   UK)	   was	   used	   with	   each	   experiment.	   The	   dye	   penetrates	  
damaged	  membranes	  of	  dead	  cells	  and	  binds	  to	  free	  amines	  inside	  and	  outside	  the	  
cells.	   In	   contrast,	   the	   dye	   does	   not	   permeate	   live	   cell	   membranes	   and	   therefore	  
binds	  to	  the	  extracellular	  amines	  (Perfetto	  et	  al.,	  2006)	  resulting	  in	  dim	  staining.	  For	  
dye	   reconstitution,	   50μl	   of	   DSMO	  was	   added	   to	   the	   vial	   and	   small	   aliquots	   were	  
stored	  at	  -­‐4°C	  in	  the	  dark	  for	  future	  use.	  
Carboxyfluorescein	  diacetate	  succinimidyl	  ester	  (CFSE,	  Molecular	  Probes,	  Invitrogen,	  
UK)	  was	  used	  in	  lymphocyte	  proliferation	  cell	  assays.	  CFSE	  is	  an	  NHS-­‐ester	  that	  only	  
becomes	  fluorescent	  when	  the	  succinimidyl	  ester	  group	  is	  hydrolysed	  by	  intracellular	  
esterases.	  On	  reaction	  with	   the	   intracellular	  amines,	   the	  dye	   is	   retained	  within	   the	  
cells	  and	  divides	  between	  each	  daughter	   cell	  upon	  proliferation	   (Lyons	  and	  Parish,	  
1994).	  CFSE	  allows	  the	  monitoring	  of	  cell	  divisions	  even	  up	  to	  10	  generations	  (Lyons,	  
2000).	  A	  10mM	  stock	  solution	  of	  CFSE	  was	  prepared	  with	  90μl	  of	  sterile	  DMSO	  and	  
frozen	  in	  aliquots,	  as	  per	  manufacturer’s	  instructions	  (Molecular	  Probes,	  Invitrogen,	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UK).	  
The	  fluorochrome-­‐conjugated	  antibodies	  that	  were	  used	   in	  this	  study	  are	  shown	  in	  
Table	  2.8.	  All	  antibodies	  shown	  are	  anti-­‐mouse	  antibodies,	  unless	  stated	  otherwise.	  
Cells	  stained	  by	  multiple	  fluorochromes	  were	  compensated	  for	  by	  the	  use	  of	  anti-­‐rat	  
and	  anti-­‐hamster	  Ig	  compensation	  beads,	  BD™	  CompBead	  (BD	  Biosciences).	  
	  
Specificity	  
(volume	  =	  200µl)	  
Clone	  
number	  
Fluorochrome	   Channel	   Source	  and	  type	  
CD11c	  (0.2µg)	   N418	   R-­‐Phycoerythrin	  
(PE)	  
Blue	  575/26	   Biolegend,	  Armenian	  
Hamster	  IgG2a	  
CD19	  (0.1µg)	  	   eBio1D3	  
(1D3)	  
eFluor-­‐450	   Violet	  450/50	   eBioscience,	   Rat	  
IgG2a	  
CD19	  (0.1µg)*	   6D5	   PE	   Blue	  575/26	   Biolegend,	  Rat	  IgG2a	  
CD80	  (0.2µg)	   16-­‐10A1	   Fluorescein	  
isothiocyanate	  
(FITC)	  
Blue	  530/30	   Biolegend,	  Armenian	  
Hamster	  IgG	  
CD86	  (0.02µg)	   GL-­‐1	   Allophycocyanin	  
conjugate	  (APC)	  
Red	  660/20	   Biolegend,	  Rat	  IgG2a	  
F4/80	  (0.2µg)	   BM8	   APC	   Red	  660/20	   Biolegend,	  Rat	  IgG2a	  
Gr-­‐1	  (0.02µg)	   RB6-­‐8C5	   PE	   Blue	  575/26	   eBioscience,	   Rat	  
IgG2b	  
CD4	  (0.02µg)	   RM4-­‐5	   PE/Cyanine7	  	  
(PE-­‐Cy7)	  
Blue	  780-­‐60	   eBioscience,	  Rat	  
IgG2b	  




PE-­‐Cy7	   Blue	  780-­‐60	   Biolegend	  




1C10	   Dylight	   650	  
NHS-­‐ester	  
Red	  730-­‐45	  	   Pierce,	  Rat	  IgG1	  
CD16/CD32	  
(0.5μg)	  
2.4G2	   N/A	   N/A	   Pharmingen,	   Rat	  
IgG2b	  
OVA	  (4µg)	   N/A	   N/A	   N/A	   Abcam,	  Rabbit	  IgG	  




R19-­‐15	   FITC	   Blue	  530/30	   BD	   Biosciences,	   Rat	  
IgG2a	  
Figure	  2.8.	  Antibodies	  used	  for	  flow	  cytometry	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2.1.5. Tissue	  culture	  media	  and	  reagents	  
2.1.5.1. Tissue	  culture	  media,	  supplements	  and	  culture	  conditions	  
Tissue	   culture	   media,	   RPMI	   1640	   and	   DMEM	   were	   both	   purchased	   from	  
BioWhittaker	   (Lonza,	  UK),	  and	   in	  all	  cases	  supplemented	  with	  10%	  fetal	  calf	   serum	  
(FCS)	   and	   50μM	   2-­‐mercaptoethanol	   (2-­‐ME).	   FCS	   was	   purchased	   from	   Nalgene	  
Bioclear	  (Wiltshire,	  UK)	  and	  2-­‐ME	  from	  Sigma-­‐Aldrich	  (Steinheim,	  Germany).	  Normal	  
culture	   conditions	   includes	   incubation	   in	   a	   humidified	   atmosphere	   at	   37°C,	   in	   the	  
presence	  of	  5%	  CO2.	  The	  plasticware	  used	  for	  tissue	  culture	  is	  shown	  in	  Table	  2.9.	  
For	   primary	   cell	   culture,	   RPMI	   1640	   was	   also	   supplemented	   with	   the	   antibiotics	  
Penicillin	  and	  Streptomycin	  (100	  U/ml,	  Sigma-­‐Aldrich).	  This	  will	  be	  referred	  to	  as	  R1.	  
For	  generation	  of	  bone	  marrow	  derived	  dendritic	  cells	  (BM-­‐DCs)	  the	  growth	  factors	  
GM-­‐CSF	  (20ng/ml)	  and	  IL-­‐4	  (10ng/ml),	  both	  purchased	  from	  Peprotech	  Inc.	  (London,	  
UK),	  were	  also	  added.	  This	  will	  be	  referred	  to	  as	  R2.	  	  
	  
Plasticware	  for	  tissue	  culture	  
Product	  	   Company	  
6-­‐well/96-­‐well	   cell	   culture	   plates	  
with	  lid	  (flat-­‐bottomed)	  
Corning	  Incorporated,	  Costar,	  Pittsburgh,	  
USA	  
48-­‐well	  cell	  culture	  plate	  	   Greiner	  Bio-­‐One	  GmbH,	  Frickenhausen,	  
Germany	  
1.5ml	  Cryogenic	  vials	   Nalge	  Nunc	  International,	  New	  York,	  USA	  
0.22μm	  Millex-­‐GP	  Syringe	  Filter	  Unit	   Millex,	  Bedford,	  MA,	  USA	  
Cell	  strainer	  (70μm	  Nylon)	   BD	  Falcon,	  New	  Jersey,	  USA	  
Table	  2.9.	  Plasticware	  used	  for	  tissue	  culture	  
	  
	  
2.1.5.2. T	  cell	  activation	  reagents	  and	  LPS	  
Concanavalin	  A	  (ConA),	  phorbol	  12-­‐myristate	  13-­‐acetate	  (PMA)	  and	  Ionomycin	  (Ion.)	  
were	   obtained	   from	   Sigma-­‐Aldrich	   and	   stored	   at	   -­‐20°C.	   Bacterial	   LPS	   from	  
Escherichia	   coli	   (serotype	   026:B6)	   was	   obtained	   from	   Sigma-­‐Aldrich.	   LPS	   was	  
prepared	  on	  the	  day	  of	  use	  in	  sterile	  PBS	  or	  tissue	  culture	  media.	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2.1.5.3. B	  cell	  positive	  selection	  
B	   cell	   positive	   selection	   from	   the	   spleen	   was	   carried	   out	   using	   anti-­‐PE	   MultiSort	  
MicroBeads,	  MACS®	  Separator	  and	  MS	  columns	  (which	  can	  hold	  up	  to	  2	  x	  108	  cells)	  
all	  purchased	  from	  Militenyi	  Biotech.	  For	  this	  procedure	  an	  EDTA-­‐containing	  buffer	  
was	  used	  	  (PBS	  pH	  7.2,	  0.5%	  BSA	  and	  2mM	  EDTA).	  
	  
2.1.6. Cell	  lines	  
2.1.6.1. CD40L929	  cell	  line	  
CD40L929	   is	   a	   an	   L929	   fibroblast	   cell	   line	   stably	   transfected	   with	   murine	   CD40	  
(Randall	   et	   al.,	   1998)	   used	   to	   determine	   the	   functional	   activity	   of	   CD40mAb.	   	   This	  
was	  a	  kind	  gift	  of	  DNAX	  Research	  Institute,	  Palo	  Alto,	  CA.	  This	  cell	  line	  is	  an	  adherent	  
cell	  line	  grown	  in	  DMEM	  culture	  medium	  supplemented	  with	  the	  selective	  antibiotic	  
geneticin	  or	  G418	  (0.5mg/ml)	  purchased	  from	  Sigma-­‐Aldrich.	  
	  
2.1.6.2. T	  cell	  hybridoma	  cell	  lines	  
Two	  T	  cell	  hybridoma	  lines	  were	  used.	  Both	  cell	   lines	  were	  grown	  in	  supplemented	  
RPMI-­‐1640.	   The	   DO11.10	   cell	   line	   (a	   kind	   gift	   from	  Dr.	   Philippa	  Marrack,	   National	  
Jewish	  Health	   Center,	   Denver)	   is	   a	   CD4+	   T	   cell	   hybridoma	  which	   recognises	   the	   C-­‐
terminal	   epitope	   OVA323-­‐339	   with	   the	   amino	   acid	   sequence	   ISQAVHAAHAEINAGR	  
(referred	  to	  as	  ISQ	  peptide,	  in	  this	  thesis),	  presented	  on	  both	  I-­‐Ad	  and	  I-­‐Ab	  (Robertson	  
et	   al.,	   2000b).	   The	   B3Z	   cell	   line	   (a	   kind	   gift	   from	   Dr.	   Eleanor	   Cheadle,	   Paterson	  
Institute	   for	   Cancer	   research,	   Manchester,	   UK)	   is	   a	   CD8+	   T	   cell	   hybridoma	   that	  
expresses	  a	  T	  cell	  receptor	  (TCR)	  specific	  for	  OVA257-­‐264	  with	  the	  amino	  acid	  sequence	  
SIINFEKL,	   presented	   on	   the	   murine	   H-­‐2Kb	  MHC	   class	   I	   molecule	   (Sanderson	   and	  
Shastri,	   1994).	   C57Bl/6	   splenocytes	   incubated	   with	   SIINFEKL	   peptide	   (Cambridge	  
Bioscience)	  stimulate	  B3Z	  hybridoma	  cells,	  whilst	  BALB/c	  splenocytes	  incubated	  with	  
ISQ	   peptide	   (Cambridge	   Bioscience)	   stimulate	   DO11.10	   hybridoma	   T	   cells.	   On	  
activation	  both	  DO11.10	  and	  B3Z	  cell	   lines	  produce	  IL-­‐2,	  measured	  in	  this	  thesis	  by	  
means	  of	  ELISA.	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2.1.6.3. A20	  tumour	  cell	  line	  
The	  BALB/c	  B	  cell	  lymphoma	  cell	  line	  used	  for	  tumour	  studies	  is	  the	  A20	  cell	  line	  that	  
is	  originally	  derived	  from	  a	  spontaneous	  reticulum	  cell	  neoplasm	  (ATCC)	  (Kim	  et	  al.,	  
1979).	  Cells	  are	  a	   suspension	  cell	   line	  maintained	   in	  culture	   in	  RPMI-­‐1640	  medium	  
supplemented	  with	  10%	  FCS,	  2mM	  L-­‐glutamine	  (Sigma-­‐Aldrich)	  and	  50µM	  2-­‐ME	  and	  
incubated	  at	  37°C,	  5%	  CO2.	  	  
	  
2.1.7. Animals	  
Female	   BALB/c	   mice	   between	   6-­‐12	   weeks	   old	   were	   used	   to	   evaluate	   antibody	  
responses	   to	   immunisation	   with	   the	   antigen-­‐mAb	   conjugate	   vaccines.	   Female	  
C57Bl/6	  mice	  of	  6	  weeks	  old	  were	  used	  for	  the	  in	  vivo	  cytotoxicity	  assay.	  Mice	  were	  
purchased	  from	  Harlan,	  UK.	  	  
BALB/c	  and	  C57Bl/6	  mice	  of	  both	  sexes	  and	  of	  age	  older	  than	  6	  weeks	  were	  used	  for	  
organs	   utilised	   in	   in	   vitro	   tests,	   as	   well	   as	   for	   the	   in	   vivo	   conjugate-­‐tracking	  
experiments.	  The	  previously	  mentioned	  mice	  were	  donated	  from	  different	  groups	  in	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2.2. Methods	  
2.2.1. Conjugation	  of	  antigen	  to	  mAbs	  by	  different	  methods	  
All	   materials,	   reagents	   and	   antibodies	   used	   for	   conjugation	   are	   shown	   in	   Section	  
2.1.2.	  mAbs	  for	  these	  procedures	  refers	  to	  CD40mAb	  and	  isotype	  control	  mAb.	  
2.2.1.1. Conjugation	   of	   A20	   antibody	   to	   mAbs	   using	   Sulphydryl-­‐maleimide	  
coupling	  (Standard	  method)	  
To	   introduce	   sulphydryl	   groups	   into	   monoclonal	   antibodies	   (mAbs,	   MW	  
approximately	  150kDa)	  SATA	  was	  added	  at	  a	  19.25	  molar	  excess.	  SATA	  was	  prepared	  
immediately	   before	   use	   according	   to	   the	   manufacturers’	   instructions	   by	   adding	  
DMSO	  to	  a	  concentration	  of	  52mM,	  and	  10µl	  SATA	  was	  thereafter	  added	  to	  1	  ml	  of	  
mAb	  of	  concentration	  4mg/ml	  (27µM).	  SATA	  was	  reacted	  with	  the	  mAbs	  at	  RT	  for	  30	  
minutes	  on	  a	  MACSMix	   tube	   rotator.	   To	   remove	  excess	  unbound	  SATA,	   the	   SATA-­‐
treated	  mAb	  was	  buffer-­‐exchanged	  against	  PBS	  using	  a	  30-­‐kDa	  MWCO	  spin	  filter	  at	  
1400rcf	   three	   times	   with	   4ml	   following	   manufacturer’s	   instructions.	   Sulphydryl	  
groups	   introduced	   into	   mAbs	   were	   de-­‐protected	   by	   adding	   100µl	   of	   0.5M	  
hydroxylamine	  buffer	  (25mM	  EDTA	  in	  PBS,	  pH	  7.2-­‐7.5)	  to	  1ml	  of	  SATA-­‐treated	  mAb	  
at	   1mg/ml.	   This	   reaction	   was	   incubated	   for	   2	   hours	   at	   RT	   on	   the	  MACSMix	   tube	  
rotator.	  	  
To	  introduce	  maleimide	  groups	  into	  the	  A20	  antibody	  (MW	  approximately	  150kDa),	  
Sulfo-­‐SMCC	   was	   added	   at	   a	   35	   molar	   excess.	   Sulfo-­‐SMCC	   solution	   was	   prepared	  
immediately	  before	  use	  according	  to	  the	  manufacturers’	  instructions	  by	  adding	  dH2O	  
at	  a	  concentration	  of	  7.56mM,	  and	  60µl	  of	  this	  solution	  was	  incubated	  with	  1ml	  of	  
A20	   antibody	   of	   concentration	   2mg/ml	   (13µM).	   Sulfo-­‐SMCC	  was	   reacted	  with	   the	  
A20	  antibody	  at	  RT	  for	  1	  hour	  on	  a	  MACSMix	  tube	  rotator.	  The	  maleimide-­‐activated	  
A20	  antibody	  was	  buffer	  exchanged	  three	  times	  with	  4	  ml	  PBS	  using	  a	  30-­‐kDa	  MWCO	  
spin	  filter	  at	  1400rcf.	  
The	   maleimide-­‐activated	   A20	   antibody	   (13µM)	   was	   incubated	   with	   SATA-­‐treated	  
mAbs	  (13µM)	  in	  a	  molar	  ratio	  of	  1:1	  at	  4°C	  on	  MACSMix	  tube	  rotator	  overnight.	  To	  
stop	   the	   reaction	   a	   final	   concentration	   of	   50mM	   L-­‐cysteine	   (prepared	   fresh)	   was	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added	  and	  incubated	  for	  15	  minutes.	  The	  conjugates	  were	  filtered	  three	  times	  with	  
4ml	  PBS	  using	  a	  30-­‐kDa	  MWCO	  spin	  filter	  at	  1400rcf,	  and	  were	  stored	  at	  4°C	  in	  1ml	  
of	  PBS	  containing	  0.01%	  sodium	  azide.	  
	  
2.2.1.2. Conjugation	  of	  OVA	  to	  mAbs	  using	  the	  Standard	  method	  	  
The	  mAbs	  were	  functionalised	  with	  SATA	  as	  described	  in	  Section	  2.2.1.1.	  	  
To	   block	   sylphydryls	   and	   prevent	   disulphide	   formation,	   3mg/ml	   ovalbumin	   (OVA,	  
MW	   of	   45kDa)	   (66.67µM)	   in	   PBS	   was	   treated	   with	   the	   equivalent	   amount	   of	   N-­‐
ethylmaleimide	   (NEM)	   for	   two	   hours	   at	   RT	   on	   the	   MACSMix	   tube	   rotator.	   To	  
maleimide	  activate	  OVA,	  7.56mM	  Sulfo-­‐SMCC	  was	  prepared	  prior	  to	  use	  and	  60µl	  (7	  
molar	  excess	  of	  Sulfo-­‐SMCC	  to	  OVA)	  was	  incubated	  with	  1ml	  OVA	  antigen	  (66.67µM)	  
solution	   for	   1	   hour	   at	   RT	   on	   the	  MACSMix	   tube	   rotator.	   The	  maleimide-­‐activated	  
OVA	  antigen	  was	  buffer	  exchanged	  three	  times	  with	  4	  ml	  PBS	  using	  a	  30-­‐kDa	  MWCO	  
spin	  filter	  as	  described	  in	  Section	  2.2.1.1.	  
Maleimide-­‐activated	  OVA	  at	   a	   concentration	  of	   22.2µM	  was	   incubated	  with	   SATA-­‐
treated	  mAbs	  at	  a	  concentration	  of	  3.33µM	  (resulting	  in	  a	  7:1	  molar	  ratio	  of	  OVA	  to	  
mAb)	  at	  4°C	  on	  the	  MACSMix	  tube	  rotator	  overnight,	  and	  the	  reaction	  was	  stopped	  
as	  in	  Section	  2.2.1.1.	  
	  
2.2.1.3. Conjugation	   of	   ImjectTM	   maleimide-­‐activated	   OVA	   to	   mAbs	   using	   the	  
Standard	  method	  
The	  mAbs	  were	  functionalised	  with	  SATA	  as	  described	  in	  Section	  2.2.1.1.	  	  
The	   ImjectTM	   maleimide-­‐activated	   OVA	   was	   reconstituted	   in	   200μl	   dH2O	   for	   a	  
concentration	   of	   10mg/ml.	   The	   maleimide-­‐activated	   OVA	   antigen	   (22.22µM)	   was	  
incubated	  with	   SATA-­‐treated	  mAbs	   (6.67µM)	   in	   a	  molar	   ratio	  of	   3:1	   (OVA:mAb)	  at	  
4°C	  on	  MACSMix	   tube	   rotator	  overnight,	   and	   then	   treated	  as	   explained	   in	   Section	  
2.2.1.1.	  A	  100-­‐kDa	  MWCO	  spin	  filter	  was	  used	  instead	  of	  a	  30-­‐kDa	  MWCO	  spin	  filter	  
for	  conjugate	  buffer	  exchange,	  for	  this	  experiment.	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2.2.1.4. Conjugation	  of	  biotinylated	  and	  non-­‐biotinylated	  peptide	  to	  mAbs	  using	  
the	  Standard	  method	  
2.2.1.4.1. ISQC	  peptide	  biotinylation	  	  
ISQC	   peptide	   (MW	  of	   1877Da)	  was	   reconstituted	   in	   PBS	   and	   200μg	  was	   added	   to	  
3.3mg	  EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	  (MW	  of	  443.43Da)	  in	  a	  total	  volume	  of	  700μl	  in	  PBS	  
(equating	   to	  50-­‐fold	  molar	  excess	  of	  Biotin	  –	  as	  advised	  by	   the	  manufacturer).	   EZ-­‐
Link	   Sulfo-­‐NHS-­‐Biotin	   was	   prepared	   immediately	   before	   use	   according	   to	   the	  
manufacturers’	  instructions	  by	  adding	  dH2O	  to	  the	  desired	  concentration.	  
This	   was	   incubated	   for	   30	  minutes	   at	   RT	   on	   a	  MACSMix	   tube	   rotator.	   The	   excess	  
unconjugated	  EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	  and	  non-­‐biotinylated	  ISQC	  were	  not	  removed	  
by	  buffer	  exchange	  because	  of	  their	  low	  MW,	  and	  potential	  loss	  of	  valuable	  sample.	  
The	  sample	  was	  refrigerated	  for	  at	  least	  1	  week	  before	  conjugation	  to	  the	  mAbs	  (this	  
ensured	  that	   the	  excess	  EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	  reagent	  was	  hydrolysed	  and	  does	  
not	   also	   conjugate	   to	   antibody).	   Therefore,	   EZ-­‐Link	   Sulfo-­‐NHS-­‐Biotin	   solution	  
reconstituted	  on	  the	  day	  of	  peptide	  biotinylation	  was	  labelled	  and	  refrigerated	  to	  be	  
used	  as	  an	  internal	  control	  during	  conjugation	  on	  a	  later	  date.	  
	  
2.2.1.4.2. SIINFEKLC	  peptide	  biotinylation	  	  
SIINFEKLC	   peptide	   (MW	   of	   1066Da)	   was	   reconstituted	   in	   dH2O,	   and	   200μg	   was	  
added	  to	  5.8mg	  EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	  (443.43Da)	  in	  a	  total	  volume	  of	  700μL	  dH2O	  
(equating	  to	  50-­‐fold	  molar	  excess	  of	  Biotin	  –	  as	  advised	  by	  the	  manufacturer),	  and	  
incubated	   for	   30	   minutes	   at	   RT	   on	   a	   MACSMix	   tube	   rotator.	   The	   rest	   of	   the	  
procedure	  is	  as	  described	  in	  Section	  2.2.1.4.1.	  	  
	  
2.2.1.4.3. Conjugation	  of	  mAbs	  to	  biotinylated	  peptide	  or	  non-­‐biotinylated	  peptide	  	  
Sulfo-­‐SMCC	  (7.6mM)	  was	  reconstituted	  in	  dH2O,	  and	  25µl	  Sulfo-­‐SMCC	  solution	  was	  
added	  to	  500µl	  mAb	  (40μM	  in	  PBS)	  at	  10-­‐fold	  molar	  excess.	  After	  1	  hour	  incubation	  
at	   RT	   on	   a	  MACSMix	   tube	   rotator,	   the	   solution	  was	   buffer	   exchanged	   three	   times	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with	   4ml	   PBS	   using	   a	   30-­‐kDa	  MWCO	   spin	   filter	   at	   1400rcf	   as	   described	   in	   Section	  
2.2.1.1,	  to	  remove	  lower	  MW	  materials.	  	  
Maleimide-­‐activated	   mAbs	   (1mg	   in	   1ml,	   6.67μM)	   were	   mixed	   with	   0.09mg	   of	  
biotinylated	   or	   non-­‐biotinylated	   ISQC	   peptide	   (47.5μM),	   as	   well	   as	   0.05mg	   of	  
biotinylated	  or	  non-­‐biotinylated	  SIINFEKLC	  peptide	  (47μM)	  at	  a	  1	  to	  7	  molar	  ratio	  of	  
mAb	  to	  peptide	   in	  a	   total	  volume	  of	  1ml	  PBS	  and	   incubated	  overnight	  at	  4°C	  on	  a	  
rotator.	  	  
Maleimide-­‐activated	  mAbs	  (1mg)	  were	  also	  mixed	  with	  0.02mg	  of	  hydrolysed	  biotin*	  
reagent	   (reconstituted	   on	   the	   day	   of	   peptide	   biotinylation,	   Section	   2.2.1.4.1.)	   in	   a	  
total	  volume	  of	  1ml	  PBS,	  and	  incubated	  overnight	  at	  4°C	  on	  a	  rotator.	  This	  served	  as	  
an	  internal	  control	  to	  ensure	  that	  the	  NHS-­‐Biotin	  in	  the	  biotinylated	  peptide	  solution	  
had	  hydrolysed	  and	  was	  not	  also	  conjugating	  to	  the	  mAbs.	  Stopping	  the	  conjugation	  
reaction	  and	  the	  remainder	  of	  the	  procedure	  was	  the	  same	  as	  in	  Section	  2.2.1.1.	  
*to	  ensure	  that	  the	  biotin	  is	  hydrolysed	  and	  non-­‐reactive,	  at	   least	  a	  week	  was	  left	  between	  
peptide	  biotinylation	  and	  conjugation.	  
	  
2.2.1.5. Conjugation	   of	   SIINFEKLCFAM	   peptide	   to	  mAbsDylight	   using	   the	   Standard	  
method	  
2.2.1.5.1. Labelling	  of	  SIINFEKLC	  peptide	  with	  NHS-­‐Fluorescein	  (FAM)	  
The	   NHS-­‐Fluorescein	   (will	   be	   referred	   to	   as	   FAM)	   was	   reconstituted	   fresh	   at	   a	  
concentration	  of	  20mg/ml	  by	  addition	  of	  50μl	  DMF	  and	  50μl	  dH2O	  to	  2mg.	  SIINFEKLC	  
(200μg)	   peptide	   was	   added	   to	   FAM	   (1.8mg)	   in	   a	   total	   volume	   of	   700μL	   dH2O	  
(equating	  to	  20-­‐fold	  molar	  excess	  of	  FAM),	  and	  incubated	  for	  30	  minutes	  at	  RT	  on	  on	  
a	   MACSMix	   tube	   rotator.	   The	   rest	   of	   the	   procedure	   is	   as	   described	   in	   Section	  
2.2.1.4.1.	  	  
	  
2.2.1.5.2. Labelling	  of	  mAbs	  with	  Dylight	  650	  NHS-­‐ester	  
The	   Dylight	   650	   NHS-­‐ester	   (will	   be	   referred	   to	   as	   Dylight)	   was	   prepared	   at	   a	  
concentration	  of	  1mg/ml	  by	  reconstitution	  of	  1mg	  in	  100μl	  DMF	  and	  900μl	  PBS.	  Four	  
sets	  of	  mAbs	  were	  prepared	  at	  a	  concentration	  of	  2mg/ml.	  The	  mAbs	  (13.3µM)	  were	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incubated	  with	  a	  molar	  excess	  of	  7	  (93.1µM),	  3.5	  (46.55µM),	  1.5	  (19.95µM)	  or	  0.75	  
(10µM)	  Dylight	   (MW	  of	  1066Da)	   for	  1	  hour	  at	  RT.	  The	   labelled	  mAbs	  were	   filtered	  
extensively	  with	  4ml	  PBS	  using	  a	  100-­‐kDa	  MWCO	  spin	  filter	  as	  described	  in	  Section	  
2.2.1.1	  and	  stored	  at	  4°C	  in	  PBS.	  	  
	  
2.2.1.5.3. Conjugation	  of	  mAbs	  or	  Dylight-­‐labelled	  mAbs	  to	  FAM-­‐labelled	  SIINFEKL	  
mAbDylight	   and	   unlabelled	   mAbs	   were	   maleimide-­‐activated	   with	   Sulfo-­‐SMCC	   as	  
explained	   in	   Section	   2.2.1.4.3.	   with	   the	   alteration	   that,	   the	   mAbs	   (3.33µM)	   was	  
treated	  with	  an	  80-­‐fold	  molar	  excess	  of	  Sulfo-­‐SMCC.	  This	  was	  performed	  because	  of	  
the	  low	  concentration	  of	  the	  mAbs,	  as	  was	  recommended	  by	  the	  manufacturer.	  
To	   make	   SIINFEKLFAM-­‐mAb	   conjugates,	   maleimide-­‐activated	   mAb	   (0.5mg	   in	   1ml,	  
3.33μM)	  was	  mixed	  with	  0.022mg	  SIINFEKLCFAM	  (20μM)	   in	  a	  1	  to	  7	  molar	  ratio	   in	  a	  
total	  volume	  of	  1ml	  PBS	  and	  incubated	  overnight	  at	  4°C	  on	  a	  MACSMix	  tube	  rotator,	  
and	   treated	   as	   in	   Section	   2.2.1.1.	   To	   make	   SIINFEKLFAM-­‐mAbDylight	   conjugates,	  
maleimide-­‐activated	  mAbDylight	  (0.5mg)	  was	  mixed	  with	  0.022mg	  SIINFEKLCFAM	  in	  a	  1	  
to	  7	  molar	   ratio	   in	  a	   total	  volume	  of	  1ml	  PBS	  and	   incubated	  overnight	  at	  4°C	  on	  a	  
MACSMix	  tube	  rotator,	  and	  treated	  as	  in	  Section	  2.2.1.1.	  	  
Maleimide-­‐activated	   mAbs	   (0.5mg)	   were	   also	   mixed	   with	   0.02mg	   of	   hydrolysed	  
FAM*	   (reconstituted	   on	   the	   day	   of	   peptide	   labelling,	   Section	   2.2.1.5.1.)	   in	   a	   total	  
volume	  of	  1ml	  PBS,	  and	  incubated	  overnight	  at	  4°C	  on	  a	  MACSMix	  tube	  rotator.	  This	  
served	  as	  an	  internal	  control	  to	  ensure	  that	  the	  FAM	  in	  the	  SIINFEKLFAM	  solution	  had	  
hydrolysed	   and	   is	   not	   also	   conjugating	   to	   the	   mAbs.	   Stopping	   the	   conjugation	  
reaction	  and	  the	  remainder	  of	  the	  procedure	  is	  the	  same	  as	  in	  Section	  2.2.1.1.	  
*to	  ensure	   that	   the	  FAM	   is	  hydrolysed	  and	  non-­‐reactive,	  at	   least	  a	  week	  was	   left	  between	  
peptide	  labelling	  and	  conjugation.	  
	  
2.2.1.6. Conjugation	  of	  A20	  antibody	  to	  mAbs	  using	  click	  chemistry	  
mAbs	  were	  prepared	  at	  a	  concentration	  of	  6mg/ml	  (40µM)	  in	  buffer	  (20mM	  NaPO4,	  
150mM	  NaCl,	  pH	  7.35),	  and	  were	  functionalised	  with	  DBCO.	  DBCO	  was	  prepared	  in	  
DMSO	  at	   a	   concentration	  of	  10mM	  and	  90µl	  was	  added	   to	  of	   the	  antibodies	   (in	   a	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total	   volume	   of	   1800µl,	   12.5	   molar	   excess	   of	   DBCO)	   and	   incubated	   at	   RT	   for	   30	  
minutes.	  The	  reaction	  was	  stopped	  by	  the	  addition	  of	  a	  quenching	  buffer	  (1M	  Tris-­‐
HCl,	  pH	  8.0)	  to	  a	  final	  concentration	  of	  50mM	  Tris.	  	  
The	  A20	   antibody	  was	   prepared	   at	   a	   concentration	   of	   6mg/ml	   (40µM)	   in	   PBS	   and	  
was	   functionalised	   with	   90µl	   of	   freshly	   prepared	   10mM	  NHS-­‐PEG4-­‐Azide	   reagent.	  
The	   reaction	   was	   allowed	   to	   proceed	   for	   30	   minutes	   at	   RT	   and	   stopped	   by	   the	  
addition	   of	   a	   quenching	   buffer	   (1M	   TRIS-­‐HCl,	   pH	   8.0)	   to	   a	   final	   concentration	   of	  
50mM	  TRIS.	  The	  functionalised	  A20	  antibody	  was	  buffer	  exchanged	  three	  times	  with	  
4ml	  PBS	  using	  a	  30-­‐kDa	  MWCO	  spin	  filter	  at	  1400rcf.	  	  
The	  NHS-­‐PEG4-­‐Azide-­‐functionalised	  A20	  antibody	  (37µM)	  was	  incubated	  with	  DBCO-­‐
functionalised	  mAbs	   (37µM)	   at	   a	   1:1	  molar	   ratio	   at	   4°C	  on	  MACSMix	   tube	   rotator	  
overnight.	   The	   conjugates	   were	   filtered	   three	   times	   with	   4ml	   PBS	   using	   a	   30-­‐kDa	  
MWCO	  spin	  filter	  at	  1400rcf,	  and	  were	  stored	  at	  4°C	  in	  1ml	  of	  PBS	  containing	  0.01%	  
sodium	  azide.	  
	  
2.2.1.7. Conjugation	  of	  OVA	  to	  mAbs	  using	  click	  chemistry	  
The	   functionalisation	   of	   mAbs	   with	   DBCO,	   and	   OVA	   with	   NHS-­‐PEG4-­‐Azide	   was	  
carried	   out	   as	   in	   Section	   2.2.1.6.	   It	   is	   noteworthy	   that	   OVA	   concentration	   was	  
6mg/ml	   (133µM),	   and	   a	   4	  molar	   excess	   of	   NHS-­‐PEG4-­‐Azide	  was	   added.	   The	   NHS-­‐
PEG4-­‐Azide	  functionalised	  OVA	  (110µM)	  was	  incubated	  with	  the	  DBCO-­‐treated	  mAbs	  
(37µM)	   in	   a	   molar	   ratio	   of	   3:1	   (OVA	   to	   mAb)	   at	   4°C	   on	   MACSMix	   tube	   rotator	  
overnight	  and	  then	  treated	  as	  in	  Section	  2.2.1.2.	  
	  
2.2.2. Fractionation	  of	  conjugates	  using	  HPLC	  
The	   click	   chemistry	   conjugates	  were	   separated	   by	   size-­‐exclusion	   high-­‐performance	  
liquid	  chromatography	  (HPLC)	  into	  several	  fractions.	  The	  HPLC	  buffer	  (25mM	  sodium	  
phosphate,	  0.1%	  TFA,	  20%	  methanol,	  pH	  6.7)	  that	  was	  degassed	  using	  Nalgene	  filter	  
of	  pore	  size	  0.22μm	  prior	   to	  use	  and	  HPLC	  conditions	  were	  optimised	  by	  Dr.	  Oliver	  
Wilkinson	  (Chemistry	  Department,	  University	  of	  Sheffield).	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To	  remove	  possible	  sample	  precipitate	   the	  sample	  was	  centrifuged	  at	  16,000rcf	   for	  
15	  minutes	  after	  which	  the	  supernatant	  was	  transferred	   into	  a	  new	  tube.	  The	  size-­‐
exclusion	  chromatography	  column	  (Phenomenex®,	  CA,	  USA)	  was	  screwed	  tightly	  to	  
the	  HPLC	  (Gilson	  Preparative	  HPLC	  system)	   instrument.	  Using	  a	  program	  previously	  
optimised	   by	   Dr.	   Oliver	  Wilkinson,	   a	   sample	   amount	   of	   50μg	   was	   injected,	   and	   a	  
print	   out	   of	   the	   data	   trace	   was	   obtained.	   The	   sample	   fractions	   of	   interest	   were	  
collected.	  The	  different	  fractions	  were	  then	  buffer	  exchanged	  three	  times	  with	  4	  ml	  
PBS	  using	  a	  30-­‐kDa	  MWCO	  spin	  filter	  at	  1400rcf,	  to	  remove	  any	  traces	  of	  methanol,	  
and	  were	  stored	  at	  4°C	  in	  1ml	  of	  PBS	  containing	  0.01%	  sodium	  azide.	  	  
	  
2.2.3. Quantification	  of	  antigen-­‐mAb	  conjugates	  by	  BCA	  Protein	  Assay	  
A	  BCA	  Protein	  Assay	  kit	  was	  used	  to	  determine	  the	  concentration	  of	  conjugates.	  An	  
ampule	  containing	  BSA	  (2	  mg/ml)	  supplied	  with	   the	  kit	  was	  used	  as	  a	   reference	  to	  
determine	  the	  protein	  concentration.	  A	  series	  of	  dilutions	  of	  known	  concentrations	  
were	  made	  starting	  at	  2mg/ml	  according	  to	  manufacturer’s	  instructions	  (Table	  2.10).	  	  
μg/ml	  protein	   Vial	   Volume	  +	  Source	  of	  BSA	  
2000	   A	   Stock	  BSA	  
1500	   B	   75μl	  stock	  +	  25μl	  PBS	  
1000	   C	   55μl	  stock	  +55μl	  PBS	  
750	   D	   30μl	  vial	  B	  +	  30μl	  PBS	  
500	   E	   55μl	  vial	  C	  +	  55μl	  PBS	  
250	   F	   55μl	  vial	  E	  +	  55μl	  PBS	  
125	   G	   45μl	  vial	  F	  +	  45μl	  PBS	  
25	   H	   12μl	  vial	  G	  +	  48μl	  PBS	  
0	   I	   PBS	  only	  
Table	  2.10.	  Serial	  dilution	  of	  Bovine	  serum	  albumin	  for	  use	  as	  standard	  curve	  
A	   25µl	   volume	   of	   each	   standard	   and	   sample	   were	   added	   to	   a	   96	   well	   plate	   and	  
tested	  in	  replicates	  of	  two.	  A	  200µl	  working	  solution	  prepared	  from	  reagents	  A	  and	  B	  
(at	   a	   ratio	   of	   50:1	   respectively)	   available	   from	   the	   kit	   were	   added	   to	   the	   well	  
containing	  the	  standard	  dilutions	  and	  the	  conjugates.	  The	  plate	  was	  incubated	  in	  the	  
dark	  at	  37°C	  for	  30	  minutes,	  and	  the	  absorbance	  was	  read	  at	  562nm	  on	  an	  ELx808™	  
Absorbance	  Microplate	  Reader	   (Bio	  Tek).	   The	   concentration	  of	   the	   conjugates	  was	  
determined	  by	  comparison	  with	  the	  standard	  curve.	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2.2.4. Verification	  of	  antigen-­‐mAb	  conjugate	  composition	  
2.2.4.1. Verification	   of	   antigen-­‐mAb	   conjugate	   composition	   by	   reducing	   and	  
non-­‐reducing	  SDS	  PAGE	  
The	  composition	  of	  the	  antigen-­‐mAb	  conjugates	  were	  analysed	  using	  reducing	  SDS-­‐
PAGE	  (BioRad)	  using	  a	  6%,	  10%	  or	  15%	  gel.	  An	  amount	  of	  1-­‐10µg	  (according	  to	  the	  
sample	  being	  tested)	  of	  conjugates	  and	  controls	  was	  prepared	  in	  a	  1:1	  ratio	  with	  2X	  
loading	   buffer	   which	   contained	   DTT	   and	   denatured	   the	   proteins	   via	   reduction	   of	  
disulphide	   bonds.	   The	   samples	   were	   also	   heated	   to	   99°C	   for	   5	   minutes,	   using	   a	  
heating	  block,	  to	  further	  denature	  proteins.	  A	  volume	  of	  20µl	  of	  each	  sample	  and	  a	  
volume	   of	   5µl	   protein	   ladder	   (PageRuler™	   Prestained	   Protein	   Ladder,	  
Fermentas)	  ranging	  from	  10-­‐170kDa,	  was	  loaded	  onto	  the	  gel	  and	  run	  for	  80	  minutes	  
at	   120V.	   The	   gel	   was	   stained	   using	   InstantBlue	   (Expedeon)	   for	   2-­‐24	   hours,	   and	  
subsequently	  washed	  and	  stored	  in	  dH2O	  at	  RT.	  The	  composition	  of	  the	  antigen-­‐mAb	  
conjugates	  was	  also	  analysed	  using	  non-­‐reducing	  SDS-­‐PAGE	  (BioRad).	  The	  alterations	  
in	   procedure	   include	   the	   use	   of	   a	   2X	   loading	   buffer	   that	   does	   not	   contain	   any	  
reducing	  agent,	  and	  the	  direct	  addition	  of	   the	  samples	  to	  the	  gel,	   thus	  missing	  the	  
heating	  step.	  	  
	  
2.2.4.2. Verification	  of	  antigen-­‐mAb	  conjugate	  composition	  by	  Western	  Blotting	  
Detection	  of	  rat	  IgG,	  mouse	  A20	  IgG,	  biotinylated	  peptides	  and	  OVA	  in	  the	  particular	  
antigen-­‐mAb	   conjugates	   was	   carried	   out	   using	   the	   antibodies	  mentioned	   in	   Table	  
2.6.	  The	  substrate	  was	  re-­‐constituted	  and	  added	  as	  explained	  in	  2.1.3.2.	  
The	  composition	  of	  the	  conjugates	  was	  confirmed	  by	  Western	  blotting.	  The	  rat	   IgG	  
(mAb)	   portion	   of	   the	   conjugate	   was	   detected	   with	   an	   HRP	   labelled	   anti-­‐rat	   IgG	  
antibody.	  The	  OVA	  portion	  was	  detected	  using	  a	  rabbit	  (IgG)	  anti-­‐OVA	  antibody	  and	  
an	  HRP-­‐conjugated	  anti-­‐rabbit	  IgG	  antibody.	  The	  A20	  antibody	  portion	  was	  detected	  
with	   an	   HRP-­‐conjugated	   polyclonal	   anti-­‐mouse	   Ig	   antibody.	   The	   biotinylated	  
peptides	  portion	  was	  detected	  with	  HRP-­‐conjugated	  streptavidin.	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SDS	   PAGE	   gel	   apparatus	   was	   disassembled	   and	   the	   gel	   was	   positioned	   onto	  
nitrocellulose	  membrane	  and	  placed	  between	  two	  filter	  papers	  soaked	  in	  1X	  transfer	  
buffer.	  The	  apparatus	  was	  placed	  in	  the	  electrophoresis	  tank	  filled	  with	  1X	  transfer	  
buffer	  and	  was	  run	  for	  60	  minutes	  at	  100V.	  The	  nitrocellulose	  membrane	  was	  then	  
placed	  into	  block	  buffer	  and	  was	  incubated	  for	  1	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  
	  
2.2.4.2.1. Rat	  IgG,	  Mouse	  IgG	  or	  Biotin-­‐specific	  Western	  blotting	  
The	   detection	   antibody	   HRP-­‐conjugated	   anti-­‐rat	   IgG	   (CD40mAb	   and	   isotype	   mAb	  
detection),	   HRP-­‐conjugated	   polyclonal	   anti-­‐mouse	   Ig	   (A20	   antibody	   detection)	   or	  
HRP-­‐conjugated	   streptavidin	   (biotinylated	   peptide	   detection)	   were	   diluted	   in	  
blocking	   buffer	   and	   added	   to	   the	   nitrocellulose	   membrane	   containing	   the	  
transferred	   samples.	   Incubation	  was	  allowed	   to	   continue	   for	   two	  hours	   at	  RT.	   The	  
blocking	   buffer	  was	   drained	   and	   the	   nitrocellulose	  membrane	  was	   incubated	  with	  
10ml	  wash	  buffer	  for	  10	  minutes	  at	  RT	  on	  the	  orbital	  shaker.	  The	  previous	  step	  was	  
repeated	  three	  times.	  After	  addition	  of	  the	  substrate,	  the	  nitrocellulose	  membrane	  
was	   left	   to	   expose	   to	   the	  X-­‐ray	   film	   for	   30	  minutes	   in	   the	   case	  of	  HRP-­‐conjugated	  
anti-­‐rat	  IgG	  and	  1-­‐2	  minutes	  in	  the	  case	  of	  HRP-­‐conjugated	  polyclonal	  anti-­‐mouse	  Ig.	  
For	  the	  biotinylated	  samples,	  the	  membrane	  was	  imaged	  using	  the	  ChemiDoc™	  XRS+	  
System	  (Biorad)	  after	  exposure	  for	  less	  than	  a	  minute.	  
	  
2.2.4.2.2. OVA-­‐specific	  Western	  blotting	  
Rabbit	   (IgG)	   anti-­‐OVA	   antibody	   was	   diluted	   in	   blocking	   buffer,	   added	   to	   the	  
nitrocellulose	   membrane	   and	   incubated	   overnight	   at	   4°C.	   The	   nitrocellulose	  
membrane	  was	  washed	  with	  wash	  buffer	  for	  10	  minutes	  at	  RT	  on	  the	  orbital	  shaker	  
for	   three	   times.	  Goat	  HRP-­‐conjugated	   anti-­‐rabbit	   IgG	  was	   thereafter	   added	   to	   the	  
nitrocellulose	   membrane	   in	   block	   buffer	   and	   incubated	   at	   RT	   for	   2	   hours	   on	   the	  
orbital	  shaker.	  The	  washing	  steps	  and	  the	  addition	  of	  substrate	  was	  the	  same	  as	  in	  
Section	   2.2.4.2.1,	   however,	   in	   this	   case	   the	   nitrocellulose	   membrane	   was	   left	   to	  
expose	  to	  X-­‐ray	  film	  for	  only	  5-­‐10	  seconds.	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2.2.4.3. Verification	   of	   antigen-­‐mAb	   conjugates	   by	   sandwich	   Enzyme-­‐Linked	  
Immunosorbent	  Assay	  (ELISA)	  
The	  ELISA	  procedures	  were	  carried	  out	  using	  the	  antibodies	  demonstrated	  in	  Table	  
2.6,	  Section	  2.1.3.	  
2.2.4.3.1. Rat	  IgG	  and	  OVA	  antigen	  –	  specific	  ELISA	  
ELISA	   96-­‐well	   plates	   were	   coated	   with	   goat	   anti-­‐rat	   IgG	   in	   PBS	   and	   incubated	  
overnight	   at	   4°C.	   The	   plates	   were	   washed	   with	   PBS	   (with	   0.05%	   Tween-­‐20)	   and	  
blocked	  for	  1	  hour	  at	  RT	  (with	  5%	  BSA)	  on	  an	  orbital	  shaker.	  After	  washing,	  a	  series	  
of	   double	   dilutions	   of	   conjugates	   or	   controls	   in	   PBS	  were	   added	   to	   the	   plate	   and	  
incubated	  for	  1	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  The	  plate	  was	  washed,	  the	  primary	  
antibody	  –	  rabbit	  anti-­‐OVA	  IgG	  in	  PBS	  was	  added	  and	  incubated	  for	  an	  hour	  at	  RT	  on	  
an	   orbital	   shaker.	   After	   a	   further	   washing	   step,	   the	   secondary	   antibody	   –	   HRP-­‐
labelled	   goat	   anti-­‐rabbit	   IgG	   in	   PBS	   was	   added	   and	   incubated	   under	   the	   same	  
conditions.	  Finally	  the	  SIGMAFAST™	  OPD	  substrate	  was	  added	  and	  incubated	  for	  10-­‐
15	  minutes	  at	  RT	  on	  an	  orbital	  shaker	  until	   the	  development	  of	  colour.	  The	  optical	  
density	  (OD)	  was	  then	  read	  using	  ELx808™	  Absorbance	  Microplate	  Reader	  (Bio	  Tek)	  
at	  450nm.	  A	  diagrammatic	  representation	  of	  this	  procedure	  is	  shown	  in	  Figure	  2.1.	  
	  
	  
Figure	  2.1.	  Diagrammatic	  representation	  of	  the	  main	  steps	  of	  the	  ELISA	  assay	  used	  to	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2.2.4.3.2. Rat	  IgG	  and	  Mouse	  Ig	  (A20	  antibody)	  –	  specific	  ELISA	  
Goat	  anti-­‐rat	   IgG	  was	  adsorbed	   to	  ELISA	  96-­‐well	  plates	  and	   incubated	  overnight	  at	  
4°C.	  The	  remainder	  of	  the	  procedure	  is	  the	  same	  as	  in	  Section	  2.2.4.3.1,	  except	  that	  
after	   the	   conjugates	   and	   controls	   were	   added	   to	   the	   plate	   and	   incubated,	   HRP-­‐
conjugated	   polyclonal	   anti-­‐mouse	   Ig	   was	   added	   to	   the	   plate	   for	   detection	   (after	  
washing).	  
	  
2.2.4.3.3. CD40mAb-­‐specific	  ELISA	  
ELISA	   96-­‐well	   plates	  were	   coated	  with	   goat	   anti-­‐human	   IgG	   in	   PBS	   and	   incubated	  
overnight	  at	  4°C.	  After	  a	  washing	  step	  with	  PBS	  (with	  0.05%	  Tween-­‐20),	  recombinant	  
mouse	   CD40/Fc	   chimera	  was	   added	   in	   PBS	   and	   incubated	   for	   1	   hour	   at	   RT.	   After	  
washing,	  the	  plates	  were	  blocked	  for	  1	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  After	  washing	  
a	  series	  of	  double	  dilutions	  of	  conjugates	  or	  controls	  in	  PBS	  were	  added	  to	  the	  plate	  
and	  incubated	  for	  1	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  The	  remainder	  of	  the	  procedure	  
was	  the	  same	  as	  2.2.4.3.2.	  	  
	  
2.2.4.4. General	  flow	  cytometry	  procedure	  
Samples	  and	  controls	  were	  incubated	  with	  1	  x	  106	  cells	  in	  200µl	  FACS	  buffer	  for	  30-­‐
60	  minutes	  at	  4°C.	  Controls	  included:	  cells	  alone	  and	  cell	  viability	  control	  using	  a	  UV	  
LIVE/DEAD	  dye.	  After	  centrifugation	  at	  400rcf	  for	  5	  minutes	  at	  4°C,	  the	  labelled	  cells	  
were	   washed	   twice	   with	   ice-­‐cold	   FACS	   buffer.	   Subsequently	   cells	   were	   incubated	  
with	   the	   primary	   antibody	   for	   30-­‐60	  minutes	   at	   4°C.	   The	   cells	   were	   then	  washed	  
twice	   with	   FACS	   buffer	   (as	   above)	   and	   the	   samples	   were	   stained	   with	   secondary	  
antibody	   (when	   indicated).	  After	   incubation	   the	  cells	  were	  washed	   twice	  with	  cold	  
FACS	  buffer	  by	  centrifuging	  at	  400rcf	  for	  5	  minutes	  at	  RT	  (as	  above).	  Cells	  were	  fixed	  
in	  1%	  paraformaldehyde	  and	  analysis	  was	  performed	  using	  the	  LSR	  II	  flow	  cytometer.	  	  
	  
CHAPTER	  2	  
	   73	  
2.2.4.4.1. Verification	  of	  antigen-­‐mAb	  conjugates	  by	  flow	  cytometry	  
All	  antibodies	  and	  reagents	  used	  for	  flow	  cytometry	  can	  be	  found	  in	  Section	  2.1.4.	  
To	  determine	  the	  functional	  activity	  of	  CD40mAb,	  the	  ability	  of	  OVA-­‐CD40mAb,	  A20-­‐
CD40mAb,	   SIINFEKLFAM-­‐CD40mAbDylight,	   SIINFEKLFAM-­‐CD40mAb	   conjugates	   and	  
CD40mAbDylight	  to	  bind	  to	  CD40	  expressed	  by	  the	  CD40L929	  cell	  line	  was	  investigated	  
by	  flow	  cytometry	  (Table	  2.11).	  	  
CD40L929	   fibroblast	   cells	   are	   an	   adherent	   cell	   line	   that	   requires	   trypsinisation	   for	  
subculture.	   Trypsinisation	   involved	   primarily	   washing	   the	   cells	   with	   PBS,	   and	  
subsequently	  adding	  2ml	  of	  pre-­‐warmed	  Trypsin	   to	   the	  cells	  and	   incubation	  of	   the	  
flask	   in	   normal	   culture	   conditions	   for	   15	   minutes.	   A	   volume	   of	   10ml	   of	   DMEM	  
supplemented	   with	   10%	   fetal	   calf	   serum	   (FCS),	   50μM	   2-­‐ME	   and	   the	   selective	  
antibiotic	  geneticin	  or	  G418	  was	  then	  added	  to	  the	  dislodged	  cells	  and	  centrifuged	  at	  
400rcf	   for	   5	   minutes	   at	   4°C.	   Cell	   pellet	   was	   resuspended	   in	   1ml,	   and	   cells	   were	  
counted.	  
The	  different	  conjugates	  were	  added	  to	  the	  106	  CD40L929	  cells	  using	  the	  procedure	  
explained	  in	  2.2.4.4.	  FITC-­‐labelled	  CD40	  antibody	  was	  used	  in	  all	  cases	  as	  a	  positive	  
control,	   to	   ensure	   that	   CD40L929	   cells	   are	   all	   expressing	   CD40.	   FITC-­‐labelled	   anti-­‐
mouse	   IgG2a	   and	   FITC-­‐labelled	   goat	   anti-­‐rabbit	   IgG	   were	   also	   added	   to	   the	  
CD40L929	  cells	  in	  the	  absence	  of	  the	  respective	  conjugate	  (Table	  2.11),	  as	  a	  negative	  
control.	  	  
	  
Conjugate	   Primary	  antibody	   Secondary	  antibody	  
A20-­‐mAb	   Anti-­‐mouse	  IgG2a	  (FITC)	   N/A	  
OVA-­‐mAb	   Rabbit	   (IgG)	   anti-­‐OVA	  
(no	  label)	  
Goat	   anti-­‐rabbit	   IgG	  
(FITC)	  
mAbDylight	   N/A	   N/A	  
SIINFEKLFAM-­‐mAb	   N/A	   N/A	  
SIINFEKLFAM-­‐mAbDylight	   N/A	   N/A	  
Table	   2.11.	   Functional	   capacity	   of	   the	   CD40mAb-­‐portion	   of	   the	   different	   conjugates	  
produced.	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2.2.5. Culture,	  maintenance	  and	  activation	  of	  cell	  lines	  
A	  further	  explanation	  of	  the	  cell	  lines	  used	  can	  be	  found	  in	  Section	  2.1.6.	  
2.2.5.1. Retrieving,	  subculturing	  and	  freezing	  of	  cell	  lines	  
Cell	  lines	  retrieved	  from	  liquid	  nitrogen	  storage	  were	  quickly	  thawed	  in	  a	  37°C	  water	  
bath	  using	  aseptic	  techniques.	  Once	  thawed	  the	  cell	  suspension	  was	  transferred	  to	  
10ml	  of	  pre-­‐warmed	  cell	  culture	  medium	  and	  centrifuged	  for	  5	  minutes	  at	  400rcf	  at	  
4°C,	  to	  remove	  DMSO.	  The	  cell	  pellet	  was	  resuspended	  in	  10ml	  media	  and	  cultured	  
in	  normal	  culture	  conditions.	  To	  maintain	  stocks	  of	  healthy	  cells,	  1ml	  ice-­‐cold	  media	  
supplemented	  with	  40%	  FCS	  and	  10%	  DMSO	  was	  added	  to	  the	  cell	  pellet,	  which	  was	  
first	  transferred	  to	  a	  -­‐80°C	  freezer	  and	  subsequently	  to	  liquid	  nitrogen	  for	  long	  term	  
storage.	  
	  
2.2.5.2. Cell	  counting	  using	  the	  hemocytometer	  
A	  volume	  of	  1ml	  cell	  suspension	  was	  thoroughly	  mixed	  and	  10µl	  was	  added	  to	  90µl	  
0.1%	   trypan	  blue.	  A	   volume	  of	  10µl	  was	  added	   to	  haemocytometer	   and	  using	  10x	  
focusing	  cells	  in	  each	  of	  the	  4	  grids	  were	  counted.	  For	  calculating	  cells	  per	  ml:	  	  
(Count	  in	  4	  grids	  /	  4)	  x	  dilution	  factor	  x	  104	  
	  
2.2.5.3. Specific	  and	  non-­‐specific	  T	  cell	  activation	  
The	   functional	   activity	   of	   T	   cell	   hybridoma	   cell	   lines,	   B3Z	   and	   DO11.10	   cells,	   was	  
tested	  by	  OVA-­‐specific	  stimulation	  using	  OVA	  peptide-­‐pulsed	  splenocytes.	  Both	  cells	  
lines	  were	  also	  tested	  by	  non-­‐specific	  stimulation	  using	  PMA	  and	  Ionomycin.	  
	  
2.2.5.3.1. Peptide-­‐specific	  stimulation	  
A	  final	  concentration	  of	  2μg/ml	  of	  peptide	  was	  added	  to	  1	  x	  107	  splenocytes	  in	  1ml	  
R1	  culture	  medium	  and	  incubated	  for	  2	  hours	  under	  normal	  cell	  culture	  conditions.	  
For	   co-­‐culture,	   105	   peptide-­‐pulsed	   spleen	   cells	   were	   co-­‐cultured	   with	   105	   T	   cell	  
hybridomas	  for	  24-­‐48	  hours	  in	  200μl	  (96-­‐well	  plate).	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2.2.5.3.2. PMA	  and	  Ionomycin	  stimulation	  
PMA	  at	  a	   final	  concentration	  of	  50ng/ml	  and	   Ionomycin	  at	  a	   final	  concentration	  of	  
1μM	  were	  added	  to	  1	  x	  105	  hybridoma	  T	  cells	  per	  well	   in	  200μl	  (96-­‐well	  plate)	  and	  
incubated	  for	  24-­‐48	  hours.	  	  
	  
2.2.6. Primary	  cell	  culture	  techniques	  
All	   materials,	   media	   and	   reagents	   utilised	   in	   tissue	   culture	   are	   shown	   in	   Section	  
2.1.5.	  
	  
2.2.6.1. Organ	  harvesting	  
Organs	  were	  collected	  after	  mice	  were	  culled	  by	  cervical	  dislocation.	  The	  surface	  of	  
the	  mouse	  was	   sterilised	  by	   spraying	  with	  70%	  methylated	   spirit.	   The	   lymph	  node	  
(excised	  by	  Professor	  Andrew	  Heath)	  and/or	  spleen	  were	  picked	  using	  sterile	  forceps	  
and	  transferred	  to	  sterile	  PBS	  on	  ice.	  For	  the	  generation	  of	  DCs	  from	  bone	  marrow	  
progenitors,	  the	  tibia	  and	  femur	  of	  both	  legs	  of	  the	  mouse	  were	  excised.	  
	  
2.2.6.2. Isolation	  of	  Mouse	  Peritoneal	  cavity	  cells	  
Cell	   lines	   that	   required	   cloning	   by	   double	   dilution	   required	   growth	   with	   mouse	  
feeder	  cells	  or	  mouse	  peritoneal	  cells	  until	  ready	  for	  first	  passage.	  Eight	  millilitres	  of	  
R1	  medium	  (RPMI	  supplemented	  with	  10%	  FCS,	  50μM	  2ME	  and	  100	  U/ml	  Penicillin	  
and	   Streptomycin)	   was	   injected	   into	   the	   peritoneal	   cavity.	   The	   peritoneum	   was	  
lightly	  pressed	  to	  bring	  the	  cells	  into	  suspension.	  The	  abdominal	  skin	  was	  dissected	  
open	   to	   expose	   peritoneum.	   The	  mouse	  was	   turned	   on	   its	   side	   and	  medium	  was	  
aspirated	   using	   a	   21-­‐gauge	   needle.	   This	   procedure	  was	   performed	   by	   Dr.	   Jennifer	  
Carlring-­‐Wright.	  The	  immune	  cells	  collected	  were	  centrifuged	  at	  400rcf	  for	  5	  minutes	  
at	  a	  temperature	  of	  4°C	  and	  the	  cell	  pellet	  was	  resuspended	  in	  10ml	  R1	  medium.	  The	  
cell	  suspension	  was	  plated	  into	  a	  96-­‐well	  plate	  in	  a	  volume	  of	  100μl	  per	  well	  and	  left	  
over-­‐night	  ready	  for	  the	  cloning	  of	  hybridoma	  T	  cells.	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2.2.6.2.1. Limited	  dilution	  cloning	  of	  hybridoma	  cell	  lines	  
Hybridoma	  cell	  lines	  were	  re-­‐cloned	  to	  maintain	  a	  homogeneous	  population	  of	  cells.	  
Cell	  suspensions	  of	  concentration	  100	  cells/ml,	  30	  cells/ml,	  10	  cells/ml	  and	  3	  cells/ml	  
were	  made.	  The	  96-­‐well	  plates	   seeded	  with	  mouse	   feeder	  cells	  24-­‐hours	  prior	   this	  
experiment	   were	   divided	   into	   2,	   half	   a	   plate	   for	   each	   of	   the	   aforementioned	   cell	  
concentrations.	  Plates	  were	  incubated	  undisturbed	  for	  5	  days,	  after	  which	  they	  were	  
examined	  microscopically	   daily.	   Wells	   that	   clearly	   only	   contained	   one	   clone	   were	  
transferred	   to	   48	   well	   plates	   and	   cultured	   for	   another	   2	   days.	   After	   microscopic	  
analysis,	   cells	   were	   transferred	   to	   6	   well	   plates	   and	   subsequently	   to	   T25	   flasks	  
containing	  5	  ml	  media.	  Clones	  were	  screened	  by	  their	  ability	  to	  produce	  IL-­‐2	  in	  the	  
supernatant,	  detected	  by	  IL-­‐2	  ELISA	  assay.	  
	  
2.2.6.3. Generation	  of	  bone	  marrow-­‐derived	  dendritic	  cells	  
The	   tibias	   and	   femurs	  were	   placed	   in	   70%	   ethanol	   for	   5	  minutes	   and	   rinsed	  with	  
sterile	  PBS	  for	  2	  minutes.	  Using	  sterile	  forceps	  and	  scissors	  the	  bone	  was	  incised	  at	  
both	  ends.	  The	  marrow	  was	   flushed	  out	  using	  a	  1ml	   syringe	  and	  25-­‐gauge	  needle.	  
The	   cell	   clusters	   in	   the	   bone	  marrow	   suspension	   were	   broken	   down	   via	   vigorous	  
pipetting.	  The	  cells	  were	  resuspended	  thoroughly	  and	  centrifuged	  for	  5	  minutes	  at	  
400rcf	   at	   4°C.	   The	   cell	   pellet	   was	   resuspended	   in	   1ml	   PBS	   and	   erythrocytes	  were	  
lysed	  by	   incubation	  with	  14ml	  1X	  erythrocyte	   lysing	  buffer	   (made-­‐up	   in	  dH2O	  fresh	  
from	   a	   stock	   solution	   of	   10x	   erythrocyte	   lysing	   buffer	   on	   the	   day	   of	   use,	   Section	  
2.1.1)	   for	   5	   minutes	   at	   4°C.	   Subsequently	   the	   cells	   were	   washed	   by	   centrifuging	  
twice	   in	   PBS	   and	   counted	   using	   0.1%	   trypan	   blue.	   The	   bone-­‐marrow	   progenitors	  
were	  cultured	   in	  R2	  medium,	  RPMI	  supplemented	  with	  10%	  fetal	  calf	   serum	  (FCS),	  
50μM	   2-­‐ME,	   the	   growth	   factors	   GM-­‐CSF	   (20ng/ml)	   and	   IL-­‐4	   (10ng/ml).	   On	   day	   0,	  
each	   Petri	   dish	  was	   seeded	   at	   2	   x	   106	   cells	   in	   10ml	  medium	   and	   incubated	   under	  
normal	   culture	   conditions.	  On	  day	  3,	  10ml	  of	  R2	  media	  was	  added,	  and	   incubated	  
until	  day	  6.	  On	  day	  6,	  10ml	  of	  medium	  was	  aspirated,	  and	  centrifuged	  at	  400rcf	  for	  5	  
minutes	   at	   4°C.	   Care	   was	   taken	   not	   to	   disturb	   adherent	   cells.	   The	   pellet	   was	  
resuspended	   in	  10ml	  fresh	  medium	  and	  plated	  back	   into	  the	  original	  plate.	  On	  day	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10,	  non-­‐adherent	  and	   semi-­‐adherent	   cells	  were	  harvested	  by	   slowly	  aspirating	   the	  
supernatant	  containing	  cells	  and	  media.	  
	  
2.2.6.3.1. Maturation	  of	  bone	  marrow-­‐derived	  dendritic	  cells	  using	  LPS	  
Ten-­‐day	  old	  BM-­‐DC	  were	   seeded	   at	   a	   concentration	  of	   5	   x	   106cells/ml	   of	   10ml	  R1	  
medium	  containing	   LPS	   (1μg/ml).	  After	  48-­‐hour	   incubation,	   the	   cells	  were	   scraped	  
off	  the	  bottom	  of	  the	  Petri	  dish	  using	  a	  cell	  scraper,	  and	  analysed	  by	  flow	  cytometry.	  
	  
2.2.6.3.2. Staining	  for	  Flow	  cytometric	  analysis	  
BM-­‐DCs	   were	   prepared	   for	   flow	   cytometry	   as	   explained	   in	   Section	   2.2.4.4.	   The	  
antibodies	  against	  CD11c,	  CD40,	  F4-­‐80	  and	  Gr-­‐1	  used	  for	  staining	  are	  demonstrated	  
in	   detail	   in	   Table	   2.8.	   The	   Fc	   receptors	   were	   blocked	   using	   rat	   anti-­‐mouse	  
CD16/CD32	  antibody	  (Rat	  IgG2b).	  	  
	  
2.2.6.4. Preparation	  of	  murine	  lymph	  nodes	  cells	  
The	  lymph	  nodes	  were	  transferred	  to	  a	  cell	  strainer	  present	  in	  a	  Petri	  dish	  containing	  
PBS.	  Using	  sterile	  forceps	  the	  tissue	  was	  teased	  apart	  until	  the	  cells	  formed	  a	  single	  
cell	  suspension.	  The	  cells	  were	  transferred	  to	  a	  centrifuge	  tube,	  and	  centrifuged	  for	  5	  
minutes	  at	  400rcf	  at	  4°C.	  Excess	  PBS	  was	  discarded	  and	  the	  pellet	  was	  resuspended	  
in	  1	  ml	  PBS	  and	  counted	  using	  0.1%	  trypan	  blue.	  	  
	  
2.2.6.5. Preparation	  of	  murine	  splenocytes	  	  
The	   resected	   spleen	   was	   washed	   in	   sterile	   PBS,	   and	   transferred	   to	   a	   cell	   strainer	  
present	   in	   a	   Petri	   dish	   containing	   PBS.	  Using	   sterile	   forceps	   the	   tissue	  was	   teased	  
apart	  until	  the	  cells	  formed	  a	  single	  cell	  suspension.	  The	  cells	  were	  transferred	  to	  a	  
centrifuge	   tube,	   and	   centrifuged	   for	   5	   minutes	   at	   400rcf	   at	   4°C.	   Excess	   PBS	   was	  
discarded	   and	   the	   pellet	   was	   resuspended	   in	   1	   ml	   PBS.	   This	   cell	   suspension	   was	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incubated	  with	   14ml	   1X	   erythrocyte	   lysing	   buffer	   for	   10	  minutes	   at	   4°C.	   The	   cells	  
were	  washed	  twice	  with	  PBS	  and	  counted	  using	  0.1%	  trypan	  blue.	  	  
	  
2.2.6.5.1. Purification	   of	   CD19+	   B	   cells	   from	   murine	   splenocytes	   using	   positive	  
magnetic	  cell	  sorting	  
To	  purify	  CD19+	  B	  cells	  from	  splenocytes	  the	  cell	  population	  was	  labelled	  with	  0.5μl	  
CD19	   PE-­‐conjugated	   antibody	   per	   107	   total	   cells	   in	   100μl	   EDTA-­‐containing	   buffer	  
(Section	  2.1.5.).	  Tubes	  were	  mixed	  well	  and	  incubated	  in	  the	  dark	  for	  10	  minutes	  at	  
4°C.	  Unbound	  antibody	  was	  removed	  by	  the	  addition	  of	  1-­‐2ml	  buffer	  per	  107	  cells,	  
and	   centrifuged	   for	   5	   minutes	   at	   400rcf	   at	   4°C	   and	   subsequently	   removing	   the	  
supernatant.	   The	   previous	   step	   was	   repeated.	   After	   carefully	   removing	   all	  
supernatant,	  the	  cell	  pellet	  was	  resuspended	  in	  90μl	  buffer	  and	  incubated	  with	  10μl	  
anti-­‐PE	  MultiSort	  MicroBeads	  for	  15	  minutes	  at	  4°C.	  The	  unbound	  antibodies	  were	  
removed	  by	  the	  addition	  of	  1-­‐2ml	  buffer	  per	  107	  cells,	  centrifuging	  for	  5	  minutes	  at	  
400rcf	   at	   4°C	   and	   subsequently	   removing	   the	   supernatant.	   The	   previous	   step	  was	  
performed	   twice.	  The	  cell	  pellet	  was	   resuspended	   in	  500μl	  buffer.	  The	  MS	  column	  
was	  placed	   in	  the	  magnetic	   field	  of	  MACS®	  Separator	   following	  the	  manufacturer’s	  
protocol.	   Briefly,	   the	   column	   was	   rinsed	   with	   500µl	   of	   EDTA	   buffer	   and	   the	   cell	  
suspension	   was	   applied	   to	   the	   column.	   The	   column	   was	   rinsed	   three	   times	   with	  
500µl	  buffer.	  The	  effluent	  was	  collected	  and	  100µl	  was	  kept	  for	  flow	  analysis,	  whilst	  
the	   rest	   was	   run	   through	   the	   column	   again.	   The	   column	  was	   again	  washed	   three	  
times	   with	   buffer.	   The	   effluent	   was	   collected	   and	   analysed	   by	   flow	   cytometric	  
analysis.	   The	   column	   was	   then	   removed	   from	   the	   cell	   separator	   and	   placed	   in	   a	  
suitable	   collection	   tube.	   One	   millilitre	   of	   buffer	   was	   added	   to	   the	   syringe	   and	  
labelled	  cells	  were	  flushed	  out	  by	  firmly	  applying	  the	  plunger	  supplied	  with	  the	  MS	  
column	   and	   the	   sample	   was	   analysed	   by	   flow	   cytometry.	   To	   determine	   the	  
percentage	  expression	  of	  CD19	  by	  splenocytes	  prior	  to	  CD19	  positive	  B	  cell	  sorting,	  1	  
x	  106	  splenocytes	  were	   incubated	  with	  PE-­‐labelled	  CD19	  antibody	  (for	  more	  details	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2.2.6.6. In	  vitro	  culture	  of	  APCs	  in	  the	  presence	  of	  antigen-­‐mAb	  conjugates	  
The	   BM-­‐DC	   or	   splenocyte	   population	   was	   seeded	   in	   a	   48-­‐well	   plate	   at	   a	  
concentration	  of	  1	  x	  106	  cells	   in	  1	  ml	  of	  R1	  medium.	  The	  cells	  were	  cultured	  for	  24	  
hours	   in	   the	   absence	   and	   presence	   of	   stimuli.	   The	   stimuli	   included	   10μg/ml	   of	  
antigen-­‐CD40mAb,	  antigen-­‐isotype	  control	  mAb	  conjugates	  as	  well	  as	  antigen	  alone	  
(negative	  control)	  and	  200ng/ml	  LPS	  (positive	  control).	  Cells	  were	  prepared	  for	  flow	  
cytometry	  as	  explained	  in	  Section	  2.2.4.4.	  Antibodies	  against	  CD11c,	  CD80	  and	  CD86	  
were	  used	  to	  label	  the	  splenocytes	  or	  BM-­‐DCs	  (for	  more	  details	  about	  the	  antibody	  
see	  Table	  2.8).	  The	  gating	  strategy	  for	  this	  experiment	  involved	  excluding	  debris	  and	  
doublets,	   followed	   by	   gating	   on	   live	   cells	   based	   on	   UV	   LIVE/DEAD	   staining	   and	  
subsequently	  on	  CD11c+	  or	  CD19+	  cells.	  The	  median	  fluorescence	   intensity	   (MFI)	  of	  
the	   CD11c+CD80+/-­‐,	   CD11c+CD86+/-­‐,	   CD19+CD80+/-­‐	   and/or	   CD19+CD86+/-­‐	   was	  
recorded	   using	   DIVA	   software.	   The	   gating	   strategy	   for	   the	   analysis	   of	   BM-­‐DC	   co-­‐
stimulatory	  expression	  of	  CD80	  and	  CD86	  is	  shown	  as	  an	  example	  in	  Figure	  2.2.	  	  
	  
Figure	   2.2.	   Gating	   strategy	   for	   the	   flow	   cytometric	   analysis	   of	   the	   expression	   of	   co-­‐
stimulatory	  molecules	  CD80	  and	  CD86	  on	  BM-­‐DCs	  (as	  an	  example)	  is	  shown.	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2.2.6.7. In	  vitro	  targeting	  of	  APCs	  by	  SIINFEKLFAM-­‐mAbDylight	  conjugates	  
A	  total	  of	  3	  x	  105	  BM-­‐DCs	  and	  splenocytes	  were	  cultured	  in	  vitro	  for	  5	  minutes	  or	  1	  
hour	   in	   the	   presence	   of	   10μg/ml	   of	   SIINFEKLFAM-­‐CD40mAbDylight,	   SIINFEKLFAM-­‐
GL117Dylight,	   SIINFEKLFAM-­‐CD40mAb,	   SIINFEKLFAM-­‐GL117,	   CD40mAbDylight	   or	  
GL117Dylight,	   in	   a	   96-­‐well	   plate	   (total	   volume	  100μl).	   The	   cells	   from	  each	  well	  were	  
carefully	  aspirated	  and	  collected	  into	  flow	  cytometry	  tubes.	  PBS	  (500μl)	  was	  added	  
to	   the	   tubes	   and	   the	   cells	   were	   centrifuged	   at	   400rcf	   for	   5	   minutes	   at	   4°C.	   This	  
centrifugation	   step	  was	   repeated	   to	   ensure	   that	   any	   excess	   unbound	   fluorophore	  
was	   removed.	   The	   cells	   were	   then	   fixed	   by	   the	   addition	   of	   100μl	   4%	  
paraformaldehyde	  for	  10	  minutes	  at	  RT.	  	  
Prior	  to	  fixation	  step,	  splenocytes	  were	  first	  incubated	  with	  eFluor-­‐450	  labelled	  CD19	  
antibody	  in	  FACS	  buffer	  for	  30	  minutes	  at	  4°C	  prior	  to	  fixation.	  This	  was	  performed	  in	  
order	   to	   identify	   the	   B	   cell	   population.	   Two	   centrifugation	   steps	  were	   carried	   out	  
using	  500μl	  FACS	  buffer	  to	  ensure	  that	  excess	  unbound	  fluorophore	  was	  removed.	  	  
The	   fixed	   BM-­‐DCs	   and	   splenocytes	   were	   then	   cytospun	   onto	   glass	   slides,	   by	   the	  
addition	  of	  100μl	  to	  the	  cytospin	  wells	  and	  spun	  at	  30rcf	  for	  5	  minutes.	  Once	  dry,	  the	  
slides	  were	  blocked	  with	  50mM	  ammonium	  chloride	  (Sigma-­‐Aldrich)	  for	  10	  minutes.	  	  
BM-­‐DCs	  were	  labelled	  with	  Rhodamine	  Phalloidin	  (146nM,	  a	  kind	  gift	  from	  Dr.	  Simon	  
Johnston,	  Department	  of	   Infection	  and	   Immunity,	  University	  of	  Sheffield),	  by	  over-­‐
night	  incubation	  at	  4°C.	  This	  dye	  served	  as	  a	  cellular	  stain	  (staining	  actin),	  which	  was	  
only	   necessary	   for	   BM-­‐DCs,	   as	   B	   cells	   were	   already	   stained	   with	   the	   cell	   surface	  
marker	   CD19	   antibody.	   Coverslips	  were	  mounted	   onto	   the	   slides	  with	   5μl	  mowiol	  
and	  antifade	  (p-­‐phenyldiamine).	  	  
	  
2.2.6.7.1. Microscopy	  imaging	  
The	  presence	  of	  Dylight	  (red	  stain)	  and	  FAM	  (green	  stain)	  co-­‐localised	  in	  the	  cell	  or	  
on	  the	  cell	  surface	  was	  determined	  by	  epiflourescent	  microscopy	  on	  Ti	  (Nikon)	  with	  
NEO	  camera	  (Andor)	  using	  NIS	  Elements	  AR	  software	  (Nikon).	  In	  the	  case	  of	  B	  cells,	  
only	   co-­‐localisation	  observed	  on	  cells	   stained	   for	  CD19	   (efluor-­‐450)	  was	   taken	   into	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consideration.	  Fluorescence	  images	  were	  captured	  using	  CFP,	  GFP	  and	  Cy7	  excitation	  
filters.	  Forty	  z-­‐sections	  every	  0.5μM	  were	  captured.	  Six	  to	  eight	  fields	  of	  view	  using	  a	  
20x	   (BM-­‐DC)	  or	  a	  40x	   (splenocytes)	  objective	  were	   recorded.	  This	  work	  was	  kindly	  
conducted	  by	  Dr.	  Simon	  Johnston	  (Department	  of	  Infection	  and	  Immunity,	  University	  
of	  Sheffield).	  
	  
2.2.6.7.2. Scoring	  of	  cells	  with	  co-­‐localised	  SIINFEKLFAM	  and	  mAbDylight	  
Images	  were	  processed	  using	  NIS	  elements	  AR	  software	  (Nikon).	  The	  control	  samples	  
stimulated	   with	   SIINFEKLFAM-­‐CD40mAb,	   SIINFEKLFAM-­‐GL117,	   CD40mAbDylight	   and	  
GL117Dylight	  were	  used	  to	  exclude	  autofluorescence	  and	  ensure	  reliable	  cell	  scoring.	  
The	  cells	  stimulated	  with	  SIINFEKLFAM-­‐CD40mAbDylight	  and	  SIINFEKLFAM-­‐GL117Dylight	  for	  
5	  minutes	  and	  1	  hour	  were	   scored.	   The	  number	  of	   co-­‐localised	  mAb	  and	  SIINFEKL	  
were	   counted	   on	   20	   different	   BM-­‐DCs	   per	   field	   (in	   a	   total	   of	   6	   fields).	   Since	   the	  
number	   of	   B	   (CD19+)	   cells	   in	   each	   field	  was	   less,	   the	   number	   of	   cells	   counted	   per	  
field	  ranged	  from	  10-­‐20	  cells.	  	  
	  
2.2.6.8. In	  vitro	  co-­‐culture	  of	  T	  cell	  hybridomas	  with	  APCs	  
Splenocytes	  (1	  x	  105),	  BM-­‐DCs	  (3	  x	  104)	  or	  positively-­‐selected	  B	  cells	   (3	  x	  104)	  were	  
incubated	  with	  different	  concentrations	  of	  stimulants	  (specified	  in	  Chapter	  5,	  Section	  
5.5)	  in	  a	  100μl	  volume	  R1	  medium	  and	  incubated	  for	  2,	  4,	  18	  or	  24	  hours	  (specified	  
in	  Chapter	  5).	  After	   the	   specified	   incubation,	  1	   x	  105	  B3Z	   cells	   in	  100μl	  media	  was	  
added	  to	  the	  stimulated	  APCs	  in	  the	  96-­‐well	  plate.	  After	  24-­‐hour	  co-­‐culture	  with	  B3Z	  
under	   normal	   culture	   conditions,	   the	   supernatants	   were	   collected	   and	   frozen	   (for	  
subsequent	   IL-­‐2	   testing).	   Splenocytes	   were	   also	   stimulated	   with	   peptides	   (see	  
Section	   2.2.5.3.1.)	   and	   the	   T	   cell	   hybridomas	   were	   stimulated	   with	   PMA	   and	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2.2.6.8.1. ELISA	  to	  detect	  IL-­‐2	  from	  co-­‐culture	  supernatant	  	  
Antibodies	   used	   for	   this	   ELISA	   procedures	   are	   demonstrated	   in	   Table	   2.6,	   Section	  
2.1.3.	  
ELISA	   96-­‐well	   plates	   were	   coated	   with	   purified	   rat	   anti-­‐mouse	   IL-­‐2	   IgG2	   and	  
incubated	  overnight	  at	  4°C.	  The	  plates	  were	  washed	  with	  PBS	   (with	  0.05%	  Tween-­‐
20)	  and	  blocked	  for	  1	  hour	  at	  RT	  with	  PBS	  (with	  5%	  BSA)	  on	  an	  orbital	  shaker.	  After	  
washing,	  a	  series	  of	  double	  dilutions	  of	  standard	  recombinant	  murine	  IL-­‐2	  was	  made	  
in	  separate	  eppendorf	  tubes.	  100μl	  of	  each	  standard	  was	  added	  in	  duplicate	  to	  the	  
96-­‐well	  test	  plate.	  100μl	  of	  the	  sample	  supernatants	  were	  also	  added	  and	  incubated	  
for	  1	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  The	  plate	  was	  washed	  and	  biotinylated	  anti-­‐
mouse	  IL-­‐2	  IgG2b	  was	  added	  and	  incubated	  for	  an	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  
After	   a	   further	   washing	   step,	   HRP-­‐labelled	   streptavidin	   antibody	   was	   added	   and	  
incubated	  under	  the	  same	  conditions.	  The	  remainder	  of	  the	  procedure	  was	  the	  same	  
as	  2.2.4.3.1.	  The	  concentration	  of	  the	  unknowns	  was	  determined	  using	  a	  polynomial	  
curve,	   using	   GraphPad	   PrismTM	   software	   version	   6.0	   (GraphPad	   Software,	   Inc.	   CA,	  
USA).	  
	  
2.2.6.8.2. Flow	   cytometric	   analysis	   of	   APCs	   in	   co-­‐culture	   presenting	   SIINFEKL	  
peptide	  	  
Splenocytes	   in	   co-­‐culture	   with	   B3Z	   hybridoma	   cells	   were	   collected	   and	   were	  
prepared	   for	   flow	   cytometry	   as	   explained	   in	   Section	   2.2.4.4.	   The	   anti-­‐mouse	  
antibodies	  against	  CD11c,	  CD19	  (eFluor-­‐450),	  CD80,	  CD86	  and	  SIINFEKL	  bound	  to	  H-­‐
2Kb	  of	  MHC	  class	  I	  were	  used	  for	  staining	  (Table	  2.8).	  SIINFEKL-­‐pulsed	  splenocytes	  in	  
vitro	  were	  used	  to	  compensate	  for	  anti-­‐mouse	  SIINFEKL	  bound	  to	  H-­‐2Kb	  of	  MHC	  class	  
antibody.	  The	  MFI	  of	  the	  CD11c+CD86+SIIN+/-­‐,	  and/or	  CD19+CD86+SIIN+/-­‐expression	  of	  
lymph	  nodes	  harvested	  from	  only	  C57Bl/6	  were	  recorded	  using	  DIVA	  software.	  The	  
gating	  strategy	  for	  the	  analysis	  of	  activated	  CD19+	  cells	  presenting	  SIINFEKL	  is	  shown	  
as	  an	  example	  in	  Figure	  2.3.	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Figure	  2.3.	  Gating	  strategy	  for	  the	  flow	  cytometric	  analysis	  of	   the	  expression	  of	  SIINFEKL	  
presented	  by	  MHC	  I	  of	  activated	  CD19+	  cells	  is	  shown	  as	  an	  example.	  	  
	  
2.2.7. In	  vivo	  experimentation	  
All	  animal	  techniques	  were	  performed	  in	  accordance	  with	  the	  Animals	  and	  Scientific	  
Procedures	   Act	   (1986).	  Mice	   were	   immunised	   by	   intravenous	   (i.v.)	   (performed	   by	  
Professor	  Andrew	  W.	  Heath),	   intraperitoneal	   (i.p.)	   or	   subcutaneous	   (s.c.).	   injection	  
(Table	   2.12).	   For	   blood	   collection	   the	   animal	   was	   placed	   in	   an	   incubator	   set	   at	   a	  
temperature	  of	  30°C	  for	  5-­‐10	  minutes.	  Blood	  was	  then	  collected	  from	  the	  immunised	  
animals	  by	  making	  a	  small	  nick	  in	  the	  tail	  dorsal	  vein	  using	  a	  scalpel	  blade.	  
Injection	  type	   Syringe	  used	   Volume	   Immunisation	  
i.p.	   25-­‐gauge	  needle	   200μl	   Peritoneal	  cavity	  
s.c.	   25-­‐gauge	  needle	   100μl	   Beneath	  the	  skin	  on	  mouse	  flank	  
i.v.	   25-­‐gauge	  needle	   200μl	   Into	  the	  dorsal	  vein	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2.2.7.1. Immunisation	  schedule	  for	  A20-­‐mAb	  conjugates	  
In	   vivo	   work	   using	   A20-­‐mAb	   conjugates	   was	   conducted	   by	   Ms.	   Amy	   Lewis.	  
Prophylactic	  tumour	  studies	  involved	  immunising	  a	  group	  of	  10	  naive	  BALB/c	  female	  
mice	  with	  10μg	  A20-­‐CD40mAb	  conjugates	  subcutaneously	  in	  the	  left	  flank.	  This	  was	  
performed	  on	  day	  -­‐28	  and	  mice	  were	  boosted	  on	  day	  -­‐14.	  The	  mice	  were	  bled	  from	  
the	  dorsal	  tail	  vein	  on	  day	  -­‐1.	  The	  blood	  samples	  collected	  were	  incubated	  overnight	  
at	   4°C.	   Samples	   were	   centrifuged	   at	   16,000rcf	   for	   10	   minutes,	   and	   sera	   were	  
separated	   from	   the	   clotted	   blood	   and	   stored	   at	   -­‐20°C.	   The	   anti-­‐A20	   specific	  
antibodies	  in	  the	  mice	  sera	  were	  analysed	  by	  ELISA.	  	  
The	  mice	  were	  challenged	  with	  tumour	  cells	   two	  weeks	  after	  boosting	  on	  day	  0.	  A	  
lethal	  dose	  of	  1	  x	  105	  A20	  cells	   in	  50µl	  was	  administered	  s.c.	   in	  the	  right	  flank.	  The	  
mice	  were	  monitored	   for	   tumour	   development	   every	  weekday	   for	   a	   period	   of	   63	  
days.	   Tumours	   were	   measured	   using	   calipers	   along	   the	   shortest	   and	   longest	  
diameter.	   The	   United	   Kingdom	   Coordinating	   Committee	   on	   Cancer	   Research	  
Guidelines	  were	  followed	  that	  allow	  a	  maximum	  tumour	  size	  of	  12mm	  (Workman	  et	  
al.,	   2010),	   and	  mice	  with	   tumours	   reaching	   a	   diameter	   of	   12mm	  were	   culled.	   The	  
tumour	  volume	  was	  measured	  by	  the	  use	  of	  the	  formula:	  ((short	  +	  long)*0.25)3*4/3π	  
were	  short	  refers	  to	  the	  shortest	  measured	  diameter	  and	  long	  refers	  to	  the	  longest	  
measured	  diameter.	  	  
	  
2.2.7.1.1. Anti-­‐A20	  antibody	  responses	  
A20-­‐Id	   Fab	   fragments	   (2.5µg/ml	   generated	   in-­‐house)	   in	   0.1M	   sodium	   bicarbonate	  
buffer	   (pH	   9.4)	  was	   adsorbed	   to	   ELISA	   96-­‐well	   plates	   overnight	   at	   4°C.	   The	   plates	  
were	  washed	  with	  PBS	  (containing	  0.05%	  Tween)	  and	  blocked	  for	  1	  hour	  at	  RT	  with	  
5%	  skimmed	  milk	  powder	  in	  PBS.	  Sera	  from	  immunised	  mice	  groups	  were	  added	  to	  
the	  plate	  at	  a	   ten-­‐fold	  starting	  dilution,	  double	  diluted	  across	   the	  plate	   in	  blocking	  
buffer	  and	   incubated	   for	  an	  hour	  at	  RT	  on	  an	  orbital	   shaker.	  The	  remainder	  of	   the	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2.2.7.2. Immunisation	  schedule	  for	  OVA-­‐mAb	  conjugates	  
Five	  female	  naive	  BALB/c	  mice	  were	  immunised	  with	  10μg	  OVA-­‐mAb	  conjugate	  per	  
group,	  via	  the	  i.p.	  route	  on	  day	  1	  and	  boosted	  on	  day	  14.	  Mice	  were	  bled	  on	  day	  13	  
and	  day	  28.	  Blood	  samples	  were	  incubated	  overnight	  at	  4°C.	  Consequently,	  samples	  
were	  centrifuged	  at	  16,000rcf	  for	  10	  minutes,	  and	  sera	  were	  collected.	  The	  anti-­‐OVA	  
antibody	  titres	  in	  the	  mice	  sera	  were	  analysed	  by	  ELISA.	  
	  
2.2.7.2.1. Anti-­‐OVA	  antibody	  responses	  
The	  blood	  samples	  collected	  were	  processed	  as	   in	  2.2.7.1.	  Anti-­‐OVA	  antibody	  end-­‐
point	  titres	  in	  the	  mice	  sera	  were	  analysed	  by	  ELISA.	  OVA	  antigen	  (10µg/ml	  in	  PBS)	  
was	  adsorbed	  to	  ELISA	  96-­‐well	  plates	  overnight	  at	  4°C.	  The	  plates	  were	  washed	  with	  
PBS	   (containing	   0.05%	   Tween-­‐20)	   and	   blocked	   for	   1	   hour	   at	   RT	  with	   5%	   skimmed	  
milk	  powder	  in	  PBS.	  Sera	  from	  immunised	  mice	  groups	  were	  added	  to	  the	  plate	  at	  a	  
ten-­‐fold	   starting	   dilution,	   double	   diluted	   across	   the	   plate	   in	   blocking	   buffer	   and	  
incubated	  for	  an	  hour	  at	  RT	  on	  an	  orbital	  shaker.	  The	  remainder	  of	  the	  procedure	  is	  
the	  same	  as	  in	  Section	  2.2.4.3.2.	  The	  end-­‐point	  titre	  was	  plotted.	  
	  
2.2.7.3. Lymphocyte	  proliferation	  in	  response	  to	  stimulus	  ex	  vivo	  
	  
2.2.7.3.1. Immunisation	  schedule	  for	  antigen-­‐mAb	  conjugates	  
Five	  BALB/c	  mice	  were	  immunised,	  on	  day	  0	  and	  were	  boosted	  on	  day	  14,	  with	  10μg	  
CLICK	  OVA-­‐CD40mAb,	  Standard	  OVA-­‐CD40mAb,	  Standard	  OVA-­‐GL117mAb	  per	  group	  
via	   the	   i.p.	   route.	  Control	   groups	   included	  5μg	   sOVA	  and	  5μg	  CD40mAb	   (Mixture),	  
5μg	   sOVA	   antigen	   and	   PBS.	   Blood	   samples	   were	   incubated	   overnight	   at	   4°C.	  
Consequently,	  samples	  were	  centrifuged	  at	  16,000rcf	  for	  10	  minutes,	  and	  sera	  were	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2.2.7.3.2. Immunisation	  schedule	  for	  ISQC-­‐mAb	  conjugates	  
This	   procedure	   is	   the	   same	   as	   Section	   2.2.7.3.1	   with	   the	   alteration	   of	   the	  
immunogens.	   BALB/c	   mice	   were	   immunised	   with	   10μg	   ISQC-­‐CD40mAb	   conjugate	  
and	   ISQC-­‐GL117mAb	   conjugate	   via	   the	   intraperitoneal	   route.	   Control	   groups	  
included;	  0.8μg	  ISQC	  and	  9.2μg	  CD40mAb	  (Mixture)	  and	  PBS.	  
	  
2.2.7.3.3. Staining	  with	  CFSE	  and	  lymphocyte	  culture	  	  
In	   order	   to	   quantify	   CD4+	   T	   cell	   proliferation,	   a	   protocol	   utilizing	   CFSE	  was	   carried	  
out.	  All	  materials	  and	  reagents	  utilised	  are	  shown	  in	  Section	  2.1.4.	  Splenocytes	  from	  
immunised	  mice	  were	  harvested	  (as	  explained	  in	  Section	  2.2.6.5.).	  Care	  was	  taken	  to	  
keep	  the	  splenocytes	  on	   ice	  at	  all	   times	  to	  minimise	  cell	  death	  and	  clumping.	  CFSE	  
was	  prepared	  on	  day	  of	   use,	   from	   stock	   aliquots	   by	   diluting	   to	   a	   concentration	  of	  
0.1mM	  in	  PBS.	  A	  concentration	  of	  2	  x	  107	  cells	  in	  2	  ml	  PBS	  were	  incubated	  at	  37°C	  for	  
15	  minutes	  with	  2μM	  CFSE.	  Unbound	  dye	  was	  quenched	  with	  2ml	  heat	   inactivated	  
FCS	  and	  incubated	  at	  RT	  in	  the	  dark	  for	  10	  minutes.	  The	  cells	  were	  centrifuged	  three	  
times	   in	   R1	   medium	   for	   5	   minutes	   at	   400rcf	   (4°C)	   and	   the	   cell	   pellet	   was	  
resuspended	  each	  time	  in	  R1	  medium.	  The	  CFSE	  labelled	  cells	  were	  seeded	  in	  a	  48-­‐
well	  plate	  at	  a	  concentration	  of	  1	  x	  106	  cells	  in	  1	  ml.	  The	  cells	  from	  each	  immunised	  
mouse	  group	  were	   incubated	   in	  normal	  cell	  culture	  conditions	   in	  the	  presence	  and	  
absence	   of	   antigen	   or	   peptide	   for	   72	   hours.	   Prior	   to	   incubation	   the	   labelled	   CFSE	  
cells	  were	  checked	  on	  the	  flow	  cytometer	  to	  observe	  whether	  the	  cells	  were	  labelled	  
appropriately.	  	  
	  
2.2.7.4. Staining	  for	  Flow	  cytometric	  analysis	  
Cells	   were	   prepared	   for	   flow	   cytometry	   as	   explained	   in	   Section	   2.2.4.4.	   The	  
antibodies	  CD19	  (eFluor-­‐labelled)	  and	  CD4	  were	  used	  (Table	  2.8).	  In	  this	  experiment	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2.2.7.5. Cytotoxicity	  assay	  
2.2.7.5.1. Immunisation	  schedule	  
A	  total	  of	  8	  C57Bl/6	  mice	  per	  group	  were	  immunised	  on	  day	  0	  with	  40μg	  SIINFEKLC-­‐
CD40mAb	  conjugate	  or	  SIINFEKLC-­‐GL117	  conjugate	  via	  the	  i.p.	  route.	  Control	  groups	  
included	   2μg	   SIINFEKLC	   and	   40μg	   CD40mAb	  mixture	   (or	  MIX)	   and	   PBS.	   On	   day	   6,	  
spleens	   from	   naive	   C57Bl/6	   mice	   were	   harvested	   and	   processed	   as	   explained	   in	  
Section	  2.2.6.5.	  Care	  was	  taken	  to	  keep	  splenocytes	  on	   ice	  at	  all	   times	  to	  minimise	  
cell	  death	  and	  clumping.	  All	  media	  used	  in	  this	  section	  was	  R1	  media	  (Section	  2.1.5.).	  
	  
2.2.7.5.2. Staining	  splenocyte	  populations	  with	  CFSE	  dye	  
The	  splenocytes	  were	  divided	  into	  three	  populations;	  (i)	  Population	  A	  was	  cultured	  in	  
media	  with	  1μg/ml	  (1μM)	  SIINFEKL	  peptide	  per	  107	  cells	  for	  one	  hour	  (to	  be	  stained	  
with	  0.2μM	  CFSE),	  (ii)	  Population	  B	  was	  cultured	  in	  medium	  only	  (to	  be	  stained	  with	  
2μM	  CFSE)	  and	  (iii)	  Population	  C	  was	  cultured	  in	  medium	  only	  and	  was	  used	  as	  an	  in	  
vitro	   control	   for	   background	   staining	   (not	   stained	   with	   CFSE).	   As	   the	   SIINFEKL	  
peptide	  used	  was	  dissolved	   in	  70%	  ethanol,	  this	  was	  added	  to	  Populations	  B	  and	  C	  
using	   the	   same	   volume	   of	   SIINFEKL	   peptide	   used	   in	   (i).	   This	   served	   as	   an	   internal	  
control,	   to	   ensure	   that	   the	   70%	   ethanol	   is	   not	   having	   a	   detrimental	   effect	   on	   the	  
cells.	   All	   splenocyte	   populations	   were	   pelleted	   by	   centrifugation	   at	   400rcf	   for	   5	  
minutes	  at	  a	  temperature	  of	  4°C.	  The	  pellet	  was	  resuspended	  in	  PBS.	  
CFSE	   was	   prepared	   to	   a	   concentration	   of	   0.1mM	   in	   PBS	   (as	   explained	   in	   Section	  
2.2.7.3.3.).	  Population	  A	  was	  stained	  with	  0.2μM	  CFSE	  (CFSELOW)	  whilst	  Population	  B	  
was	   stained	   with	   2μM	   CFSE	   (CFSEHIGH)	   in	   PBS.	   CFSE	   staining	   was	   carried	   out	   as	  
explained	   in	   Section	   2.2.8.	   After	   CFSE	   staining,	   the	   cells	   in	   each	   population	   were	  
counted.	  Population	  A	  and	  B	  were	  mixed	  in	  a	  1:1	  ratio.	  A	  number	  of	  cells	  from	  each	  
population,	   as	   well	   as	   the	  mixed	   population	   (5	   x105	   cells)	   were	   checked	   for	   CFSE	  
staining	   prior	   to	   immunisation	   by	   flow	   cytometric	   analysis.	   After	   ensuring	   the	  
presence	  of	  both	  populations,	  a	  total	  number	  of	  cells	  ranging	  from	  1	  x	  106	  –	  1	  x	  107	  
were	  immunised	  per	  mouse	  i.v.	  via	  the	  dorsal	  tail	  vein.	  An	  in	  vitro	  control	  of	  1	  x	  106	  
of	  the	  mixed	  population	  of	  cells	  was	  incubated	  in	  R1	  media	  overnight.	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2.2.7.5.3. Flow	  cytometric	  analysis	  of	  splenocytes	  
After	  18	  hours	  of	   i.v.	   immunisation,	  the	  spleens	  from	  all	   the	   immunised	  mice	  were	  
harvested	  as	  in	  Section	  2.3.6.5.	  Cells	  were	  centrifuged	  twice	  for	  5	  minutes	  at	  400rcf	  
(4°C)	   and	   the	   cell	   pellet	   was	   resuspended	   first	   in	   FACS	   buffer	   and	   second	   in	   1%	  
paraformaldehyde.	  Cells	  were	  analysed	  by	  flow	  cytometric	  analysis	  on	  the	  LSRII.	  At	  
least	   1	   million	   events	   (gated	   on	   the	   splenocyte	   population)	   were	   collected	   per	  
sample.	  
	  
2.2.7.5.4. Percentage	  lysis	  calculation	  
The	  percentage	  lysis	  of	  each	  group	  was	  calculated	  by	  the	  following	  formulae:	  
Formula	  1:	  	  	   r	  =	   number	  CFSEHIGH	  population	  events	  collected	  
number	  CFSELOW	  population	  events	  collected	  
	  
Formula	  2:	  	   Percentage	  lysis	  =	  (1	  -­‐	  (rPBS	  group/rimmunised	  groups))	  X	  100	  
	  
	  
2.2.7.6. In	  vivo	  tracking	  SIINFEKL-­‐mAb	  conjugates	  
2.2.7.6.1. Immunisation	  schedule	  for	  SIINFEKL-­‐mAb	  conjugates	  
A	  group	  of	  5	  naïve	  C57Bl/6	  mice	  and	  3	  BALB/c	  mice	  were	  immunised	  subcutaneously	  
with	   10μg	   (in	   a	   200μl	   volume)	   SIINFEKLC-­‐CD40mAb	   (right	   flank)	   and	   SIINFEKLC-­‐
GL117mAb	   (left	   flank)	   conjugate,	   per	   group.	   After	   24	   hours	   the	   inguinal	   draining	  
lymph	  nodes	  were	  excised	   and	  processed.	   The	   spleen	  was	   also	  harvested	   for	   flow	  
cytometric	  single	  cell	  staining.	  
	  
2.2.7.6.2. Flow	  cytometric	  analysis	  of	  APC	  presenting	  SIINFEKL	  
Lymph	   nodes	   were	   processed	   as	   explained	   in	   Section	   2.2.6.2.	   Flow	   cytometric	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2.2.8. Other	  techniques	  and	  analysis	  
2.2.8.1. Endotoxin	  Assay	  	  
To	   determine	   endotoxin	   levels	   of	   conjugates,	   antibodies	   and	   OVA	   the	   Endpoint	  
Chromogenic	  LAL	  test	  was	  carried	  out.	  Prior	  to	  the	  assay	  all	  glass	  tubes	  to	  be	  used	  
were	   rendered	   endotoxin-­‐free	   by	   heating	   at	   250°C	   for	   at	   least	   2	   hours.	   Reagents	  
were	  prepared	  according	  to	  the	  manufacturer’s	  instructions.	  Briefly,	  the	  LAL	  reagent	  
was	  reconstituted	  right	  before	  use,	  by	  the	  addition	  of	  1.4ml	  endotoxin-­‐free	  reagent	  
water	  to	  the	  reagent	  vial.	  The	  lyophilised	  chromogenic	  substrate	  was	  reconstituted	  
by	   the	   addition	   of	   6.5ml	   of	   LAL	   endotoxin-­‐free	   reagent	   water	   yielding	   a	  
concentration	   of	   approximately	   2mM.	   This	   was	   kept	   protected	   from	   light.	   The	  
lyophilized	   endotoxin	   was	   reconstituted	   by	   the	   addition	   of	   1.0ml	   reagent	   water	  
(warmed	  to	  RT).	  The	  actual	  concentration	  of	  the	  endotoxin	  standard	  was	  determined	  
from	   the	   certificate	  of	   analysis.	   Prior	   to	  preparation	  of	   the	   standards,	   the	   solution	  
was	  vigorously	  vortexed	  continuously	  for	  15	  minutes	  to	  prevent	  endotoxin	  attaching	  











1.0	   0.1	  ml	   -­‐-­‐	   (X-­‐1)/10ml	  
0.5	   -­‐-­‐	   0.5ml	   0.5ml	  
0.25	   -­‐-­‐	   0.5ml	   1.5ml	  
0.1	   -­‐-­‐	   0.1ml	   0.9ml	  
Table	  2.13.	  Preparation	  of	  standards	  for	  the	  endotoxin	  assay	  
X	  =	  endotoxin	  concentration	  of	  the	  vial	  	  
	  
Samples	  were	  prepared	  at	  10μg	  in	  50μl	  (final	  concentration	  of	  200μg/ml)	  endotoxin-­‐
free	  reagent	  water	  in	  glass	  tubes.	  Four	  endotoxin	  standards	  were	  used	  in	  duplicate,	  
namely	  1.0	  EU/ml,	  0.5	  EU/ml,	  0.25	  EU/ml	  and	  0.1	  EU/ml	  (Table	  2.13).	  A	  blank	  sample	  
that	  consisted	  of	  50μl	  endotoxin-­‐free	  reagent	  water	  only	  was	  also	  used	  per	  test.	  The	  
order	  of	  addition	  of	  reagents	  from	  vessel	  to	  vessel	  and	  the	  rate	  of	  pipetting	  was	  kept	  
consistent	  from	  sample	  to	  sample	  at	  each	  step.	  Freshly	  reconstituted	  LAL	  (50μl)	  was	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added	  to	  the	  reaction	  vessel.	  Timing	  was	  started	  as	  soon	  as	  the	  reagent	  was	  added	  
to	   the	   sample.	   Each	   sample	   was	   thoroughly	   mixed.	   After	   10	   minutes	   incubation,	  
100μl	  of	  chromogenic	  substrate	  solution	  (pre-­‐warmed	  to	  37°C	  prior	  to	  addition)	  was	  
added	   to	   the	   sample,	   thoroughly	  mixed,	   and	   incubated	   at	   37°C	   for	   6	  minutes.	   To	  
stop	   the	   reaction	   100μl	   of	   10%	   SDS	   was	   added,	   and	   200μl	   of	   each	   sample	   was	  
transferred	   to	   a	   sterile	   individually	   wrapped	   96-­‐well	   plate.	   The	   absorbance	   was	  
quickly	   read	   at	   405nm	   using	   ELx808™	   Absorbance	   Microplate	   Reader.	   The	  
concentration	  of	  the	  unknown	  samples	  was	  determined	  using	  a	  standard	  curve.	  
	  
2.2.8.2. Statistical	  Analysis	  
All	   statistical	  analysis	  was	  performed	  using	  GraphPad	  Prism	  6	  software.	  The	  values	  
having	  a	  p<0.05	  were	  deemed	  significant	  from	  controls	  and	  marked	  with	  an	  asterisk.	  
Data	  was	  expressed	  as	  mean	  +/-­‐	  standard	  deviation	  (SD).	  To	  determine	  the	  statistical	  
significance	   between	   two	   groups	   an	   unpaired	   or	   paired,	   two-­‐tailed	   Student	   t	   test	  
was	   performed.	   A	   Mann-­‐Whitney	   test	   was	   used	   for	   sample	   data	   not	   normally	  
distributed.	  To	  determine	  the	  statistical	  significance	  between	  more	  than	  two	  groups	  
an	   unpaired,	   one-­‐way	   ANOVA	   was	   used	   together	   with	   either	   Dunnett’s	   post-­‐test	  
(compares	  every	  mean	  to	  a	  control	  mean),	  Tukey’s	  post-­‐test	  (compares	  every	  mean	  
with	   every	   other	   mean)	   or	   Sidak’s	   post-­‐test	   (comparisons	   between	   means	   of	  
selected	   groups)	   was	   performed.	   An	   unpaired	   Dunn’s	   (non-­‐parametric)	   multiple	  
comparison	   test	  was	  used	   to	  determine	  statistical	   significance	   for	   sample	  data	  not	  
normally	   distributed.	   Kaplan-­‐Meier	   survival	   analysis	   was	   carried	   out	   to	   determine	  
the	  overall	  survival	  between	  groups	  using	  a	  log-­‐rank	  test.	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3.1.	  Introduction	  
The	  impact	  of	  bioconjugation	  in	  vaccine	  development	  and	  design	  is	  substantial.	  The	  
importance	   of	   vaccine	   design	   and	   composition	   should	   not	   be	   underestimated	  
because	   the	   immunogenicity	   and	   efficacy	   of	   the	   vaccine	   does	   not	   just	   rely	   on	   the	  
carrier	  protein	  or	  adjuvant,	   the	  method	  of	  conjugation	  also	  plays	  a	  significant	  role.	  
As	   a	   consequence	   novel	   vaccines	   are	   developed	   using	   more	   refined	   conjugation	  
techniques.	  One	  example	  includes	  the	  conjugation	  strategies	  used	  to	  link	  lymphoma-­‐
specific	  antigen	  to	  carrier	  proteins.	  
B	   cell	   lymphomas	   express	   a	   unique	   Ig,	   referred	   to	   as	   an	   idiotype	   (Id),	   which	   is	  
considered	  a	  tumour-­‐specific	  antigen	  (Stevenson	  and	  Stevenson,	  1975).	  Lymphoma-­‐
Id	   is	  not	   immunogenic	  enough	  when	  injected	  alone,	  so	   it	   is	  generally	   linked	  to	  KLH	  
(KLH-­‐Id),	   using	   glutaraldehyde	   conjugation,	   which	   was	   tested	   in	   phase	   III	   clinical	  
studies	   (Bendandi,	   2009).	  More	   recently,	   KLH-­‐Id	   conjugation	  was	   performed	   using	  
maleimide	  coupling,	  which	  was	  found	  to	  dramatically	  enhance	  vaccine	  efficacy	   in	  a	  
murine	   lymphoma	   model	   (Betting	   et	   al.,	   2008).	   The	   authors	   suggested	   that	   the	  
conjugation	   strategy	   was	   possibly	   superior	   because	   the	   reaction	   is	   limited	   to	  
reduced	  cysteine	  sulphydryl	  groups,	  resulting	  in	  less	  precipitation	  and	  the	  formation	  
of	   fewer	   high	   MW	   complexes	   (Kafi	   et	   al.,	   2009).	   Alternatively,	   glutaraldehyde	  
treatment	  causes	  extensive	  cross-­‐linking	  of	  the	  tumour	  antigen	  that	  may	  potentially	  
destroy	  valuable	  epitopes.	  Furthermore,	  sulphydryl-­‐maleimide	  coupling	  of	  CD40mAb	  
to	  lymphoma-­‐Id	  is	  superior	  to	  the	  use	  of	  KLH	  in	  a	  murine	  lymphoma	  model	  (Carlring	  
et	  al.,	  2012).	  	  
Sulphydryl-­‐maleimide	   coupling	   of	   the	   adjuvant	   CD40mAb	   to	   antigen	   has	   been	   the	  
method	  of	  choice	   in	  our	   lab	   for	  making	  CD40mAb	  vaccine	  conjugates	   (Figure	  3.1A)	  
for	  more	  than	  a	  decade	  (Barr	  et	  al.,	  2003,	  Carlring	  et	  al.,	  2004,	  Hatzifoti	  and	  Heath,	  
2007,	  Carlring	  et	  al.,	  2012).	  Briefly,	  sulphydryl-­‐maleimide	  coupling	  consists	  of	  the	  use	  
of	   the	   heterobifunctional	   molecules	   Sulfosuccinimidyl	   4-­‐[N-­‐maleimidomethyl]-­‐
cyclohexane-­‐1-­‐carboxylate	  (Sulfo-­‐SMCC),	  which	  introduces	  a	  maleimide	  group	  to	  the	  
antigen	   via	   amines	   and	   the	   N-­‐Succinimidyl	   S-­‐Acetylthioacetate	   (SATA),	   which	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introduces	   sulphydryl	   groups	   to	   the	   antibody	   via	   amines.	   The	  maleimide	   activated	  
protein	  reacts	  with	  sulphydryls	  on	  the	  antibody	  to	  form	  a	  stable	  thioether	  bond.	  	  
Early	   studies	   conducted	   in	   our	   laboratory	   using	   sulphydryl-­‐maleimide	   coupling	  
showed	   that	   CD40mAb,	   when	   chemically	   conjugated	   to	   the	   model	   antigen	   OVA	  
enhanced	  primary	  antibody	  responses	  against	  OVA,	  compared	  to	  OVA	  antigen	  alone	  
or	   a	   mixture	   of	   CD40mAb	   and	   OVA	   antigen	   (Barr	   et	   al.,	   2003).	   This	   showed	   the	  
potential	   of	   CD40mAb-­‐adjuvanted	   conjugates	   as	   vaccine	   candidates.	   Despite	   the	  
advantages	  of	  using	   sulphydryl-­‐maleimide	  coupling,	  CD40mAb	  conjugates	  made	  by	  
this	  method	  are	  poorly	  defined	  and	  heterogeneous.	  This	  means	  that	  a	  conjugate	  will	  
consist	  of	  more	  than	  one	  antigen	  molecule	  linked	  to	  one	  antibody	  molecule	  and	  vice	  
versa,	  leading	  to	  a	  mixture	  of	  high	  and	  low	  molecular	  weight	  (MW)	  products.	  	  
It	  is	  known	  that	  CD40mAb	  works	  better	  as	  an	  adjuvant	  in	  a	  monomeric	  state	  (Heath	  
and	   Laing,	   2004).	  We	   therefore	   hypothesised	   that	   CD40mAb	   conjugates	   of	   lowest	  
MW	   and	   greatest	   CD40mAb	   accessibility	   would	  make	   the	  most	   efficient	   vaccines.	  
This	  led	  us	  to	  assess	  the	  cutting-­‐edge	  technology	  click	  chemistry	  (Kolb	  et	  al.,	  2001)	  to	  
further	  refine	  conjugates	  of	  CD40mAb	  and	  antigen.	  The	  name	  ‘Click	  Chemistry’	  was	  
created	  by	  Kolb	  and	  colleagues	  in	  the	  early	  21st	  century	  to	  describe	  a	  high	  yielding,	  
very	   specific	   reaction	   with	   by-­‐products	   that	   could	   be	   easily	   removed	   (Kolb	   et	   al.,	  
2001).	   Click	   chemistry	   has	   been	   applied	   in	   conjugation	   of	   heterogeneous	  
polysaccharides	   to	   vaccine	   antigens	   or	   carriers,	   for	   example	   the	   non-­‐toxic	   cross-­‐
reacting	  material	   of	   diphtheria	   toxin	   (CRM197)	   (Crotti	   et	   al.,	   2014),	   chicken	   serum	  
albumin	   (Lipinski	   et	   al.,	   2011)	   and	   tetanus	   toxoid	   (Lipinski	   et	   al.,	   2013,	  Wu	   et	   al.,	  
2013)	   refining	   polysaccharide-­‐based	   conjugate	   vaccines.	   Click	   chemistry	   has	   also	  
been	   applied	   in	   lymphoma	   immunotherapy	   research	   (Patel	   and	   Swartz,	   2011),	   in	  
conjugation	  of	  the	  cytokine	  GM-­‐CSF,	  the	  immunostimulatory	  molecule	  CpG	  DNA	  and	  
lymphoma-­‐Id	   to	   VLPs.	   Click	   chemistry	   conjugation	   allowed	  more	   control	   over	   the	  
ratio	  of	  the	  molecules	  conjugated	  to	  VLPs.	  	  
The	   click	   chemistry	   method	   (Figure	   3.1B)	   used	   in	   this	   study	   involves	   a	   reaction	  
between	   a	   dibenzylcyclooctyne-­‐NHS	   ester	   (DBCO-­‐NHS)	   linker	   and	   an	   15-­‐Azido-­‐
4,7,10,13-­‐tetraoxa-­‐pentadecanoic	  acid	  succinimidyl	  ester	  (NHS-­‐PEG4-­‐Azide)	  linker	  (in	  
a	  copper	  free	  system).	  These	  reagents	  are	  very	  narrowly	  reactive	  only	  to	  each	  other	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leading	   to	   very	   efficient	   and	   specific	   linkage	   between	   the	   proteins	   even	   in	   the	  
presence	  of	  other	  functional	  groups	  such	  as	  amine	  and	  sulphydryl	  groups,	  producing	  
a	   less	   heterogeneous	   conjugate.	   The	   use	   of	   a	   copper-­‐free	   reaction	   also	   known	   as	  
strain-­‐promoted	   alkyne-­‐azide	   cycloaddition,	   overcomes	   the	   problem	   of	   possible	  
copper	  toxicity.	  
In	   this	   chapter,	   two	   CD40mAb-­‐adjuvanted	   conjugates	   made	   using	   sulphydryl-­‐
maleimide	   coupling	   (Standard	   conjugates)	   and	   click	   chemistry	   (CLICK	   conjugates)	  
(Figure	  3.1.)	  were	  evaluated.	  Firstly,	  CD40mAb	  was	  conjugated	  to	  A20	  murine	  B	  cell	  
lymphoma	   Id,	   referred	   to	   as	   the	   A20	   antibody	   (A20-­‐mAb	   conjugates),	   by	   both	  
methods.	   The	   two	  methods	  were	   compared	   by	   prophylactic	  murine	   immunisation	  
and	   subsequent	   challenge	  with	   A20	   lymphoma	   cells	   in	   a	  mouse	  model.	   Secondly,	  
CD40mAb	  was	  conjugated	  to	  the	  model	  antigen	  OVA	  (OVA-­‐mAb	  conjugates)	  by	  both	  
methods	  and	  the	  immunogenicity	  of	  the	  conjugates	  was	  compared.	  OVA	  antigen	  has	  
been	  chosen	  as	  a	  model	  because	  it	  allows	  convenient	  testing	  of	  CD4+	  and	  CD8+	  T	  cell	  
responses	   due	   to	   the	   readily	   available	  OVA-­‐specific	   reagents,	  which	  would	   not	   be	  
possible	  if	  A20-­‐CD40mAb	  conjugates	  are	  used.	  	  
To	   test	   our	   hypothesis,	   HPLC	   was	   used	   to	   isolate	   the	   A20-­‐CD40mAb	   and	   OVA-­‐
CD40mAb	   conjugates	   of	   lowest	   average	   MW	   made	   by	   click	   chemistry.	   The	  
unfractionated	   CLICK	   conjugates	   as	   well	   as	   the	   highest	   and	   lowest	   average	   MW	  
conjugates	   were	   compared	   to	   Standard	   conjugates	   and	   characterised	   primarily	   in	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A.	   	  
	  
B.	   	  
Figure	   3.1.	   Schematic	   representation	   of	   the	   two	   conjugation	   strategies	   used	   in	   this	  
chapter:	  sulphydryl-­‐maleimide	  chemistry	  (A)	  and	  click	  chemistry	  (B).	  	  
A.	   Sulphydryl-­‐maleimide	   chemistry	   or	   Standard	   method.	   OVA	   or	   A20	   antibody	   are	  
maleimide-­‐activated	  with	   heterobifunctional	   agent	   Sulfo-­‐SMCC.	   Antibody	   is	   functionalised	  
with	  SATA	  to	   introduce	  protected	  sulphydryl	  groups,	  by	   forming	  a	  stable	  amide	  bond	  with	  
amines	  on	  the	  antibody.	  The	  addition	  of	  hydroxylamine	  results	   in	   the	  de-­‐protection	  of	   the	  
sulphydryl	   groups.	  Maleimide-­‐activated	   OVA	   antigen	   or	   A20	   antibody	   are	  mixed	  with	   the	  
functionalised	   antibody.	   The	  maleimide	   group	  obtained	   from	  SMCC	   reacts	  with	   sulphydryl	  
on	  the	  antibody	  to	  form	  a	  stable	  thioether	  bond.	  	  
B.	  Click	   chemistry	  method.	   CD40mAb	   is	   functionalised	   on	   lysine	   residues	  with	  DBCO-­‐NHS	  
and	  reacted	  with	  NHS-­‐PEG4-­‐Azide	  functionalized	  antigen	  (OVA	  antigen	  or	  A20	  antibody)	  to	  
form	  a	  stable	  triazole	  between	  the	  two.	  	  
Antibody	   =	   CD40mAb	   or	   corresponding	   isotype	   control	   mAb	   (20C2mAb);	   Protein	   =	   A20	  
antibody	   or	   OVA;	   SMCC	   =	   Succinimidyl	   4-­‐[N-­‐maleimidomethyl]-­‐cyclohexane-­‐1-­‐carboxylate;	  
SATA	  =	  N-­‐Succinimidyl	  S-­‐Acetylthioacetate;	  DBCO	  =	  Dibenzylcyclooctyne-­‐NHS	  ester;	  Azide	  =	  
























26102 SATA (N-Succinimidyl S-Acetylthioacetate), 50 mg 
 Molecular Weight: 231.23 
 Spacer Arm Length (from amine to sulfur after conjugation): 2.8 Å  
 CAS #76931-93-6 
 
26100 SATP (N-Succinimidyl S-Acetylthiopropionate), 50 mg 
 Molecular Weight: 245.25 
 Spacer Arm Length (from amine to sulfur after conjugation): 4.1 Å 
 CAS #84271-78-3 
 Storage: Upon receipt store desiccated at -20°C. Product is shipped at ambient temperature. 
 
Introduction 
SATA and SATP are reagents for introducing protected sulfhydryls into proteins, peptides and other molecules. They are the 
N-hydroxysuccinimide (NHS) esters of S-acetylthioacetic and propionic acid (Figure 1). A stable, covalent amide bond is 
formed from the reaction of the NHS ester with primary amines. The amine reacts with the NHS ester by nucleophilic attack, 
with N-hydroxysuccinimide being released as a by-product. Deprotection (deacylation) to generate a sulfhydryl for use in 
cross-linking and other applications is accomplished using hydroxylamine•HCl (See Related Thermo Scientific Products). 
Sulfhydryl groups present on proteins, peptides and other compounds are important in protein chemistry/modification 
reactions. In several cases, thiols are unavailable or absent within the molecules of interest. While several reagents and 
techniques1,2 are available for introducing sulfhydryl groups or disulfides into proteins and peptides including Traut’s 
Reagent and SPDP (see Related Thermo Scientific Products at the end of these instructions), SATA and SATP have several 
features and benefits for sulfhydryl addition applications: 
x Reaction conditions are mild and non-denaturing. NHS ester reactions may be performed in a variety of non-amine 
buffers at pH 7-9 and temperatures 4-37°C, with incubation times ranging from few minutes to overnight. 
x The reaction is specific toward primary amines. See Appendix for a schematic of the SATA reaction. 
x Sulfhydryl groups are introduced in a protected form, allowing the modified molecule to be stored indefinitely and then 
















Figure 1a. Molecular structure of SATA 
(N-succinimidyl S-acetylthioacetate). 
Figure 1b. Molecular structure of SATP 
(N-succinimidyl S-acetylthiopropionate). 
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3.2. Efficacy	  of	  a	  lymphoma	  antigen	  and	  CD40mAb	  conjugate	  
as	  a	  prophylactic	  vaccine	  in	  a	  murine	  lymphoma	  model	  
3.2.1. Fractionation	  of	  A20-­‐mAb	  conjugates	  by	  HPLC	  
A20	   antibody	   was	   conjugated	   to	   CD40mAb	   and	   the	   isotype	   control	   antibody,	  
20C2mAb	  using	  the	  standard	  method	  (see	  Section	  2.2.1.1.),	  and	  the	  click	  chemistry	  
method	  (see	  Section	  2.2.1.6.).	  	  
To	   determine	   whether	   the	   A20-­‐CD40mAb	   conjugate	   consisted	   of	   a	   mixture	   of	  
conjugates	   ranging	   from	   very	   high	   to	   very	   low	   average	   MW,	   as	   well	   as	   free	  
unconjugated	  CD40mAb	  and	  A20	  antibody,	   the	  conjugates	  were	  analysed	  by	  HPLC.	  
The	   sample	   buffer	   and	   the	   conditions	   under	   which	   the	   samples	   were	   run	   were	  
optimised	  by	  Dr.	  Oliver	  Wilkinson	  (Department	  of	  Chemistry,	  University	  of	  Sheffield),	  
as	  described	  in	  Materials	  and	  Methods	  (see	  Section	  2.2.2).	  
In	   order	   to	   accurately	   investigate	   the	   composition	   of	   the	   heterogeneous	   A20-­‐
CD40mAb	   conjugate,	   standards	   of	   sizes	   ranging	   from	   13.7kDa	   to	   660kDa	   were	  
separated	   by	  HPLC	   (Figure	   3.2).	   The	   highest	  MW	   standard	  was	   observed	   first	   (7.2	  
minutes)	  whilst	   the	   lowest	  MW	  standard	  was	   observed	   last	   (11.4	  minutes)	   on	   the	  
HPLC	  chromatogram.	  
In	   addition	   to	   the	   standards,	   the	   antibody	   alone	   as	   well	   as	   the	   antibody	  
functionalised	   with	   DBCO-­‐NHS	   or	   NHS-­‐PEG4-­‐Azide	   were	   analysed	   as	   part	   of	   the	  
optimisation	   process	   (Figure	   3.3).	   The	   A20	   antibody	   peak	   was	   observed	   at	   8.578	  
minutes	  whilst	  CD40mAb	  and	  the	  isotype	  control	  antibody,	  20C2mAb	  were	  observed	  
at	  9.2	  and	  9.24	  minutes	  respectively	  (Figure	  3.3A).	  This	  means	  that	  the	  A20	  antibody	  
is	  of	  higher	  MW	  than	  the	  other	  two	  antibodies.	  When	  functionalised	  with	  NHS-­‐PEG4-­‐
Azide	  the	  A20	  antibody	  peak	  was	  observed	  slightly	  earlier	  at	  8.541	  minutes.	  When	  
functionalised	  with	   DBCO-­‐NHS	   the	   CD40mAb	  was	   observed	   at	   9.2	  minutes,	   whilst	  
the	   isotype	   control	   antibody	   was	   observed	   at	   9.206	   minutes	   (Figure	   3.3B).	  
Conjugation	   with	   NHS-­‐PEG4-­‐Azide-­‐linker	   or	   DBCO-­‐NHS-­‐linker	   only	   slightly	   affected	  
the	   time	   at	  which	   the	   peaks	  were	   observed.	   This	   information	   allowed	   us	   to	  more	  
informatively	   identify	   the	   conjugate	   fractions	   of	   interest	   in	   the	   A20-­‐CD40mAb	  
conjugates.	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A	  50μg	  sample	  of	  CLICK	  and	  Standard	  A20-­‐CD40mAb	  conjugates	  were	  analysed	  on	  
the	   HPLC	   size-­‐exclusion	   column	   (SEC),	   and	   by	   comparing	   to	   the	   MW	   standards	  
(Figure	  3.2),	  the	  CLICK	  conjugate	  fractions	  of	  interest	  could	  be	  identified	  (Figure	  3.4).	  
Considering	  that	  the	  standard	  of	  MW	  660kDa	  emerged	  around	  7	  minutes,	  the	  peak	  
observed	   at	   5	  minutes	   would	   be	   with	   high	   probability	   a	   conjugate	   of	   the	   highest	  
average	   MW.	   Furthermore,	   as	   the	   results	   showed	   that	   the	   free	   unconjugated	  
antibodies,	   as	  well	   as	   the	  NHS-­‐PEG4-­‐Azide	   or	   DBCO-­‐NHS	   functionalised	   antibodies	  
emerged	   after	   8.2	   minutes	   (Figure	   3.3),	   we	   assumed	   that	   a	   peak	   emerging	   just	  
before	  would	  correspond	  to	  a	  conjugate	  containing	  one	  CD40mAb	  conjugated	  to	  one	  
A20	  antibody.	  	  
On	  comparing	  the	  conjugates	  made	  by	  the	  two	  different	  methods	   (Figure	  3.4),	   the	  
peaks	   appeared	   at	   similar	   times,	   however,	   Standard	   A20-­‐CD40mAb	   conjugate	  
contains	   mostly	   higher	   average	   MW	   proteins	   (5-­‐6	   minutes),	   whilst	   CLICK	   A20-­‐
CD40mAb	   conjugate	   contained	   more	   lower	   average	   MW	   proteins	   (6-­‐8	   minutes)	  
observed	  after	  the	  5	  minute	  peak.	  Once	  the	  fractions	  of	  interest	  were	  identified	  the	  
CLICK	   conjugates	   were	   centrifuged	   to	   remove	   precipitates	   and	   the	   samples	   were	  
analysed	  on	  the	  HPLC	  SEC	  to	  be	  separated.	  Four	  fractions	  were	  collected	  from	  A20-­‐
CD40mAb	  conjugates	   (Figure	  3.5),	  and	  these	  are	  tabulated	   in	  Table	  3.1.	  Respective	  
fractions	   from	   CLICK	   A20-­‐istoype	   control	   antibody	   conjugates	   were	   also	   collected	  
(Figure	  3.5).	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Figure	   3.2.	  HPLC	  optimisation	  using	  different	   standards	   of	  MW	   ranging	   from	  13.7kDa	   to	  
660kDa.	  The	  time	  in	  red	  corresponds	  to	  the	  highest	  peak	  of	  each	  standard.	  The	  absorbance	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Figure	  3.3.	  HPLC	  chromatograms	  of	  unconjugated	  antibodies,	  as	  well	   as	  NHS-­‐PEG4-­‐Azide	  
functionalised	   A20	   and	   DBCO-­‐NHS	   functionalised	   antibodies.	   The	   numbers	   shown	   in	   red	  
represent	   the	   time	   taken	   for	   the	   peak	   of	   the	   antibody	   or	   the	   functionalised	   antibody	   to	  
emerge	   on	   the	   HPLC	   chromatogram.	   The	   absorbance	   readings	   on	   the	   HPLC	   plots	   were	  
measured	  at	  280nm.	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Figure	  3.4.	  Representative	  HPLC	  chromatograms	  of	  the	  Standard	  and	  CLICK	  A20-­‐CD40mAb	  
conjugates.	   The	   numbers	   shown	   in	   red	   represent	   the	   time	   taken	   for	   the	   peak	   of	   the	  
particular	   fraction	  to	  emerge	  on	  the	  HPLC	  chromatogram.	  The	  absorbance	  readings	  on	  the	  
HPLC	  plots	  were	  measured	  at	  280nm.	  
	  
	  
Figure	  3.5.	  Representative	  HPLC	  chromatograms	  of	  the	  CLICK	  A20-­‐mAb	  conjugates	  and	  the	  
different	   fractions	   collected.	   The	   fractions	   collected	   included:	   Fraction	   1	   (blue)	   from	   5	  
minute	  to	  5.8	  minutes,	  Fraction	  2	  (pink)	  collected	  from	  5.9	  minutes	  to	  7.5	  minutes,	  Fraction	  
3	  (purple)	  collected	  from	  7.6	  minutes	  to	  8.1	  minutes	  and	  Fraction	  4	  (orange)	  collected	  from	  
8.2	  minutes	   to	  11	  minutes.	  The	  absorbance	   readings	  on	   the	  HPLC	  plots	  were	  measured	  at	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A	  BCA	  assay	   (see	   Section	  2.2.3.)	  was	  used	  to	  quantify	   the	  protein	  concentration	  of	  
each	  fraction.	  The	  four	  fractions	  of	  the	  CLICK	  A20-­‐mAb	  conjugates	  were	  labelled	  as	  
explained	   in	  Table	  3.1	  and	  will	  be	  referred	  to	  as	  Fraction	  1,	  2,	  3	  or	  4	   (according	  to	  
decreasing	  average	  MW)	  from	  this	  point	  on.	  	  
	  
CLICK	  A20-­‐mAb	  conjugate	  fractions	  collected	  
5	  -­‐	  5.8	  minutes	  
(Fraction	  1)	  
5.9	  –	  7.5	  minutes	  
(Fraction	  2)	  
7.6	  –	  8.1	  minutes	  
(Fraction	  3)	  
8.2	  -­‐	  11	  minutes	  
(Fraction	  4)	  
Table	  3.1.	  CLICK	  A20-­‐mAb	  conjugate	  fractions	  collected	  by	  minutes	  on	  HPLC	  
	  
From	   the	   four	   fractions	   collected,	   Fraction	  1,	  which	   contained	   the	  highest	  average	  
MW	  protein	  and	  Fraction	  3,	  which	  contained	  the	  lowest	  average	  MW	  protein,	  were	  
the	  fractions	  of	  greatest	  interest	  to	  test	  our	  hypothesis	  that	  CD40mAb	  conjugates	  of	  
lowest	  MW	  would	  make	  better	   vaccines.	   Comparative	   studies	  with	   Fraction	   2	   and	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3.2.2. Characterisation	  of	  unfractionated	  and	  fractionated	  A20-­‐mAb	  
conjugates	  in	  vitro	  
3.2.2.1. Characterisation	   of	   A20-­‐mAb	   conjugates	   using	   an	   anti-­‐rat	   IgG	   and	  
anti-­‐mouse	  IgG	  antibody	  ELISA	  
Efficient	   conjugation	   of	   CD40mAb	   or	   isotype	   control	   20C2mAb	   (Rat	   IgG1)	   to	   A20	  
antibody	   (Mouse	   IgG2a)	  was	  confirmed	  by	  sandwich	  ELISA.	  Two	  types	  of	   sandwich	  
ELISAs	  (Figures	  3.6	  and	  3.7)	  were	  used,	  (i)	  sandwich	  ELISA	  I	  (rat	  IgG	  and	  mouse	  IgG	  
specific):	   used	   goat	   anti-­‐rat	   IgG	   to	   capture	   CD40mAb	   or	   isotype	   control	  mAb	   and	  
peroxidase-­‐labelled	   goat	   anti-­‐mouse	   IgG	   to	   detect	   A20	   antibody	   (see	   Section	  
2.2.4.3.2.)	   and	   (ii)	   sandwich	   ELISA	   II	   (CD40mAb	   and	   mouse	   IgG	   specific):	   used	   a	  
recombinant	  CD40/Fc	  chimera	  to	  capture	  CD40mAb	  and	  a	  peroxidase-­‐labelled	  goat	  
anti-­‐mouse	  IgG	  to	  detect	  A20	  antibody	  (see	  Section	  2.2.4.3.3.).	  
Due	  to	  the	  specificity	  of	  ELISA	  I	  only	  A20	  antibody	  conjugated	  to	  CD40mAb	  or	  control	  
mAb	   would	   be	   detected	   whereas	   unconjugated	   A20	   antibody,	   CD40mAb	   and	  
20C2mAb	   would	   be	   undetected.	   ELISA	   I	   confirmed	   that	   A20	   antibody	   was	  
successfully	  conjugated	  to	  CD40mAb	  and	  20C2mAb	  (Figure	  3.6).	  A	  closer	  look	  at	  the	  
results	  demonstrates	  that	  unfractionated	  CLICK	  A20-­‐mAb	  conjugates	  have	  a	  greater	  
conjugate	   purity	   as	   a	   higher	   OD	   is	   observed	   compared	   to	   the	   Standard	   A20-­‐mAb	  
conjugates	   (Figure	   3.6A).	   Fractions	   2,	   3	   and	   4	   bind	   to	   the	   ELISA	   I	   antibodies	  
efficiently	   down	   to	   a	   concentration	   of	   less	   than	   31.3ng/ml.	   In	   contrast,	   Fraction	   1	  
efficient	   binding	   to	   the	   ELISA	   I	   antibodies	   was	   only	   observed	   down	   to	   a	  
concentration	   of	   31.3ng/ml	   (Figure	   3.6B),	   similar	   to	   the	   Standard	   A20-­‐mAb	  
conjugates	  (Figure	  3.6A).	  	  
When	  considering	  the	  dilution	  factor	   (from	  a	  starting	  concentration	  1µg/ml)	  at	   the	  
specific	   OD	   of	   0.5,	   Fraction	   2	   contains	   the	   greatest	   conjugate	   purity,	   followed	   by	  
Fraction	  3	  and	  unfractionated	  CLICK	  conjugate.	  Considering	   that	   the	   functionalised	  
A20	   antibody	   emerged	   at	   8.541	  minutes	   on	   the	  HPLC	   (Figure	   3.3),	   Fraction	   4	   that	  
was	   collected	   from	   8.2-­‐11	   minutes	   would	   contain	   with	   high	   probability	   free	  
unconjugated	   A20	   antibody,	   CD40mAb	   or	   20C2mAb.	   However,	   some	   A20-­‐mAb	  
CHAPTER	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conjugate	  is	  still	  present	  in	  Fraction	  4,	  observed	  due	  to	  the	  increase	  in	  OD	  compared	  
to	  the	  antibody	  controls	  (Figure	  3.6C).	  Fraction	  1	  and	  whole	  Standard	  conjugate	  bind	  
least	  efficiently	  to	  the	  ELISA	  I	  antibodies,	  showing	  least	  conjugate	  purity,	  which	  could	  
be	  due	  to	  high	  MW	  complexes	  masking	  the	  binding	  sites	  of	  the	  ELISA	  antibodies.	  
As	   ELISA	   II	   utilises	   recombinant	   CD40/Fc	   chimera	   instead	   of	   anti-­‐rat	   IgG	   as	   a	  
capturing	   antibody,	   limiting	   its	   specificity	   to	   A20-­‐CD40mAb	   conjugates,	   only	   A20	  
antibody	  conjugated	  to	  CD40mAb	  (but	  not	  control	  mAb)	  have	  the	  potential	  to	  give	  a	  
positive	  signal	   in	  this	  assay,	  demonstrated	  by	  an	   increase	   in	  OD.	  The	  unconjugated	  
A20	  antibody,	  CD40mAb	  and	  20C2mAb	  would	  also	  remain	  undetected.	  ELISA	   II	  not	  
only	  demonstrates	   that	   the	  A20	  antibody	   is	  conjugated	  to	  CD40mAb	  but	  also,	   that	  
the	  CD40mAb	  is	  still	  able	  to	  bind	  to	  CD40	  after	  conjugation.	  
The	  unfractionated	  A20-­‐CD40mAb	  conjugates,	   the	   fraction	  of	  highest	  average	  MW	  
(Fraction	   1)	   and	   the	   fraction	   of	   lowest	   average	   MW	   (with	   possible	   limited	   free	  
contaminating	  antibodies)	  (Fraction	  3)	  were	  compared	  to	  each	  other	  using	  ELISA	  II.	  
Fraction	  1,	  Fraction	  3	  and	  both	  unfractionated	  conjugates	  contained	  A20-­‐CD40mAb	  
conjugates	  (Figure	  3.7A),	  confirmed	  by	  the	  increase	  in	  OD	  compared	  to	  the	  antibody	  
only	  controls.	  When	  observing	  the	  relative	  binding	  of	  the	  conjugates	  at	  the	  specific	  
OD	  of	  1.0,	   the	  unfractionated	  CLICK	  conjugate	  consists	  of	  highest	  conjugate	  purity,	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A.	  	  	   	  
B.	  	   	  
C.	   	  
Figure	   3.6.	   Confirmation	   of	   CD40mAb	   (or	   isotype	   control	   mAb)	   conjugation	   to	   A20	  
antibody	  by	  means	  of	  sandwich	  ELISA	  I.	  Goat	  anti-­‐rat	  IgG	  antibody	  was	  used	  to	  capture	  and	  
peroxidase-­‐conjugated	   polyclonal	   anti–mouse	   Ig	   antibody	   was	   used	   to	   detect	   A20-­‐mAb	  
conjugates.	  Presence	  of	  A20-­‐mAb	  conjugate	  is	  demonstrated	  by	  an	  increase	  in	  OD	  at	  450nm.	  
Parental	  A20	  antibody,	  CD40mAb	  and	  20C2mAb	  were	  used	  as	  negative	  controls.	  A.	  Relative	  
binding	   of	   unfractionated	   CLICK	   and	   Standard	  A20-­‐mAb	   conjugates.	   B.	   Relative	   binding	   of	  
A20-­‐CD40mAb	   conjugate	   fractions	   and	   unconjugated	   antibody	   controls.	   C.	   Comparison	   of	  
the	  interpolated	  1/dilution	  of	  the	  A20-­‐mAb	  conjugate	  concentration	  giving	  an	  OD	  of	  0.5.	  The	  
dilution	  corresponding	  to	  1/1	  is	  1000ng/ml	  (starting	  concentration).	  20C2	  =	  isotype	  control	  
mAb.	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A. 	  
	  
B.	   	  
Figure	  3.7.	  Relative	  binding	  of	  the	  A20-­‐CD40mAb	  conjugates	  and	  fractions	  via	  recombinant	  
CD40/anti-­‐mouse	   Ig	  hybrid	  ELISA.	  Recombinant	  CD40/Fc	  chimera	  was	  used	  to	  capture	  and	  
peroxidase-­‐conjugated	  polyclonal	  anti–mouse	  Ig	  antibody	  was	  used	  to	  detect	  A20-­‐CD40mAb	  
conjugates.	  The	  presence	  of	  A20-­‐CD40mAb	  conjugate	  is	  demonstrated	  by	  an	  increase	  in	  OD	  
at	  450nm.	  Parental	  A20	  antibody,	  CD40mAb	  and	  20C2mAb	  were	  used	  as	  negative	  controls.	  
A.	   Relative	   binding	   of	   Fractions	   1	   and	   3,	   as	   well	   as	   unfractionated	   CLICK	   and	   Standard	  
conjugates.	   B.	   Comparison	   of	   the	   interpolated	   1/dilution	   of	   the	   A20-­‐CD40mAb	   conjugate	  
concentration	  giving	  an	  OD	  of	  1.0.	  The	  dilution	  corresponding	  to	  1/1	  is	  10,000ng/ml	  (starting	  
concentration).	  20C2	  =	  isotype	  control	  mAb.	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3.2.2.2. Determination	   of	   functionality	   of	   CD40mAb-­‐containing	   conjugates	  
using	  flow	  cytometry	  
	  
CD40	  transfected	  fibroblast	  cells	  (CD40L929	  cells,	  see	  Section	  2.1.6.1)	  were	  used	  to	  
ensure	   that	   the	   CD40mAb	   was	   still	   able	   to	   recognise	   and	   bind	   to	   full-­‐length	  
membrane	  bound	  CD40	  expressed	  in	  vitro,	  following	  conjugation	  to	  A20	  antibody.	  	  
To	   verify	   that	   A20	   antibody	   is	   conjugated	   to	   CD40mAb,	   a	   secondary	   antibody,	  
namely	   FITC-­‐labelled	   anti-­‐mouse	   IgG,	   specific	   to	  mouse	   IgG	  was	   used	   (see	   Section	  
2.2.4.4.1.).	  Therefore	  only	  the	  A20-­‐CD40mAb	  conjugates	  would	  be	  detected	  due	  to	  
CD40mAb	   binding	   to	   the	   CD40	   expressing	   CD40L929	   cells,	   demonstrated	   by	   an	  
increase	   in	  fluorescence.	  The	  A20-­‐20C2mAb	  conjugates	  served	  as	  negative	  controls	  
in	  this	  assay.	  
CD40L929	  cells	  were	   incubated	  with	  10μg	  of	  each	  conjugate,	  conjugate	   fraction	  or	  
control.	   The	   CD40mAb	   was	   able	   to	   bind	   CD40	   expressed	   by	   CD40L929	   cells	   after	  
conjugation	  as	  well	  as	  after	  HPLC	  fractionation,	  observed	  by	  a	  shift	  of	  the	  peak	  to	  the	  
right	  indicating	  increased	  fluorescence,	  compared	  to	  the	  isotype	  control	  conjugates	  
and	   fractions	   (Figure	   3.8A,B).	   Comparison	   to	   the	   respective	   isoytpe	   control	  
conjugates	  and	  fractions	  was	  important	  to	  ensure	  that	  the	  increase	  in	  fluorescence	  
compared	  to	  the	  unstained	  cells	  was	  not	  due	  to	  non-­‐specific	  binding.	  Flow	  cytometry	  
on	   CD40L929	   cells	   confirmed	   that	   both	   the	   unfractionated	   conjugates	   and	   the	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A.	   	  
B.	  	   	  
Figure	   3.8.	   Functional	   capacity	   of	   the	   A20-­‐CD40mAb	   conjugate	   to	   bind	   to	   the	   CD40	  
receptor	  of	  CD40L929	  fibroblast	  cells,	  detected	  by	  a	  FITC	  labelled	  anti-­‐mouse	  IgG	  antibody.	  
A.	   Relative	   binding	   of	   unfractionated	   Standard	   and	   CLICK	   conjugate	   (dark	   blue	   and	   dark	  
green	   outlines	   respectively)	   compared	   to	   unfractionated	   Standard	   and	   CLICK	   A20-­‐20C2	  
conjugate	  (light	  blue	  and	  light	  green	  outlines	  that	  appear	  superimposed)	  B.	  Relative	  binding	  
of	  the	  four	  A20-­‐CD40mAb	  fractions	  (solid	  histograms)	  compared	  with	  their	  respective	  A20-­‐
20C2mAb	   fractions	   (outline	   histograms).	   Fraction	   1	   (blue),	   Fraction	   2	   (red),	   Fraction	   3	  
(purple),	  Fraction	  4	  (orange).	  20C2	  =	  isotype	  control	  mAb.	  
	  
Sample %
230212 - CD40L cells A20 conjugates_10C8-A20 sata smcc.fcs 99.8
230212 - CD40L cells A20 conjugates_20C2-A20 sata smcC.fcs 99.9
230212 - CD40L cells A20 conjugates_10C8-A20 CLICK.fcs 99.8
230212 - CD40L cells A20 conjugates_20C2-A20 CLICK.fcs 99.9















230212 - CD40L cells A20 conjugates_10C8-A20 Fraction 1 (aggregate).fcs 99.9
230212 - CD40L cells A20 conjugates_20C2-A20 Fraction 1 (aggregate).fcs 99.9
















230212 - CD40L cells A20 conjugates_10C8-A20 Fraction 3 (1,3a,1,3f,).fcs 99.7
230212 - CD40L cells A20 conjugates_20C2-A20 Fraction 3 (1,3a,1,3f,).fcs 99.8















230212 - CD40L cells A20 conjugates_10C8-A20 Fraction 4.fcs 99.7
230212 - CD40L cells A20 conjugates_20C2-A20 Fraction 4.fcs 99.9















230212 - CD40L cells A20 conjugates_10C8-A20 Fraction 2.fcs 99.9
230212 - CD40L cells A20 conjugates_20C2-A20 Fraction 2.fcs 99.9
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3.2.2.3. Detection	   of	   A20	   antibody	   present	   in	   the	   A20-­‐mAb	   conjugates	   by	  
means	  of	  Western	  blotting	  
	  
HPLC	  analysis	  of	  A20	  antibody	  and	  CD40mAb	  showed	  that	  A20	  antibody	  is	  of	  higher	  
MW	  than	  CD40mAb	   (Figure	  3.3).	   To	   investigate	   if	   free	  unconjugated	  A20	  antibody	  
was	  present	   in	   Fraction	  3,	   1μg	  of	   the	  A20-­‐CD40mAb	  conjugate	   and	   fractions	  were	  
analysed	   by	   Western	   Blot	   (see	   Section	   2.2.4.2.1.),	   using	   peroxidase	   labelled	   anti-­‐
mouse	  IgG	  to	  detect	  (Figure	  3.9).	  The	  results	  showed	  that	  A20	  antibody	  was	  present	  
in	   all	   of	   the	   A20-­‐mAb	   conjugate	   fractions,	   as	  well	   as	   in	   unfractionated	   conjugates	  
(Figure	  3.9A).	  Fractions	  1	  and	  2	  contained	  material	  of	  very	  high	  average	  MW	  and	  did	  
not	   separate	   out	   into	   the	   resolving	   gel.	   Furthermore,	   Fractions	   3	   and	   4	   contained	  
material	  of	  the	  lowest	  average	  MW.	  Also,	  judging	  from	  the	  size	  of	  the	  A20	  antibody	  
only	   control,	   Fraction	   4	   contained	   material	   of	   the	   same	   apparent	   MW	   as	  
unconjugated	  A20	  antibody,	  a	  band	  that	  was	  not	  apparent	  in	  Fraction	  3.	  This	  shows	  
the	  possibility	  that	  Fraction	  3	  contained	  none	  to	  minimal	  amounts	  of	  unconjugated	  
A20	  antibody.	  	  
Figure	  3.9B	  demonstrates	  that	  non-­‐specific	  detection	  of	  CD40mAb	  (negative	  control)	  
demonstrated	  in	  Figure	  3.9A	  was	  due	  to	  prolonged	  exposure	  time.	  On	  this	  occasion	  
the	  membrane	  was	  visualised	  using	  the	  ChemiDoc™	  XRS+	  System	  (Biorad),	  allowing	  
the	   MW	   protein	   ladder	   to	   be	   merged	   onto	   the	   Western	   Blotting	   image.	  
Unconjugated	  A20	  antibody	  was	  detected	  by	  peroxidase	  labelled	  anti-­‐mouse	  IgG	  and	  




















B.	   	  
	  
Figure	  3.9.	  Detection	  of	  A20	  antibody	  in	  the	  conjugate	  and	  conjugate	  fractions	  by	  Western	  
Blot,	  using	  peroxidase-­‐conjugated	  polyclonal	  anti–mouse	  Ig	  to	  detect.	  A.	  A20	  antibody	  only	  
(mouse	   IgG),	   labelled	  as	  A20,	  was	  used	  as	   a	  positive	   control.	   CD40mAb	  only	   (rat	   IgG)	  was	  
used	   a	   negative	   control.	   The	   fractions	   shown	   are	   the	   A20-­‐CD40mAb	   conjugates	   and	  
fractions.	   B.	   Coomassie	   blue	   stained	   non-­‐reducing	   SDS-­‐PAGE	   gel	   (left)	   and	   respective	  
Western	  Blot	  (right)	  of	  A20	  antibody	  only	  (mouse	  IgG,	  positive	  control)	  and	  CD40mAb	  only	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3.2.3. Comparison	   of	   lymphoma	   antigen	   and	   CD40mAb	   conjugate	  
made	  by	  novel	  and	  standard	  techniques	  in	  a	  murine	  lymphoma	  
model	  
Comparative	  immunogenicity	  and	  anti-­‐tumour	  vaccine	  efficacy	  of	  an	  A20-­‐CD40mAb	  
conjugate	   made	   by	   standard	   methods	   and	   (1)	   a	   novel	   unfractionated	   conjugate	  
(CLICK	  unfractionated	  conjugate),	  (2)	  a	  low	  average	  MW	  conjugate	  (Fraction	  3)	  or	  (3)	  
a	  very	  high	  average	  MW	  conjugate	  (Fraction	  1)	  was	  assessed	  in	  an	  established	  A20	  
lymphoma	  murine	  model.	  The	  prophylactic	  immunisation	  schedule	  used	  is	  shown	  in	  
Figure	  3.10	  (see	  Section	  2.2.7.1.).	  
Groups	  of	  10	  female	  BALB/c	  mice	  were	  immunised	  twice	  (10μg	  in	  50μl	  volume)	  with	  
the	  immunogens	  subcutaneously	  in	  the	  left	  flank.	  After	  28	  days	  of	  first	  immunisation	  
a	  lethal	  dose	  of	  1	  x	  105	  A20	  cells	  in	  50µl	  was	  given	  subcutaneously	  on	  the	  opposite	  
flank.	  Immunisation	  of	  the	  mice,	  performance	  of	  tail	  bleeds,	  inoculation	  of	  A20	  cells	  
and	   monitoring	   of	   tumour	   growth	   was	   performed	   by	   Ms	   Amy	   Lewis	   in	   the	  
Department	  of	  Infection	  and	  Immunity.	  
	  
	  	  
Figure	  3.10.	  Immunisation	  schedule	  using	  the	  A20-­‐CD40mAb	  conjugates.	  BALB/c	  mice	  were	  
immunised	   subcutaneously	   in	   the	   left	   flank	  on	  day	   -­‐28	  and	  boosted	  on	  day	   -­‐14	   (blue).	  On	  
day	   -­‐1	  mice	  were	   bled	   (red).	   A	   subcutaneous	   lethal	   dose	   of	   1	   x	   105	   A20	   cells	   in	   50µl	  was	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Serum	   anti-­‐mouse	   Ig	   antibody	   titres	   were	   determined	   by	   ELISA	   using	   peroxidase-­‐
labelled	  goat	  anti-­‐mouse	  IgG	  to	  detect	  (see	  Section	  2.2.7.1.1.).	  Mice	  immunised	  with	  
unfractionated	   Standard	   A20-­‐CD40mAb	   conjugate,	   unfractionated	   CLICK	   A20-­‐
CD40mAb	   conjugate,	   Fraction	   1	   and	   Fraction	   3	   all	   raised	   antibodies	   against	   A20	  
antibody	  compared	  with	  the	  vehicle	  control	  PBS	  (Figure	  3.11).	  The	  results	  showed	  no	  
statistically	   significant	   difference	   between	   the	   antibody	   titres	   produced	   by	   the	  
unfractionated	   Standard	   and	   CLICK	   A20-­‐CD40mAb	   immunised	   groups.	   However,	  
interestingly,	  sera	  from	  Fraction	  3	  (low	  average	  MW	  conjugate)	  immunised	  mice	  had	  
significantly	   higher	   anti-­‐A20	   antibody	   titres	   compared	   to	   sera	   from	   the	   Standard	  
conjugate	   immunised	   group	   (p<0.05,	   one-­‐way	   ANOVA,	   using	   Dunnett’s	   post-­‐test)	  
(Figure	  3.11),	  whereas	  Fraction	  1	  (high	  average	  MW	  conjugate)	  did	  not.	  These	  results	  
indicated	   that	   CD40mAb-­‐adjuvanted	   vaccines	   of	   low	   average	  MW	   are	   superior	   to	  
more	  heterogeneous	  vaccines.	  
In	  order	  to	  determine	  if	  the	  anti-­‐tumour	  efficacy	  of	  each	  of	  the	  CLICK	  A20-­‐CD40mAb	  
conjugates	   or	   fractions	   was	   better	   than	   the	   Standard	   conjugate,	   the	   mice	   were	  
challenged	  with	  A20	  tumour	  cells.	  We	  were	  interested	  to	  see	  whether	  prophylactic	  
immunisation	  with	  a	  more	  defined	  CD40mAb-­‐adjuvanted	  conjugate	  would	  have	  the	  
potential	  to	  prevent	  or	  delay	  tumour	  progression,	  compared	  to	  more	  heterogeneous	  
conjugates.	  Enhanced	  median	  and/or	  overall	  survival	  would	  indicate	  the	  vaccine	  was	  
more	  effective.	  
The	  overall	  survival	  of	  the	  Standard	  A20-­‐CD40mAb	  immunised	  group	  was	  compared	  
to	   the	   PBS	   group	   to	   assess	   the	   vaccine	   efficacy	   of	   the	   Standard	   conjugation	  
technique.	   The	   overall	   survival	   of	   Standard	   A20-­‐CD40mAb	   immunised	   mice	   was	  
significantly	   enhanced	   compared	   to	   the	   control	   group	   (p<0.05)	   (Figure	   3.12),	  with	  
the	   median	   survival	   extended	   by	   11	   days	   (33	   days	   for	   Standard	   A20-­‐CD40mAb	  
conjugate	  compared	  to	  22	  days	  for	  PBS	  immunised	  group).	  	  
The	  median	  survival	  of	  the	  tumour	  challenged	  mice	  immunised	  with	  Standard	  whole	  
conjugate	  was	   compared	   to	   the	  mice	   immunised	  with	   CLICK	  whole	   conjugate	   and	  
fractions.	   Immunisation	   with	   unfractionated	   CLICK	   conjugates,	   Fraction	   1	   and	  
Fraction	   3	   showed	   an	   enhanced	   median	   survival	   by	   8.5	   days	   (p=0.3),	   15	   days	  
(p=0.39)	   and	  more	   than	   33	   days	   (p=0.07)	   respectively	   compared	   to	   immunisation	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with	   unfractionated	   Standard	   conjugate.	   This	  means	   that	   although	   a	   strong	   trend	  
was	   observed,	   the	   difference	   in	   the	   median	   survival	   between	   the	   groups	   is	   not	  
significant.	  However,	  the	  percentage	  overall	  survival	  in	  the	  Standard	  A20-­‐CD40mAb	  
conjugate	   group	   (12%)	   was	   considerably	   less	   than	   in	   the	   CLICK	   A20-­‐CD40mAb	  
conjugate	   (40%),	   Fraction	   1	   (50%)	   and	   especially,	   Fraction	   3	   (60%)	   immunised	  
groups.	  
The	  tumour	  burden	  or	  tumour	  volume	  in	  cubic	  millimetres,	  calculated	  by	  measuring	  
the	   long	   and	   short	   diameter	   of	   the	   tumour	   and	   using	   the	   formula:	   ((short	   +	  
long)*0.25)3*4/3π	   (see	   Section	   2.2.7.1.),	   was	   investigated	   on	   day	   19	   in	   all	   groups	  
(Figure	  3.13A).	  Day	  19	  was	  chosen	  because	  on	  this	  day	  the	   first	  mouse	   immunised	  
with	   the	   Standard	   conjugate	   had	   to	   be	   culled	   due	   to	   the	   tumour	   reaching	   the	  
maximum	   permissible	   tumour	   diameter	   (12mm).	   The	   PBS	   group	   was	   excluded	  
because	   the	   first	   mouse	   in	   this	   group	   had	   already	   been	   culled	   on	   this	   date.	  
Interestingly,	  Fraction	  3	  and	  unfractionated	  CLICK	  conjugate	  immunised	  mice	  had	  a	  
significantly	   lower	   average	   tumour	   burden	   than	   the	   unfractionated	   Standard	  
conjugate	  immunised	  mice	  (Figure	  3.13A,	  p<0.05,	  One-­‐way	  ANOVA,	  using	  Dunnett’s	  
post	  test).	  However,	  there	  was	  no	  significant	  difference	  between	  the	  tumour	  burden	  
in	   groups	   immunised	   with	   Fraction	   1	   and	   the	   unfractionated	   Standard	   conjugate.	  
Furthermore,	   the	   Fraction	   3	   immunised	   group	   demonstrated	   the	   slowest	   onset	   of	  
tumour	  growth.	  The	  Fraction	  3	  immunised	  group	  started	  to	  develop	  tumours	  at	  day	  
21,	   whilst	   in	   all	   other	   groups	   tumours	   were	   observed	   on	   day	   17	   post-­‐challenge	  





	   113	  
	  
Figure	  3.11.	  Anti-­‐A20	  specific	  antibody	  end-­‐point	  titre	   level	  after	  boost	  (day	  -­‐1).	  Anti-­‐A20	  
antibody	   levels	   detected	   in	   sera	   of	   mice	   prophylactically	   immunised	   with	   unfractionated	  
Standard	   conjugate	   (green),	   unfractionated	   CLICK	   conjugate	   (red),	   high	   average	   MW	  
conjugate	   -­‐	   Fraction	   1	   (blue),	   low	   average	   MW	   conjugate	   -­‐	   Fraction	   3	   (purple)	   and	   PBS	  
(black)	   are	   shown.	  One-­‐way	  ANOVA	  using	  Dunnett’s	  multiple	   comparison	   post-­‐test	   (mean	  




Figure	   3.12.	   The	   efficacy	   of	   the	   A20-­‐CD40mAb	   vaccines	   in	   the	   A20	   lymphoma	   mouse	  
model.	   A	   Kaplan-­‐Meier	   survival	   curve	   was	   used	   to	   determine	   the	   overall	   survival	   of	   A20	  
tumour	  challenged	  mice	  prophylactically	  immunised	  with	  A20-­‐CD40mAb	  conjugate	  made	  by	  
standard	  methods	   and	  novel	  methods	   compared	   to	  mice	  prophylactically	   immunised	  with	  
PBS	   (control	   group).	   Statistical	   significance	   was	   determined	   by	   means	   of	   a	   log-­‐rank	   test.	  
*p<0.05.	  ****p<0.0001.	  PBS,	  CLICK	  whole	  conjugate,	  Fraction	  1,	  Fraction	  3,	  n	  =	  10;	  Standard	  
whole	  conjugate,	  n	  =	  9.	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A.	   	  
B.	   	  	  
Figure	   3.13.	   Difference	   in	   tumour	   burden	   between	   the	   immunised	   groups.	   The	   tumour	  
burden	  on	  day	   19	   post	   challenge	   (A)	   and	   speed	  of	   tumour	   growth	   (B)	   in	  mice	   immunised	  
with	   Standard	   A20-­‐CD40mAb	   conjugate	   (green)	   compared	   to	  mice	   immunised	  with	   CLICK	  
unfractionated	   A20-­‐CD40mAb	   conjugate	   (red),	   Fractions	   1	   (blue)	   and	   Fraction	   3	   (purple).	  
Mice	  immunized	  with	  PBS	  group	  are	  shown	  in	  black.	  Statistical	  significance	  was	  determined	  
by	  means	  of	  One-­‐way	  ANOVA	  using	  Dunnett’s	  multiple	  comparison	  test	  (mean	  +/-­‐	  SD)	  was	  
used	   to	   determine	   statistical	   significance.	   *p<0.05.	   ns	   –	   non-­‐significant.	   PBS,	   CLICK	  
unfractionated	  conjugate,	  Fraction	  1,	  Fraction	  3,	  n	  =	  10;	  Standard	  conjugate,	  n	  =	  9.	  Each	  dot	  
corresponds	  to	  one	  mouse.	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3.3. Comparative	   immunogenicity	   of	   OVA	   antigen	   and	  
CD40mAb	   conjugate	   made	   by	   different	   conjugation	  
strategies	  in	  a	  murine	  system	  
Low	  average	  MW	  A20-­‐CD40mAb	  conjugates	  made	  by	  click	  chemistry	  showed	  to	  be	  
superior	  vaccines	  to	  the	  more	  heterogeneous	  vaccines	  made	  by	  standard	  methods.	  
Following	   these	   very	   encouraging	   results,	   OVA-­‐mAb	   conjugates	   were	   made	   using	  
click	   chemistry	   (see	   Section	   2.2.1.7.)	   and	   standard	  methods	   (see	   Section	   2.2.1.2.),	  
separated	   into	   fractions	   by	  HPLC	   and	   characterised	   as	   described	   for	   the	   A20-­‐mAb	  
conjugates.	  
OVA	  antigen	  has	  been	  chosen	  as	  a	  model	  antigen	  due	  to	  the	  readily	  available	  OVA-­‐
specific	   reagents,	   that	   would	   allow	   convenient	   testing	   of	   CD4+	   and	   CD8+	   T	   cell	  
responses	   (studied	   in	   the	   next	   chapters	   shown	   in	   this	   thesis).	   The	   various	   OVA-­‐
CD40mAb	  conjugates’	  ability	  to	   induce	  antibody	  responses	  to	  OVA	  was	  assessed	   in	  
vivo.	   It	   was	   of	   particular	   interest	   to	   determine	   whether	   the	   lowest	   average	   MW	  
OVA-­‐CD40mAb	  conjugate	  would	  be	  the	  most	  immunogenic.	  	  
	  
3.3.1. Fractionation	  of	  OVA-­‐mAb	  conjugate	  by	  HPLC	  
The	   fact	   that	   the	  OVA-­‐CD40mAb	  conjugates	  are	  made	  up	  of	  OVA	  antigen	   (45	  kDa)	  
conjugated	  to	  CD40mAb	  and	  not	  A20	  antibody	  (approximately	  150	  kDa)	  would	  affect	  
the	   time	   the	   peaks	   are	   observed	   on	   the	   chromatogram	   after	   size-­‐exclusion	  
chromatography.	   Therefore,	   the	   time	   at	   which	   the	   peak	   of	   unconjugated	   and	  
functionalised	  OVA	  antigen,	  CD40mAb	  and	  20C2mAb	  emerged	  was	  again	  observed.	  
This	  allowed	  for	  a	  more	  informed	  decision	  on	  the	  time	  the	  fractions	  of	  interest	  need	  
to	  be	  collected,	  especially	  the	  lowest	  average	  MW	  fraction.	  CD40mAb	  and	  20C2mAb,	  
were	  observed	  at	  9.24	  minutes,	  whilst	  OVA	  antigen	  which	  is	  of	  lower	  MW	  than	  the	  
antibodies	  was	  observed	  at	  9.85	  minutes.	  DBCO-­‐NHS	  functionalised	  antibodies	  and	  
NHS-­‐PEG4-­‐Azide	   functionalised	  OVA	  were	   observed	   earlier	   at	   9.2	  minutes	   and	   9.8	  
minutes	  respectively	  (Figure	  3.14).	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A	  50μg	  sample	  of	  CLICK	  OVA-­‐CD40mAb	  and	  Standard	  OVA-­‐CD40mAb	  were	  analysed	  
on	   the	   HPLC	   SEC,	   and	   the	   CLICK	   conjugate	   fractions	   of	   interest	   were	   identified	  
(Figure	  3.15),	  by	  referring	  to	  the	  chromatogram	  containing	  various	  standards	  (Figure	  
3.2).	  The	  standard	  of	  MW	  660kDa	  emerged	  around	  7	  minutes	  therefore	  we	  assumed	  
that	  the	  peak	  observed	  at	  5	  minutes	  would	  be	  with	  high	  probability	  a	  conjugate	  of	  
the	  highest	  average	  MW	  (Figure	  3.15).	  Considering	  that	  CD40mAb	  peak	  emerged	  at	  
9.2	  minutes,	  the	  fraction	  we	  hypothesized	  was	  of	  lowest	  average	  MW	  with	  minimal	  
to	   no	   contaminating	   mAb,	   was	   collected	   from	   8.1	   minutes	   to	   8.7	   minutes.	   A	  
conjugate	  fraction	  of	   lower	  average	  MW	  was	  not	  collected	  because	  in	  optimisation	  
experiments	   conjugate	   fractions	   collected	   closer	   to	   9	   minutes	   seemed	   to	   contain	  
unconjugated	  OVA	  antigen	  detected	  by	  Western	  Blot	   analysis	   (results	   not	   shown).	  
This	  was	  surprising	  because	  the	  peak	  containing	  NHS-­‐PEG4-­‐Azide-­‐functionalised	  OVA	  
antigen	  alone	  was	  observed	  later	  at	  9.8	  minutes	  (Figure	  3.14).	  The	  four	  fractions	  of	  


























Figure	   3.14.	  HPLC	   chromatograms	   showing	  unconjugated	  CD40mAb,	   20C2mAb	  and	  OVA,	  
as	   well	   as	   NHS-­‐PEG4-­‐Azide	   functionalised	   OVA	   and	   DBCO-­‐NHS	   functionalised	   CD40mAb	  
and	  20C2mAb.	  The	  numbers	  shown	  in	  red	  represent	  the	  time	  taken	  for	  the	  peak	  of	  the	  non-­‐
functionalised	  and	   functionalised	  OVA	  or	  antibody	   to	  emerge	  on	   the	  HPLC	  chromatogram.	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Figure	   3.15.	   Representative	   HPLC	   chromatograms	   of	   the	   CLICK	   and	   Standard	   OVA-­‐
CD40mAb	  conjugates.	  The	  numbers	  shown	  in	  red	  represent	  the	  time	  taken	  for	  the	  peak	  of	  
the	  particular	  fraction	  to	  emerge	  on	  the	  HPLC	  chromatogram.	  The	  absorbance	  readings	  on	  
the	  HPLC	  plots	  were	  measured	  at	  280nm.	  
	  
	  
Figure	   3.16.	   Representative	   HPLC	   chromatogram	   of	   CLICK	   OVA-­‐CD40mAb	   conjugate	   and	  
the	  different	   fractions	   collected.	  The	  fractions	  collected	   included:	  Fraction	  1	  (blue)	  from	  5	  
minute	  to	  5.4	  minutes,	  Fraction	  2	  (pink)	  collected	  from	  5.5	  minutes	  to	  8.0	  minutes,	  Fraction	  
3	  (purple)	  collected	  from	  8.1	  minutes	  to	  8.7	  minutes	  and	  Fraction	  4	  (orange)	  collected	  from	  


























































B. Standard Method 
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A	  BCA	  assay	   (see	   Section	  2.2.3.)	  was	  used	  to	  quantify	   the	  protein	  concentration	  of	  
each	   fraction.	   The	   four	   fractions	   of	   the	   OVA-­‐mAb	   conjugates	   were	   labelled	   as	  
explained	   in	  Table	  3.2	  and	  will	  be	  referred	  to	  as	  Fraction	  1,	  2,	  3	  or	  4	   (according	  to	  
decreasing	  apparent	  MW)	  from	  this	  point	  on.	  Respective	  fractions	  from	  OVA	  antigen	  
conjugated	   to	   isotype	  control	  mAb	  made	  by	   the	   click	   chemistry	  method	  were	  also	  
collected	  (results	  not	  shown).	  	  
	  
OVA-­‐mAb	  conjugate	  fractions	  
collected	  
5	  -­‐	  5.4	  minutes	  
(Fraction	  1)	  
5.5	  –	  8	  minutes	  
(Fraction	  2)	  
8.1	  –	  8.7	  minutes	  
(Fraction	  3)	  
8.8	  -­‐	  11	  minutes	  
(Fraction	  4)	  
Table	  3.2.	  OVA-­‐mAb	  conjugate	  fractions	  collected	  by	  minutes	  on	  HPLC.	  	  
	  
From	   the	   four	   fractions	   collected,	   Fraction	   1	   and	   Fraction	   3	  were	   the	   fractions	   of	  
interest	   to	  evaluate	   the	  hypothesis	   that	  CD40mAb-­‐adjuvanted	   conjugates	  of	   lower	  
average	   MW	   and	   greater	   CD40mAb	   accessibility	   are	   most	   immunogenic.	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3.3.2. Characterisation	   of	   unfractionated	   and	   fractionated	   OVA-­‐mAb	  
conjugates	  in	  vitro	  
3.3.2.1. Characterisation	  using	  an	  anti-­‐rat	  IgG	  and	  anti-­‐OVA	  antibody	  ELISA	  
The	  conjugation	  of	  CD40mAb	  or	  20C2mAb	  (rat	  IgG1)	  to	  OVA	  antigen	  was	  confirmed	  
by	  sandwich	  ELISA.	  Firstly,	  rat	  IgG	  was	  captured	  with	  an	  anti-­‐rat	  IgG	  antibody	  and	  the	  
conjugation	  of	  rat	  IgG	  to	  OVA	  was	  confirmed	  by	  simultaneous	  binding	  to	  rabbit	  (IgG)	  
anti-­‐OVA	   antibody	   followed	   by	   peroxidase	   conjugated	   goat	   anti-­‐rabbit	   IgG	   (see	  
Section	  2.2.4.3.1.).	  This	  was	  visualised	  colorimetrically	  by	  an	   increase	   in	  OD	  (Figure	  
3.17).	  	  
The	   CLICK	   unfractionated	   OVA-­‐CD40mAb	   conjugate	   and	   Fractions	   2,	   3,	   4	   had	   the	  
highest	  conjugate	  purity	  and	  bound	  the	  ELISA	  antibodies	  to	  a	  concentration	  equal	  to	  
or	   greater	   than	   7.8ng/ml,	   whilst	   Fraction	   1	   and	   Standard	   unfractionated	   OVA-­‐
CD40mAb	   conjugate	   only	   bind	   ELISA	   antibodies	   to	   a	   concentration	   of	   31.3ng/ml	  
(Figure	   3.17A,B).	   When	   observing	   the	   relative	   binding	   of	   the	   conjugates	   at	   the	  
specific	   OD	   of	   0.5,	   Fraction	   3	   consisted	   of	   highest	   conjugate	   purity.	   The	  
unfractionated	  OVA-­‐CD40mAb	  Standard	  conjugate	  and	  Fraction	  1	  consisted	  of	  least	  
conjugate	   purity	   (Figure	   3.17C).	   We	   hypothesised	   that	   the	   reason	   for	   this	   was	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A.	   	  
B.	   	  
C.	   	  
Figure	  3.17.	  Confirmation	  of	  OVA	  to	  rat	  IgG	  conjugation	  via	  sandwich	  ELISA.	  	  Goat	  anti-­‐rat	  
IgG	   antibody	   and	   rabbit	   (IgG)	   anti-­‐OVA	   antibody	   simultaneously	   bind	   to	   the	   OVA-­‐mAb	  
conjugates	  and	  are	  detected	  by	  peroxidase	  conjugated	  anti-­‐rabbit	  IgG	  antibody.	  Presence	  of	  
OVA-­‐mAb	  conjugate	  is	  demonstrated	  by	  an	  increase	  in	  OD	  at	  450nm.	  Parental	  A20	  antibody,	  
CD40mAb	   and	   20C2mAb	   were	   used	   as	   negative	   controls.	   A.	   Relative	   binding	   of	  
unfractionated	   CLICK	   and	   Standard	   OVA-­‐mAb	   conjugates.	   B.	   Relative	   binding	   of	   OVA-­‐
CD40mAb	  conjugate	  fractions	  and	  controls.	  C.	  Comparison	  of	  the	  interpolated	  dilution	  factor	  
of	   the	   OVA-­‐CD40mAb	   conjugate	   concentration	   giving	   an	   OD	   of	   0.5.	   The	   dilution	  
corresponding	  to	  1/1	  is	  1000ng/ml	  (starting	  concentration).	  20C2	  =	  isotype	  control	  mAb.	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3.3.2.2. Characterisation	  using	   flow	   cytometry	  on	  CD40	  expressing	   fibroblast	  
cells	  
CD40L929	   fibroblast	   cells	  were	  used	   to	  ensure	   that	   the	  CD40mAb	  was	   still	   able	   to	  
recognise	   and	   bind	   to	   full-­‐length	   membrane-­‐bound	   CD40	   expressed	   in	   vitro,	  
following	  conjugation	  to	  OVA,	  by	  flow	  cytometry	  (see	  Section	  2.2.4.4.1.).	  	  
Binding	   of	   CD40mAb	   to	   CD40L929	   cells,	   and	   the	   simultaneous	   binding	   of	   OVA	  
antigen	  to	  rabbit	  (IgG)	  anti-­‐OVA	  antibody	  was	  detected	  by	  a	  FITC	  labelled	  anti-­‐rabbit	  
IgG	   antibody	   in	   the	   presence	   of	   the	   OVA-­‐CD40mAb.	   OVA	   antigen	   conjugated	   to	  
20C2mAb	  and	  respective	  fractions	  that	  do	  not	  contain	  CD40mAb	  served	  as	  negative	  
controls.	   A	   10μg	   sample	   of	   each	   OVA-­‐mAb	   conjugate	   and	   conjugate	   fraction	   was	  
analysed	  on	  CD40L929	  cells	  per	  test.	  Both	  OVA-­‐CD40mAb	  unfractionated	  conjugates	  
(Figure	  3.18A)	  and	  conjugate	  fractions	  (Figure	  3.18B)	  bound	  to	  the	  CD40	  expressing	  
cells,	  which	  can	  be	  observed	  by	  an	   increased	  fluorescence	  or	  a	  shift	   to	  the	  right	   in	  
the	   overlaid	   histogram	   compared	   to	   their	   respective	   isotype	   control	   conjugates.	  
Comparison	   to	   the	   isotype	   control	   conjugates	   was	   important	   to	   ensure	   that	   the	  
increase	   in	   fluorescence	  observed	  with	  the	  OVA-­‐CD40mAb	  conjugates	  was	  not	  due	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A.	   	  
B.	   	  
Figure	   3.18.	   Functional	   capacity	   of	   the	   OVA-­‐CD40mAb	   conjugate	   to	   bind	   to	   the	   CD40	  
receptor	   of	   CD40L929	   fibroblast	   cells.	  A.	  Relative	  binding	  of	  unfractionated	  Standard	  and	  
CLICK	   conjugate	   (dark	   blue	   and	   dark	   green	   outlines	   respectively)	   compared	   to	  
unfractionated	  Standard	  and	  CLICK	  OVA-­‐20C2	  conjugate	  (light	  blue	  and	  light	  green	  outlines	  
respectively).	   The	   black	   outline	   represents	   the	   FITC	   labelled	   anti-­‐rabbit	   IgG	   antibody	   only	  
control.	   (B)	   Relative	   binding	   of	   the	   four	   OVA-­‐CD40mAb	   conjugate	   fractions	   (solid	  
histograms)	   compared	  with	   their	   respective	   isotype	   control	   conjugate	   fractions	   (outlines);	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230212 - CD40L cells OVA conjgates_OVA-20C2 Fraction 2_001.fcs 99.8
230212 - CD40L cells OVA conjgates_OVA-10C8 Fraction 2.fcs 99.7
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230212 - CD40L cells OVA conjgates_OVA-20C2 Fraction 1 (aggregate)_001.fcs 99.8
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230212 - CD40L cells OVA conjgates_OVA-20C2 Fraction 1 (aggregate)_001.fcs 99.8
230212 - CD40L cells OVA conjgates_OVA-10C8 Fraction 1 (aggregate).fcs 99.8
Sample %
230212 - CD40L cells OVA conjgates_OVA-20C2 Fraction 4_001.fcs 99.8
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3.3.2.3. Detection	  of	  OVA	  antigen	  and	  CD40mAb	  present	  in	  the	  conjugates	  by	  
means	  of	  Western	  blotting	  	  
The	   purpose	   of	   the	  Western	   blot	   analysis	   was	   not	   only	   to	   establish	   the	   antigenic	  
composition	  of	   the	   conjugate	  and	   fractions	  but	   it	  was	   also	   important	   to	   analyse	   if	  
unconjugated	   OVA	   antigen	   or	   CD40mAb	   were	   present	   in	   Fraction	   3.	   Free	  
unconjugated	  CD40mAb	  should	  be	  the	  major	  contaminating	  material	  because	  of	  its	  
MW.	  However,	  although	  unconjugated	  OVA	  antigen	  should	  be	  of	  too	  low	  a	  MW	  to	  
be	   detected,	   previous	   optimisation	   experiments	   showed	   that	   it	   sometimes	   is	  
detected	   in	  higher	  average	  MW	  peaks	   (data	  not	  shown),	  perhaps	  because	   it	   forms	  
dimers	   in	   solution.	   Therefore,	   1μg	   of	   the	   different	   conjugates	   and	   fractions	   was	  
analysed	   by	   Western	   Blotting	   in	   two	   ways	   (see	   Section	   2.2.4.2.).	   To	   verify	   that	  
CD40mAb	  was	  present	   in	  the	  conjugate	  a	  peroxidase	   labelled	  anti-­‐rat	   IgG	  antibody	  
was	  used	  for	  detection.	  	  The	  peroxidase	  labelled	  anti-­‐rat	  IgG	  antibody	  does	  not	  show	  
any	  non-­‐specific	  binding	  to	  OVA	  antigen	  (Figure	  3.19).	  To	  verify	  OVA	  was	  present	  in	  
the	   conjugate	   a	   rabbit	   anti-­‐OVA	   IgG	   was	   used	   as	   a	   primary	   antibody	   and	   a	  
peroxidase-­‐labelled	  anti-­‐rabbit	  IgG	  was	  used	  as	  a	  secondary	  antibody	  to	  detect	  OVA.	  
The	   latter	  antibodies	  do	  not	  show	  any	  non-­‐specific	  binding	  to	  rat	   IgG.	  Figure	  3.19A	  
shows	   a	   non-­‐reducing	   SDS-­‐PAGE	   of	   unconjugated	   OVA	   and	   CD40mAb,	   and	   the	  
respective	  OVA-­‐specific	  Western	  Blot.	  This	  was	  visualised	  using	  the	  ChemiDoc™	  XRS+	  
System	   allowing	   the	  MW	   protein	   ladder	   to	   be	  merged	   onto	   the	  Western	   Blotting	  
image.	  Due	  to	  the	  absence	  of	  a	  marker	  in	  Figure	  3.19B,	  the	  MW	  protein	  ladder	  used	  
in	  Figure	  3.19A	  was	  used	  to	  estimate	  the	  MW.	  
The	   results	   showed	   that	   OVA	   and	   CD40mAb	   were	   present	   in	   all	   of	   the	   OVA-­‐
CD40mAb	  conjugate	  fractions,	  as	  well	  as	  in	  unfractionated	  conjugates	  (Figure	  3.19A).	  
Fraction	  1	  contained	  material	  of	  very	  high	  average	  MW,	  which	  did	  not	  migrate	  into	  
the	  resolving	  gel.	  Fractions	  2	  and	  3	  contained	  material	  of	  lower	  average	  MW	  showed	  
better	   separation	   in	   the	   resolving	  gel.	  Both	   these	   fractions	   (particularly	  Fraction	  3)	  
contain	  some	  material	  of	  the	  same	  apparent	  MW	  as	  free	  unconjugated	  OVA.	  Judging	  
from	  the	  bands	  apparent	  in	  Fraction	  4	  and	  CD40mAb	  only	  positive	  control,	  Fraction	  3	  
contains	   minimal	   amounts	   of	   unconjugated	   CD40mAb.	   On	   comparing	   the	  
unfractionated	  CLICK	  to	  the	  unfractionated	  Standard	  conjugate,	  the	  latter	  seems	  to	  
have	  more	  unconjugated	  OVA	  and	  mAb	  (consistent	  with	  the	  HPLC	  plots	  Figure	  3.14).	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Figure	  3.19.	  Western	  blot	  analysis	  of	  the	  OVA-­‐CD40mAb	  conjugate	  and	  fractions.	  	  
A.	   Non-­‐reducing	   SDS-­‐PAGE	   showing	   unconjugated	   CD40mAb	   and	   OVA	   (left)	   and	   the	  
respective	   Western	   Blot	   using	   peroxidase-­‐labelled	   goat	   anti-­‐rabbit	   IgG	   to	   detect	   OVA	  
antigen	  bound	  to	  the	  primary	  antibody	  rabbit	   (IgG)	  anti-­‐OVA	  (right).	  B.	  Peroxidase-­‐labelled	  
goat	  anti-­‐rabbit	  IgG	  was	  used	  to	  detect	  OVA	  antigen	  of	  the	  conjugate	  bound	  to	  the	  primary	  
antibody	  rabbit	   (IgG)	  anti-­‐OVA	  (left).	  Peroxidase-­‐labelled	  anti-­‐rat	   IgG	  antibody	  was	  used	  to	  
detect	   rat	   IgG	   (CD40mAb)	   (right).	   The	  MW	  markers	   shown	   are	   an	   estimate	   based	   on	   the	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3.3.3. Evaluation	   of	   the	   anti-­‐OVA	   response	   induced	   by	   OVA	   antigen	  
and	   CD40mAb	   conjugate	   made	   by	   novel	   and	   standard	  
techniques	  in	  vivo	  
Comparative	   immunogenicity	   of	   an	   OVA-­‐CD40mAb	   conjugate	   made	   by	   standard	  
methods	  and	  (1)	  a	  novel	  unfractionated	  conjugate	  (CLICK	  unfractionated	  conjugate),	  
(2)	  a	  defined	  low	  average	  MW	  conjugate	  (Fraction	  3)	  or	  (3)	  a	  very	  high	  average	  MW	  
conjugate	   (Fraction	  1)	  was	   assessed	   in	   a	  murine	   system,	  by	   investigating	   anti-­‐OVA	  
specific	   titres	   in	   sera	   of	   immunised	  mice.	   The	   prophylactic	   immunisation	   schedule	  
used	   is	   shown	   in	   Figure	   3.20	   (see	   Section	   2.2.7.2.).	   Sera	   from	   immunised	   mice	  
collected	  at	  days	  13	  and	  28	  were	  analysed	  by	  ELISA	  (see	  Section	  2.2.7.2.1.).	  	  
	  
Figure	   3.20.	   Immunisation	   schedule	   for	   OVA-­‐CD40mAb	   conjugates.	   BALB/c	   mice	   were	  
immunised	  with	   10μg	   unfractionated	   CLICK	   and	   Standard	   conjugate,	   as	  well	   as	   Fraction	   1	  
and	  Fraction	  3	  on	  day	  1	  and	  boosted	  on	  day	  14.	  Mice	  were	  bled	  on	  day	  13	  and	  day	  28.	  Each	  
immunisation	  group	  consisted	  of	  5	  mice.	  
	  
Anti-­‐OVA	   end-­‐point	   titres	   showed	   that	   CLICK	   unfractionated	   conjugate	   as	   well	   as	  
Fraction	   1	   and	   Fraction	   3	   significantly	   enhanced	   antibody	   responses	   against	   OVA	  
antigen	   when	   compared	   to	   Standard	   unfractionated	   conjugate	   at	   day	   13	   (before	  
boost)	   (p<0.0001,	   One-­‐way	   ANOVA,	   using	   Dunnett’s	   post-­‐test)	   (Figure	   3.21A).	  
However,	  surprisingly,	  anti-­‐OVA	  end-­‐point	  titres	  at	  day	  28	  (after	  boost)	  showed	  that	  
only	  Fraction	  3	  did	  not	  significantly	  enhance	  antibody	  responses	  against	  OVA	  antigen	  
Figure	   3.21B.	   However,	   a	   trend	   was	   observed	   (p=0.051,	   One-­‐way	   ANOVA,	   using	  
Dunnett’s	  post-­‐test).	  It	  is	  worthy	  to	  note	  that	  after	  the	  boost	  each	  immunised	  group	  
(except	  for	  PBS	  group)	  demonstrated	  very	  high	  OVA	  end-­‐point	  titres,	  including	  mice	  
immunised	   with	   Standard	   OVA-­‐CD40mAb	   vaccines.	   There	   was	   a	   significant	  
difference	   in	   the	   anti-­‐OVA	   endpoint	   titres	   between	   the	   sera	   from	   Standard	  
conjugate	  and	  PBS	  immunised	  mice	  both	  pre-­‐boost	  and	  post-­‐boost.	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A.	   	  
B.	   	  
Figure	  3.21.	  Serum	  anti-­‐OVA	  antibody	  end-­‐point	  titre	  level	  at	  day	  13	  (A)	  and	  day	  28	  
(B)	  (following	  boost).	  Statistical	  significance	  was	  determined	  by	  the	  use	  of	  One-­‐way	  
ANOVA	  using	  Dunnett’s	  multiple	  comparison	  test	  (mean	  +/-­‐	  SD,	  n	  =	  4	  or	  5)	  was	  used	  
to	   determine	   statistical	   significance.	   *p<0.05	   **p<0.01,	   ****p<0.0001.	   Each	   dot	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Discussion	  
Vaccines	  designed	   for	   clinical	  use	   should	  be	  potent	  and	  consistent	   in	   composition.	  
Conjugation	   strategies	   used	   so	   far,	   including	   the	   standard	   method	   used	   in	   our	  
laboratory	   yield	   products	   that	   are	   heterogeneous	   and	   contain	   high	   average	   MW	  
complexes	   that	   may	   mask	   the	   immunogenic	   epitopes	   of	   the	   vaccine.	   CD40mAb	  
works	  best	   as	   an	  adjuvant	   in	   a	  monomeric	   state	   (Heath	  and	   Laing,	  2004).	   Thus,	   in	  
order	  to	  maximise	  the	  potential	  of	  CD40mAb	  as	  an	  adjuvant	   in	  conjugate	  vaccines,	  
the	  novel,	  highly	  specific	  conjugation	  strategy	  –	  click	  chemistry,	  was	  used	  together	  
with	   size-­‐exclusion	   HPLC,	   in	   an	   effort	   to	   produce	   more	   clearly	   defined	   and	   less	  
heterogeneous	  conjugates	  of	  low	  average	  MW.	  
The	   reagents	   used	   to	   produce	   the	   CLICK	   and	   Standard	   conjugates	   in	   this	   chapter	  
namely,	   NHS-­‐PEG4-­‐Azide,	   DBCO-­‐NHS,	   Sulfo-­‐SMCC	   and	   SATA	   all	   have	   an	   amine-­‐
reactive	   group	   (NHS	   ester).	   OVA	   antigen	   contains	   20	   lysine	   residues	   that	   contain	  
amines	  for	  conjugation.	  Amines	  are	  present	  all	  over	  the	  antibody	  structure	  with	  21	  
present	  on	  the	  heavy	  chain	  constant	  region	  of	  rat	  IgG1	  and	  8	  present	  on	  the	  heavy	  
chain	   constant	   region	  of	  mouse	   IgG1.	  Even	   though	   there	  are	  multiple	   sites	   for	   the	  
formation	  of	  an	  amide	  bond,	  the	  NHS	  ester	  reagents	  are	  still	  usually	  used	  in	  excess,	  
as	  the	  reaction	  is	  not	  100%	  efficient	  (Adamczyk	  et	  al.,	  1996).	  This	  means	  that	  most	  
likely	  more	  than	  one	  NHS	  ester	  group	  could	  be	  binding	  to	  OVA	  antigen	  or	  antibody	  
(CD40mAb,	  20C2mAb	  or	  A20	  antibody).	  For	  example	   in	   the	  case	  of	  OVA-­‐CD40mAb	  
conjugates,	  more	  than	  one	  CD40mAb	  can	  bind	  to	  one	  OVA	  antigen	  and	  vice	  versa.	  
This	  could	   lead	  to	  the	  formation	  of	   large	  complexes	  of	  conjugate	  and	  could	  be	  the	  
reason	   why	   even	   though	   the	   DBCO-­‐NHS	   and	   NHS-­‐PEG4-­‐Azide	   are	   very	   narrowly	  
reactive	  to	  each	  other,	  conjugates	  containing	  more	  than	  one	  antibody	  conjugated	  to	  
one	  antibody/OVA	  occur.	  This	  is	  the	  reason	  why	  size-­‐exclusion	  HPLC	  was	  utilised	  to	  
isolate	  the	  lowest	  average	  MW	  fraction	  of	  the	  CD40mAb-­‐adjuvanted	  conjugates.	  
The	  HPLC	  chromatograms	  of	  A20-­‐CD40mAb	  conjugates	  made	  by	  standard	  and	  click	  
chemistry	   methods	   were	   analysed	   first	   to	   investigate	   if	   there	   was	   an	   apparent	  
difference	  in	  protein	  composition.	  Both	  conjugates	  consisted	  of	  products	  of	  varying	  
MW	  (Figure	  3.4).	  HPLC	  chromatograms	  of	  CLICK	  A20-­‐CD40mAb	  conjugates	  showed	  a	  
distinct	  peak	  containing	  high	  average	  MW	  protein,	  as	  well	  as	  multiple	  distinct	  peaks	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containing	   lower	   average	   MW	   proteins	   (Figure	   3.4A).	   However	   the	   HPLC	  
chromatograms	  of	   the	   Standard	   conjugate	   only	   showed	   two	  distinct	   peaks	   (Figure	  
3.4B),	   a	   high	   average	  MW	   peak	   that	   was	   observed	   at	   5	  minutes	   that	   tapered	   off	  
considerably	   until	   the	   peak	   at	   8.4	   minutes	   emerged.	   This	   latter	   peak	   possibly	  
contained	   the	   unconjugated	   antibody.	   The	   former	   possibly	   contained	   very	   high	  
average	  A20-­‐CD40mAb	  conjugate	  complexes.	  
In	  vitro	  similarity	  of	  the	  Standard	  A20-­‐CD40mAb	  conjugates	  to	  Fraction	  1	  (very	  high	  
average	  MW	  protein)	  and	  Fraction	  4	  (mainly	  unconjugated	  antibody)	  demonstrated	  
by	   ELISA,	   was	   consistent	   with	   the	   fact	   that	   the	   Standard	   conjugates	   consisted	   of	  
predominantly	  high	  average	  MW	  fractions	  and	  unconjugated	  antibody	   (Figures	  3.6	  
and	  Figure	  3.7).	  Both	  Fraction	  1	  and	  Standard	  conjugate	  showed	  a	  low	  OD	  signal	  in	  
both	   sandwich	   ELISAs.	   This	   could	   be	   due	   to	   the	   extensive	   cross-­‐linking	   of	   the	  
conjugates	   that	   possibly	   mask	   CD40mAb	   antigen-­‐binding	   sites	   or	   OVA	   epitopes	  
important	   for	   binding	   ELISA	   antibodies.	   Fractions	   2	   and	   3	   (of	   decreasing	   average	  
MW)	   and	   unfractionated	   CLICK	   A20-­‐CD40mAb,	   all	   showed	   high	   conjugate	   purity,	  
possibly	  meaning	  that	  binding	  to	  ELISA	  antibodies	  was	  not	  hindered	  by	  the	  presence	  
of	  aggregates	  (Figure	  3.6	  and	  3.7).	  The	  ability	  of	  the	  CD40mAb	  in	  all	  conjugates,	  to	  
bind	  to	  full-­‐length	  membrane	  bound	  CD40	  receptor	   in	  vitro	  was	  confirmed	  by	  flow	  
cytometry	  on	  CD40L929	  cells	  (Figure	  3.8).	  	  	  	  
The	  anti-­‐Id	   response	   to	   the	  A20-­‐CD40mAb	  conjugates	  produced	  by	   the	   immunised	  
mice	  was	  assessed.	  All	  immunised	  groups	  of	  mice	  produced	  detectable	  levels	  of	  anti-­‐
A20	  specific	  antibodies	  after	  boost	  (Figure	  3.11)	  indicating	  that	  all	  the	  A20-­‐CD40mAb	  
conjugates	  were	  immunogenic.	  The	  anti-­‐Id	  antibody	  responses	  to	  the	  Standard	  A20-­‐
CD40mAb	  unfractionated	   conjugate	  were	   comparable	   to	  previous	   studies	   (Carlring	  
et	  al.,	  2012).	  With	  great	  interest	  to	  this	  study,	  only	  sera	  from	  mice	  immunised	  with	  
Fraction	   3	   (low	   average	   MW	   conjugate	   vaccine)	   showed	   a	   significantly	   enhanced	  
anti-­‐A20	   antibody	   titre	   (Figure	   3.11)	   compared	   to	   the	   unfractionated	   Standard	  
conjugate,	   demonstrating	   that	   a	   low	   MW	   conjugate	   enhances	   vaccine	  
immunogenicity.	  	  
A	  specific	  anti-­‐Id	  antibody	  response	  was	   found	  to	  be	  absolutely	  essential	   to	  confer	  
protection	   against	   tumour	   in	   a	   B	   cell	   leukemia/lymphoma	   murine	   model	   (Cesco-­‐
Gaspere	  et	  al.,	  2005),	  and	  	  boosting	  the	  anti-­‐Id	  response	  in	  vivo	  positively	  correlated	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with	  tumour	  protection	  (Cesco-­‐Gaspere	  et	  al.,	  2008).	  Furthermore,	  a	  follow-­‐up	  study	  
10	   years	   after	   follicular	   lymphoma	   patients	   were	   Id-­‐vaccinated	   showed	   that	   the	  
specific	   anti-­‐Id	   antibody	   response	   also	   correlated	  with	   overall	   survival.	   In	   fact,	   the	  
overall	   survival	   was	   90%	   in	   patients	   with	   anti-­‐Id	   responses	   and	   69%	   in	   patients	  
without	  anti-­‐id	  responses	  (Ai	  et	  al.,	  2009).	  	  
The	   Standard	   A20-­‐CD40mAb	   conjugate	   immunised	   mice	   subsequently	   challenged	  
with	   A20	   tumour	   cells	   showed	   significantly	   enhanced	  median	   and	   overall	   survival	  
compared	   to	   the	   control	   group	   (Figure	   3.12).	   Intriguingly,	   amongst	   the	   CLICK	  
unfractionated	   conjugate	   and	   fractions,	   Fraction	   3	   (low	   average	   MW	   conjugate	  
vaccine)	   showed	   the	   highest	  median	   survival	   of	   immunised	  mice	   compared	   to	   the	  
Standard	  vaccine	   immunised	  mice.	  This	   trend	  was	  however	  not	   significant	  possibly	  
because	   more	   than	   just	   10	   mice	   were	   required	   to	   reach	   statistical	   significance.	  
However,	   this	   is	   very	  promising,	  and	  does	   support	   the	  hypothesis	   that	   the	  vaccine	  
efficacy	   of	   heterogeneous	   conjugates	   is	   inferior	   compared	   to	   more	   defined	  
conjugates.	  Moreover,	   the	   tumour	  burden	   in	  mice	   immunised	  with	   Fraction	  3	   and	  
CLICK	  unfractionated	  conjugates	  but	  not	  with	  Fraction	  1	  was	  significantly	   less	   than	  
that	   of	   the	   Standard	   conjugate	   immunised	   mice	   (Figure	   3.13).	   The	   Fraction	   3	  
immunised	  group	  also	  demonstrated	  the	  slowest	  tumour	  onset.	  It	  is	  noteworthy	  that	  
Fraction	   3	   also	   produced	  highest	   anti-­‐Id	   titres,	   and	   in	   accordance	   to	   other	   studies	  
(Cesco-­‐Gaspere	  et	  al.,	  2005,	  Cesco-­‐Gaspere	  et	  al.,	  2008,	  Ai	  et	  al.,	  2009)	   it	  was	  also	  
the	   vaccine	   that	   induced	   the	   best	   tumour	   protection.	   This	   is	   very	   interesting	   as	   it	  
confirms	   that	  conjugation	  strategy	  plays	  an	   important	   role	   in	   the	  speed	  of	   tumour	  
progression.	  	  
Different	  studies	  have	  demonstrated	  that	  prophylactic	  immunisation	  of	  mice	  delays	  
tumour	  onset	  and	  progression,	  or	  completely	  protects	  against	  the	  tumours	  (Soares	  
et	  al.,	  2001,	  Timmerman	  et	  al.,	  2001,	  Armstrong	  et	  al.,	  2002).	   In	  accordance	  to	  our	  
study,	  different	  vaccine	  compositions	  and	  formulations	  containing	  the	  same	  tumour	  
antigen	   showed	   different	   degrees	   of	   tumour	   rejection.	   For	   example	   the	   use	   of	  
idiotype-­‐encoding	   recombinant	   adenoviral	   vectors	   (Armstrong	   et	   al.,	   2002),	   as	  
opposed	  to	  the	  idiotype-­‐encoding	  plasmid	  vaccine	  encoding	  the	  idiotypic	  gene	  (King	  
et	   al.,	   1998)	   were	   found	   to	   be	   more	   efficient	   at	   inducing	   tumour	   protection	   in	  
syngeneic	  A20	   lymphoma	  murine	  model.	  Another	  study	  showed	  that	   immunisation	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with	  tumour	  antigen	  co-­‐administered	  with	  either	  the	  cytokine	  GM-­‐CSF	  or	  the	  oil	   in	  
water	   emulsion	   containing	  QS-­‐21	   and	  MPL	  prior	   to	   tumour	   challenge	  did	  not	   stop	  
tumour	   development.	   In	   contrast,	   immunisation	   with	   tumour	   antigen	   pulsed	   DCs	  
resulted	  in	  90%	  tumour	  rejection	  (Soares	  et	  al.,	  2001).	  	  
A	  previous	  study	  in	  our	  laboratory	  showed	  that	  CD8+	  T	  cell	  depletion	  but	  not	  CD4+	  T	  
cell	  depletion	  two	  days	  prior	  to	  tumour	  challenge	  significantly	  reduced	  median	  and	  
overall	   survival	  of	  A20-­‐CD40mAb	   immunised	  mice	   (Carlring	  et	  al.,	  2012).	  While	   the	  
reduction	  of	   vaccine	  anti-­‐tumour	  efficacy	  by	  CD8	  depletion	  would	  point	   towards	  a	  
role	   for	   CTL	   responses	   in	   controlling	   tumour	   growth,	   these	   were	   not	   directly	  
measured	  in	  the	  previous	  study.	  To	  help	  determine	  the	  mode	  of	  action	  of	  CD40mAb-­‐
adjuvanted	  conjugates	  (investigated	  in	  Chapters	  4	  and	  5)	  and	  to	  simplify	  assessment	  
of	  CTL	  responses	  (investigated	  in	  Chapter	  5),	  we	  moved	  to	  an	  OVA	  antigen	  model.	  To	  
ensure	   that	   the	   OVA	   model	   produced	   consistent	   results	   with	   the	   A20-­‐CD40mAb	  
conjugates,	   the	   immunogenicity	   of	   OVA-­‐CD40mAb	   conjugates	   made	   by	   the	   two	  
different	   conjugation	   strategies	   was	   evaluated.	   The	   HPLC	   chromatogram	   of	   CLICK	  
OVA-­‐CD40mAb	  conjugates	  protein	  composition	  showed	  the	  same	  trend	  as	  the	  CLICK	  
A20-­‐CD40mAb	   conjugates	   (Figure	   3.15A).	   Standard	   OVA-­‐CD40mAb	   conjugate	  
contained	   less	  high	  average	  MW	  protein	   (Fraction	  1)	   than	  Standard	  A20-­‐CD40mAb	  
conjugates,	  but	  more	  unconjugated	  antibody	  and	  unconjugated	  OVA	  (Figure	  3.15B).	  
In	   vitro	   analysis	   of	   the	   OVA-­‐CD40mAb	   conjugates	   and	   fractions	   showed	   the	   same	  
trend	   as	   A20-­‐CD40mAb	   conjugates	   and	   fractions	   (Figures	   3.16,	   3.17,	   3.18),	   and	  
confirmed	  the	  presence	  of	  OVA-­‐CD40mAb	  conjugates.	  
An	   in	   vivo	   investigation	   of	   the	   immunogenicity	   of	   Standard	   OVA-­‐CD40mAb,	   CLICK	  
OVA-­‐CD40mAb,	  Fraction	  3	  (low	  average	  MW	  conjugate	  vaccine)	  and	  Fraction	  1	  (high	  
average	  MW	   conjugate	   vaccine)	   conjugates	   in	   a	  murine	  model	   revealed	   that	   anti-­‐
OVA	  specific	  antibody	  responses	  were	  generated	  by	  each	  of	  the	  immunised	  groups	  
(apart	   from	   the	   control	   group).	   The	   primary	   responses	   against	   OVA	   produced	   by	  
unfractionated	   CLICK	   conjugate,	   Fraction	   1	   and	   Fraction	   3	   immunised	   mice	   were	  
significantly	   higher	   that	   produced	   by	   the	   unfractionated	   Standard	   conjugate	  
immunised	   mice	   (Figure	   3.21).	   This	   shows	   that	   the	   CD40mAb-­‐antigen	   conjugate	  
vaccines	   made	   by	   click	   chemistry	   are	   superior	   to	   the	   ones	   made	   by	   standard	  
methods.	   However,	   it	   is	   noteworthy	   that	   the	   anti-­‐OVA	   antibody	   end-­‐point	   titre	   in	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response	  Standard	  conjugate	  immunisation	  was	  lower	  compared	  to	  previous	  studies	  
conducted	  in	  our	  laboratory	  (Barr	  et	  al.,	  2003).	  	  
	  
Conclusion	  
Click	  chemistry	  is	  a	  promising	  conjugation	  strategy	  that	  should	  be	  exploited	  further	  
in	   the	   field	   of	   vaccine	   development	   and	   design.	   CD40mAb-­‐antigen	   conjugates	  
produced	  by	  click	  chemistry	  were	  more	  immunogenic	  than	  those	  made	  by	  standard	  
methods.	  
This	   technology	   lead	   us	   to	   the	   production	   of	   a	   more	   defined,	   low	   average	   MW	  
conjugate	  vaccine	  which	  was	  superior	  to	  Standard	  conjugate	  vaccines	  in	  a	  murine	  B	  
cell	  lymphoma	  setting.	  This	  supports	  our	  hypothesis	  that	  the	  potential	  of	  CD40mAb	  
as	  an	  adjuvant	  in	  conjugate	  vaccines	  is	  maximised	  when	  used	  in	  more	  defined,	   low	  
average	  MW	  conjugates,	  leading	  to	  enhanced	  vaccine	  efficacy.	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4.1. Introduction	  
Adjuvants	  have	  been	  classed	  into	  (i)	  immunostimulatory	  components,	  which	  have	  a	  
direct	  effect	  on	  certain	  receptors	  of	  the	  innate	  immune	  system	  for	  example	  TLRs,	  (ii)	  
delivery	  systems,	  which	  deliver	  the	  antigen	  of	  interest	  leading	  to	  enhanced	  antigen	  
presentation	  to	  the	  immune	  system	  for	  example	  liposomes	  or	  (iii)	  adjuvant	  systems	  
that	  include	  a	  combination	  of	  both	  (i)	  and	  (ii)	  (Reed	  et	  al.,	  2013).	  
Due	  to	  its	  agonistic	  properties	  CD40mAb,	  is	  thought	  to	  work	  by	  ligation	  of	  the	  CD40	  
receptor	   on	   APCs,	   much	   like	   the	   extensively	   studied	   CD40-­‐CD154	   interaction	  
between	  APCs	  and	  activated	  T	  cells	  (as	  explained	  in	  detail	  in	  Chapter	  1,	  see	  Section	  
1.1.7).	   Chemical	   conjugation	   of	   antigen	   to	   CD40mAb	   also	   enhances	   the	   likelihood	  
that	   the	   antigen	   will	   be	   co-­‐delivered	   to	   the	   very	   same	   APC	   that	   receive	   CD40	  
receptor	   stimulation.	   Furthermore,	   CD40	   is	   expressed	   on	   all	   APCs.	   Therefore,	  
CD40mAb-­‐adjuvanted	  vaccines,	  which	  contain	  antigen	  chemically	  conjugated	  to	  the	  
CD40mAb,	  have	  the	  potential	  to	  work	  as	  both	  immunostimulatory	  components	  and	  
as	   delivery	   systems	   to	   B	   cells,	   DCs	   or	   macrophages.	   The	   immunostimulatory	   and	  
antigen	   delivery	   properties	   of	   CD40mAb-­‐adjuvanted	   vaccines	   to	   APCs	   were	  
investigated	  further	  to	  better	  understand	  the	  mode	  of	  action	  of	  the	  CD40mAb	  as	  an	  
adjuvant.	  
It	  has	  been	  demonstrated	  that	  CD40mAb	  conjugated	  to	  a	  lymphoma	  antigen	  can	  be	  
taken	  up	  by	  B	  cells,	  DCs	  and	  macrophages	  following	  short	  term	  culture	  with	  murine	  
splenocytes	   in	   vitro	   (Carlring	   et	   al.,	   2012).	   Significant	   upregulation	   of	   the	   co-­‐
stimulatory	  molecules	  on	  B	  cells	  showed	  that	  they	  had	  become	  activated,	  however	  
this	  was	  not	  the	  case	  for	  DCs	  and	  macrophages.	  The	  percentage	  of	  CD11c+	  DCs	  in	  the	  
spleen	   is	   very	   low	   (14%)	   (Duriancik	   and	   Hoag,	   2009),	   and	   consists	   of	   a	  
heterogeneous	   population	   of	   DC	   subsets,	   specialised	   for	   different	   functions	   (see	  
Section	  1.1.2.1.).	  We	  therefore	  wanted	  to	  investigate	  whether	  a	  more	  homogeneous	  
immature	   population	   of	   DCs	   could	   become	   activated	   in	   this	   experimental	   setting	  
using	   OVA	   as	   a	   model	   antigen	   conjugated	   to	   CD40mAb	   (referred	   to	   as	   OVA-­‐
CD40mAb).	   This	   is	  why	  we	  optimised	  a	   technique	   to	  generate	   immature	  DCs	   from	  
murine	   bone	   marrow	   cells.	   Furthermore,	   as	   the	   spleen	   contains	   a	   diversity	   of	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professional	  APCs,	  B	   cells	  were	  purified	   to	  allow	   focussing	  experiments	   specifically	  
on	  a	  B	  cell	  population,	  without	  contamination	  of	  other	  APCs.	  	  
To	   investigate	   the	   effect	   of	   OVA-­‐CD40mAb	   conjugate	   on	   antigen	   presentation	   to	  
antigen-­‐specific	   CD4+	   T	   cells	   the	   DO11.10	   T	   hybridoma	   cell	   line	   was	   used.	   This	  
hybridoma	   is	   ideal	   as	   it	   is	   OVA-­‐specific	   and	   expresses	   CD4.	   DO11.10	   T	   hybridoma	  
cells	  are	  co-­‐stimulation	  independent	  and	  recognise	  the	  immunodominant	  CD4+	  T	  cell	  
epitope	  OVA323-­‐339,	  having	  the	  protein	  sequence	  ISQAVHAAHAEINEAGR	  (which	  will	  be	  
referred	   to	   as	   ISQ)	   presented	   on	   the	   MHC	   class	   II	   of	   the	   H-­‐2d	   haplotype	   (I-­‐Ad)	  
(Shimonkevitz	   et	   al.,	   1984).	   In	   addition,	   the	   activation	   status	   of	   the	   DO11.10	   T	  
hybridoma	  cells	  can	  be	  measured	  by	  their	  capacity	  to	  produce	  IL-­‐2.	  An	  increase	  in	  IL-­‐
2	  levels	  is	  an	  indication	  of	  DO11.10	  T	  hybridoma	  cell	  activation.	  
CD40mAb	   (rat	   IgG2a)	   administered	   alone	   as	   an	   adjuvant	   enhanced	   CD4+	   T	   cell	  
response	   ex	   vivo	   to	   its	   own	   rat	   Fc	   portion	   (Carlring	   et	   al.,	   2004).	   SCID	   mice	  
transferred	  with	  CD4+	  T	  cells	  from	  CD40	  immunised	  mice	  and	  B220+	  cells	  from	  IgG2a	  
mAb	   control	   immunised	   mice,	   displayed	   an	   enhanced	   serum	   anti-­‐IgG2a	   antibody	  
titre	   after	   immunisation	  with	   IgG2a.	   This	   response	   that	  was	   not	   observed	   in	   SCID	  
mice	  transferred	  with	  B220+	  cells	  from	  CD40	  immunized	  mice	  and	  CD4+	  T	  cells	  from	  
IgG2a	  immunised	  mice	  (Carlring	  et	  al.,	  2004).	  The	  former	  studies	  are	  building	  blocks	  
to	  understanding	  if	  CD40mAb-­‐adjuvanted	  conjugates	  have	  a	  role	  in	  enhancing	  CD4+	  
T	  cell	  responses,	  but	  only	  show	  that	  CD40mAb	  administered	  alone	  enhances	  CD4+	  T	  
cell	   proliferation	   to	   itself.	   Therefore	   other	   studies	   were	   conducted	   to	   investigate	  
whether	  a	  CD4+	  T	  cell	  response	  is	  required	  or	  enhanced	  as	  part	  of	  vaccine-­‐mediated	  
immunity	   against	   the	   conjugated	   antigen.	   CD40mAb	   conjugated	   to	   lymphoma	  
antigen	  vaccine	  used	  in	  a	   lymphoma	  murine	  model	  required	  both	  CD4+	  and	  CD8+	  T	  
cell	   responses	   to	   achieve	   maximum	   efficacy	   in	   vivo	   (Carlring	   et	   al.,	   2012).	  
Furthermore,	   CD40mAb	   conjugated	   to	   antigen	   also	   enhances	   lymphocyte	  
proliferation	  in	  response	  to	  the	  antigen	  ex	  vivo	  (Hatzifoti	  and	  Heath,	  2007)	  however,	  
in	  this	  study	  a	  CD4+	  marker	  was	  not	  used	  and	  the	  proliferating	  cells	  were	  assumed	  to	  
be	  CD4+	  T	  cells.	  Therefore,	  finally,	  in	  this	  chapter	  the	  effect	  of	  CD40mAb	  conjugated	  
to	  antigen	  on	  specifically	  CD4+	  T	  cell	  responses	  ex	  vivo	  was	  reviewed.	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4.2. The	   effect	   of	   OVA-­‐CD40mAb	   conjugates	   on	   antigen-­‐
presentation	  to	  DO11.10	  T	  hybridoma	  cells	  
	  
4.2.1. Isolation	  and	  generation	  of	  APCs	  	  
4.2.1.1. Generation	  of	  bone	  marrow	  dendritic	  cells	  
The	  technique	  used	  to	  generate	  DCs	  from	  murine	  C57Bl/6	  and	  BALB/c	  bone	  marrow	  	  
cell	   populations	   was	   based	   on	   other	   studies	   (Lutz	   et	   al.,	   1999,	   Lutz	   et	   al.,	   2002,	  
Galea-­‐Lauri	   et	   al.,	   2004).	   In	   these	   studies	   granulocyte	   macrophage-­‐colony	  
stimulating	  factor	  (GM-­‐CSF)	  and	  IL-­‐4	  were	  the	  growth	  factors	  used	  to	  drive	  the	  bone	  
marrow	  progenitors	  to	  produce	  immature	  dendritic	  cells	  (BM-­‐DC).	  IL-­‐4	  is	  particularly	  
important	   as	   a	   growth	   factor,	   as	   it	   has	   been	   shown	   to	   prevent	   or	   reduce	   the	  
neutrophil	  and	  macrophage	  contamination	  (Galea-­‐Lauri	  et	  al.,	  2004).	  	  
BM-­‐DCs	   were	   analysed	   for	   the	   expression	   of	   the	   phenotypic	   murine	   DC	   marker	  
CD11c	  as	  well	   as	  Gr-­‐1	  expression	  and	  F4-­‐80	  expression	   (to	  exclude	  neutrophil	   and	  
macrophage	  contamination	  respectively)	  by	  flow	  cytometry	  (see	  Section	  2.2.6.3.2.).	  
Immature	  DCs	  were	  characterised	  in	  other	  studies	  by	  high	  expression	  of	  CD11c	  and	  
low	  expression	  of	  adhesive	  and	  co-­‐stimulatory	  molecules	  including	  CD40,	  CD86	  and	  
CD83	  (Lutz	  et	  al.,	  1999,	  Son	  et	  al.,	  2002).	  	  
Ten-­‐day	  old	  semi-­‐adherent	  and	  non-­‐adherent	  BM-­‐DC	  generated	  by	  this	  protocol	  (see	  
Section	  2.2.6.3.)	  yielded	  2	  x	  107	  (+/-­‐	  1	  x	  107)	  cells	  from	  a	  starting	  cell	  number	  of	  2	  x	  
107	  cells	   (n=5).	  The	  BM-­‐DCs	  demonstrated	  more	   than	  85%	  CD11c	  expression	   (n=5)	  
(Figure	  4.1).	  This	  is	  comparable	  to	  the	  percentage	  purity	  obtained	  in	  other	  studies,	  in	  
which	   70%	  was	   taken	   as	   the	   acceptable	   lowest	   expression	   level	   (Lutz	   et	   al.,	   1999,	  
Galea-­‐Lauri	  et	  al.,	  2004,	  Creusot	  et	  al.,	  2009,	  Han	  et	  al.,	  2010).	  The	  expression	  levels	  
of	   F4-­‐80	   (macrophage	   marker)	   were	   less	   than	   10%	   (n=4)	   (Figure	   4.1),	   and	   are	  
comparable	  to	  BM-­‐DCs	  generated	  by	  other	  studies	  (Lutz	  et	  al.,	  1999).	  The	  expression	  
levels	   of	   Gr-­‐1	   (an	   early	   myeloid/granulocyte	   marker)	   were	   less	   than	   13%	   (n=4)	  
(Figure	  4.1).	  These	  characteristics	  are	  also	  consistent	  with	  other	  studies	  (Son	  et	  al.,	  
2002,	   Galea-­‐Lauri	   et	   al.,	   2004)	   suggesting	   that	   the	   BM-­‐DC	   population	   generated	  
using	  this	  protocol	   is	  of	  myeloid	  origin,	  especially	  since	   it	  has	  been	  shown	  that	  the	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depletion	  of	  progenitors	  of	  T	  and	  B	  cells	   is	  not	  a	  requirement	  for	  the	  generation	  of	  
myeloid	  DCs	   (Galea-­‐Lauri	  et	  al.,	  2004).	  Myeloid	  BM-­‐DCs	  are	   ideal	  especially	   for	   the	  
purpose	  of	  this	  chapter	  as	  they	  are	  better	  at	  the	  generation	  of	  antigen-­‐specific	  T–cell	  
responses	  compared	  to	  lymphoid	  DCs	  (Banchereau	  and	  Steinman,	  1998).	  
To	  demonstrate	  that	  the	  cell	  population	  generated	  by	  this	  protocol	  was	   immature,	  
and	  thus	  capable	  of	  antigen	  sampling,	  the	  level	  of	  CD40	  expression	  on	  BM-­‐DC	  before	  
and	  after	  LPS-­‐induced	  maturation	  was	  determined	  (see	  Section	  2.2.6.3.1.).	  As	  can	  be	  
observed	  in	  Figure	  4.2	  on	  day	  10,	  BM-­‐DCs	  had	  low	  CD40	  expression	  (<10%,	  n=3).	  This	  
expression	   increased	   to	   36-­‐44%	   after	   48-­‐hour	   stimulation	   with	   1μg/ml	   LPS	   (n=3)	  
(Figure	  4.2),	   in	  conformity	  to	  other	  studies	  (Lutz	  et	  al.,	  1999,	  Son	  et	  al.,	  2002).	  This	  
adds	  to	  the	  information	  that	  the	  BM-­‐DCs	  generated	  by	  this	  protocol	  were	  immature	  
and	  therefore	  had	  the	  best	  potential	  for	  antigen-­‐uptake.	  
Activation	   of	   BM-­‐DCs	   by	   LPS	   stimulation	   is	   not	   only	   observed	   via	   upregulation	   of	  
adhesion	   and	   co-­‐stimulatory	  molecules	   of	   DC	   but	   also	   via	  morphological	   changes,	  
including	   the	   production	   of	   veiled	   cells	   (Granucci	   et	   al.,	   1999,	   Lutz	   et	   al.,	   1999,	  
Verdijk	   et	   al.,	   2004).	   Brightfield	   microscopy	   of	   DCs	   at	   day	   12	   after	   48-­‐hour	   LPS	  
stimulation	  and	  at	  day	  8	  (no	  stimulation)	  was	  carried	  out	  to	  observe	  the	  contrast	  in	  
appearance	  (Figure	  4.3).	  The	  DCs	  morphology	  changes	  from	  round	  cells	  with	  limited	  
projections	   to	   the	   characteristic	   LPS-­‐induced	   ‘large	   veils’	   or	   cytoplasmic	   sheet-­‐like	  
processes	  when	  mature.	  These	  cytoplasmic	  projections	  are	   important	   for	  DC-­‐T	  cell	  
interactions	  and	  these	  can	  be	  clearly	  observed	  under	  the	  40X	  magnification	  (Figure	  
4.3B).	   This	   phenotype	   is	   consistent	   with	   BM-­‐DC	   cultures	   that	   are	   grown	   in	   the	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Figure	  4.1.	  Dendritic	  cell	  population	  generated	  after	  10	  days	  in	  culture	  from	  C57Bl/6	  bone	  
marrow	  cells.	  A.	  The	  gating	  strategy	  excluded	  debris	  and	  doublets,	  with	  subsequent	  gating	  
on	  live	  cells	  based	  on	  UV	  live/dead	  staining	  (UV	  450/50).	  Representative	  histogram	  plots	  of	  
CD11c	   expression,	   F4-­‐80	   expression	   and	  Gr-­‐1	   expression	   (blue	   peaks),	   as	  well	   as	   live	   cells	  
only	  stained	  with	  live/dead	  discrimination	  dye	  (red	  solid	  peak)	  are	  shown.	  	  
	  
	   	  
Figure	   4.2.	  CD40	   expression	   as	   determined	   by	   flow	   cytometry	   at	   day	   10	   of	   culture	   and	  
after	   stimulation	  with	   LPS	   for	  48	  hours.	  Histogram	  plot	  of	  CD40	  expression	  on	  BM-­‐DCs	  at	  
day	  10	  of	   culture	   (blue	  peak)	   and	  after	   LPS	   stimulation	   (orange	  peak),	   as	  well	   as	   live	   cells	  
only	  stained	  with	  live/dead	  discrimination	  dye	  (red	  solid	  peak)	  are	  shown.	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A. 	  
	  B. 	  
Figure	   4.3.	  Brightfield	  micrographs	   illustrating	   the	   immature	  BM-­‐DC	  phenotype	   at	   day	   8	  
(A)	  and	  the	  mature	  BM-­‐DC	  phenotype	  at	  day	  12	  after	  48	  hour	  LPS	  stimulation	  (B).	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4.2.1.2. Isolation	  of	  splenic	  B	  cells	  by	  positive	  selection	  
B	  cells	  were	  isolated	  from	  the	  spleens	  of	  C57Bl/6	  or	  BALB/c	  mice.	  B	  cell	  isolation	  was	  
performed	  using	  magnetic	  cell	  sorting,	  via	  positive	  selection	  (see	  Section	  2.2.6.5.1.).	  
This	  procedure	  produced	  a	  cell	  yield	  of	  2	  x	  106	  (+/-­‐	  0.5	  x	  106)	  CD19-­‐labelled	  cells	  from	  
a	  starting	  cell	  number	  of	  2	  x	  107	  spleen	  cells	   (n=5).	  CD19	  staining	  before	  and	  after	  
sorting	   was	   carried	   out	   by	   flow	   cytometry	   using	   PE-­‐labelled	   CD19	   antibody.	   The	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4.2.2.	  Generation	  of	  the	  DO11.10	  T	  hybridoma	  cell	  clone	  most	  sensitive	  
to	  the	  OVA	  peptide	  
It	  became	  evident	  during	  this	  study	  that	  the	  DO11.10	  hybridoma	  CD4+	  T	  cell	  line	  was	  
unstable	   and	   lost	   sensitivity	   to	   the	   ISQ	   peptide	   presented	   by	   the	   APCs	   with	   each	  
passage	  in	  cell	  culture.	  This	  was	  concluded	  from	  the	  decreasing	  IL-­‐2	  levels	  produced	  
by	  the	  DO11.10	  T	  hybridoma	  cells	  measured	  by	  ELISA.	  
The	  CD4+	  DO11.10	   T	   hybridoma	   cells	  were	   therefore	   re-­‐cloned	  by	   limiting	  dilution	  
(see	  Section	  2.2.6.2.1.)	  in	  order	  to	  identify	  the	  cell	  clones	  that	  were	  most	  sensitive	  to	  
the	   ISQ	  peptide.	   	   Eleven	  clones	  were	   tested	   for	   responsiveness	   to	   the	   ISQ	  peptide	  
(Figure	   4.5)	   (see	   Section	   2.2.5.3.).	   The	   concentration	   of	   IL-­‐2	   secreted	   into	   the	  
supernatant	  by	  each	  clone	  was	  determined	  by	  ELISA	   (see	   Section	  2.2.6.8.1.).	  Clone	  
G4	   produced	   the	   highest	   amount	   of	   IL-­‐2	   (3000pg/ml)	   on	   stimulation	   with	   ISQ	  
peptide	   (Figure	   4.5).	   This	   level	   of	   IL-­‐2	   production	   is	   comparable	   to	   other	   studies	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Figure	  4.5.	  Levels	  of	  IL-­‐2	  secreted	  into	  the	  supernatant	  by	  activated	  DO11.10	  T	  hybridoma	  
cell	   clones.	   The	   DO11.10	   T	   hybridoma	   cell	   clones	   produced	   by	   limiting	   dilution	   were	  
stimulated	  specifically	  via	  C57Bl/6	   splenocytes	  pulsed	  with	  2µg/ml	   (1µM)	   ISQ	  peptide	   (red	  
bars)	  and	  non-­‐specifically	  with	  50ng/ml	  PMA	  (0.1µM)	  and	   Ionomycin	  (1µM)	  (blue	  bars)	   for	  
48	   hours.	  No	   clone	   refers	   to	   splenocytes	   pulsed	  with	   ISQ	  peptide	  without	   co-­‐culture	  with	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4.2.3. Optimisation	   of	   the	   co-­‐culture	   of	   APCs	   with	   DO11.10	   T	  
hybridoma	  cells	  
To	   determine	   whether	   the	   OVA-­‐CD40mAb	   conjugate	   enhances	   APC	   antigen	  
presentation	   to	   CD4+	   T	   cells	   compared	   to	   the	   isotype	  OVA-­‐mAb	   control	   conjugate	  
(OVA-­‐20C2mAb),	  clone	  G4	  was	  co-­‐cultured	  with	  BM-­‐DCs	  and	  B	  cells	   in	  the	  absence	  
or	  presence	  of	  stimuli	  in	  vitro.	  	  
For	   the	   purpose	   of	   optimisation	   of	   this	   co-­‐culture	   system	  only	   the	   Standard	  OVA-­‐
mAb	   conjugates	   were	   used.	   The	   starting	   concentration	   for	   the	   Standard	   OVA-­‐
CD40mAb	   conjugate	   and	   Standard	   OVA-­‐20C2mAb	   conjugate	   stimulants	   was	  
10µg/ml.	  B	   cells	  or	  BM-­‐DCs	   (104)	  were	   co-­‐cultured	  with	  105	  DO11.10	  T	  hybridoma	  
cells	   in	   a	   96	   well	   plate	   (200µl	   volume)	   for	   48	   hours	   and	   IL-­‐2	   secreted	   into	  
supernatant	  was	  measured	  by	  ELISA	  (see	  Section	  2.2.6.8.1.).	  Stimulation	  of	  BM-­‐DCs	  
and	  B	  cells	  with	  Standard	  OVA-­‐CD40mAb	  conjugates	  at	  10µg/ml	  did	  not	  activate	  the	  
DO11.10	  T	  hybridoma	  cells	  to	  produce	  detectable	  IL-­‐2	  levels	  (Figure	  4.6A	  and	  B).	  In	  
fact	   the	   IL-­‐2	   concentration	   in	   the	   supernatants	   was	   not	   higher	   than	   the	   negative	  
controls.	   This	   could	   be	   attributed	   to	   the	   fact	   that	   too	   low	   a	   concentration	   of	  
conjugate	   was	   used,	   and	   not	   enough	   ISQ-­‐peptide	   from	   the	   OVA	   antigen	   in	   the	  
conjugate	  was	  presented	  on	  the	  APC	  surface	  to	  activate	   the	  DO11.10	  T	  hybridoma	  
cells.	  	  
The	  positive	  controls	  showed	  that	  the	  DO11.10	  T	  hybridoma	  cells	  were	  responding	  
optimally,	   and	   producing	   detectable	   IL-­‐2	   levels	   in	   the	   supernatant.	   DO11.10	   T	  
hybridoma	   cells	   co-­‐cultured	   with	   B	   cells	   pulsed	   with	   ISQ	   peptide	   and	   CD40mAb	  
produced	   a	   considerably	   lower	   IL-­‐2	   concentration	   in	   the	   supernatant	   (3000pg/ml)	  
after	  48	  hour	  culture	  (Figure	  4.6B)	  compared	  to	  co-­‐culture	  with	  BM-­‐DC	  pulsed	  with	  
the	  same	  stimuli	  (Figure	  4.6A)	  and	  the	  positive	  control	  (8000pg/ml).	  
Due	   to	   these	   results,	   splenocytes	   and	   BM-­‐DCs	   were	   used	   for	   subsequent	  
experiments	   to	   focus	  on	   identifying	  primarily	  which	   is	   the	   lowest	   concentration	  of	  
OVA	   antigen	   required	   to	   activate	   the	   DO11.10	   T	   hybridoma	   cells	   to	   produce	  
detectable	  levels	  of	  IL-­‐2	  in	  co-­‐culture	  with	  APCs.	  
CHAPTER	  4	  
	   144	  
A. 	  
B. 	  
Figure	   4.6.	   Co-­‐culture	   of	   BM-­‐DCs	   (A)	   or	   B	   cells	   (B)	   isolated	   from	   C57Bl/6	   mice	   with	  
DO11.10	  T	  hybridoma	  cells.	  Splenocytes	  were	  stimulated	  with	  2µg/ml	  (1µM)	  ISQ	  peptide	  or	  
50ng/ml	   PMA	   (0.1µM)	   and	   Ionomycin	   (1µM)	   and	   the	   ability	   of	   the	   DO11.10	   T	   hybridoma	  
cells	  to	  produce	  IL-­‐2	  on	  co-­‐culture	  was	  shown	  (red	  bars	  -­‐	  labelled	  Positive	  control).	  Negative	  
controls	  included	  stimulation	  of	  BM-­‐DC	  (A)	  or	  B	  cells	  (B)	  with	  10µg/ml	  of	  CD40mAb	  antibody	  
only,	   20C2	   isotype	   control	   mAb	   only,	   as	   well	   as	   2µg/ml	   (2µM)	   of	   irrelevant	   (SIINFEKL)	  
peptide	   (black	   bars	   –	   labelled	   as	   Negative	   control).	   APCs	  were	   stimulated	  with	   CD40mAb	  
(10µg/ml)	   and	   SIINFEKL	   or	   ISQ	   (2µg/ml)	   peptide	   mixture	   (green	   bars).	   APCs	   were	   also	  
stimulated	   with	   10µg/ml	   of	   Standard	   OVA-­‐mAb	   conjugates	   (blue	   bars).	   This	   figure	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4.2.3.1. DO11.10	   T	   hybridoma	   cell	   response	   to	   ISQ	  peptide	  on	   I-­‐Ad	   versus	   I-­‐Ab	  
backgrounds	  	  
In	   spite	   of	   the	   fact	   that	   the	   DO11.10	   T	   hybridoma	   cells	   were	   cultured	   at	   a	  
concentration	  of	  	  <	  5	  x	  105	  cells/ml	  (following	  the	  advice	  given	  by	  Professor	  Philippa	  
Marrack,	   Kappler	   Marrack	   Research	   Laboratory,	   Denver)	   subsequent	   co-­‐cultures	  
using	   the	   DO11.10	   T	   hybridoma	   clone	   G4	   were	   unsuccessful	   as	   the	   IL-­‐2	  
concentration	   produced	   by	   the	   DO11.10	   T	   hybridoma	   cell	   clone	   when	   stimulated	  
with	   splenocytes-­‐pulsed	  with	   ISQ	   peptide	  was	   below	   ELISA	   baseline	   levels.	   A	   new	  
DO11.10	   T	   hybridoma	   cell	   line	   was	   obtained	   (with	   thanks	   to	   Kappler/Marrack	  
Research	  Laboratory,	  Denver),	  and	  used	  in	  subsequent	  experiments.	  
The	   CD4+	   DO11.10	   T	   cells	   were	   originally	   generated	   by	   immunisation	   with	   OVA	  
protein	   to	  prime	  BALB/c	  mice	   (Marrack	   et	   al.,	   1983).	  However,	   it	   has	  been	   shown	  
that	   DO11.10	   T	   cells	   respond	   to	   the	   ISQ	   peptide	   from	  both	   I-­‐Ad	   (BALB/c)	   and	   I-­‐Ab	  
(C57BL/6)	   backgrounds	   (Robertson	   et	   al.,	   2000a).	   To	   ensure	   that	   the	   lack	   of	   IL-­‐2	  
production	  was	  not	  due	  to	  the	  MHC	  class	  II	  background,	  splenocytes	  obtained	  from	  
C57Bl/6	   and	   BALB/c	   mice	   were	   pulsed	   with	   ISQ	   peptide	   and	   compared	   to	  
unstimulated	   controls	   (Figure	   4.7).	   The	   results	   showed	   that	   these	   DO11.10	   T	  
hybridoma	  cells	   only	   respond	   to	   splenocytes	  pulsed	  with	   ISQ	  peptide	   from	  an	   I-­‐Ad	  
(BALB/c)	  background	  (p<0.0001,	  two-­‐way	  ANOVA	  using	  Sidak’s	  multiple	  comparisons	  
post-­‐test).	   Due	   to	   these	   results	   splenocytes	   and	   BM-­‐DCs	   harvested	   from	   BALB/c	  















Figure	   4.7.	   New	   DO11.10	   T	   hybridoma	   cells	   tested	   in	   co-­‐culture	   with	   ISQ-­‐pulsed	  
splenocytes	   harvested	   from	   BALB/c	   (red	   bar)	   and	   C57Bl/6	   mice	   strains	   (black	   bar).	  
Supernatants	  were	  collected	  after	  48	  hours,	  and	  the	  IL-­‐2	  concentration	  was	  measured	  using	  
ELISA.	   Two-­‐way	   ANOVA	   using	   Sidak’s	   multiple	   comparisons	   test	   (mean	   +/-­‐	   SD).	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4.2.3.2. Dose	  response	  of	  DO11.10	  T	  hybridoma	  cells	  to	  OVA	  antigen	  	  
	  
To	   identify	   which	   concentration	   of	   OVA	   was	   required	   to	   achieve	   measurable	   IL-­‐2	  
levels,	   splenocytes	   and	   DO11.10	   T	   hybridoma	   cells	   were	   co-­‐cultured	   in	   vitro.	   The	  
OVA	  concentrations	  used	  in	  published	  studies	  vary,	  some	  use	  OVA	  concentrations	  as	  
high	  as	  5000μg/ml,	  however,	  500-­‐1000μg/ml	  OVA	  has	  been	  used	  in	  most	  similar	  co-­‐
culture	   systems	   (Bennett	   et	   al.,	   1992,	   Mutini	   et	   al.,	   1999,	   Cycon	   et	   al.,	   2009,	  
Prokopowicz	   et	   al.,	   2010).	   Based	   on	   results	   from	   these	   studies	   1000μg/ml	   of	  OVA	  
was	   used	   as	   a	   starting	   concentration,	   together	   with	   concentrations	   of	   500μg/ml,	  
250μg/ml,	  125μg/ml,	  60μg/ml,	  30μg/ml	  and	  16μg/ml.	  
	  
Firstly,	   the	  co-­‐culture	   technique	  used	   involved	   treating	  1	  x	  107	  BALB/c	   splenocytes	  
(instead	   of	   pure	   BM-­‐DC	   or	   B	   cells)	   in	   1ml	   with	   serial	   OVA	   dilutions	   (starting	   at	  
1000μg/ml),	   or	   2μg/ml	   ISQ	  peptide	   for	   6	   hours	   in	   a	   24-­‐well	   plate.	   Secondly,	  OVA-­‐
pulsed	   or	   ISQ-­‐pulsed	   (used	   as	   a	   positive	   control)	   splenocytes	   (1	   x	   105)	   were	   co-­‐
cultured	  with	  DO11.10	  T	  hybridoma	  cells	  (1	  x	  105)	   in	  a	  96	  well	  plate	  in	  a	  volume	  of	  
200μl.	  Supernatants	  were	  collected	  after	  24,	  48	  and	  72	  hour	  incubation,	  and	  tested	  
for	  the	  presence	  of	  IL-­‐2	  by	  ELISA.	  	  
	  
Stimulation	  with	  ISQ	  peptide	  resulted	  in	  high	  levels	  of	  IL-­‐2	  production	  by	  DO11.10	  T	  
hybridoma	  cells	  at	  all	  three	  time-­‐points	  (Figure	  4.8),	  indicating	  that	  the	  amount	  of	  IL-­‐
2	  produced	  in	  the	  supernatant	  is	  proportional	  to	  the	  time	  in	  co-­‐culture.	  However,	  no	  
detectable	   IL-­‐2	   levels	  were	  produced	  on	  co-­‐culture	  with	   splenocytes	   stimulated	  by	  
OVA	  concentrations	  ranging	  from	  1000μg/ml	  to	  16μg/ml	  (not	  shown).	  Similar	  results	  
were	  observed	  when	  the	  DO11.10	  T	  hybridoma	  cells	  were	  co-­‐cultured	  with	  BM-­‐DC	  
(results	  not	  shown).	  The	  lack	  of	  IL-­‐2	  detected	  could	  be	  attributed	  to	  the	  fact	  that	  the	  
ELISA	   used	   was	   not	   sensitive	   enough	   i.e.	   the	   amount	   of	   IL-­‐2	   produced	   by	   these	  
DO11.10	  T	  hybridoma	  cell	  numbers	  is	  too	  low	  to	  be	  detected.	  The	  IL-­‐2	  ELISA	  utilised	  
for	  this	  work	  accurately	  detects	  concentrations	  higher	  than	  1000pg/ml.	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To	  address	  this,	  the	  number	  of	  cells	  co-­‐cultured	  together	  was	   increased.	  T	  cell:APC	  
cell	   ratios	   of	   1:6	   and	   1:10	  were	   used	   to	   further	   improve	   the	   sensitivity	   of	   the	   co-­‐
culture	  system.	  DO11.10	  T	  hybridoma	  cells	  were	  co-­‐cultured	  with	  1	  x	  105	  BM-­‐DCs	  in	  
a	   cell	   ratio	   of	   1:6	   and	  1:10	   (respectively),	   in	   a	   volume	  of	   500μl,	   in	   a	   48	  well	   plate	  
(Figure	  4.9).	  An	  OVA	  concentration	  of	  500μg/ml	  was	  added	  directly	   to	  the	  BM-­‐DCs	  
and	  DO11.10	  T	  hybridoma	  cells	  in	  the	  24-­‐well	  plate.	  No	  washing	  steps	  were	  included	  
in	  this	  experimental	  setup.	  Using	  higher	  cell	  numbers	  showed	  a	  significant	  increase	  
(p<0.0001,	  Two-­‐way	  ANOVA	  using	  Sidak’s	  multiple	  comparisons	  post-­‐test)	  in	  the	  IL-­‐2	  
concentration	   compared	   to	   the	   OVA-­‐pulsed	   BM-­‐DCs	   only	   control.	   Both	   cell	   ratios	  
showed	   significant	   increase	   in	   IL-­‐2	   detection	   in	   the	   supernatant.	   In	   subsequent	  
experiments,	   higher	   cell	   numbers	   were	   used	   at	   a	   cell	   ratio	   of	   1:6	   (DO11.10	   T	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Figure	  4.8.	  Co-­‐culture	  of	  DO11.10	  T	  hybridoma	  cells	  with	  ISQ-­‐pulsed	  splenocytes	  for	  24,	  48	  
and	  72	  hours.	  This	  figure	  represents	  one	  experiment.	  Technical	  replicate	  =	  3.	  
	  
	  
1	  x	  105	  BM-­‐DC	   +	   +	   +	  
OVA	   antigen	  
(500μg/ml)	  
+	   +	   +	  
6	  x	  105	  DO11.10	  T	  cells	   -­‐	   +	   -­‐	  
1	  x	  106	  DO11.10	  T	  cells	   -­‐	   -­‐	   +	  
	  
Figure	  4.9.	  BM-­‐DCs	  co-­‐cultured	  with	  DO11.10	  T	  hybridoma	  cells	  at	  different	  cell	  ratios	  in	  a	  
500μl	   volume	   (48-­‐well	   plate),	   using	   500μg/ml	  OVA	   as	   a	   stimulant	   for	   48	   hours.	  BM-­‐DCs	  
(105)	   stimulated	   with	   500μg/ml	   OVA	   without	   co-­‐culture	   with	   DO11.10	   T	   hybridoma	   cells	  
(black	  bar-­‐negative	  control),	  co-­‐culture	  with	  6	  x	  105	  DO11.10	  T	  hybridoma	  cells	  (red	  bar)	  and	  
co-­‐culture	  with	  1	  x	  106	  DO11.10	  T	  hybridoma	  cells	   (blue	  bar)	   is	  shown.	  Supernatants	  were	  
collected	   after	   48	  hours,	   and	   the	   IL-­‐2	   concentration	  was	  measured	  using	   ELISA.	   	  One-­‐way	  
ANOVA	   using	   Tukey’s	   multiple	   comparison	   test	   (mean	   +/-­‐	   SD)	   was	   used	   to	   determine	  
statistical	  significance.	  *p<0.05,	  ****p<0.0001.	  This	  figure	  represents	  one	  experiment	  from	  
a	  total	  of	  2	  individual	  experiments.	  Technical	  replicate	  =	  3.	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4.2.4.	  Dose-­‐dependent	  effect	  of	  CD40mAb	  on	  the	  antigen	  presentation	  
of	  BM-­‐DCs	  to	  DO11.10	  T	  hybridoma	  cells	  
To	  test	  the	  effect	  of	  the	  CD40mAb	  on	  the	  BM-­‐DC	  antigen-­‐presentation	  to	  T	  cells,	  the	  
co-­‐culture	  experiment	  was	  repeated	  using	  BM-­‐DC	  stimulated	  with	  a	  mixture	  of	  OVA	  
and	   antibody	   (either	   CD40mAb	   or	   20C2mAb)	   in	   a	   1:1	   weight	   ratio.	   This	   was	  
performed	  since	  Standard	  OVA-­‐mAb	  conjugates	  were	  conjugated	  using	  a	  1:1	  weight	  
ratio.	  
A	  starting	  concentration	  of	  250μg/ml	  OVA	  antigen	  mixed	  with	  250μg/ml	  CD40mAb	  
or	   20C2mAb	  was	   used	   to	   stimulate	   BM-­‐DCs.	   OVA	   antigen	   and	   CD40mAb	   or	   20C2	  
isotype	  antibody	  mixtures	  of	  100μg/ml	  (each)	  and	  50μg/ml	  (each)	  were	  also	  used	  to	  
see	   if	   the	   use	   of	   CD40mAb	   causes	   increased	   antigen-­‐presentation	   to	   DO11.10	   T	  
hybridoma	   cells	   resulting	   in	   production	   of	   a	   higher	   concentration	   of	   IL-­‐2	   in	   the	  
supernatant	  compared	  to	  the	  20C2mAb	  or	  OVA	  antigen	  alone.	  	  
Detectable	  levels	  of	  IL-­‐2	  were	  only	  measured	  when	  OVA	  antigen	  and	  mAb	  mixtures	  
were	  used	  at	  a	  concentration	  of	  250μg/ml	   (Figure	  4.10).	  The	  addition	  of	  CD40mAb	  
did	  not	  enhance	  antigen	  presentation	  of	  BM-­‐DC	  to	  T	  cells	  compared	  to	  both	  the	  OVA	  
antigen	   alone	   as	   well	   as	   the	   20C2mAb.	   Due	   to	   these	   results,	   the	   OVA-­‐CD40mAb	  
conjugates	  were	  not	   tested	   in	   this	  co-­‐culture	  system,	  and	  experiments	   focusing	  on	  
the	   effect	   of	   the	   CD40mAb-­‐adjuvanted	   conjugates	   on	   the	   APC	   co-­‐stimulatory	  















DO11.10	   +	   -­‐	   +	   +	   +	  
BM-­‐DC	   -­‐	   +	   +	   +	   +	  
OVA	   +	   +	   +	   +	   +	  
CD40mAb	   -­‐	   -­‐	   -­‐	   +	   -­‐	  
20C2mAb	   -­‐	   -­‐	   -­‐	   -­‐	   +	  
	  
Figure	   4.10.	   The	   effect	   of	   CD40mAb	   on	   the	   BM-­‐DC	   antigen-­‐presentation	   to	   DO11.10	   T	  
hybridoma	  cells.	  1	  x	  105	  BM-­‐DCs	  were	  co-­‐cultured	  with	  6	  x	  105	  DO11.10	  T	  hybridoma	  cells	  in	  
a	  500μl	  volume	  (48-­‐well	  plate),	  using	  different	  concentrations	  of	  OVA	  antigen	  and	  CD40mAb	  
or	   20C2mAb	   mixtures.	   Supernatants	   were	   collected	   after	   48	   hours,	   and	   the	   IL-­‐2	  
concentration	  was	  measured	  using	  ELISA.	   	  Negative	  controls	   included	  stimulation	  of	  either	  
DO11.10	   T	   hybridoma	   cells	   or	   BM-­‐DC	   only	  with	  OVA	   antigen,	   as	  well	   as	   the	   co-­‐culture	   of	  
DO11.10	   T	   hybridoma	   cells	   and	   BM-­‐DC	   with	   no	   stimulation.	   This	   figure	   represents	   one	  
experiment.	   Technical	   replicate	   =	   3.	   Dotted	   line	   represents	   lowest	   detectable	   ELISA	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4.3. Investigation	   of	   the	   adjuvant	   effect	   of	   CD40mAb	  
conjugated	  to	  OVA	  in	  vitro	  and	  in	  vivo	  
	  
4.3.1. Characterisation	   of	   the	   CLICK	   and	   Standard	   OVA-­‐CD40mAb	  
conjugates	  in	  vitro	  
OVA-­‐CD40mAb	  conjugates	  made	  using	  the	  standard	  method	  gave	  a	  lower	  antibody	  
response	  against	  OVA	  (see	  Section	  3.3.3.)	  compared	  to	  a	  previous	  study	  (Barr	  et	  al.,	  
2003).	   The	   aforementioned	   study	   used	   Imject™	   maleimide-­‐activated	   OVA	   rather	  
than	  OVA	  (Sigma)	  that	  had	  been	  Sulfo-­‐SMCC	  treated	  in	  the	  laboratory.	  To	  investigate	  
whether	   anti-­‐OVA	   antibody	   responses	   could	   be	   improved	   upon,	   CD40mAb	   (clone	  
1C10)	  or	   isotype	  control	  antibody	  (GL117mAb)	  were	  conjugated	  to	  OVA	  antigen	  by	  
click	  chemistry	  (using	  OVA	  from	  Sigma,	  that	  will	  be	  referred	  to	  as	  sOVA)	  (see	  Section	  
2.2.1.7.)	   or	   the	   standard	   method	   (using	   Imject™	   maleimide-­‐activated	   OVA	   from	  
Thermo	   Scientific,	   OVA)	   (see	   Section	   2.2.1.3.).	   The	   sOVA	   antigen	   was	   used	   as	   a	  
control	   for	   immunisation,	   ex	   vivo	   proliferation	   and	   in	   vitro	   APC	   activation	  
experiments.	  
The	   conjugation	   of	   CD40mAb	   or	   GL117mAb	   (rat	   IgG2a)	   to	   OVA	   antigen	   was	  
confirmed	  by	  sandwich	  ELISA	  (see	  Section	  2.2.4.3.1.).	  Rat	  IgG	  was	  captured	  with	  an	  
anti-­‐rat	   IgG	   antibody	   and	   the	   conjugation	   of	   rat	   IgG	   to	   OVA	   was	   confirmed	   by	  
simultaneous	   binding	   to	   rabbit	   (IgG)	   anti-­‐OVA	   antibody	   followed	   by	   peroxidase	  
conjugated	   goat	   anti-­‐rabbit	   IgG.	   An	   increase	   in	   optical	   density	   (OD)	   by	   the	   OVA-­‐
CD40mAb	   and	   OVA-­‐GL117mAb	   conjugates,	   compared	   to	   unconjugated	   OVA	   and	  
mAbs	   (negative	   controls)	   confirmed	   that	   the	   OVA	   antigen	   was	   conjugated	   to	   the	  
mAb	  (Figure	  4.11A).	  The	  CLICK	  sOVA-­‐mAb	  conjugates	  contain	  higher	  conjugate	  purity	  
than	   the	   Standard	   OVA-­‐mAb	   conjugates.	   In	   fact,	   the	   CLICK	   sOVA-­‐CD40mAb	  
conjugate	   bound	   the	   ELISA	   antibodies	   at	   a	   concentration	   5-­‐fold	   lower	   than	   the	  
Standard	   OVA-­‐CD40mAb	   conjugate	   (Figure	   4.11B).	   Flow	   cytometry	   analysis	   using	  
CD40L929	   cells	   (see	   Section	   2.2.4.4.1.)	   showed	   that	   CD40mAb	   of	   the	   OVA-­‐mAb	  
conjugates	  made	  by	  both	  methods,	  were	  still	  able	  to	  bind	  to	  full-­‐length	  membrane-­‐
bound	  CD40	  expressed	  in	  vitro	  after	  conjugation	  (results	  not	  shown).	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Figure	  4.11.	  Confirmation	  of	  OVA	  to	  Rat	   IgG	  conjugation	  using	  sandwich	  ELISA.	  The	  sOVA	  
antigen,	  CD40mAb	  and	  GL117mAb	  were	  used	  as	  negative	   controls.	   (A)	  Relative	  binding	  of	  
CLICK	  and	  Standard	  OVA-­‐mAb	  conjugates.	   (B)	  Comparison	  of	  the	   interpolated	  1/dilution	  of	  
the	  OVA-­‐mAb	   conjugate	   concentration	   giving	   an	  OD	  of	   0.5.	   The	   dilution	   corresponding	   to	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4.3.2. Effects	   of	   OVA-­‐CD40mAb	   conjugates	   on	   APC	   co-­‐stimulatory	  
molecule	  expression	  
The	  expression	  of	   the	  co-­‐stimulatory	  molecule	  CD86	  on	  B	   cells	   and	   splenic	  CD11c+	  
DCs	  was	   investigated	   following	   incubation	  of	   splenocytes	  with	  10μg/ml	   conjugates	  
and	  sOVA,	  as	  well	  as	  200ng/ml	  LPS	  (Figure	  4.12).	  The	  experiment	  was	  repeated	  using	  
BM-­‐DCs	  to	  investigate	  whether	  the	  results	  were	  consistent	  upon	  the	  use	  of	  a	  more	  
homogenous	  immature	  population	  of	  DCs	  (Figure	  4.13).	  Both	  the	  Standard	  and	  CLICK	  
conjugates	   were	   investigated.	   LPS,	   a	   well-­‐characterised	   PAMP	   (see	   Section	   1.1.1,	  
Table	  1.1.)	  that	  activates	  the	  immune	  system	  via	  TLRs,	  was	  used	  as	  a	  positive	  control.	  
The	  fold	  increase	  in	  median	  fluorescence	  intensity	  of	  CD86	  expression	  on	  CD19+	  and	  
CD11c+	  cells	  above	  the	  unstimulated	  control	  was	  investigated	  by	  flow	  cytometry	  (see	  
Section	  2.2.6.6.).	  
With	   regards	   to	   splenic	   B	   cells	   (Figure	   4.12A),	   the	   results	   were	   consistent	   with	  
previous	   studies	   (Carlring	   et	   al.,	   2012).	   CD86	   expression	   levels	   were	   significantly	  
enhanced	  (p<0.0001,	  unpaired,	  two-­‐tailed	  Student	  t	  test,	  Figure	  4.12B)	  by	  both	  the	  
Standard	   and	   CLICK	   sOVA-­‐CD40mAb	   conjugates	   compared	   to	   the	   corresponding	  
OVA-­‐GL117mAb	  conjugates.	  	  
In	   the	   case	   of	   splenic	   CD11c+	   DCs,	   both	   Standard	   and	   CLICK	   OVA-­‐CD40mAb	  
conjugates	   significantly	   enhanced	   upregulation	   of	   CD86	   expression	   (p<0.05,	   two-­‐
tailed,	  unpaired	  Student’s	  t	  test)	  (Figure	  4.12B).	  	  
Interestingly,	   only	   the	   CLICK	   sOVA-­‐CD40mAb	   conjugate	   significantly	   enhanced	   the	  
BM-­‐DC	   CD86	   expression	   compared	   to	   the	   sOVA-­‐GL117mAb	   conjugate	   (p<0.0001,	  
unpaired,	  two-­‐tailed	  Student	  t	  test,	  Figure	  4.13).	  	  There	  was	  no	  significant	  difference	  
between	  the	  CD86	  expression	  of	  BM-­‐DC	  stimulated	  by	  the	  Standard	  OVA-­‐CD40mAb	  
or	  Standard	  OVA-­‐GL117mAb	  conjugates.	  
On	   a	   closer	   look	   at	   the	   results,	   stimulation	   with	   sOVA	   alone	   increased	   the	   CD86,	  
however	   this	  was	   not	   significantly	   different	   to	   either	   of	   the	   conjugates	   (unpaired,	  
two-­‐tailed	  Student	  t	  test).	  LPS	  did	  not	  seem	  to	  have	  an	  effect	  on	  splenic	  CD19+	  and	  
CD11c+	   DC	   CD86	   expression	   (Figure	   4.12A	   and	   B).	   However,	   LPS	   enhanced	   co-­‐
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stimulatory	  molecule	  expression	  on	  BM-­‐DCs,	  demonstrating	  an	  immature	  population	  
(Figure	  4.13).	  
In	  summary,	  both	  Standard	  and	  CLICK	  OVA-­‐CD40mAb	  conjugates	  markedly	  enhance	  
B	   cell	   CD86	   expression	   compared	   to	   the	   isotype	   antibody	   controls.	   Experiments	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A.	  	   	  B.	   	  
Figure	  4.12.	  The	  effect	  of	  OVA-­‐mAb	  conjugates	  on	  the	  CD86	  expression	  on	  splenic	  B	  cells	  
and	   DCs.	   Splenocytes	   (1	   x	   106	   cells/ml)	   were	   incubated	   in	   the	   presence	   of	   stimulant;	  
10μg/ml	   Standard	   OVA-­‐mAb	   conjugates,	   10μg/ml	   CLICK	   OVA-­‐mAb	   conjugates,	   10μg/ml	  
OVA,	  200ng/ml	   LPS,	   as	  well	   as	   in	   the	  absence	  of	   stimulant	   for	  24	  hours	   in	  a	  48-­‐well	  plate	  
(1ml).	  The	  fold	  increase	  in	  median	  fluorescence	  intensity	  above	  the	  unstimulated	  control	  of	  
CD86	   expression	   on	   CD19+	   cells	   (A)	   and	   CD11c+	   cells	   (B)	   is	   shown.	   A	   two-­‐tailed,	   unpaired	  
Student’s	   t-­‐test	   (mean	  +/-­‐	  SD).	  *p<0.05,	  ****p<0.0001.	  This	   figure	   represents	   results	   from	  
three	  separate	  experiments.	  Technical	  replicates	  =	  1.	  
	  	  
Figure	  4.13.	  The	  effect	  of	  OVA-­‐mAb	  conjugates	  on	  the	  CD86	  expression	  of	  BM-­‐DCs.	  BM-­‐DC	  
(1	   x	   106	   cells/ml)	   were	   incubated	   in	   the	   presence	   of	   stimulant;	   10μg/ml	   Standard	   OVA-­‐
antibody	   conjugates,	   10μg/ml	   CLICK	   OVA-­‐antibody	   conjugates,	   10μg/ml	   sOVA,	   200ng/ml	  
LPS,	   as	  well	   as	   in	   the	   absence	  of	   stimulant	   for	   24	  hours	   in	   a	   48-­‐well	   plate	   (1ml).	   The	   fold	  
increase	   in	   median	   fluorescence	   intensity	   above	   the	   unstimulated	   control	   of	   CD86	  
expression	  on	  BM-­‐DCs	   is	  shown.	  A	  two-­‐tailed,	  unpaired	  Student’s	  t-­‐test	   (mean	  +/-­‐	  SD)	  was	  
used.	   *p<0.05.	   ns	   =	   not	   significant.	   This	   figure	   represents	   results	   from	   three	   separate	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4.3.3.	   Investigation	   of	   lymphocyte	   and	   antibody	   responses	   to	   OVA-­‐
CD40mAb	  conjugates	  in	  vivo	  
	  
Since	   it	  has	  been	  demonstrated	   that	  when	  CD40mAb	   is	  conjugated	  to	  antigen,	   the	  
antigen	   specific	   antibody	   titres	   are	   approximately	   a	   1000-­‐fold	   better	   than	   when	  
CD40mAb	  and	   antigen	   are	   inoculated	   as	   a	  mixture	   (Barr	   et	   al.,	   2003),	   the	  mixture	  
and	  sOVA	  controls	  were	  important	  to	  ensure	  the	  quality	  of	  the	  conjugates.	  Antibody	  
and	  CD4+	  T	  cell	  responses	  were	  investigated	  in	  vivo.	  BALB/c	  mice	  were	  immunised	  on	  
day	   0	   and	   were	   boosted	   on	   day	   14	   (Figure	   4.14),	   with	   10μg	   immunogen	   via	   the	  
intraperitoneal	   route.	   Control	   groups	   included	   5μg	   sOVA	   and	   5μg	   CD40mAb	  





Figure	   4.14.	   Immunisation	   schedule	   for	   OVA-­‐mAb	   conjugates	   and	   controls.	   BALB/c	  mice	  
were	  immunized	  with	  CLICK	  sOVA-­‐CD40mAb	  conjugate,	  Standard	  OVA-­‐CD40mAb	  and	  OVA-­‐
GL117mAb	  conjugates,	  as	  well	  as	  Mixture,	  sOVA	  only	  and	  PBS.	  BALB/c	  mice	  were	  boosted	  on	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4.3.3.1. Investigation	   of	   the	   anti-­‐OVA	   specific	   antibody	   titres	   in	   response	   to	  
immunogen	  
The	  anti-­‐OVA	  specific	  antibody	  titre	  (see	  Section	  2.2.7.2.)	  was	  assessed	  alongside	  the	  
ex	  vivo	  CD4+	  T	  cell	  proliferation	  (see	  Section	  2.2.7.3.)	  experiment.	  At	  day	  13	  (before	  
boost,	  Figure	  4.15A)	  and	  day	  28	  (after	  boost,	  Figure	  4.15B),	  the	  CLICK	  conjugate,	  the	  
Mixture	  and	  sOVA	  antigen	  all	  induced	  significantly	  higher	  anti-­‐OVA	  titres,	  compared	  
to	   the	   Standard	   conjugates	   (p<0.0001,	  One-­‐way	  ANOVA	  using	  Dunnett’s	   post-­‐test)	  
(Figure	  4.15A).	  	  However,	  there	  was	  no	  significant	  difference	  between	  the	  anti-­‐OVA	  
end-­‐point	  antibody	  titres	  produced	  by	  CLICK	  sOVA-­‐CD40mAb	  conjugate,	  the	  Mixture	  
or	  the	  sOVA.	  
The	   anti-­‐OVA	  end-­‐point	   titres	   in	   the	   sera	   from	  Standard	  OVA-­‐CD40mAb	   conjugate	  
immunised	  mice	  was	  minimal	   compared	   to	   the	   titres	   obtained	   in	   previous	   studies	  
(Barr	  et	  al.,	  2003)	  as	  well	  as	   the	   results	  obtained	   in	  Chapter	  3,	  at	  both	  before	  and	  
after	  boost	  (Figure	  3.21).	  Furthermore,	  the	  anti-­‐OVA	  antibody	  titres	  produced	  by	  the	  
Mixture	   and	   the	   sOVA	   immunised	   mice	   were	   abnormally	   high.	   Both	   results	   were	  
inconsistent	  with	  previous	  studies	  (Barr	  et	  al.,	  2003).	  	  
In	  summary,	  there	  was	  no	  difference	  between	  the	  anti-­‐OVA	  antibody	  titres	  in	  sera	  of	  
CLICK	  OVA-­‐CD40mAb	  conjugate	  and	  the	  Mixture	  or	  sOVA	  antigen	  immunised	  groups.	  
Furthermore,	   even	   though	   the	   Standard	   OVA-­‐CD40mAb	   conjugate	   was	   slightly	  
immunogenic	  after	  boost,	  anti-­‐OVA	  antibody	  titres	  are	  at	  least	  1000-­‐fold	  lower	  than	  






	   159	  
A.	   	  
B.	   	  
Figure	  4.15.	  Anti-­‐OVA	  specific	  antibody	  end-­‐point	   titre	   level	  at	  day	  13	   (before	  boost)	   (A)	  
and	  at	  day	  28	   (after	  boost)	   (B).	  Anti-­‐OVA	  specific	  antibody	  levels	  detected	  in	  sera	  of	  mice	  
immunised	  with	   CLICK	   conjugate	   (red),	   Standard	   conjugates	   (blue),	  Mixture	   (green),	   sOVA	  
(orange)	   and	   PBS	   (black).	   One-­‐way	   ANOVA	   with	   Dunnett’s	   post-­‐test	   (mean	   +/-­‐	   SD)	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4.3.3.2.	  Investigation	  of	  lymphocyte	  proliferation	  in	  response	  to	  stimulus	  ex	  vivo	  
To	  determine	  the	  CD4+	  cell	  proliferation	  in	  response	  to	  sOVA,	  splenocytes	  from	  each	  
immunised	   group	   were	   labelled	   with	   2μM	   CFSE	   (see	   Section	   2.2.7.3.3.)	   and	  
incubated	  with	   sOVA	   antigen	   or	   in	   the	   absence	   of	   antigen	   for	   72	   hours.	   After	   72	  
hours,	  cells	  were	  prepared	  for	   flow	  cytometry.	  Lymphocytes	  were	  stained	  with	  PE-­‐
Cy7	  labelled	  CD4	  antibody	  to	  monitor	  CD4+	  T	  cell	  proliferation,	  as	  well	  as	  efluor-­‐450	  
labelled	   CD19	   antibody	   to	   monitor	   non-­‐specific	   proliferation.	   The	   percentage	  
lymphocytes	  in	  the	  original	  sample	  that	  have	  divided	  was	  recorded.	  	  
An	  optimisation	  assay	  was	  carried	  out	  using	  one	  BALB/c	  mice	  immunised	  with	  either	  
Standard	  OVA-­‐CD40mAb	  conjugate,	  Mixture	  or	  PBS.	  Two	  mice	  were	  immunised	  with	  
sOVA	  antigen.	  The	   five	  mice	  were	  sacrificed	  at	  day	  13	  after	   immunisation,	  and	  the	  
spleens	  were	  harvested.	  	  
For	  the	  purpose	  of	  the	  optimisation	  assay	  the	  concentration	  of	  (i)	  1000μg/ml	  and	  (ii)	  
500μg/ml	  of	   sOVA	  antigen	  were	  used	   for	  ex	   vivo	   stimulation.	   Surprisingly	   after	   72	  
hours	  incubation	  CD19+	  cell	  proliferation	  was	  observed	  even	  in	  mice	  immunised	  with	  
PBS	  (Figure	  4.16).	  This	  was	  indicative	  of	  non-­‐specific	  proliferation,	  which	  was	  dose-­‐
dependent	  as	  there	  was	  an	  increase	  in	  proliferation	  when	  1000μg/ml	  sOVA	  was	  used	  
compared	  to	  when	  500μg/ml	  sOVA	  was	  used.	  	  
From	   the	   five	  mice	   used	   in	   this	   experiment	  minimal	   CD4+	  T	   cell	   proliferation	   was	  
observed	  with	   lymphocytes	  of	  one	   sOVA	   immunised	  group,	  however,	  no	   statistical	  
measures	   could	   be	   carried	   out	   due	   to	   number	   of	   mice	   that	   were	   tested,	   for	   the	  
purpose	  of	  this	  optimisation	  assay	  (Figure	  4.17,	  4.18).	  A	  flow	  cytometric	  plot	  of	  each	  
sample	  from	  each	  immunisation	  group	  is	  shown	  in	  Figure	  4.17.	  
Since	   B	   cells	   from	   the	   spleens	   of	   the	   control	   group	   (PBS	   immunised	   mice)	  
unexpectedly	   markedly	   proliferated	   in	   response	   to	   sOVA	   antigen,	   endotoxin	  
contamination	  was	   suspected,	   therefore	   all	   the	   samples	  were	   subsequently	   tested	  









Figure	  4.16.	  The	   gating	   strategy	  used	   for	   flow	   cytometric	   analysis	   of	  B	   cell	   proliferation.	  
The	   gating	   strategy	   was	   designed	   to	   exclude	   debris,	   include	   only	   live	   cells	   based	   on	   UV	  
live/dead	  staining	  (UV	  450/50),	  and	  gating	  on	  cell	  surface	  expression	  marker	  CD19+	  cells.	  The	  
percentage	  CD19+cells	  in	  the	  original	  population	  of	  PBS	  immunised	  mice	  that	  have	  divided	  in	  
response	   to	   500μg/ml	   sOVA	   (blue)	   and	   1000μg/ml	   sOVA	   (green),	   and	   in	   the	   absence	   of	  
stimulation	  (red)	  is	  shown	  as	  a	  representative.	  




























































































































































































Figure	  4.17.	  The	  percentage	  CD4+	  cells	  in	  the	  lymphocyte	  population	  that	  have	  divided	  in	  
























































































































































































































































































































































Figure	  4.18.	  CD4+	  T	  cell	  proliferation	  on	  stimulation	  with	  500μg/ml	  or	  1000μg/ml	  OVA	  ex	  
vivo.	  Fold	  percentage	  increase	  in	  CD4	  proliferation	  above	  the	  unstimulated	  control	  of	  each	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4.3.4.	  Determination	  of	  endotoxin	  levels	  in	  immunogens	  
The	   sOVA	   used	   to	   make	   CLICK	   conjugates;	   (i)	   enhanced	   immature	   BM-­‐DC	   CD86	  
molecule	  expression	  (Figure	  4.13),	  (ii)	  induced	  antibody	  responses	  higher	  than	  those	  
produced	   by	   OVA-­‐CD40mAb	   conjugates	   (Figure	   4.15)	   and	   (iii)	   induced	   B	   cell	  
proliferation	  ex	  vivo	  even	  in	  PBS	  immunised	  groups	  (Figure	  4.16).	  These	  results	  lead	  
us	   to	   investigate	   whether	   sOVA	   was	   contaminated	   with	   endotoxin.	   The	   levels	   of	  
endotoxin	  in	  the	  Standard	  and	  CLICK	  conjugates	  made	  in	  Section	  4.3.1,	  together	  with	  
CD40mAb,	   GL117mAb	   and	   sOVA	   used	   for	   immunisation	   were	   quantitated	   by	   a	  
Limulus	   amebocyte	   lysate	   assay	   (QCL-­‐1000TM)	   (see	   Section	   2.8.1).	   The	   endotoxin	  
activity	   present	   in	   1μg	   of	   Standard	   and	   CLICK	   conjugates,	   antibodies	   and	   sOVA	   is	  
shown	  in	  Figure	  4.19.	  	  
Different	   kinds	   of	   LPS	   are	   produced	   by	   different	   pathogens,	   in	   fact,	   LPS	   from	  
different	  pathogens	  are	  capable	  to	  generate	  different	  forms	  of	  immune	  response	  in	  
vivo	   (Pulendran	   et	   al.,	   2001).	   The	   endotoxin	   activity	   measured	   by	   the	   LAL	   assay	  
varies	  with	  the	  type	  of	  LPS	  standard	  used,	  so	  since	  the	  type	  of	  endotoxin	  present	  in	  
sOVA	   is	   unknown,	   it	   is	   very	   difficult	   to	   obtain	   an	   accurate	   measure.	   A	   study	   by	  
Watanabe	  et	  al.	  (2003),	  found	  that	  3μg/ml	  commercially	  available	  OVA	  contained	  0.5	  
EU/ml	   of	   endotoxic	   activity.	   This	   amount	   was	   found	   enough	   to	   fully	   activate	  
endothelial	   cells.	   A	   very	   recent	   study	   showed	   that	   the	   endotoxin	   level	   in	   four	  
different	  batches	  of	  the	  same	  commercial	  source	  of	  OVA	  used	   in	  this	  study	  ranged	  
from	  7.5ng	  to	  141.5ng	  per	  1μg	  OVA	  (Mac	  Sharry	  et	  al.,	  2014).	  Studies	   investigating	  
the	   immune	   responses	   in	   the	   presence	   or	   absence	   of	   LPS	   (Pulendran	   et	   al.,	   2001,	  
Watanabe	  et	  al.,	  2003,	  Bal	  et	  al.,	  2011,	  Abdi	  et	  al.,	  2012),	  or	  the	  mode	  of	  action	  of	  
adjuvants	  of	  particularly	  LPS-­‐based	  adjuvants	  (Hartmann	  et	  al.,	  1999,	  Yoshino	  et	  al.,	  
2013)	  always	  ensure	  that	  controls	  contain	  <0.25	  EU/ml	  endotoxin,	  or	  are	  endotoxin-­‐
free.	   All	   immunogens	   at	   a	   concentration	   of	   50μg/ml,	   which	   is	   the	   concentration	  
immunised	   (10μg	   in	   200μl	   PBS)	   contained	   15-­‐30	   EU/ml	   endotoxin	   activity,	   which	  
would	  be	  a	  reason	  why	  the	  high	  anti-­‐OVA	  antibody	  responses	  and	  the	  ex	  vivo	  non-­‐















Figure	  4.19.	  Endotoxin	  activity	  in	  1μg	  sOVA,	  unconjugated	  mAbs	  and	  Standard	  sOVA-­‐mAb	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4.4.	  Investigation	  of	  the	  effect	  of	  ISQC-­‐CD40mAb	  conjugates	  in	  
vitro	  and	  in	  vivo	  
Due	  to	  the	  disappointing	  results	  from	  the	  use	  of	  OVA	  conjugates	  ex	  vivo	  and	  in	  vivo,	  
we	  moved	  on	  to	  using	  the	  OVA	  immunodominant	  CD4+	  T	  cell	  epitope	  OVA323-­‐339	  or	  
ISQAVHAAHAEINEAGR	  (ISQ	  peptide)	  instead.	  For	  the	  context	  of	  this	  chapter,	  the	  use	  
of	   the	   CD4+	   T	   cell	   epitope	   ISQAVHAAHAEINEAGR	  would	   be	   the	   ideal	  way	   to	   show	  
what	  impact	  the	  CD40mAb	  adjuvants	  have	  on	  CD4	  T	  cell	  responses,	  as	  well	  as	  B	  cell	  
and	  DC	  activation.	  	  
4.4.1. Production	  and	  characterisation	  of	  ISQC-­‐conjugates	  in	  vitro	  
ISQ	  peptide	  was	  synthesised	  with	  a	  cysteine	  on	  the	  C-­‐terminal	  end	  (purchased	  from	  
GeneCust);	   ISQAVHAAHAEINEAGRC	   (which	   will	   be	   referred	   to	   as	   ISQC).	   CD40mAb	  
was	   treated	   with	   Sulfo-­‐SMCC	   and	   conjugated	   to	   the	   sulphydryl	   groups	   on	   the	  
cysteine	  present	  on	  the	  C-­‐terminal	  end	  of	  the	  peptide	  (see	  Section	  2.2.1.4.).	  
The	  peptide	  was	  first	  biotinylated	  using	  EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin.	  EZ-­‐Link	  Sulfo-­‐NHS-­‐
Biotin	  is	  an	  NHS-­‐ester	  that	  reacts	  with	  side-­‐chain	  of	  lysines	  (K)	  or	  the	  amino-­‐terminal	  
(NH2)	   group.	   Since	   the	   ISQC	   peptide	   does	   not	   contain	   any	   lysines,	   biotinylation	  
occurred	  via	  the	  amino-­‐terminal	  group	  of	  the	  peptide.	  	  
Biotinylation	   was	   necessary	   as	   the	   conjugation	   of	   the	   ISQC	   peptide	   to	   CD40mAb	  
could	   not	   be	   confirmed	   by	   traditional	   characterisation	  methods	   like	   ELISA	   or	   flow	  
cytometry,	  due	  to	  the	   lack	  of	  antibodies	  that	  recognise	   ISQ	  peptide.	  The	  CD40mAb	  
was	  conjugated	  to	  both	  biotinylated	  and	  non-­‐biotinylated	  ISQC	  peptide	  (see	  Section	  
2.2.1.4.3.).	   Due	   to	   the	   peptide	   being	   biotinylated	   conjugation	   of	   the	   CD40mAb	   or	  
GL117mAb	  to	  biotinylated	  ISQC	  peptide	  could	  be	  confirmed	  by	  Western	  blotting	  (see	  
Section	  2.2.4.2.1).	  	  
Firstly,	   peptide	   biotinylation	   was	   confirmed	   by	   Western	   Blotting	   by	   the	   use	   of	  
horseradish	  peroxidase	  (HRP)	  enzyme	  conjugated	  to	  streptavidin	  protein.	  A	  15%	  SDS	  
PAGE	  gel	  was	  run	  using	  a	  10μg	  sample	  of	  ISQC	  peptide	  (1877Da),	  biotin	  (443Da)	  and	  
biotinylated	   ISQC	   peptide.	   Once	   the	   streptavidin	   protein	   binds	   to	   biotin	   on	   the	  
peptide,	  the	  HRP	  catalyses	  the	  reaction	  with	  the	  substrate	  that	  allows	  for	  detection	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(Figure	  4.20).	  Peptide	  only	  and	  biotin	  only	  were	  also	  run	  as	  controls	  on	  the	  gel,	  but	  
no	  band	  was	  observed.	  This	  could	  be	  due	   to	   the	   fact	   that	   the	  Coomassie	  Blue	  dye	  
used	  to	  stain	  the	  gel	  stains	  NH2	  groups	  that	  are	  absent	  on	  the	  biotinylation	  reagent	  
only,	  and	  only	  one	  is	  present	  on	  the	  peptide.	  
After	  confirming	  ISQC	  peptide	  biotinylation,	  conjugation	  of	  biotinylated	  ISQC	  peptide	  
alongside	  non-­‐biotinylated	  ISQC	  peptide	  to	  CD40mAb	  and	  istoype	  control	  mAb	  was	  
performed.	  	  
ISQC	  peptide	  has	  a	  MW	  of	  1877Da,	  therefore,	  since	  the	  smallest	  dialysis	  membrane	  
available	   had	   a	   pore	   size	   of	   1000Da,	   excess	   biotinylation	   reagent	   could	   not	   be	  
removed	  by	  buffer	  exchange,	  without	  the	  risk	  of	  losing	  valuable	  sample.	  Due	  to	  this,	  
precautions	   had	   to	   be	   taken	   to	   ensure	   that	   only	   biotinylated	   ISQC	   peptide	   is	  
conjugated	   to	   the	  mAb	   and	   the	  biotinylation	   reagent	   in	   excess	   does	   not.	   The	   first	  
precaution	  was	   to	  ensure	   that	   the	  conjugation	  experiment	  was	  performed	  at	   least	  
one	  week	  after	  the	  peptide	  biotinylation	  had	  been	  performed.	  The	  purpose	  for	  this	  
was	  to	  ensure	  that	  the	  NHS-­‐ester	  of	  the	  biotin	  reagent	   is	  non-­‐reactive	  and	  will	  not	  
also	  bind	  to	  the	  antibody	  during	  biotinylated	  peptide-­‐antibody	  conjugation.	  Another	  
precaution	  taken	  included	  the	  conjugation	  of	  the	  biotinylation	  reagent	  opened	  and	  
used	  on	  the	  day	  of	  peptide	  biotinylation,	  to	  the	  antibody	  as	  a	  control.	  Lack	  of	  biotin	  
detection	   by	  means	   of	  HRP-­‐labelled	   streptavidin	   on	   the	   antibody	   control	   confirms	  
that	   the	  biotinylation	   reagent	   is	  non-­‐reactive.	  A	  quenching	  buffer	  was	  not	  used	   to	  
react	  with	  all	   the	  NHS	  esters	   remaining	  on	  the	  surface	  of	   the	   ISQC	  peptide	  so	  that	  
the	  subsequent	  conjugation	  reaction	  to	  the	  mAbs	  would	  not	  be	  affected.	  
A	   reducing	   15%	   SDS	   page	   gel	   was	   run	   using	   a	   10μg	   sample	   of	   conjugates	   and	  
controls.	  Biotinylated	  conjugates	  were	  detected	  via	  Western	  blot	  using	  HRP-­‐labelled	  
Streptavidin	  (Figure	  4.21).	  Western	  Blot	  shows	  that	  only	  the	  biotinylated	  ISQC-­‐mAb	  
conjugates	  were	  detected	  by	  the	  HRP-­‐labelled	  streptavidin.	  No	  bands	  were	  observed	  
in	  the	  biotinylated	  reagent	  and	  mAb	  control.	  This	  meant	  that	  all	  the	  bands	  observed	  
in	  lanes	  5	  and	  10	  correspond	  to	  biotinylated	  ISQC	  peptide	  conjugated	  to	  the	  mAb.	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Figure	   4.20.	   Confirmation	   of	   biotinylaton	   of	   ISQC	   peptide.	   15%	   SDS	   page	   reducing	   gel	   is	  
shown	  on	  the	   left.	  Western	  Blot	  using	  HRP	   labelled	  streptavidin	   to	  detect	   is	  shown	  on	  the	  
right.	  	  
	  
Figure	   4.21.	   Confirmation	   of	   conjugation	   of	   ISQC	   peptide	   to	   CD40mAb.	   15%	   SDS	   PAGE	  
reducing	  gel	   is	  shown	  on	  the	  left.	  Western	  blot	  using	  HRP-­‐labelled	  streptavidin	  to	  detect	   is	  
shown	  on	  the	  right.	  Lane	  1:	  ISQC	  peptide,	  Lane	  2:	  CD40mAb,	  Lane	  3:	  CD40mAb	  treated	  with	  
biotin	   reagent	   control,	   Lane	   4:	   ISQC-­‐CD40mAb	   conjugate,	   Lane	   5:	   Biotinylated	   ISQC-­‐
CD40mAb	   conjugate,	   Lane	   6:	   Ladder,	   Lane	   7:	  GL117mAb,	   Lane	   8:	  GL117mAb	   treated	  with	  
biotin	   reagent	   control,	   Lane	   9:	   ISQC-­‐GL117mAb	   conjugate,	   Lane	   10:	   Biotinylated	   ISQC-­‐














	   169	  
Biotinylated	   ISQC	  peptide	  did	  conjugate	   to	   the	  both	  CD40mAb	  and	   isotype	  control	  
mAb.	  Therefore,	  we	  assumed	  that	  the	  non-­‐biotinylated	  ISQC	  peptide	  also	  conjugated	  
to	   the	   CD40mAb	   and	   isotype	   control	   mAb.	   Only	   the	   non-­‐biotinylated	   ISQC-­‐mAb	  
conjugates	  were	  used	  for	  the	  subsequent	  experiments.	  	  
	  
To	   further	   ensure	   that	   the	   conjugation	   was	   successful	   6%	   and	   15%	   SDS	   PAGE	  
reducing	  gels	  were	  run	  at	  60V	   in	  order	  to	  obtain	  bands	  of	  higher	  definition	  (Figure	  
4.22).	   As	   observed	   from	   the	   6%	   gel,	   the	   ISQC-­‐mAb	   conjugate	   band	   running	   at	  
approximately	  150kDa	  (according	  to	  the	  MW	  protein	  standard)	  is	  of	  higher	  apparent	  
MW	  than	  corresponding	  antibody	  alone	  controls	  (Figure	  4.22A).	  Furthermore,	  when	  
observing	   the	   15%	   gel,	   the	   bands	   showing	   heavy	   chains	   and	   light	   chains	   of	   the	  
antibody	   of	   the	   ISQC-­‐mAb	   conjugates,	   are	   of	   higher	   apparent	   MW	   than	   the	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A. 	  
	  
B.	   	  
Figure	   4.22.	   Confirmation	   of	   conjugation	   of	   ISQC	   peptide	   to	   CD40mAb	   via	   reducing	   SDS	  
PAGE.	  A.	  6%	  SS	  PAGE	   reducing	  gel.	  B.	  15%	  SDS	  PAGE	   reducing	  gel.	   L	   shows	   the	  molecular	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4.4.2.	   Effects	   of	   ISQC-­‐CD40mAb	   conjugates	   on	   APC	   co-­‐stimulatory	  
molecule	  expression	  
Splenic	   B	   cells,	   splenic	   CD11c+	   cells	   as	  well	   as	   BM-­‐DCs	  were	   used	   to	   evaluate	   the	  
effect	  of	   the	   ISQC-­‐CD40mAb	  conjugates	  on	  the	  co-­‐stimulatory	  molecule	  expression	  
(see	   Section	   2.2.6.6.).	   The	   endotoxin	   activity	   of	   these	   conjugates	   was	   tested	   and	  
found	  to	  be	  <0.01	  EU/μg	  conjugate.	  
The	   expression	   of	   the	   co-­‐stimulatory	  molecules	   CD80	   and	   CD86	   on	   splenic	   B	   cells	  
and	   CD11c+	   DC	   cells	  was	   investigated	   by	   incubating	  with	   10μg/ml	   conjugates,	   ISQ	  
peptide,	  which	   served	  as	  a	  negative	   control,	   and	  200ng/ml	   LPS,	  which	   served	  as	  a	  
positive	   control	   (Figure	   4.23).	   The	   fold	   increase	   in	   median	   fluorescence	   intensity	  
above	   the	   unstimulated	   control,	   of	   CD80	   (Figure	   4.23A)	   and	   CD86	   (Figure	   4.23B)	  
expression	   on	   CD19+	   and	   CD11c+	   cells	   was	   determined	   using	   flow	   cytometry.	   The	  
experiment	   was	   repeated	   using	   BM-­‐DC	   to	   investigate	   whether	   the	   results	   were	  
consistent	  upon	  the	  use	  of	  an	  immature	  population	  of	  DCs.	  	  
Splenic	  B	  cell	  results	  were	  consistent	  with	  previous	  studies	  and	  the	  results	  shown	  in	  
Section	   4.4.	   Both	   CD80	   and	   CD86	   expression	   were	   significantly	   (p<0.01,	   p<0.001,	  
two-­‐tailed,	   unpaired	   Student	   t	   test)	   enhanced	   on	   stimulation	   with	   the	   ISQC-­‐
CD40mAb	   conjugate	   compared	   to	   the	   ISQC-­‐GL117mAb	   conjugate	   control	   (Figure	  
4.23B).	  	  
Splenic	  CD11c+	  DC	  results	  were	  also	  consistent	  with	  previous	  studies,	  showing	  that	  
stimulation	  with	   ISQC-­‐CD40mAb	  conjugate	  did	  not	  significantly	  upregulate	  CD80	  or	  
CD86	  expression	  on	  splenic	  DC	  compared	  to	  the	  controls	  (Figure	  4.23A).	  Interestingly	  
however,	   CD80	   and	   CD86	   expression	   were	   both	   significantly	   enhanced	   (p<0.05,	  
p<0.01,	  two-­‐tailed	  unpaired	  Student	  t	  test)	  on	  the	  immature	  population	  of	  BM-­‐DCs	  
on	   stimulation	  with	   the	   CD40mAb-­‐adjuvanted	   conjugate	   (Figure	   4.24).	   This	   shows	  
that	  the	  CD40mAb-­‐antigen	  conjugates	  target	  and	  activate	  both	  B	  cells	  and	  DCs.	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Figure	  4.23.	  The	  effects	  of	  ISQC-­‐antibody	  conjugates	  on	  the	  CD80	  and	  CD86	  expression	  of	  
splenic	   B	   cells	   and	   CD11c+	   DCs.	   Splenocytes	   (1	   x	   106	   cells/ml)	   were	   incubated	   in	   the	  
presence	  of	   stimulant;	  10μg/ml	   ISQC-­‐antibody	  conjugates,	  10μg/ml	   ISQ	  peptide,	  200ng/ml	  
LPS,	  as	  well	  as	  in	  the	  absence	  of	  stimulant	  for	  24	  hours	  in	  a	  48-­‐well	  plate	  (1ml).	  A.	  The	  fold	  
increase	  in	  median	  fluorescence	  intensity	  of	  the	  CD80	  expression	  on	  CD11c+	  (left)	  and	  CD19+	  
cells	  (right),	  above	  the	  unstimulated	  control	  of	  each	  group	  is	  shown.	  B.	  The	  fold	  increase	  in	  
median	   fluorescence	   intensity	   of	   the	   CD86	   expression	   on	   CD11c+	   (left)	   and	   CD19+	   cells	  
(right),	   above	   the	   unstimulated	   control	   of	   each	   group	   is	   shown.	   Two-­‐tailed,	   unpaired	  
Student’s	   t-­‐test	   (mean	   +/-­‐	   SD)	   **p<0.01,	   ***p<0.001,	   ns	   =	   not	   significant.	   This	   figure	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Figure	  4.24.	  The	  effects	  of	  ISQC-­‐antibody	  conjugates	  on	  the	  CD80	  and	  CD86	  expression	  of	  
BM-­‐DCs.	   BM-­‐DCs	   (1	   x	   106	   cells/ml)	  were	   incubated	   in	   the	  presence	  of	   stimulant;	   10μg/ml	  
ISQC-­‐antibody	  conjugates,	  10μg/ml	  ISQ	  peptide,	  200ng/ml	  LPS,	  as	  well	  as	  in	  the	  absence	  of	  
stimulant	   for	   24	   hours	   in	   a	   48-­‐well	   plate	   (1ml).	   The	   fold	   increase	   in	  median	   fluorescence	  
intensity	  of	  CD80	  expression	  (top)	  and	  CD86	  expression	  (bottom)	  on	  CD11c+	  BM-­‐DC,	  above	  
the	   unstimulated	   control	   of	   each	   group	   is	   shown.	   Two-­‐tailed,	   unpaired	   Student’s	   t-­‐test	  
(mean	   +/-­‐	   SD)	   *p<0.05,	   **p<0.01.	   This	   figure	   represents	   results	   from	   three	   separate	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4.4.3.	   Evaluation	  of	   the	   antibody	   and	   lymphocyte	   responses	   to	   ISQC-­‐
mAb	  conjugates	  in	  vivo	  
Twenty	  BALB/c	  mice	  were	  immunised	  on	  day	  0,	  and	  day	  15	  (Figure	  4.25)	  with	  10μg	  
ISQC-­‐CD40mAb	   conjugate	   and	   ISQC-­‐GL117mAb	   conjugate	   via	   the	   intraperitoneal	  
route.	  Control	  groups	  included;	  0.8μg	  ISQC	  and	  9.2μg	  CD40mAb	  (Mixture)	  and	  PBS.	  
The	  Mixture	   control	  was	  used	   to	  ensure	   the	  quality	  of	   the	   ISQC-­‐CD40mAb	  vaccine	  
conjugates.	  Blood	  was	  collected	  and	  spleens	  were	  harvested	  on	  day	  31	   in	  order	  to	  
investigate	  the	  sera	  anti-­‐OVA	  specific	  antibody	  titre	  and	  CD4+	  T	  cell	  responses	  using	  
a	  lymphocyte	  proliferation	  assay	  (see	  Section	  2.2.8).	  
	  
Figure	   4.25.	   Immunisation	   schedule	   for	   ISQC-­‐mAb	   conjugates.	   BALB/c	   mice	   were	  
immunized	   with	   ISQC-­‐CD40mAb	   conjugate,	   ISQC-­‐GL117mAb	   conjugate,	   Mixture	   and	   PBS.	  
BALB/c	  mice	  were	  boosted	  on	  day	  15	  using	  the	  same	  immunogens.	  Mice	  were	  bled	  on	  day	  
31.	  Spleens	  were	  harvested	  for	  the	  ex	  vivo	  lymphocyte	  proliferation	  assay	  on	  Day	  31.	  
	  
4.3.3.1. Investigation	   of	   the	   anti-­‐OVA	   specific	   antibody	   titre	   in	   response	   to	  
immunogen	  
The	  antibody	  response	  against	  the	  ISQ	  peptide	  was	  determined	  by	  ELISA	  using	  OVA	  
protein	   to	   coat	   the	   plate	   (see	   Section	   	   2.2.7.3.2.).	   Mice	   immunised	   with	   ISQC-­‐
CD40mAb	   as	   well	   as	   ISQC-­‐GL117mAb	   conjugates	   produced	   anti-­‐OVA	   specific	  
antibodies,	   indicating	   that	   they	   were	   immunogenic	   (Figure	   4.26).	   Results	   showed	  
that	  mice	  immunised	  with	  ISQC-­‐CD40mAb	  conjugate	  produced	  a	  significantly	  higher	  
anti-­‐OVA	   titre	   compared	   to	   ISQC-­‐GL117mAb,	   Mixture	   and	   PBS	   immunised	   groups	  
(p<0.05,	  One-­‐way	  ANOVA	  using	  Sidak’s	  multiple	  comparisons	  post-­‐test).	  This	  was	  a	  
very	  promising	  result	  showing	  conjugation	  of	  ISQC	  peptide	  to	  CD40mAb	  led	  to	  a	  10-­‐
fold	  and	  100-­‐fold	  enhancement	  of	  secondary	  antibody	  responses	  against	  the	  peptide	  

















Figure	   4.26.	  Anti-­‐OVA	   specific	   antibody	  end-­‐point	   titre	   level	   at	   day	  31.	  Anti-­‐OVA	  specific	  
antibody	   levels	   detected	   in	   sera	   of	  mice	   immunised	  with	   ISQC-­‐CD40mAb	   conjugate	   (red),	  
ISQC-­‐GL117	   conjugate	   (blue),	   Mixture	   (green)	   and	   PBS	   (black).	   One-­‐way	   ANOVA	   using	  
Sidak’s	  multiple	   comparisons	  post-­‐test	   (mean	  +/-­‐	   SD)	  *p<0.05,	   **p<0.01,	  p<0.001.	  n	  =	  3-­‐5	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4.3.3.2. Evaluation	   of	   lymphocyte	   proliferation	   in	   response	   to	   ISQ	   peptide	   ex	  
vivo	  
To	   determine	   CD4+	   cell	   proliferation	   in	   response	   to	   ISQ	   peptide,	   splenocytes	   from	  
each	   immunised	   group	   were	   harvested	   and	   labelled	   with	   2μM	   CFSE	   (see	   Section	  
2.2.7.3.3.)	  and	  incubated	  with	  1μg/ml	  ISQ	  peptide	  or	  in	  the	  absence	  of	  antigen	  for	  72	  
hours.	   After	   72	   hours,	   each	   cell	   group	   was	   stained	   with	   efluor-­‐450	   labelled	   CD19	  
antibody	   and	   PE-­‐Cy7	   labelled	   CD4	   antibody	   and	   assessed	   by	   flow	   cytometry	   (see	  
Section	  2.2.2.7.4.).	  The	  IL-­‐2	  concentration	  in	  the	  supernatants	  was	  also	  measured	  by	  
IL-­‐2	  ELISA	  (see	  Section	  2.2.6.8.1.).	  
The	  proliferation	  of	  CD4+	  cells	  was	   investigated	  by	  excluding	  dead	  cells	  and	  debris,	  
gating	  on	  CD4+	  cells	  and	  subsequently	  the	  percentage	  of	  lymphocytes	  in	  the	  original	  
sample	   that	   have	   divided	  was	   recorded	   (Figure	   4.27).	   CD19+	   cell	   proliferation	  was	  
assessed	   to	   ensure	   that	   there	   was	   no	   non-­‐specific	   proliferation	   (for	   the	   gating	  
strategy	  of	  CD19+	  cell	  proliferation	  see	  Figure	  4.16).	  	  
There	   was	   no	   CD4+	   T	   cell	   (Figure	   4.29)	   or	   CD19+	   cell	   (Figure	   4.30)	   proliferation	  
observed	   with	   lymphocytes	   harvested	   from	   ISQC-­‐CD40mAb	   conjugate,	   ISQC-­‐
GL117mAb	   conjugate,	   Mixture	   or	   PBS	   immunised.	   A	   representative	   plot	   of	   one	  
sample	   from	   each	   immunisation	   group	   is	   shown	   in	   Figure	   4.28.	   Results	   show	   that	  
CD4	  T	  cell	   response	   is	  not	  enhanced	  by	  the	   ISQC-­‐CD40mAb	  conjugates	  when	  using	  
ISQ	  peptide	  as	  a	  conjugated	  antigen.	  This	  result	  was	  further	  verified	  by	  the	  fact	  that	  
the	  supernatants	  of	  unstimulated	  and	  stimulated	  samples	  did	  not	  show	  a	  difference	  
in	  IL-­‐2	  concentration	  (results	  not	  shown).	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Figure	   4.27.	   The	   gating	   strategy	   used	   for	   flow	   cytometric	   analysis	   of	   CD4+	   T	   cell	  
proliferation.	   The	   gating	   strategy	   included	   first	   gating	   on	   the	   spleen	   cell	   population,	  
followed	  by	  live	  cells	  based	  on	  UV	  live/dead	  staining	  (UV	  450/50),	  and	  subsequently	  on	  cell	  
surface	  expression	  marker	  CD4+	  cells.	  The	  percentage	  of	  CD4+	  T	  cells	   in	  the	  original	  sample	  
that	  have	  divided	  was	  recorded.	  A	  representative	  plot	  of	  one	  sample	  stimulated	  with	  ConA	  
(positive	  control)	  is	  also	  shown.	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Figure	   4.28.	   Representative	   plots	   analysed	   by	   FlowJo	   software	   for	   the	   investigation	   of	  
CD4+	  cell	  proliferation	  on	  stimulation	  ex	  vivo	  with	  1μg/ml	  ISQ	  peptide,	  or	  in	  the	  absence	  of	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Figure	  4.29.	  CD4+	  T	  cell	  proliferation	  on	  stimulation	  with	  1μg/ml	  ISQ	  peptide	  ex	  vivo.	  The	  
percentage	  of	  CD4+	  cells	  from	  the	  original	  population	  that	  have	  divided	  were	  recorded.	  Fold	  
increase	   in	   CD4+	   T	   cell	   proliferation	   above	   unstimulated	   control	   of	   each	   group	   is	   shown.	  
One-­‐way	   ANOVA	   with	   Sidak’s	   multiple	   comparisons	   post-­‐test	   (mean	   +/-­‐	   SD).	   	   ns	   =	   non-­‐




Figure	  4.30.	  CD19+	  cell	  proliferation	  on	  stimulation	  with	  1μg/ml	  ISQ	  peptide	  ex	  vivo.	  A.	  The	  
gating	   strategy	   included	   first	   gating	   on	   the	   spleen	   cell	   population,	   followed	   by	   live	   cells	  
based	   on	  UV	   live/dead	   staining	   (UV	   450/50),	   and	   subsequently	   on	   cell	   surface	   expression	  
marker	   CD19+	   cells.	   The	   percentage	   of	   CD19+	   cells	   from	   the	   original	   population	   that	   have	  
divided	   when	   stimulated	   by	   LPS	   is	   shown.	   B.	   Overlaid	   histogram	   of	   a	   representative	   plot	  
from	   a	   ISQC-­‐CD40mAb	   immunised	   mouse.	   Cells	   stimulated	   with	   LPS	   (red),	   1μg/ml	   ISQ	  
peptide	   (blue)	   and	   unstimulated	   (black)	   are	   shown.	   FlowJo	   software	   was	   used	   for	   data	  
analysis.	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Discussion	  
The	   main	   role	   of	   traditional	   adjuvants	   made	   by	   an	   empirical	   approach	   was	   to	  
enhance	   antibody	   responses	   against	   co-­‐inoculated	   antigen	   or	   the	   removal	   of	  
infection.	   These	   adjuvants	   were	   effective	   for	   vaccines	   that	   are	   commercially	  
available	   against	   bacterial	   and	   certain	   viral	   diseases,	   such	   as	   diphtheria,	   tetanus,	  
pertussis	  (Black	  et	  al.,	  2008)	  and	  hepatitis	  A	  (Ashur	  et	  al.,	  1999).	  For	  the	  generation	  
of	   an	   effective	   vaccine-­‐mediated	   immune	   response	   against	   other	   diseases	   like	  
cancer,	  antibody	  responses	  only	  are	  not	  enough	  to	  confer	  protection.	  Induction	  of	  T	  
cell	  responses	  as	  well	  as	  antibody	  responses	  is	  crucial.	  
In	  this	  chapter	  we	  wanted	  to	  determine	  which	  APC	  is	  important	  for	  the	  mechanism	  
of	  CD40mAb-­‐adjuvanted	  vaccines	  with	  focus	  on	  their	  downstream	  effect	  on	  CD4+	  T	  
cell	   responses.	   The	   effect	   of	   CD40mAb-­‐adjuvanted	   vaccines	   on	   the	   (i)	   antigen-­‐
presentation	   to	  CD4+	  T	  cells	   in	  vitro,	   (ii)	  APC	  co-­‐stimulatory	  molecule	  expression	   in	  
vitro	   and	   (iii)	   CD4+	   T	   cell	   responses	   to	   vaccine	   antigen	   ex	   vivo,	   was	   therefore	  
investigated	  using	  OVA-­‐CD40mAb	  conjugates	  or	  ISQC-­‐CD40mAb	  conjugates	  or	  both.	  
OVA	   is	   a	   poorly	   immunogenic	   antigen	   recommended	   as	   the	   standard	  model	  weak	  
immunogen	   (McGee	   et	   al.,	   1994).	   The	   vaccine	   consisting	   of	   OVA	   conjugated	   to	  
CD40mAb	  has	   shown	   to	   generate	   significantly	   higher	   titres	   of	   anti-­‐OVA	   antibodies	  
compared	   to	   the	   CD40mAb	   and	   OVA	  mixture	   (Barr	   et	   al.,	   2003).	   The	   use	   of	   OVA	  
antigen	  as	  a	  model	  was	  beneficial	  as	   it	  allowed	  testing	  of	   the	  antigen	  presentation	  
capability	  of	  APCs	  to	  CD4+	  T	  cells	   in	  vitro,	  by	  means	  of	   the	  OVA-­‐specific	  DO11.10	  T	  
cell	  hybridoma	  cell	   line.	  BM-­‐DCs,	  B	  cells	  and	  splenocytes	  were	  used	   in	  an	  effort	   to	  
investigate	   the	  effect	  of	   the	  OVA-­‐CD40mAb	  conjugates	  on	  antigen	  presentation	   to	  
DO11.10	  T	  hybridoma	  cells.	  	  
The	   disheartening	   fact	   was	   that	   in	   these	   experiments,	   the	   IL-­‐2	   produced	   in	   the	  
supernatant	  during	   co-­‐culture	  was	  not	  above	   the	  minimum	  detectable	   limit	  of	   the	  
ELISA	  being	  used,	  which	  made	   it	   difficult	   to	   formulate	   a	   conclusion	   (Figure	   4.6).	   A	  
trend	  was	  only	  observed	  when	  the	  numbers	  of	  BM-­‐DCs	  and	  T	  cells	  in	  co-­‐culture	  were	  
increased.	   Moreover	   using	   the	   co-­‐culture	   system	   with	   increased	   BM-­‐DC	   and	  
DO11.10	   T	   hybridoma	   cell	   numbers,	   CD40mAb	   did	   not	   enhance	   BM-­‐DC	   antigen	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presentation	   to	   T	   cells	   compared	   to	   the	   isotype	   control	   mAb	   or	   the	   OVA	   alone	  
control	   (Figure	   4.10).	   This	   result	   was	   inconsistent	   with	   a	   very	   recent	   study	   that	  
showed	   that	   anti-­‐CD40	   antibody	   was	   more	   efficient	   at	   mediating	   presentation	   of	  
conjugated	   peptides	   on	   MHC	   class	   II	   compared	   to	   other	   antibodies	   against	   cell	  
surface	  receptors	  (for	  example	  anti-­‐DEC205)	  (Chatterjee	  et	  al.,	  2012).	  Furthermore,	  
in	   the	   aforementioned	   study	   anti-­‐CD40	   conjugated	   to	   peptides	   lead	   to	   enhanced	  
CD4+	  T	  cell	  production	  of	  IL-­‐2	  and	  IFN-­‐γ.	  IFN-­‐γ	  being	  the	  chief	  cytokine	  produced	  by	  
TH1	  differentiated	  cells.	  The	  latter	  experiments	  were	  conducted	  using	  a	  different	  co-­‐
culture	  	  system,	  set-­‐up	  with	  human	  blood	  isolated	  DCs	  and	  CD4+	  T	  cells	  
Due	   to	   the	   results	   obtained	   using	   the	   DO11.10	   hybridoma	   cell	   line,	   we	   did	   not	  
proceed	   to	   investigating	   the	   effect	   of	   the	   CD40mAb	   conjugates	   in	   the	   co-­‐culture	  
system.	  Different	  methods	  in	  similar	  co-­‐culture	  systems	  have	  been	  used	  to	  measure	  
DO11.10	   T	   hybridoma	   cell	   activation.	   Published	   studies	   utilised	   a	   more	   sensitive	  
ELISA	  to	  detect	   IL-­‐2	   in	  the	  supernatant	   (Cycon	  et	  al.,	  2009,	  Aubin	  et	  al.,	  2010)	  that	  
was	   not	   used	   in	   this	   study	   due	   to	   financial	   limitations.	   Other	   studies	   utilised	   the	  
murine	   IL-­‐2-­‐dependent	  CTLL-­‐2	  cell	   line	   that	  only	  proliferate	   in	   the	  presence	  of	   IL-­‐2	  
(Bennett	  et	  al.,	  1992,	  Mutini	  et	  al.,	  1999,	  Prokopowicz	  et	  al.,	  2010).	  This	  cell	  line	  was	  
not	  used	  due	  to	  practical	   limitations.	  CTLL-­‐2	  proliferation	  could	  be	  measured	  using	  
an	   isotope	   incorporation	   assay	   with	   3H-­‐thymidine	   (3H-­‐TdR)	   that	   required	   a	  
scintillation	   counter	   that	   was	   unavailable	   and	   special	   radiation	   training.	   CTLL-­‐2	  
proliferation	  could	  also	  be	  detected	  by	  means	  of	  a	  colorimetric	  assay	  using	  MTT	  [3-­‐
(4,5-­‐dimethylthiazol-­‐2-­‐yl)-­‐2,5-­‐diphenyltetrazolium	  bromide],	  however	  this	  assay	  was	  
found	  less	  sensitive	  than	  3H-­‐TdR	  (Russell	  and	  Vindelov,	  1998).	  	  
DO11.10	  T	  hybridoma	  cells	  containing	  a	  gene	  encoding	  for	  GFP	  (DO11-­‐GFP),	  which	  is	  
under	   the	   control	  of	   a	  nuclear	   factor	  of	   activated	  T	   cells	   regulated	  promoter	  have	  
also	  been	  used	  by	  other	  studies	  (Underhill	  et	  al.,	  1999,	  Sun	  et	  al.,	  2003,	  Brewer	  et	  al.,	  
2004).	   On	   activation	   these	   cells	   become	   fluorescent	   and	   can	   be	   detected	   by	   flow	  
cytometry.	  Studies	  have	  also	  used	  CD4+	  cells	  from	  DO11.10	  BALB/c,	  specific	  to	  H-­‐2d	  
(Son	  et	  al.,	  2002,	  Aubin	  et	  al.,	  2010),	  or	  OT-­‐II	  C57Bl/6,	   specific	   to	  H-­‐2b	   (Kool	  et	  al.,	  
2011)	   transgenic	   mice	   having	   an	   OVA-­‐reactive	   T	   cell	   receptor	   for	   antigen	  
presentation	   assays.	   Considering	   the	  unstable	  nature	  of	   the	  DO11.10	  T	  hybridoma	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cells	   and	   the	   low	   IL-­‐2	   concentration	   produced	   by	   these	   cells	   in	   the	   supernatants,	  
perhaps	   the	   use	   of	   different	   cells	   in	   this	   study	  would	   have	   contributed	   to	   a	  more	  
robust	  conclusive	  result.	  
The	   identification	  of	   the	  principal	  APC	  having	  a	   role	   in	   the	  mechanism	  of	  action	  of	  
CD40mAb-­‐adjuvanted	  vaccines	  was	  also	  investigated.	  Work	  carried	  out	  in	  Chapter	  3	  
and	  a	  recent	  study	  carried	  out	  in	  our	  laboratory	  by	  Carlring	  et	  al.	  (2012),	  showed	  that	  
a	   vaccine	   consisting	   of	   CD40mAb	   conjugated	   to	   a	   lymphoma	   idiotype	   significantly	  
enhanced	   overall	  mouse	   survival	   as	   a	   prophylactic	   vaccine	   in	   a	  murine	   lymphoma	  
tumour	   model	   (discussed	   in	   detail	   in	   Chapter	   3).	   The	   routine	   treatment	   for	  
lymphoma	   is	   the	   use	   of	   a	  monoclonal	   antibody	   (Rituximab)	   directed	   against	   CD20	  
antigen	   present	   on	   B	   cells.	   This	   leads	   to	   depletion	   of	   B	   cells	   (Anolik	   et	   al.,	   2007).	  
Therefore	   understanding	   whether	   CD40mAb	   targets	   the	   CD40	   receptor	   of	   other	  
APCs,	   for	   example	   DCs,	   would	   shed	   some	   light	   on	   whether	   CD40mAb-­‐Id	   therapy	  
could	  be	  used	  as	  an	  adjunct	  to	  therapies	  such	  as	  Rituximab.	  
The	  DC	  has	  been	  described	  as	  ‘nature’s	  adjuvant’	  because	  many	  agents	  for	  example	  
MF59,	  bacterial	  CpG	  motifs,	  MPL,	  bacterial	  endotoxin	  and	  Freund’s	  adjuvant	  are	  able	  
to	  boost	  the	  immune	  response	  via	  direct	  or	  indirect	  activation	  and	  maturation	  of	  DC	  
(De	  Smedt	  et	  al.,	  1996,	  De	  Becker	  et	  al.,	  2000,	  Ismaili	  et	  al.,	  2002,	  Shah	  et	  al.,	  2003,	  
Lambrecht	   et	   al.,	   2009).	   On	   activation,	   the	   DCs	   upregulate	   essential	   surface	   co-­‐
stimulatory	  molecules	  in	  order	  to	  efficiently	  activate	  naive	  T	  cells,	  linking	  the	  innate	  
and	   adaptive	   immune	   response.	   CD40mAb-­‐adjuvanted	   conjugates	   target	  
professional	  APCs	  like	  B	  cells,	  DCs	  and	  macrophages,	  however	  in	  these	  experiments	  
only	  B	  cells	  become	  activated	  as	  shown	  by	  an	  enhanced	  expression	  of	  MHC	  class	   II	  
(Carlring	  et	  al.,	  2012).	  Consistent	  with	  the	  previously	  mentioned	  study,	  B	  cells	  were	  
found	   to	   be	   the	   one	   of	   the	   crucial	   targets	   of	   CD40mAb.	   Both	   the	   OVA-­‐CD40mAb	  
conjugate	   vaccines	   as	   well	   as	   a	   novel	   epitope-­‐based	   vaccine,	   ISQC-­‐CD40mAb	  
significantly	   enhanced	   the	   co-­‐stimulatory	   molecule	   expression	   compared	   to	   their	  
respective	  isotype	  mAb	  control	  conjugates.	  	  
The	  CLICK	   sOVA-­‐CD40mAb	  conjugate	  was	  better	  at	  DC	  activation	   compared	   to	   the	  
isotype	   mAb	   control	   and	   the	   Standard	   OVA-­‐CD40mAb	   conjugates	   (Figure	   4.12),	  
however,	  since	  (i)	  the	  sOVA	  used	  to	  make	  the	  OVA-­‐CD40mAb	  conjugates	  contained	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endotoxin	   (Figures	   4.13,	   4.15,	   4.16,	   4.19)	   and	   (ii)	   the	   Standard	   OVA-­‐CD40mAb	  
conjugate	  was	  not	  optimal	  (due	  to	  the	  very	  minimal	  anti-­‐OVA	  specific	  antibody	  titre	  
produced	  –	  Figure	  4.15),	   the	   results	  were	  conflicting	  and	  difficult	   to	   interpret.	  The	  
CLICK	   sOVA-­‐CD40mAb	   conjugate	   could	   be	   enhancing	   the	   co-­‐stimulatory	   molecule	  
expression	  through	  CD40	  receptor	  ligation,	  but	  it	  is	  possible	  that	  the	  effect	  is	  due	  to	  
a	  synergistic	  effect	  of	  the	  CD40	  receptor	  binding	  and	  the	  endotoxin	  contamination	  of	  
sOVA.	   Published	  work	   has	   shown	   that	   CD40mAb	  has	   a	   synergistic	   effect	  with	   LPS.	  
Immunisation	  of	  LPS	  admixed	  with	  CD40mAb	  enhanced	  anti-­‐LPS	  IgG	  levels	  compared	  
to	  immunisation	  of	  LPS	  admixed	  with	  the	  respective	  isotype	  mAb	  control	  (Barr	  and	  
Heath,	   1999).	   Moreover,	   immunisation	   with	   a	   vaccine	   formulation	   consisting	   of	  
CD40mAb	  conjugated	  to	  lymphoma	  idiotype	  and	  MPL	  (lipid	  A	  portion	  of	  Salmonella	  
minnesota	   LPS)	   enhanced	   tumour	   rejection	   compared	   to	   CD40mAb	   conjugated	   to	  
antigen	  used	  alone	   in	  a	  murine	   lymphoma	  model	   (Carlring	  et	  al.,	  2012).	  This	  effect	  
could	  have	  been	   the	   reason	  why	   the	   anti-­‐OVA	  antibody	   response	   against	   sOVA	  as	  
well	   as	   sOVA	  admixed	  with	  CD40mAb	  were	  not	   significantly	  different	   to	   the	  CLICK	  
sOVA-­‐CD40mAb	   conjugates	   (Figure	   4.15).	   The	   reason	   why	   very	   low	   anti-­‐OVA	  
responses	  were	   generated	   from	   Standard	   OVA-­‐CD40mAb	   is	   not	   understood,	   as	   in	  
vitro	  testing	  of	  this	  conjugate	  confirmed	  conjugation.	  
With	  regards	  to	  the	  DC	  co-­‐stimulatory	  molecule	  expression,	  the	  results	  using	   ISQC-­‐
antibody	  conjugates	  were	  more	  straightforward.	  ISQC-­‐CD40mAb	  conjugates	  had	  no	  
effect	  on	  the	  CD80	  or	  the	  CD86	  expression	  of	  splenic	  CD11c+	  DCs	  compared	  to	  the	  
isotype	  mAb	  control	  conjugate	  (Figure	  4.23).	  Judging	  from	  the	  lack	  of	  upregulation	  of	  
co-­‐stimulatory	   molecule	   expression	   induced	   by	   LPS,	   the	   splenic	   DCs	   used	   for	   this	  
work	  were	  already	  mature	  (fully	  expressing	  co-­‐stimulatory	  molecules).	  The	  effect	  of	  
the	   ISQC-­‐CD40mAb	   conjugate	   on	   the	   homogeneous	   immature	   BM-­‐DC	   population	  
optimised	   for	   this	  work	   showed	  more	   straightforward	   results.	   Both	   LPS	   and	   sOVA	  
alone	  but	  not	  ISQ	  peptide	  alone,	  had	  a	  substantial	  effect	  on	  the	  upregulation	  of	  BM-­‐
DC	   CD80	   and	   CD86	   expression.	   ISQC-­‐CD40mAb	   conjugates	   showed	   a	   significant	  
increase	   of	   both	   CD80	   and	   CD86	   expression	   of	   BM-­‐DC	   compared	   to	   isotype	  mAb	  
control	  conjugate	  and	  controls	  (Figure	  4.24).	  DC	  activation	  by	  CD40mAb-­‐adjuvanted	  
conjugates	   is	  different	  to	  other	  adjuvants	   like	  unmethylated	  CpG	  motifs	  on	  TLRs	  or	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endotoxin	  because	   the	  DCs	  are	  not	  activated	  by	   recognition	  of	  PAMPs,	  but	  via	   the	  
CD40	  receptor.	  	  
An	   investigation	   into	  the	  uptake	  of	  CD40mAb-­‐antigen	  conjugates	  would	  shed	  more	  
light	  on	  the	  interpretation	  of	  the	  mechanism.	  Although,	  B	  cells	  have	  been	  assumed	  
to	   be	   the	   principal	   target	   of	   CD40mAb	   the	   fact	   that	   DCs	   are	   more	   efficient	   at	  
antigen-­‐uptake	   should	   be	   kept	   in	   mind.	   Uptake	   of	   the	   CD40mAb-­‐adjuvanted	  
conjugates	   at	   the	   site	   of	   inoculation	   could	   be	   by	   means	   of	   receptor-­‐mediated	  
endocytosis,	  phagocytosis	  and	  macropinocytosis	  (Guermonprez	  et	  al.,	  2002),	  as	  well	  
as	  possibly	  the	  CD40	  receptor	  (investigated	  in	  Chapter	  5).	  	  
Mice	  immunised	  with	  ISQC-­‐mAb	  conjugates	  produced	  detectable	  levels	  of	  anti-­‐OVA	  
specific	  antibodies	  after	  boost	  (Figure	  4.25)	  indicating	  that	  they	  were	  immunogenic.	  	  
Furthermore,	   the	   fact	   that	   mice	   immunised	   with	   ISQC-­‐CD40mAb	   produced	   a	  
significantly	  higher	  anti-­‐OVA	  specific	  response	  compared	  to	  the	   ISQC	  admixed	  with	  
CD40mAb	  and	  ISQC-­‐GL117mAb	  conjugate,	  shows	  that	  the	  conjugation	  of	  CD40mAb	  
to	  antigen	  is	  a	  step	  in	  the	  right	  direction	  to	  overcoming	  the	  lack	  of	  immunogenicity	  
of	  epitope-­‐based	  vaccines.	  	  
The	  evidence	  to	  date	  shows	  the	  role	  of	  CD40mAb-­‐adjuvanted	  vaccines	  in	  enhancing	  
antibody	   responses	   (Barr	   et	   al.,	   2003,	   Carlring	   et	   al.,	   2012)	   and	   T	   cell	   responses	  
(Carlring	  et	  al.,	   2004,	  Hatzifoti	   and	  Heath,	  2007)	  however,	   the	   type	  of	  T	   cell	   (CD4+	  
versus	   CD8+)	   response	   had	   not	   yet	   been	   directly	   investigated.	   Understanding	   the	  
type	   of	   immune	   response	   the	   adjuvant	   helps	   to	   shape,	   will	   allow	   the	   use	   of	   the	  
adjuvant	   for	   the	   correct	   application.	   The	   final	   role	   of	   CD40mab-­‐adjuvanted	  
conjugates	   investigated	   in	   this	   chapter	   was	   the	   effect	   of	   the	   CD40mAb-­‐conjugate	  
vaccines	  on	  antibody	  and	  CD4+	  T	  cell	   responses	  to	  antigen	  stimulation	  ex	  vivo.	  The	  
ISQC-­‐CD40mAb	  vaccine	  showed	  a	  trend	  of	  increased	  CD4+	  T	  cell	  responses	  compared	  
to	   the	   isotype	  antibody	  control	  conjugate.	  This	   suggests	   that	   ISQC-­‐CD40mAb	  could	  
be	   inducing	  CD4+	  T	  cell	   responses	  however,	  more	  numbers	   than	   just	   four	  mice	  are	  
required	  to	  reach	  significance	  (Figure	  4.27).	  	  
Multiple	   adjuvants	   currently	   being	   researched	   have	   shown	   promise	   in	   enhancing	  
CD4+	  T	  cell	   responses	   including	  the	  use	  of	  alum	  compounds.	  However	  the	   immune	  
response	   induced	  by	  alum	  was	   found	   to	  be	   largely	   limited	   to	   the	   induction	  of	   TH2	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responses	  (Grun	  and	  Maurer,	  1989,	  Brewer	  et	  al.,	  1996,	  Brewer	  et	  al.,	  1999).	  The	  use	  
of	  the	  TLR4	  agonist	  together	  with	  aluminium	  salts,	  in	  the	  AS04	  adjuvant,	  used	  in	  two	  
licensed	   vaccines	   CevarixTM	   (HPV)	   and	   FendrixTM	   (HBV)	   also	   led	   to	   enhanced	   TH1	  
responses	   achieving	   the	   desirable	   effect	   (Levie	   et	   al.,	   2002,	   Giannini	   et	   al.,	   2006,	  
Didierlaurent	  et	  al.,	  2009).	  Induction	  of	  a	  TH1	  response	  is	  an	  unmet	  requirement	  for	  
vaccination	   against	   many	   diseases	   including	   cancer,	   as	   TH1	   cytokines	   stimulate	  
tumour	  specific	  CD8+	  CTL	  responses	  that	  are	  critical	  for	  anti-­‐tumour	  immunity.	  	  
	  
Conclusion	  
In	   conclusion,	   epitope-­‐based	   CD40mAb	   conjugates	   are	   promising	   models	   for	   the	  
investigation	   of	   the	   mechanism	   of	   action	   of	   CD40mAb	   adjuvant,	   better	   than	   the	  
previously	   used	   OVA	   model	   due	   to	   their	   very	   poor	   immunogenicity	   when	  
administered	  alone.	  The	  ISQC-­‐CD40mAb	  conjugate	  was	  more	  immunogenic	  than	  the	  
mixture	  or	   the	   isotype	  conjugate.	  The	   results	   in	   this	   chapter	  point	   to	   the	   fact	   that	  
both	  splenic	  B	  cells	  and	   immature	  DCs	  have	  a	  role	   in	  the	  mechanism	  of	  CD40mAb-­‐
adjuvanted	  vaccines.	  However,	  whether	  the	  CD4+	  T	  cells	  are	  mediators	  for	  CD40mAb	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5.1. Introduction	  
Robust	   CD8+	   T	   cell	   responses	   are	   important	   for	   protection	   against	   cancers	   and	  
infectious	   diseases,	   which	   together	   with	   safety,	   is	   where	   most	   novel	   vaccine	  
adjuvants	   fall	   short.	   CD40mAb	  has	  been	  used	  as	   immunotherapy	   in	  human	   cancer	  
Phase	   I	   clinical	   trials	   (Vonderheide	   et	   al.,	   2007,	   Beatty	   et	   al.,	   2013).	   The	   fact	   that	  
CD40mAb	   used	   alone	   as	   immunotherapy	   was	   well	   tolerated	   with	   only	   mild	   to	  
moderate	   cytokine	   release	   syndrome	   as	   side-­‐effects	   that	  manifest	   as	   chills,	   fever,	  
rigors	  soon	  after	  infusion,	  shows	  that	  the	  use	  of	  CD40mAb	  as	  an	  adjuvant	  is	  a	  step	  in	  
the	  right	  direction.	  
A	   study	   carried	   out	   in	   our	   laboratory	   demonstrated	   that	   murine	   CD40mAb-­‐
adjuvanted	   vaccine	   anti-­‐tumour	   efficacy	   was	   significantly	   reduced	   on	   CD8+	   T	   cell	  
depletion	   (Carlring	   et	   al.,	   2012),	  which	   suggested	   that	   CD8+	   T	   cells	  were	   the	  main	  
effectors	  against	  B	  cell	  lymphoma.	  However,	  the	  cytotoxic	  T	  cell	  response	  crucial	  for	  
controlling	   tumour	   growth	   was	   not	   directly	   measured.	   Therefore,	   we	   wanted	   to	  
investigate	   the	   impact	   of	   CD40mAb-­‐adjuvanted	   conjugates	   on	   the	   CD8+	   T	   cell	  
responses,	   which	   was	   assessed	   by	   conjugating	   the	   immunodominant	   CD8+	   T	   cell	  
epitope	   of	   OVA	   (OVA257-­‐264	   or	   SIINFEKL)	   to	   CD40mAb.	   This	   was	   performed	   in	   the	  
present	  study	  using	  an	  in	  vivo	  killing	  or	  cytotoxicity	  assay.	  
In	   Chapter	   4,	   the	   APCs	   implicated	   in	   the	  mode	   of	   action	   of	   CD40mAb-­‐adjuvanted	  
vaccines	   and	   their	   downstream	   adjuvant	   effects	   on	   CD4+	   T	   cell	   responses	   were	  
investigated.	  In	  this	  chapter	  the	  hypothesis	  that	  both	  B	  cells	  and	  DCs	  have	  an	  impact	  
on	   the	  mechanism	  of	  action	  of	  CD40mAb-­‐adjuvanted	  conjugates	   leading	   to	  CD8+	  T	  
cell	  responses	  were	  investigated.	  This	  was	  explored	  in	  more	  detail	  in	  vitro	  by	  taking	  a	  
closer	  look	  into	  antigen-­‐delivery	  and	  uptake	  as	  well	  as	  B	  cell	  and	  DC	  activation	  status	  
and	  antigen-­‐presentation	  to	  CD8+	  T	  cells.	  	  
The	  study	  by	  Carlring	  et	  al.	  (2012)	  showed	  in	  vitro	  that	  the	  conjugate	  was	  targeted	  to	  
the	   CD40	   receptor	   of	   splenic	   B	   cells,	   DCs	   and	  macrophages	   (Carlring	   et	   al.,	   2012).	  
However,	  whether	  the	  CD40mAb	  and	  the	  conjugated	  antigen	  were	  co-­‐delivered	  and	  
internalised	   by	   the	   same	   APC	   could	   not	   be	   established	   as	   only	   the	   antigen	   was	  
fluorescently	   labelled.	   The	   fluorescently	   labelled	   CD40mAb-­‐antigen	   conjugate	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immunised	  subcutaneously	  was	  detected	  in	  the	  harvested	  draining	  lymph	  node	  cells	  
by	  confocal	  microscopy.	  However,	  in	  the	  in	  vivo	  experiment,	  which	  APCs	  were	  taking	  
up	   the	   CD40mAb-­‐antigen	   conjugates	   was	   not	   specified.	   To	   investigate	   this,	   the	  
SIINFEKL	   peptide	   and	   the	   CD40mAb	   were	   fluorescently	   labelled	   with	   different	  
fluorophores	  prior	   to	   conjugation.	  Co-­‐localisation	  and	   internalisation	  of	   co-­‐labelled	  
SIINFEKL-­‐CD40mAb	   conjugate	   by	   B	   cells	   and	   BM-­‐DCs	   was	   investigated	   in	   vitro	   by	  
epifluorescence	  microscopy.	  
The	  effect	  of	  SIINFEKL-­‐CD40mAb	  conjugates	  on	  antigen	  processing	  and	  presentation	  
to	   CD8+	   T	   cells	   was	   demonstrated	   in	   vitro	   using	   the	   well-­‐characterised	   B3Z	  
hybridoma	  CD8+	   T	   cell	   line.	   These	   cells	   recognise	   SIINFEKL	   presented	  on	   the	  MHC	  
class	   I	   of	   the	   H-­‐2Kb	   haplotype	   (Sanderson	   and	   Shastri,	   1994),	   in	   a	   quantitative	  
manner.	  On	  recognition	  and	  binding	  of	  the	  TCR	  to	  SIINFEKL/H-­‐2Kb	  complex,	  activated	  
B3Z	   cells	   produce	   IL-­‐2.	   Therefore,	   the	   activation	   status	   of	   the	   B3Z	   was	  measured	  
using	   IL-­‐2	  ELISA.	  Furthermore,	   the	  ability	  of	   the	  APCs	   to	  present	  SIINFEKL	  was	  also	  
investigated	  by	  flow	  cytometry	  by	  means	  of	  a	  fluorescently	  labelled	  anti-­‐SIINFEKL/H-­‐
2Kb	   complex	   antibody.	   Finally,	   to	   further	   investigate	   the	   effect	   of	   the	   SIINFEKL-­‐
CD40mAb	   conjugate	  on	  APC	   co-­‐stimulatory	  molecule	   expression	   and	  presentation,	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5.2. Impact	   of	   an	   epitope-­‐based	   CD40mAb-­‐adjuvanted	  
conjugate	  on	  CD8+	  T	  cell	  responses	  in	  vivo	  
	  
5.2.1. Production	  and	  characterisation	  of	  SIINFEKLC-­‐mAb	  conjugates	  in	  
vitro	  
For	   the	   context	   of	   this	   chapter,	   the	   CD8+	   T	   cell	   epitope	   SIINFEKL	  was	   synthesised	  
with	   a	   cysteine	   on	   the	   C-­‐terminal	   end	   (SIINFEKLC).	   The	   CD40mAb	   and	   the	   isotype	  
control	   mAb	   (GL117mAb)	   were	   treated	   with	   Sulfo-­‐SMCC	   and	   conjugated	   to	   the	  
sulphydryl	   group	   on	   the	   cysteine	   present	   on	   the	   C-­‐terminal	   end	   of	   the	   SIINFEKLC	  
peptide	  (see	  Section	  2.2.1.4.).	  The	  endotoxin	  activity	  of	  these	  conjugates	  was	  tested	  
and	   found	   to	  be	  <0.01	  EU/μg	  conjugate.	  As	  explained	   in	  Section	  4.4.1,	  using	   ISQC-­‐
mAb	  conjugates,	  conjugation	  of	  peptide	  to	  CD40mAb	  and	  respective	  isotype	  control	  
mAb	  could	  not	  be	  confirmed	  by	  ELISA	  or	   flow	  cytometry,	   therefore,	  CD40mAb	  was	  
also	  conjugated	  to	  biotinylated	  SIINFEKLC	  (see	  Section	  2.2.1.4).	  	  
SIINFEKLC	  was	  biotinylated	  using	  EZ-­‐Link	  Sulfo-­‐NHS-­‐Biotin	  that	  reacts	  with	  side-­‐chain	  
of	   lysines	   (K)	   or	   the	   amino-­‐terminal	   (NH2)	   group.	   SIINFEKLC	   peptide	   has	   a	  MW	  of	  
1066Da	  therefore,	  since	  the	  smallest	  dialysis	  membrane	  available	  has	  a	  pore	  size	  of	  
1000Da,	   excess	   biotinylation	   reagent	   could	   not	   be	   removed	   by	   buffer	   exchange,	  
without	   the	   risk	   of	   losing	   valuable	   sample.	   The	   same	   precautions	   were	   taken	   as	  
explained	  in	  detail	  in	  Section	  4.4.1.	  Briefly,	  NHS-­‐biotin	  used	  to	  biotinylate	  SIINFEKLC	  
was	  also	  mixed	  with	  SMCC-­‐treated	  mAb	  in	  order	  to	  ensure	  that	  the	  NHS-­‐ester	  was	  
non-­‐reactive	  and	  would	  not	  also	  bind	  to	  the	  mAb	  during	  biotinylated	  peptide-­‐mAb	  
conjugation.	  	  
A	  10μg	  sample	  of	  SIINFEKLC-­‐mAb	  conjugates	  and	  controls	  were	  separated	  on	  a	  15%	  
reducing	   SDS-­‐PAGE	   gel.	   Biotinylated	   conjugates	   were	   detected	   with	   HRP-­‐labelled	  
streptavidin	  by	  Western	  blotting	  (Figure	  5.1,	  see	  Section	  2.2.4.2.1.).	  This	  showed	  that	  
only	  the	  biotinylated	  SIINFEKLC-­‐mAb	  conjugates	  were	  detected	  by	  the	  HRP-­‐labelled	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Figure	  5.1.	  Confirmation	  of	  conjugation	  of	  SIINFEKLC	  peptide	  to	  CD40mAb.	  15%	  SDS	  PAGE	  
reducing	   gel	   is	   shown	   on	   the	   left.	  Western	   blot	   using	   HRP-­‐labelled	   streptavidin	   to	   detect	  
biotin	   is	   shown	   on	   the	   right.	   SIINFEKLC-­‐CD40mAb	   refers	   to	   the	   SIINFEKLC-­‐CD40mAb	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To	   further	   ensure	   that	   the	   conjugation	   was	   successful	   6%	   and	   15%	   SDS	   PAGE	  
reducing	   gels	   were	   run	   at	   60V	   in	   order	   to	   obtain	   better	   separation	   between	   the	  
bands	   (Figure	   5.2.).	   The	   6%	   SDS	   PAGE	   gel	   shows	   that	   the	   SIINFEKLC-­‐CD40mAb	  
conjugate	  bands	  running	  at	  approximately	  150kDa	  and	  50kDa	  are	  of	  higher	  apparent	  
MW	  than	  corresponding	  mAb	  alone	  controls	  (Figure	  5.2A).	  When	  observing	  the	  15%	  
gel,	   the	   bands	   showing	   heavy	   chains	   of	   the	   mAb	   portion	   of	   the	   SIINFEKLC-­‐mAb	  
conjugates	  running	  at	  approximately	  50kDa,	  are	  of	  slightly	  higher	  apparent	  MW	  than	  
the	  corresponding	  mAb	  controls	  (Figure	  5.2B).	  The	  increase	  in	  the	  apparent	  MW	  of	  
the	   antibody	   heavy	   chains	   in	   the	   lanes	   containing	   the	   SIINFEKLC-­‐CD40mAb	  
conjugates	  compared	  to	  the	  mAb	  only	  control	  lanes,	  suggest	  that	  SIINFEKLC	  peptide	  
is	  conjugated	  to	  the	  mAb.	  Since	  the	  biotinylated	  SIINFEKLC	  peptide	  did	  conjugate	  to	  
the	  mAb	  (Figure	  5.1),	  we	  assumed	  that	  the	  non-­‐biotinylated	  SIINFEKLC	  peptide	  had	  
also	  conjugated	  to	  the	  mAbs.	  Only	  non-­‐biotinylated	  SIINFEKLC-­‐mAb	  conjugates	  were	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A.	   	  
B.	  	   	  
	  
Figure	  5.2.	  Confirmation	  of	  conjugation	  of	  SIINFEKLC	  peptide	  to	  CD40mAb	  via	  reducing	  SDS	  
PAGE.	   A.	   6%	   SDS	   PAGE	   reducing	   gel.	   B.	   15%	   SDS	   PAGE	   reducing	   gel.	   SIINFEKLC-­‐CD40mAb	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5.2.2. Investigation	  of	  the	  effect	  of	  SIINFEKLC-­‐CD40mAb	  conjugates	  on	  
CD8+	  T	  cell	  responses	  by	  means	  of	  an	  in	  vivo	  cytotoxicity	  assay	  	  
The	  impact	  of	  the	  SIINFEKLC-­‐CD40mAb	  conjugates	  on	  the	  CD8+	  T	  cell	  response	  was	  
carried	  out	  using	  a	  cytotoxicity	  assay	  in	  a	  murine	  model.	  The	  assay	  involved	  primarily	  
dividing	  splenocytes	  from	  naive	  mice	  into	  two	  populations,	  one	  of	  which	  was	  pulsed	  
with	   2μM	   SIINFEKL	   peptide	   and	   stained	   with	   low	   concentration	   CFSE,	   whilst	   the	  
other	  population	  was	   left	  unpulsed	  and	  stained	  with	  a	  high	  concentration	  of	  CFSE.	  
The	   two	   splenocyte	   populations	   were	   mixed	   in	   a	   1:1	   ratio	   and	   injected	   i.v.	   into	  
previously	   SIINFEKLC-­‐CD40mAb	   immunised	   mice.	   After	   18	   hours,	   the	   SIINFEKL-­‐
directed	  cytolytic	  activity	  was	  measured	  by	  flow	  cytometry	  (see	  Section	  2.2.7.5.).	  	  
	  
5.2.2.1. Optimisation	  of	  the	  parameters	  of	  the	  in	  vivo	  cytotoxicity	  assay	  
Prior	   to	   immunising	   with	   SIINFEKLC-­‐CD40mAb	   conjugates	   and	   controls,	   certain	  
parameters	  of	  the	  assay	  had	  to	  be	  optimised	  in	  order	  to	  ensure	  that:	  	  
(1)	  SIINFEKL-­‐pulsed	  splenocytes	  retained	  the	  SIINFEKL	  peptide	  on	  their	  MHC	  class	   I	  
even	  after	  the	  series	  of	  washing	  steps	  involved	  during	  staining	  with	  CFSE	  dye	  
(2)	  cell	  death	  was	  due	  to	  the	  direct	  cytotoxic	  CD8+	  T	  cell	   response,	  and	  not	  due	  to	  
the	  SIINFEKL	  being	  toxic	  to	  the	  splenocytes	  
(3)	   CFSE	   concentration	   used	   to	   stain	   the	   splenocytes	  was	   of	   sufficient	   fluorescent	  
intensity	  for	  subsequent	  analysis	  by	  flow	  cytometry	  
	  
Therefore,	  as	   illustrated	   in	  Figure	  5.3,	  a	   spleen	   from	  a	  naive	  mouse	  was	  harvested	  
and	   a	   single	   cell	   suspension	   prepared.	   Splenocytes	   were	   divided	   into	   two	  
populations;	   one	   population	  was	   pulsed	  with	   2μM	  SIINFEKL	   peptide	   by	   incubation	  
with	   SIINFEKL	   peptide	   for	   1	   hour,	   whilst	   the	   other	   population	   was	   left	   unpulsed.	  
Subsequently	  both	  populations	  were	  stained	  with	  different	  concentrations	  of	  CFSE.	  
Unpulsed	   population	   was	   stained	   with	   0.2µM	   CFSE	   (or	   CFSEHIGH)	   whilst	   SIINFEKL-­‐
pulsed	  population	  was	  stained	  with	  0.02µM	  CFSE	  (or	  CFSELOW),	  for	  this	  optimisation	  
experiment.	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Figure	   5.3.	   A	   diagrammatic	   representation	   of	   the	   optimisation	   of	   the	   CFSE-­‐based	  
cytotoxicity	  assay.	  
	  
Other	   studies	   that	   performed	   in	   vivo	   cytotoxicity	   assays	   either	   pulsed	   with	   the	  
relevant	  peptide	  prior	  to	  CFSE	  staining	  (Curtsinger	  et	  al.,	  2003,	  Byers	  et	  al.,	  2003)	  or	  
post-­‐CFSE	  staining	  (Barber	  et	  al.,	  2003,	  Yang	  et	  al.,	  2004).	  In	  this	  study,	  splenocytes	  
were	  pulsed	  with	  SIINFEKL	  peptide	  prior	  to	  staining.	  Therefore	  the	  105	  CFSE-­‐stained	  
SIINFEKL-­‐pulsed	  splenocytes	  were	  co-­‐cultured	  with	  105	  B3Z	  cells	  (in	  a	  total	  volume	  of	  
200μl)	   that	   recognise	   SIINFEKL/H-­‐2Kb	   complex	   and	   produce	   IL-­‐2	   on	   activation,	   to	  
ensure	   that	   the	   SIINFEKL	   peptide	   did	   not	   detach	   from	   the	   MHC	   class	   I	   complex	  
(Figure	  5.4).	  The	  IL-­‐2	  concentration	  in	  the	  supernatant	  after	  24-­‐hour	  co-­‐culture	  was	  
measured	  by	   ELISA	   (see	   Section	   2.2.6.8.1.).	   Figure	   5.4	   shows	   that	   on	   co-­‐culture	   of	  
B3Z	  with	  SIINFEKL-­‐pulsed	  splenocytes,	  a	  significant	  amount	  of	  IL-­‐2	  was	  produced	  in	  
the	   supernatant	   compared	   to	   the	   cells	   only	   controls	   (p<0.0001,	   One-­‐way	   ANOVA	  
using	   Dunnett’s	   multiple	   comparisons	   post-­‐test)	   demonstrating	   that	   SIINFEKL	  
peptide	   was	   still	   present	   on	   the	   splenocyte	   MHC	   class	   I	   complexes	   post	   CFSE	  
staining.	  
The	  concentration	  of	  CFSE	  used	  for	  staining	   in	  cytotoxicity	  assay	  between	  different	  
studies	  is	  also	  variable.	  Some	  studies	  have	  used	  concentrations	  as	  high	  as	  5µM	  CFSE	  
(Curtsinger	  et	  al.,	  2003,	  Yang	  et	  al.,	  2004),	  whilst	  others	  have	  used	  concentrations	  as	  
low	  as	  1nM	  CFSE	  (Barber	  et	  al.,	  2003).	  Based	  on	  this	  information,	  in	  the	  optimisation	  
experiments,	   SIINFEKL-­‐pulsed	   splenocyte	   population	   was	   stained	   with	   0.02µM	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The	  two	  different	  splenocyte	  populations	  were	  mixed	  in	  a	  1:1	  cell	  ratio,	  and	  analysed	  
by	   flow	   cytometry,	   prior	   to	   i.v.	   injection	   (Figure	   5.5A).	   Since	   two	   cell	   peaks	   of	  
sufficient	  intensity	  were	  observed	  a	  total	  number	  of	  107	  splenocytes	  containing	  the	  
two	  populations	  were	  injected	  i.v.	  into	  a	  naive	  mouse.	  An	  in	  vitro	  control	  of	  106	  cells	  
of	  the	  two	  populations	  was	  incubated	  overnight	  in	  a	  T25	  flask	  at	  37°C,	  5%	  CO2.	  After	  
18	  hours,	   the	  spleen	  was	  harvested	  and	  analysed	  on	  flow	  cytometry	  together	  with	  
the	  in	  vitro	  control	  (Figure	  5.5B,	  C).	  
Flow	  cytometric	  analysis	  of	   the	  splenocyte	  populations	  showed	  that	  although	  prior	  
to	   the	   injection	   the	   two	   CFSE-­‐stained	   populations	   were	   of	   sufficient	   fluorescence	  
intensity	   (Figure	   5.5A),	   this	   was	   not	   the	   case	   for	   both	   the	   harvested	   spleen	   cells	  
(Figure	   5.5B)	   and	   the	   in	   vitro	   control	   (Figure	   5.5C).	   Results	   showed	   that	   the	   CFSE	  
concentrations	   used	   for	   staining	   should	   be	   increased.	  However,	   on	   observation	   of	  
the	  height	  of	  the	  CFSEHIGH	  and	  CFSELOW	  peaks,	  staining	  with	  CFSE	  nor	  pulsing	  with	  the	  
SIINFEKL	   peptide	   was	   toxic	   to	   the	   cells	   at	   the	   concentrations	   used.	   However,	   the	  
CFSE	  concentrations	  chosen	  were	  not	  of	  sufficient	  fluorescent	  brightness.	  Therefore,	  
for	   the	  main	   assay,	   considering	   that	   other	   studies	   used	   concentrations	   as	   high	   as	  
5µM	  CFSE	  (Curtsinger	  et	  al.,	  2003,	  Yang	  et	  al.,	  2004),	  CFSE	  staining	  was	  carried	  out	  































Figure	   5.4.	   Co-­‐culture	   of	   CFSE-­‐stained	   splenocytes	   stimulated	   with	   2µM	   SIINFEKL	  
peptide	  and	  B3Z	  T	  cell	  hybridoma.	  The	  ability	  of	  B3Z	  to	  produce	  IL-­‐2	  in	  the	  supernatant	  
after	  24-­‐hours	  co-­‐culture	  is	  shown.	  B3Z	  alone,	  and	  SIINFEKL-­‐pulsed	  splenocytes	  alone	  with	  
no	   co-­‐culture	   served	   as	   negative	   controls.	   This	   figure	   represents	   one	   experiment.	  
Technical	   replicates	   =	   3.	   One-­‐way	   ANOVA	   using	   Dunnett’s	   multiple	   comparisons	   test	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Figure	  5.5.	   Flow	   cytometric	   analysis	  of	   two	   splenocyte	  populations	   stained	  with	  0.02µM	  
(CFSELOW)	  and	  0.2µM	  CFSE	  (CFSEHIGH).	  A.	  Two	  mixed	  populations	  prior	  to	  i.v.	  injection.	  B.	  Two	  
mixed	  populations	  18	  hours	  post	  i.v.	   injection.	  C.	  Two	  mixed	  populations	  incubated	   in	  vitro	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5.2.2.2. Targeting	  of	  SIINFEKL-­‐pulsed	  cells	  by	  effector	  CD8+	  T	  cells	  
To	   determine	  whether	   antigen-­‐specific	   CD8+	   T	   cells	   target	   and	   kill	   cells	   presenting	  
the	   SIINFEKL	   peptide,	   unpulsed	   (control	   cells,	   stained	   with	   CFSEHIGH),	   and	   specific	  
SIINFEKL-­‐pulsed	   (target	   cells,	   stained	   with	   CFSELOW)	   splenocytes	   were	   transferred	  
into	   mice	   previously	   immunised	   with	   the	   SIINFEKLC-­‐mAb	   conjugates	   and	   controls	  
(Figure	  5.6).	  
	  The	   CFSE-­‐stained	   transferred	   splenocyte	   populations	   migrate	   to	   the	   secondary	  
lymphoid	  organs	  like	  the	  spleen	  but	  the	  target	  cells	  would	  only	  be	  lysed	  if	  peptide-­‐
specific	   CD8+	   T	   cells	   were	   generated.	   The	   relative	   decrease	   of	   specific	   SIINFEKL-­‐
pulsed	  target	  cell	  numbers	   to	   the	  unpulsed	  control	  cell	  numbers	  was	  measured	  by	  
flow	   cytometry	   as	   a	  means	   to	   identify	   CD8+	   T	   cell	   lysis	   in	   vivo.	  Target	   splenocytes	  
were	  distinguished	  from	  control	  splenocytes	  based	  on	  the	  intensity	  of	  CFSE	  staining.	  
Five	   C57BL/6	   mice	   per	   group	   were	   immunised	   on	   day	   0	   with	   40μg	   SIINFEKLC-­‐
CD40mAb	  conjugate	  or	  SIINFEKLC-­‐GL117mAb	  conjugate	  i.p.	  Control	  groups	  included	  
2μg	  SIINFEKLC	  and	  40μg	  CD40mAb	  mixture	  (or	  MIX)	  and	  PBS	  (Figure	  5.6).	  A	  summary	  
of	   the	   experimental	   design	   of	   the	   in	   vivo	   cytotoxicity	   assay	   and	   immunisation	  






















	   	  
Figure	  5.6.	  The	  experimental	  design	  of	   the	   in	  vivo	   cytotoxicity	  assay.	  A.	  A	  total	  of	  twenty	  
C57Bl/6	  mice	   (5	  mice	  per	  group)	  were	   immunised	   i.p	  with	  SIINFEKLC-­‐CD40mAb	  conjugate,	  
SIINFEKLC-­‐GL117mAb	   conjugate,	   SIINFEKLC	   and	   CD40mAb	   mixture	   or	   PBS.	   On	   day	   6,	  
SIINFEKL-­‐pulsed	  target	  cells,	  harvested	  from	  naive	  mice	  were	  stained	  with	  CFSELOW	  (0.2µM)	  
and	  unpulsed	  control	   cells	   stained	  with	  CFSEHIGH	   (2µM)	  and	   thereafter	   injected	   i.v	   into	   the	  
immunised	  mice.	  	  The	  experiment	  was	  terminated	  on	  day	  7	  at	  which	  point	  mice	  were	  culled	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Flow	   cytometric	   analysis	   of	   splenocytes	   showed	   that	   antigen-­‐specific	   CD8+	   T	   cells	  
were	  generated	  and	  SIINFEKL-­‐pulsed	   target	   cells	  were	   lysed	  only	   in	   the	  CD40mAb-­‐
adjuvanted	   immunised	   groups	   (Figure	   5.7).	   The	   percentage	   lysis	  was	   calculated	   as	  
explained	   in	   Section	   2.2.7.5.3.	   Fifty	   percent	   and	   51%	   of	   the	   SIINFEKL-­‐pulsed	  
splenocytes	  were	  lysed	  in	  mice	  immunised	  with	  SIINFEKLC-­‐CD40mAb	  conjugate	  and	  
MIX	  respectively.	  This	  was	  significantly	  higher	  than	  that	  for	  the	  SIINFEKLC-­‐GL117mAb	  
control	   immunised	   mice	   (p<0.05,	   One-­‐way	   ANOVA	   using	   Tukey’s	   multiple	  
comparisons	   post-­‐test).	   There	  was	   no	   difference	   observed	   between	   the	   CD40mAb	  
SIINFEKLC	  mixture	  (MIX)	  and	  the	  SIINFEKLC-­‐CD40mAb	  conjugate.	  	  
Cell	  death	  was	  observed	  at	  a	  CFSE	  concentration	  of	  2µM,	  assumed	  because	  a	  relative	  
loss	   of	   unpulsed	   control	   CFSEHIGH	   stained	   population	   compared	   to	   CFSELOW	   was	  
observed	   in	   all	   groups	   including	   PBS	   (Figure	   5.8).	   As	   already	   mentioned,	  
concentrations	   of	   CFSE	   as	   high	   as	   5µM	  was	   used	   by	   other	   studies	   (Sullivan	   et	   al.,	  
2003,	   Curtsinger	   et	   al.,	   2003,	   Ahonen	   et	   al.,	   2004,	   Yang	   et	   al.,	   2004),	   whilst	  
optimisation	   experiments	   have	   shown	   that	   the	   CFSELOW	   population	  was	   not	   bright	  
enough	   to	   observe	   by	   flow	   cytometry.	   This	   was	   the	   reason	   why	   the	   CFSE	  
concentrations	   of	   2µM	   and	   0.2µM	   were	   chosen.	   In	   spite	   of	   this,	   there	   was	   a	  
dramatic	   loss	   of	   CFSELOW	   population	   only	   in	   the	   SIINFEKLC-­‐CD40mAb	   immunised	  
group	  (Figure	  5.8)	  and	  Mixture	  group	  (not	  shown).	  	  
Since	  the	  CD40mAb	  adjuvanted	  conjugates	  induced	  killing	  of	  SIINFEKL-­‐pulsed	  target	  
cells	   in	  vivo,	  SIINFEKLC-­‐CD40mAb	  and	   its	   respective	   isotype	  mAb	  control	  conjugate	  
were	  used	  for	  the	  rest	  of	  this	  chapter	  as	  a	  model	  to	  understand	  further	  which	  APCs	  
are	  instrumental	  in	  the	  mechanism	  of	  action	  of	  CD40mAb-­‐adjuvanted	  conjugates	  as	  
adjuvants	  upstream	  of	  CD8+	  T	  cell	  responses.	  This	  was	  investigated	  primarily	  in	  vitro	  
and	  subsequently	  in	  vivo.	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Figure	  5.7.	  Percentage	  antigen-­‐specific	  CD8+	  T	  cell	  lysis	  of	  SIINFEKL-­‐pulsed	  target	  cells	  in	  
the	   spleen.	   The	   value	   shown	   represents	   the	   relative	   percentage	   lysis	   of	   the	   SIINFEKLC-­‐
CD40mAb,	  MIX	  and	  GL117mAb	  conjugate	  immunised	  groups	  to	  the	  PBS	  immunised	  group,	  
using	   the	   formula:	   (1	   -­‐	   (rPBS/rimmunised))	   X	   100.	   The	   results	   are	   representative	   of	   two	  
experiments	  of	  a	  total	  of	  8	  mice	  for	  each	  group.	  One-­‐way	  ANOVA	  using	  Tukey’s	  multiple	  
comparisons	  test	  (mean	  +/-­‐	  SD)	  was	  used	  to	  determine	  statistical	  significance,	  *p<0.05.	  	  
r	  =	  number	  of	  CFSEHIGH	  events/number	  of	  CFSELOW	  events	  of	  each	  mouse	  spleen.	  	  	  
	  
	  
Figure	   5.8.	   Representative	   results	   from	   one	   spleen	   harvested	   from	   PBS,	   SIINFEKLC-­‐
CD40mAb	   and	   SIINFEKLC-­‐GL117mAb	   conjugate	   immunised	   mice.	   Histograms	   show	  
numbers	   of	   control	   unpulsed	   CFSEHIGH	   stained	   cells	   and	   target	   SIINFEKL-­‐pulsed	   CFSELOW	  
stained	  cells	  in	  the	  spleens.	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5.3. Effects	   of	   SIINFEKLC-­‐mAb	   conjugates	   on	   APC	   co-­‐
stimulatory	  molecule	  expression	  in	  vitro	  
Prior	   to	   proceeding	   to	   SIINFEKLC-­‐CD40mAb	   uptake	   and	   targeting	   experiments,	  we	  
wanted	   to	   demonstrate	   whether	   this	   conjugate	   also	   enhanced	   co-­‐stimulatory	  
molecule	   expression	   of	   DCs	   and	   B	   cells.	   Similar	   to	   Section	   4.3.2,	   CD80	   and	   CD86	  
expression	   by	   splenic	   B	   cells	   and	   splenic	   CD11c+	   DCs	   was	   investigated	   following	  
incubation	   of	   splenocytes	   with	   10μg/ml	   SIINFEKLC-­‐mAb	   conjugates	   or	   SIINFEKLC	  
peptide,	   as	   well	   as	   200ng/ml	   LPS,	   which	   served	   as	   a	   positive	   control	   (Figure	   5.9).	  	  
SIINFEKLC	   alone	   served	   as	   a	   negative	   control.	   Flow	   cytometric	   analysis	   of	   the	   fold	  
increase	   in	  median	   fluorescence	   intensity	   of	   CD80	   and	   CD86	   expression	   on	   CD19+	  
(Figure	   5.9A)	   and	   CD11c+	   (Figure	   5.9B)	   cells	   above	   the	   unstimulated	   control	   was	  
performed	   (see	   Section	   2.2.6.6.).	   The	   experiment	   was	   repeated	   using	   BM-­‐DC	   to	  
investigate	   whether	   the	   results	   were	   consistent	   upon	   the	   use	   of	   an	   immature	  
homogeneous	  population	  of	  DCs	  (Figure	  5.10).	  	  
Splenic	  B	  cell	  results	  were	  consistent	  with	  previous	  studies	  (Carlring	  et	  al.,	  2012)	  as	  
well	   as	   the	   results	   shown	   in	   Chapter	   4.	   Both	   CD80	   and	   CD86	   expression	   were	  
significantly	   enhanced	   (p<0.01,	   p<0.001,	   two-­‐tailed,	   unpaired	   Student	   t	   test)	   on	  
stimulation	   with	   the	   SIINFEKLC-­‐CD40mAb	   conjugate	   compared	   to	   the	   SIINFEKLC-­‐
GL117Ab	   conjugate	   control	   (Figure	   5.9).	   Interestingly,	   SIINFEKLC-­‐CD40mAb	  
conjugate	   significantly	   upregulated	   both	   splenic	   CD11c+	   (Figure	   5.9B)	   and	   BM-­‐DC	  
(Figure	   5.10)	   CD80	   and	   CD86	   expression	   compared	   to	   controls	   (p<0.05,	   two-­‐tailed	  
unpaired	  Student	  t	  test).	  	  
In	   summary,	   SIINFEKLC-­‐CD40mAb	   conjugates	   enhanced	   co-­‐stimulatory	   molecule	  
expression	  of	  both	  B	  cells	  and	  DCs	  compared	  to	  the	  SIINFEKLC-­‐GL117mAb	  conjugate	  











A.	   	   	   	  
B.	   	   	  
Figure	  5.9.	  CD80	  and	  CD86	  expression	  on	  splenic	  B	  cells	  and	  CD11c+	  DCs	  upon	  incubation	  
with	   SIINFEKLC-­‐mAb	   conjugate.	   Splenocytes	   (1	   x	   106	   cells/ml)	   were	   incubated	   in	   the	  
presence	   of	   stimulant;	   10μg/ml	   SIINFEKL-­‐mAb	   conjugates,	   10μg/ml	   SIINFEKL	   peptide,	  
200ng/ml	  LPS,	  or	  in	  the	  absence	  of	  stimulant	  for	  24	  hours	  in	  a	  48-­‐well	  plate	  (1ml).	  	  The	  fold	  
increase	   in	   median	   fluorescence	   intensity	   (MFI)	   of	   the	   (A)	   CD80	   expression	   or	   (B)	   CD86	  
expression	  above	  the	  unstimulated	  control	  on	  CD11c+	  cells	  (left)	  (A)	  and	  CD19+	  cells	  (right)	  is	  
shown.	  Unpaired	  two-­‐tailed	  Student’s	  t-­‐test	  (mean	  +/-­‐	  SD)	  was	  used	  to	  determine	  statistical	  
significance.	   	   *P<0.05,	   **P<0.01,	   ***P<0.001.	   This	   figure	   represents	   results	   from	   three	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A. 	  
B. 	  
Figure	  5.10.	  CD80	  and	  CD86	  expression	  on	  BM-­‐DCs	  upon	   incubation	  with	  SIINFEKLC-­‐mAb	  
conjugate.	  BM-­‐DCs	  (1	  x	  106	  cells/ml)	  were	  incubated	  in	  the	  presence	  of	  stimulant;	  10μg/ml	  
SIINFEKL-­‐mAb	   conjugates,	   10μg/ml	   SIINFEKL	   peptide,	   200ng/ml	   LPS,	   or	   in	   the	   absence	   of	  
stimulant	   for	   24	   hours	   in	   a	   48-­‐well	   plate	   (1ml).	   The	   fold	   increase	   in	  median	   fluorescence	  
intensity	   (MFI)	   of	   the	   CD80	   (A)	   or	   CD86	   (B)	   on	   CD11c+	   BM-­‐DCs	   expression	   above	   the	  
unstimulated	  control	  is	  shown.	  Unpaired	  two-­‐tailed	  Student’s	  t-­‐test	  (mean	  +/-­‐	  SD)	  was	  used	  
to	   determine	   statistical	   significance.	   	   *p<0.05.	   This	   figure	   represents	   results	   from	   three	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5.4. Investigation	   into	   CD40mAb-­‐adjuvanted	   conjugate	  
targeting	  and	  uptake	  by	  B	  cells	  and	  BM-­‐DCs	  in	  vitro	  
To	   investigate	   whether	   both	   the	   CD40mAb	   and	   the	   conjugated	   antigen	   are	   co-­‐
delivered	   to	   the	   same	   APC	   and	   internalised,	   SIINFEKLC	   and	   CD40mAb	   were	  
fluorescently	  labelled	  prior	  to	  conjugation.	  It	  has	  been	  shown	  that	  CD40mAb	  targets	  
B	  cells,	  DCs	  and	  macrophages	  and	  that	  co-­‐stimulatory	  molecule	  expression	  on	  B	  cells	  
is	  enhanced	  as	  a	  result	  in	  vitro	  (Carlring	  et	  al.,	  2012).	  More	  information	  regarding	  the	  
uptake	  of	  CD40mAb-­‐adjuvanted	  conjugates	  would	   shed	   light	  on	   the	  mechanism	  of	  
action	  of	  the	  adjuvant.	  	  
	  
5.4.1. Production	   and	   in	   vitro	   testing	   of	   fluorescently-­‐labelled	  
SIINFEKLC-­‐mAb	  conjugates	  
SIINFEKLC	   (1066Da)	   was	   fluorescently	   labelled	   with	   NHS-­‐fluorescein	   (473.4Da),	  
whilst	  CD40mAb	  (approximately	  150kDa)	  was	  fluorescently	  labelled	  with	  DyLight	  650	  
NHS	   ester	   (1066Da)	   (see	   Section	   2.2.1.5.).	   Both	   NHS-­‐fluorescein,	   which	   will	   be	  
referred	  to	  as	  FAM	  and	  Dylight	  650	  NHS-­‐ester,	  which	  will	  be	  referred	  to	  as	  Dylight,	  
were	  chosen	  due	  to	  (i)	  their	  relatively	  low	  MW	  (especially	  FAM)	  (ii)	  amine-­‐reactivity	  
and	  (iii)	  emission	  spectra	  (which	  do	  not	  overlap).	  	  
The	  MW	  was	   taken	   into	   consideration,	   and	   both	   FAM	   and	   Dylight	   have	   low	  MW	  
relative	   to	   SIINFEKLC	   and	   CD40mAb	   respectively.	   This	  was	   performed	   to	  minimise	  
any	   interference	   of	   the	   labelled	   dye	  with	   the	   conjugation	   between	   SIINFEKLC	   and	  
CD40mAb,	   and	   to	   ensure	   that	   the	   results	   were	   representative	   of	   the	   unlabelled	  
CD40mAb-­‐adjuvanted	  conjugates.	  
NHS-­‐ester	  chemistry	  was	  used	  to	  both	  label	  the	  CD40mAb	  via	  side-­‐chains	  of	  lysines	  
(K)	  or	  the	  amino-­‐terminal	  (NH2)	  group,	  and	  conjugate	  it	  to	  the	  sulphydryl	  groups	  on	  
the	   cysteine	   present	   on	   the	   C-­‐terminal	   end	   of	   the	   SIINFEKLC	   peptide.	  Due	   to	   this	  
Dylight	   was	   first	   conjugated	   to	   the	   CD40mAb	   or	   isotype	   control	   antibody,	  
GL117mAb,	   at	   different	   molar	   excess,	   starting	   at	   a	   molar	   excess	   of	   7	   (as	  
recommended	   by	   the	   manufacturer,	   see	   Section	   2.2.1.5.2.).	   Labelling	   at	   a	   molar	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excess	   of	   3.5,	   1.75	   and	   1	   was	   also	   performed.	   This	   was	   to	   ensure	   that	   sufficient	  
amino	  groups	  were	  available	  for	  treatment	  with	  Sulfo-­‐SMCC	  (another	  amine-­‐reactive	  
reagent)	  and	  subsequent	  conjugation	  to	  SIINFEKLC	  peptide.	  Excess	  dye	  was	  removed	  
by	  means	  of	  a	  100kDa	  filter.	  A	  filter	  with	  such	  a	  large	  pore	  size	  was	  used	  to	  ensure	  
the	   removal	  of	   all	   excess	  dye,	   including	  dye	   complexes.	   To	   investigate	   the	   relative	  
brightness,	   the	   labelled	   antibodies	   were	   analysed	   on	   CD40L929	   cells	   by	   flow	  
cytometry	  (Figure	  5.11,	  see	  Section	  2.2.4.4.1.).	  
An	   increase	   in	   fluorescence	  was	  observed	  with	  all	   labelled	  CD40mAb	  compared	   to	  
their	   respective	   labelled	   isotype	   mAb	   controls	   (Figure	   5.11A).	   Considering	   that	  
labelling	   at	   the	   molar	   excess	   of	   7	   was	   the	   brightest,	   and	   recommended	   by	   the	  
manufacturer	  for	  best	  labelling	  of	  the	  CD40mAb,	  we	  assumed	  that	  not	  many	  amino	  
groups	   would	   remain	   available	   for	   optimal	   conjugation	   to	   SIINFEKLC.	   On	   the	  
contrary,	  labelling	  at	  a	  molar	  excess	  of	  1.75	  and	  0.9	  was	  not	  of	  sufficient	  fluorescent	  
intensity	  for	  use	  (Figure	  5.11B).	  Therefore	  the	  CD40mAb	  labelled	  with	  a	  molar	  excess	  

















Figure	  5.11.	  Fluorescence	   intensity	  of	  CD40mAb	   labelled	  with	  a	   range	  of	  molar	  excess	  of	  
Dylight	   650.	  A.	   Relative	   binding	   of	   CD40mAbDylight	   at	   a	  molar	   excess	   of	   7	   (red),	   3.5	   (blue),	  
1.75	  (orange),	  0.9	  (green)	  and	  their	  respective	  labelled	  isotype	  controls	  (outline	  histograms)	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SIINFEKLC	  was	  labelled	  with	  a	  20	  molar	  excess	  of	  FAM	  dye.	  Once	  again	  since	  no	  filter	  
with	  pore	  size	  small	  enough	  to	  remove	  excess	  FAM	  dye	  by	  buffer	  exchange	  without	  
losing	   valuable	   sample	   is	   available,	   the	   same	   precautions	   discussed	   in	   detail	   in	  
Section	  4.4.1.	  with	  biotin	  labelling	  were	  taken	  (see	  Section	  2.2.1.5.3.).	  	  
CD40mAb	  (or	  respective	  isotype	  mAb	  control)	  labelled	  with	  3.5	  molar	  excess	  Dylight	  
(CD40mAbDylight)	  was	   subsequently	   treated	  with	   Sulfo-­‐SMCC	  and	   conjugated	   to	   the	  
sulphydryl	   groups	  on	   the	   cysteine	  present	  on	   the	  C-­‐terminal	   end	  of	   the	   SIINFEKLC	  
labelled	  with	   FAM	   (SIINFEKLCFAM).	   SIINFEKLCFAM	  was	   also	   conjugated	   to	   unlabelled	  
CD40mAb	  for	  use	  as	  a	  control	  in	  the	  experiments	  carried	  out	  in	  Section	  5.4.2.	  	  
FAM	   used	   to	   label	   SIINFEKLC	  was	   also	  mixed	  with	   SMCC-­‐treated	  mAb	   in	   order	   to	  
ensure	   that	   the	   NHS-­‐ester	  was	   non-­‐reactive	   and	  would	   not	   also	   bind	   to	   the	  mAb	  
during	   FAM-­‐labelled	   peptide-­‐mAb	   conjugation	   (see	   Section	   2.2.1.5.3.).	   This	  will	   be	  
referred	  to	  as	  FAM+CD40mAb.	  
Confirmation	   of	   conjugation	   was	   performed	   by	   flow	   cytometric	   analysis	   on	  
CD40L929	  fibroblast	  cells	  (Figure	  5.12).	  	  Since	  the	  experiments	  carried	  out	  in	  Section	  
5.4.2	   just	   involved	   the	   addition	   of	   SIINFEKLCFAM-­‐CD40mAbDylight	   conjugate	   and	  
SIINFEKLCFAM-­‐GL117Dylight	  to	   the	  APCs	  without	   any	  washing	   steps,	   no	  washing	   steps	  
were	  carried	  out	  during	  staining	  with	  CD40L929	  cells.	  This	  was	  carried	  out	  to	  ensure	  
that	  a	   shift	  was	   still	  observed	  by	  SIINFEKLCFAM-­‐CD40mAbDylight	   conjugate	   relative	   to	  
SIINFEKLCFAM-­‐GL117Dylight	   conjugate,	   when	   excess	   unbound	   conjugate	   was	   not	  
removed.	  	  
A	   shift	   to	   the	   right	  of	   the	   SIINFEKLCFAM-­‐CD40mAbDylight	   and	   SIINFEKLCFAM-­‐CD40mAb	  
conjugate	   bound	   to	   the	   CD40L929	   cells,	   relative	   to	   SIINFEKLCFAM-­‐GL117Dylight	   and	  
SIINFEKLCFAM-­‐GL117	  (respectively)	  by	  both	  FAM	  (Figure	  5.12A,B)	  and	  Dylight	  (Figure	  
5.12C)	   histograms	   confirm	   conjugation.	   A	   shift	   to	   the	   right	   of	   the	   SIINFEKLCFAM-­‐
CD40mAbDylight	  and	  SIINFEKLCFAM-­‐CD40mAb	  conjugate	  was	  also	  observed	  relative	   to	  
FAM+CD40mAb	   indicating	   that	   FAM	   did	   not	   conjugate	   to	   the	   CD40mAb.	   The	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A.	   B. 	  
C.	   	  
Figure	   5.12.	   Fluorescence	   intensity	   of	   labelled	   SIINFEKLC-­‐CD40mAb	  conjugates	   bound	   to	  
CD40L929	   cells.	   A.	   Relative	   binding	   of	   SIINFEKLCFAM-­‐CD40mAb	   (solid,	   light	   green),	  
SIINFEKLCFAM-­‐GL117mAb	  (outline,	  light	  green)	  and	  FAM+CD40mAb	  (dark	  green)	  to	  CD40L929	  
cells.	   B.	   Relative	   binding	   of	   SIINFEKLCFAM-­‐CD40mAbDylight	   (solid,	   light	   green),	   SIINFEKLCFAM-­‐
GL117mAbDylight	  (outline,	  light	  green)	  and	  FAM+CD40mAb	  (dark	  green)	  to	  CD40L929	  cells.	  C.	  
Relative	  binding	  of	  SIINFEKLCFAM-­‐CD40mAbDylight	  (solid,	  red)	  and	  SIINFEKLCFAM-­‐GL117mAbDylight	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5.4.2. Targeting	   and	   uptake	   of	   fluorescently	   labelled	   SIINFEKLC-­‐
CD40mAb	   conjugates	   by	   BM-­‐DCs	   and	   B	   cells	   at	   different	   time-­‐
points	  
Fluorescently	   labelled	   SIINFEKLFAM-­‐CD40mAbDylight	   conjugates	   were	   used	   to	  
investigate	  whether	   both	   SIINFEKLFAM	   and	  CD40mAbDylight	  were	   co-­‐delivered	   to	   the	  
same	   APC	   in	   vitro	   using	   epifluorescence	   microscopy	   (see	   Section	   2.2.6.7.).	   	   To	  
investigate	  whether	  the	  uptake	  was	  time-­‐dependent	  BM-­‐DCs	  and	  splenocytes	  were	  
cultured	   in	   vitro	   in	   the	   presence	   of	   10μg/ml	   of	   SIINFEKLFAM-­‐CD40mAbDylight	   or	  
SIINFEKLFAM-­‐GL117Dylight	   (control	   conjugate)	   in	   a	   96-­‐well	   plate	   (in	   a	   total	   volume	  of	  
100μl),	   for	   5	   minutes	   or	   60	   minutes.	   SIINFEKLFAM-­‐CD40mAb	   and	   SIINFEKLFAM-­‐
GL117mAb	   as	   well	   as	   CD40mAbDylight	   and	   GL117Dylight	   were	   used	   as	   single	   stain	  
control	  samples	  to	  exclude	  autofluorescence.	  SIINFEKLCFAM	  (observed	  as	  green	  dots)	  
and	   mAbDylight	   (observed	   as	   red	   dots)	   co-­‐localised	   in	   or	   on	   the	   cell	   surface	   were	  
scored	  at	  each	  time-­‐point.	  	  
	  
5.4.2.1. Targeting	  and	  uptake	  of	  SIINFEKLFAM-­‐mAbDylight	  conjugates	  by	  BM-­‐DCs	  
Targeting	   and	   uptake	   of	   co-­‐labelled	   SIINFEKLC-­‐mAb	   conjugates	   by	   BM-­‐DCs	   was	  
investigated	   using	   normal	   wide-­‐field	   fluorescence	   microscopy.	   A	   representative	  
image	   of	   one	   BM-­‐DC	   stimulated	   with	   10μg/ml	   of	   SIINFEKLFAM-­‐CD40mAbDylight	   or	  
SIINFEKLFAM-­‐GL117Dylight	   at	   different	   time-­‐points	   is	   shown	   in	   Figure	   5.12.	   The	   co-­‐
localised	  Dylight	  (red	  dots)	  and	  FAM	  (green	  dots)	   inside	  the	  BM-­‐DCs	  or	  on	  the	  BM-­‐
DC	  surface	  were	  scored.	  The	  number	  of	  co-­‐localised	  mAb	  and	  SIINFEKL	  were	  counted	  
on	  twenty	  different	  BM-­‐DCs	  per	  field	  (in	  a	  total	  of	  six	  fields)	  
BM-­‐DCs	   stimulated	  with	   SIINFEKLFAM-­‐CD40mAbDylight	   for	   5	  minutes	   looked	  different	  
to	   the	   BM-­‐DCs	   stimulated	   for	   60	   minutes	   (Figure	   5.12A)	   in	   that	   the	   FAM	   dye	  
appeared	  brighter	  at	  5	  minutes	  than	  at	  60	  minutes,	  whilst	  the	  Dylight	  dye	  kept	  the	  
same	  intensity.	  This	   lead	  to	  the	  assumption	  that	  the	  SIINFEKLFAM	  might	  be	  directed	  
to	  a	  different	  cellular	  compartment	  of	  lower	  pH	  between	  5	  and	  60	  minutes	  causing	  
the	  intensity	  of	  the	  dye	  to	  be	  slightly	  quenched.	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There	   was	   a	   morphological	   difference	   between	   stimulation	   with	   SIINFEKLFAM-­‐
CD40mAbDylight	   or	   the	   SIINFEKLFAM-­‐GL117Dylight	   at	   both	   time	   points	   (Figure	   5.12B).	  
Both	   stimulated	   BM-­‐DCs	   showed	   co-­‐localised	   red	   and	   green	   dots,	   however,	   the	  
merged	   image	   of	   BM-­‐DCs	   stimulated	   at	   5	   minutes	   with	   SIINFEKLFAM-­‐GL117Dylight	  
showed	   brighter	   dots.	   This	   is	   an	   indication	   that	   the	   SIINFEKLFAM-­‐GL117Dylight	  
conjugate	  was	  being	  internalised	  by	  another	  route	  and	  present	  in	  a	  different	  cellular	  
compartment.	  In	  addition,	  whereas	  a	  decrease	  in	  FAM	  brightness	  was	  observed	  after	  
60	  minutes	  of	  stimulation	  with	  SIINFEKLFAM-­‐CD40mAbDylight,	  this	  decrease	  in	  intensity	  
was	  not	  observed	  by	  stimulation	  with	  SIINFEKLFAM-­‐GL117Dylight	  conjugate.	  In	  fact,	  on	  
closer	  examination	  of	   the	  SIINFEKLFAM-­‐GL117Dylight	  merged	   image,	  although	  red	  and	  
green	   dots	   were	   observed	   next	   to	   each	   other,	   they	   are	   not	   overlaid	   like	   the	  
SIINFEKLFAM-­‐CD40mAbDylight	   merged	   image.	   This	   could	   mean	   that	   SIINFEKLC	   and	  
GL117	  might	  not	  be	  still	  bound	  together.	  
After	   5	  minutes	   of	   BM-­‐DC	   stimulation	   the	   number	   of	   co-­‐localised	   SIINFEKLFAM	  and	  
mAbDylight	  on	  the	  surface	  or	  inside	  120	  BM-­‐DCs	  was	  statistically	  (p<0.0001,	  unpaired	  
Mann-­‐Whitney	   test)	   higher	   when	   cells	   were	   stimulated	   with	   SIINFEKLFAM-­‐
CD40mAbDylight	  than	  with	  SIINFEKLFAM-­‐GL117Dylight	  conjugate	  (Figure	  5.13A).	  The	  result	  
was	  not	  dependent	  on	  the	  field	  of	  view	  (Figure	  5.13B),	  as	  the	  average	  number	  of	  co-­‐
localised	  dots	  per	  cell	  counted	  between	  the	  different	  fields	  of	  view	  was	  similar,	  and	  a	  
significant	   difference	   (p<0.01,	   unpaired	  Mann-­‐Whitney	   test)	   between	   SIINFEKLFAM-­‐
CD40mAbDylight	  and	  SIINFEKLFAM-­‐GL117Dylight	   conjugate	  was	  still	  observed.	  Moreover,	  
10	  or	  more	   co-­‐localised	  dots	  were	   counted	   in	  98%	  of	   the	  BM-­‐DCs	   stimulated	  with	  
SIINFEKLFAM-­‐CD40mAbDylight	   conjugate	   and	   in	   51%	   on	   those	   stimulated	   with	  
SIINFEKLFAM-­‐GL117Dylight	  conjugate	  (Figure	  5.14).	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Figure	  5.12.	  Representative	   images	  of	  BM-­‐DCs	   incubated	  with	  SIINFEKLFAM-­‐CD40mAbDylight	  
conjugate	   (A)	   and	   SIINFEKLFAM-­‐GL117Dylight	   conjugate	   (B)	   for	   5	   minutes	   or	   60	   minutes.	  
Shown	  are	   fluorescence	  microscopy	   images	  of	   CD40mAbDylight	   or	  GL117Dylight	   component	  of	  
conjugate	   observed	   as	   red	   dots,	   SIINFEKLCFAM	   component	   of	   conjugate	   observed	   as	   green	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A. 	  
B.	   	  
Figure	   5.13.	   Quantification	   of	   co-­‐localised	   SIINFEKLCFAM-­‐mAbDylight	   conjugates	   in	   BM-­‐DCs	  
after	   5	   minutes	   of	   incubation	   in	   vitro.	   The	   number	   of	   co-­‐localised	   mAb	   and	   SIINFEKLC	  
internalised	   or	   on	   BM-­‐DC	   surface	  were	   counted	   on	   20	   cells	   per	   field	   of	   view	   (total	   of	   six	  
fields).	  A.	  Pooled	  data	  of	  all	   fields	  of	  view	   (120	  cells).	  B.	  The	  mean	  number	  of	  co-­‐localised	  
mAb	  and	  SIINFEKLC	  in	  each	  cell	  in	  each	  of	  the	  six	  fields	  of	  view.	  An	  unpaired	  Mann-­‐Whitney	  













































































Figure	  5.14.	  Percentage	  of	  cells	  containing	  co-­‐localised	  SIINFEKLC	  and	  mAb	  after	  5	  minutes	  
of	  incubation.	  The	  number	  of	  cells	  containing	  >10	  (red	  or	  blue)	  and	  ≤10	  (black)	  co-­‐localised	  
mAb	  and	  SIINFEKL	  are	  shown	  as	  a	  percentage	  of	  all	  the	  cells	  counted	  in	  the	  six	  fields	  of	  view.	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After	   60	   minutes	   stimulation	   of	   BM-­‐DCs	   with	   fluorescently	   labelled	   conjugates,	  
results	   were	   similar	   to	   the	   results	   observed	   after	   5	   minutes	   of	   stimulation.	   The	  
number	  of	   co-­‐localised	  SIINFEKLFAM	  and	  mAbDylight	  targeting	  and	   internalised	  by	  120	  
BM-­‐DCs	  was	  statistically	  higher	  (p<0.0001,	  unpaired	  Mann-­‐Whitney	  test)	  when	  cells	  
were	   stimulated	  with	   SIINFEKLFAM-­‐CD40mAbDylight	   than	  with	   SIINFEKLFAM-­‐GL117Dylight	  
conjugate	  (Figure	  5.15A).	  The	  result	  was	  not	  dependent	  on	  the	  field	  of	  view	  (Figure	  
5.15B,	   p<0.01,	   unpaired	   Mann-­‐Whitney	   test).	   The	   number	   of	   co-­‐localised	   dots	  
counted	   in	   BM-­‐DCs	   stimulated	   with	   SIINFEKLFAM-­‐GL117Dylight	   conjugate	   did	   not	  
increase	  after	  60	  minute	  incubation	  and	  was	  still	  observed	  in	  52%	  of	  all	  cells	  (Figure	  
5.16).	  Uptake	  of	  SIINFEKLFAM-­‐CD40mAbDylight	  conjugate	  was	  time-­‐dependent	  (p<0.01,	  
two-­‐tailed,	   unpaired	   Mann-­‐Whitney	   test)	   (Figure	   5.17).	   Even	   though	   the	   results	  
showed	   that	   targeting	   and	   uptake	   occurs	   very	   quickly	   (after	   5	   minutes),	   after	   60	  
minute	   stimulation	   cells	   internalise	  an	   increased	  amount	  of	   conjugate,	   in	   fact	  10%	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A. 	  
B. 	  
Figure	   5.15.	   Quantification	   of	   co-­‐localised	   SIINFEKLCFAM-­‐mAbDylight	   conjugates	   in	   BM-­‐DCs	  
after	   a	   60	   minute	   incubation	   in	   vitro.	   The	   number	   of	   co-­‐localised	   mAb	   and	   SIINFEKL	  
internalised	  or	  on	  BM-­‐DC	  surface	  were	  counted	  on	  20	  cells	  in	  six	  fields	  of	  view	  (a	  total	  of	  120	  
cells).	   A.	   Pooled	   data	   of	   all	   fields	   of	   view.	   B.	   The	  mean	   number	   of	   co-­‐localised	  mAb	   and	  
SIINFEKL	   in	  each	  cell	   in	  each	  of	  the	  six	   fields	  of	  view.	  An	  unpaired	  Mann-­‐Whitney	  test	  was	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A.	   B. 	  
Figure	  5.16.	  Percentage	  of	  cells	  containing	  co-­‐localised	  SIINFEKLC	  and	  mAb	  after	  60	  minute	  
incubation.	  The	  number	  of	  cells	  containing	  >	  10	  (red	  or	  blue)	  and	  ≤	  10	  (black)	  co-­‐localised	  
mAb	  and	  SIINFEKL	  are	  shown	  as	  a	  percentage	  number	  of	  all	  the	  cells	  counted	  in	  the	  six	  fields	  




Figure	  5.17.	  Time	  dependent	  uptake	  by	  BM-­‐DC	  stimulated	  with	  SIINFEKLFAM-­‐CD40mAbDylight	  
conjugate.	  The	  number	  of	  co-­‐localised	  mAb	  and	  SIINFEKL	  internalised	  or	  on	  BM-­‐DC	  surface	  
were	   counted	  on	  20	   cells	   in	   six	   fields	  of	   view.	  The	  mean	  number	  of	   co-­‐localised	  mAb	  and	  
SIINFEKL	   in	  each	  cell	   in	  each	   field	  of	  view,	  after	  5	  minutes	   (pale	  red)	  and	  60	  minutes	   (red)	  
incubation	   is	   shown.	   An	   unpaired	   Mann-­‐Whitney	   test	   was	   used	   to	   determine	   statistical	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5.4.2.2. Targeting	  and	  uptake	  of	  SIINFEKLFAM-­‐mAbDylight	  conjugates	  by	  B	  cells	  	  
The	   study	   was	   expanded	   to	   investigate	   targeting	   and	   uptake	   of	   co-­‐labelled	  
SIINFEKLC-­‐mAb	  conjugates	  by	  B	  cells.	  A	  representative	  image	  of	  one	  B	  cell	  stimulated	  
with	   10μg/ml	   of	   SIINFEKLFAM-­‐CD40mAbDylight	   or	   SIINFEKLFAM-­‐GL117Dylight	   at	   different	  
time-­‐points	   is	  shown	   in	  Figure	  5.18.	  As	  splenocytes	  were	  used	   in	  this	  experimental	  
setup,	  a	  CD19+	  marker	  was	  used	  to	   identify	   the	  B	  cells	   (visualised	   in	  blue).	  The	  co-­‐
localised	  Dylight	  (red)	  and	  FAM	  (green)	  dots	  within	  the	  CD19+	  B	  cell	  stimulated	  with	  
SIINFEKLFAM-­‐CD40mAbDylight	   or	   SIINFEKLFAM-­‐GL117Dylight	   for	   5	   and	   60	   minutes	   were	  
scored	  (see	  Section	  2.2.6.7.2.).	  Co-­‐localised	  red	  and	  green	  dots	  observed	  inside	  or	  on	  
the	  surface	  of	  B	  cells	  when	  stimulated	  with	  SIINFEKLFAM-­‐CD40mAbDylight	  for	  5	  minutes	  
were	   dimmer	   than	   after	   60	   minute	   stimulation	   (Figure	   5.18A),	   possibly	   indicating	  
that	   the	   conjugates	   were	   only	   internalised	   after	   5	   minutes	   of	   incubation.	  
Interestingly,	   the	   opposite	   occurred	   in	   B	   cells	   stimulated	   with	   SIINFEKLFAM-­‐
GL117Dylight	  (Figure	  5.18B).	  This	  could	  be	  due	  to	  the	   isotype-­‐control	  conjugate	  being	  
internalised	   by	   another	   mechanism	   (not	   via	   the	   CD40	   receptor),	   and	   therefore	  
processed	  differently.	  	  
Fewer	  cells	  were	  observed	  in	  each	  field	  of	  view	  compared	  to	  the	  BM-­‐DC	  experiments	  
because	  the	  magnification	  used	  was	  higher.	  Therefore	  the	  maximum	  number	  of	  cells	  
per	   field	   (in	   a	   total	   of	   six	   fields)	  were	   scored.	   This	   resulted	   in	   a	   total	   of	   112	   cells	  
counted	   for	   SIINFEKLFAM-­‐CD40mAbDylight	   conjugate	   group	  and	   a	   total	   of	   76	   cells	   for	  
the	   SIINFEKLFAM-­‐GL117Dylight	   conjugate	   group	   (Figure	   5.19).	   The	   number	   of	   B	   cell	  
surface	   or	   internalised	   co-­‐localised	   SIINFEKLFAM	  and	  mAbDylight	   was	   not	   significantly	  
different	  when	  cells	  were	  stimulated	  for	  5	  minutes	  with	  SIINFEKLFAM-­‐CD40mAbDylight	  
than	  with	  SIINFEKLFAM-­‐GL117Dylight	  conjugate	  (Figure	  5.19A).	  Figure	  5.19B	  shows	  that	  
the	  number	  of	  co-­‐localised	  dots	  varies	  between	  the	  different	  fields	  of	  view	  ranging	  
from	  an	  average	  of	  1.5	  per	  field	  to	  6.5	  per	  field.	  In	  addition,	  there	  was	  no	  difference	  
in	   the	   percentage	   of	   co-­‐localised	   dots	   observed	   with	   SIINFEKLFAM-­‐CD40mAbDylight	  











Figure	   5.18.	   Representative	   images	   of	   B	   cells	   incubated	   with	   SIINFEKLFAM-­‐CD40mAbDylight	  
conjugate	  (A)	  and	  SIINFEKLFAM-­‐GL117Dylight	  conjugate	  (B)	  for	  5	  minutes	  and	  60	  minutes	  at	  a	  
magnification	   of	   X40.	   Shown	   are	   fluorescence	   microscopy	   images	   of	   CD40mAbDylight	   or	  
GL117Dylight	   component	   of	   conjugate	   observed	   as	   red	   dots,	   SIINFEKLCFAM	   component	   of	  
conjugate	  observed	  as	  green	  dots,	  CD19+	  B	  cells	  observed	  in	  blue	  and	  an	  overlay	  or	  merged	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A. 	  
B.	   	  
Figure	   5.19.	   Quantification	   of	   co-­‐localised	   SIINFEKLCFAM-­‐mAbDylight	   conjugates	   in	   B	   cells	  
after	   a	   5	   minute	   incubation	   in	   vitro.	   The	   number	   of	   co-­‐localised	   mAb	   and	   SIINFEKL	  
internalised	  or	   on	  B	   cell	   surface	  were	   counted	  on	  10-­‐20	  CD19+	   cells	   per	   field	   of	   view	   in	   a	  
total	  of	   six	   fields	  of	   view.	  A.	  Pooled	  data	  of	   all	   fields	  of	   view.	  B.	   The	  mean	  number	  of	   co-­‐
localised	  mAb	  and	   SIINFEKL	   in	   each	   cell	   in	   each	   field	  of	   view.	  An	  unpaired	  Mann-­‐Whitney	  









































































A.	   	  
B.	   	  
Figure	  5.20.	  Percentage	  of	  cells	  containing	  co-­‐localised	  SIINFEKLC	  and	  mAb	  after	  5	  minutes	  
of	   incubation.	  The	  number	  of	  cells	  containing	  >5	  and	  ≤5	  co-­‐localised	  mAb	  and	  SIINFEKL	  are	  
shown	   as	   a	   percentage	   number	   of	   all	   the	   cells	   counted	   in	   the	   six	   fields	   of	   view.	   A.	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After	  60	  minutes	  of	  stimulation	  CD19+	  B	  cells	  showed	  significantly	  increased	  (p<0.01,	  
unpaired	   Mann-­‐Whitney	   test)	   co-­‐localised	   red	   and	   green	   dots	   with	   SIINFEKLFAM-­‐
CD40mAbDylight	   conjugate	   compared	   to	   SIINFEKLFAM-­‐GL117Dylight	   conjugate	   (Figure	  
5.21A).	  The	  mean	  number	  of	  co-­‐localised	  dots	  per	  cell	  (Figure	  5.21B)	  in	  each	  field	  is	  
less	   variable	   compared	   to	   results	   observed	   after	   5	   minutes	   of	   incubation	   (Figure	  
5.19).	   However,	   interestingly,	   this	   difference	   was	   not	   due	   to	   increased	   uptake	   of	  
SIINFEKLFAM-­‐CD40mAbDylight.	   In	   fact	   the	   mean	   number	   of	   co-­‐localised	   dots	   did	   not	  
increase.	   The	   difference	   was	   due	   to	   the	   fact	   that	   the	   co-­‐localised	   dots	   on	   B	   cells	  
stimulated	   with	   SIINFEKLFAM-­‐GL117Dylight	   conjugate	   decreased	   after	   60	   minutes	   of	  
incubation	  (Figure	  5.22).	  The	  number	  of	  cells	  stimulated	  with	  SIINFEKLFAM-­‐GL117Dylight	  
containing	   >5	   dots	   decreased	   to	   12%	   from	   29%	   observed	   after	   5	   minutes	   of	  
incubation.	  Targeting	  and	  uptake	  at	  5	  minutes	  and	  at	  60	  minutes	  only	  varied	  slightly	  
on	  stimulation	  with	  the	  SIINFEKLFAM-­‐CD40mAbDylight	  conjugate	  (Figure	  5.23),	  possibly	  
because	   the	   B	   cells	   were	   already	   saturated	   with	   SIINFEKLFAM-­‐CD40mAbDylight	  
conjugate	  after	  5	  minutes.	  However,	  a	  significant	  difference	  was	  observed	  between	  
stimulation	   with	   SIINFEKLFAM-­‐CD40mAbDylight	   conjugate	   and	   SIINFEKLFAM-­‐GL117Dylight	  
conjugate	   at	   60	   minutes	   (p<0.01,	   unpaired	   Dunn’s	   multiple	   comparison	   test),	  

















B.	   	  
Figure	   5.21.	   Quantification	   of	   co-­‐localised	   SIINFEKLCFAM-­‐mAbDylight	   conjugates	   in	   B	   cells	  
after	   a	   60	   minute	   incubation	   in	   vitro.	   The	   number	   of	   co-­‐localised	   mAb	   and	   SIINFEKL	  
internalised	  or	  on	  B	  cell	  surface	  were	  counted	  on	  10-­‐20,	  CD19+	  cells	  in	  six	  fields	  of	  view.	  A.	  
Pooled	  data	  of	  all	   fields	  of	  view.	  B.	  The	  mean	  number	  of	  co-­‐localised	  mAb	  and	  SIINFEKL	   in	  
each	   cell	   in	   each	   field	   of	   view.	   An	   unpaired	   Mann-­‐Whitney	   test	   was	   used	   to	   determine	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A. B 	  
Figure	  5.22.	  Percentage	  of	  cells	  containing	  co-­‐localised	  SIINFEKLC	  and	  mAb	  after	  60	  minute	  
incubation.	  The	  number	  of	  cells	  containing	  >5	  and	  ≤5	  co-­‐localised	  antibody	  and	  SIINFEKL	  are	  
shown	   as	   a	   percentage	   of	   all	   the	   cells	   counted	   in	   the	   six	   fields	   of	   view.	   A.	   SIINFEKLFAM-­‐
CD40mAbDylight	  percentage	  uptake.	  B.	  SIINFEKLFAM-­‐GL117Dylight	  percentage	  uptake.	  	  	  
	  
	  
Figure	   5.23.	   Time	   dependent	   uptake	   by	   B	   cells	   stimulated	   with	   SIINFEKLFAM-­‐mAbDylight	  
conjugate.	  The	  number	  of	  co-­‐localised	  mAb	  and	  SIINFEKLC	  internalised	  or	  on	  B	  cell	  surface	  
were	  counted	  in	  six	  fields	  of	  view.	  The	  mean	  number	  of	  co-­‐localised	  antibody	  and	  SIINFEKL	  
in	  each	  cell	   in	  each	   field	  of	  view,	  after	  5	  minutes	   (pale	   red	  and	  pale	  blue)	  and	  60	  minutes	  
(dark	   red	   and	   dark	   blue)	   incubation	   is	   shown.	   SIINFEKLFAM-­‐CD40mAbDylight	   is	   shown	   in	   red.	  
SIINFEKLFAM-­‐GL117Dylight	   is	   shown	   in	   blue.	   	   An	   unpaired	   Dunn’s	   (non-­‐parametric)	   multiple	  
comparison	  test	  was	  used	  to	  determine	  statistical	  significance	  (mean	  +/-­‐	  SD).	  *p<0.05.	  
Total=100
>5 red and green dots per cell




>5 red and green dots per cell








































































	   226	  
5.5. Effect	  of	  CD40mAb	  on	  B	  cell	  and	  DC	  antigen	  presentation	  
to	  B3Z	  T	  hybridoma	  cells	  
The	  effect	  that	  SIINFEKLC-­‐mAb	  conjugates,	  SIINFEKL	  peptide	  and	  CD40mAb	  mixtures	  
had	  on	  B	  cell	  and	  BM-­‐DC	  antigen-­‐presentation	  to	  T	  cells	  in	  vitro	  was	  investigated,	  as	  
was	  the	  ability	  of	  DCs	  or	  B	  cells	  to	  cross-­‐present	  SIINFEKL	  to	  the	  OVA-­‐specific	  B3Z	  T	  
hybridoma	  cells	  (see	  Section	  2.2.6.8.).	  Splenocytes	  were	  primarily	  used	  in	  co-­‐culture	  
with	   B3Z	   cells	   to	   establish	   the	   optimal	   concentration	   at	   which	   the	   SIINFEKLC-­‐
CD40mAb	  conjugate	  or	  mixture	  to	  be	  used	  in	  vitro.	  
Firstly,	  105	  splenocytes	  were	  stimulated	  with	  a	  mixture	  of	  CD40mAb	  (or	  GL117mAb)	  
and	   SIINFEKL	   at	   a	   starting	   concentration	   of	   20μg/ml	   and	   2μg/ml	   respectively,	   and	  
secondly	   SIINFEKLC-­‐CD40mAb	   and	   SIINFEKLC-­‐GL117	   conjugates	   starting	   at	   a	  
concentration	  of	  20μg/ml.	  Two	  fold	  dilutions	  were	  then	  made	  to	  a	  concentration	  of	  
1.25μg/ml	  (mAb	  or	  SIINFEKL-­‐mAb	  conjugate)	  and	  0.125μg/ml	  (SIINFEKL).	  
Splenocytes	  were	  stimulated	  for	  2	  hours	  (Figure	  5.24),	  18	  hours	  (results	  not	  shown)	  
and	  24	  hours	  (results	  not	  shown)	  prior	  to	  addition	  of	  B3Z	  hybridoma	  cells.	  After	  the	  
stimulation	  period,	  105	  B3Z	  cells	  were	  added,	  and	  co-­‐cultured	  with	  the	  splenocytes	  
in	   a	   total	   volume	   of	   200μl	   for	   24	   hours.	   Figure	   5.24A	   shows	   that	   CD40mAb	   with	  
SIINFEKL	   peptide	   as	   a	   mixture	   significantly	   enhanced	   antigen	   presentation	   to	   B3Z	  
cells	   compared	   to	   the	   isotype	   antibody	   control	   mixture.	   This	   difference	   was	  
observed	  down-­‐to	  a	  concentration	  of	  2.5μg/ml	  CD40mAb	  and	  0.125μg/ml	  SIINFEKL	  
peptide	   mixture	   (p<0.05,	   unpaired	   two-­‐tailed	   Student	   t	   test).	   This	   difference	   was	  
observed	  at	  all	  stimulation	  time	  points.	  	  Interestingly,	  SIINFEKLC-­‐CD40mAb	  conjugate	  
did	   not	   enhance	   antigen	   presentation	   to	   B3Z	   cells	   compared	   to	   SIINFEKLC-­‐GL117	  
conjugates	  (ns,	  unpaired	  two-­‐tailed	  Student	  t	  test).	  	  
To	   ensure	   that	   the	   latter	   result	   was	   not	   due	   to	   low	   splenocyte	   viability,	   SIINFEKL	  
peptide	  was	   also	   added	   to	   the	   SIINFEKLC-­‐mAb	   conjugates	   to	   observe	   if	   CD40mAb	  
enhanced	   antigen-­‐presentation	   (Figure	   5.25).	   Therefore,	   105	   splenocytes	   were	  
stimulated	   with	   20µg/ml,	   10µg/ml,	   5µg/ml,	   2.5µg/ml	   or	   1.25µg/ml	   SIINFEKLC-­‐
CD40mAb	   or	   SIINFEKLC-­‐GL117	   conjugates	   as	   well	   as	   2µg/ml,	   1µg/ml,	   0.5µg/ml,	  
0.25µg/ml	   or	   0.125µg/ml	   SIINFEKL	   peptide	   (respectively).	   Again,	   splenocytes	  were	  
CHAPTER	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stimulated	   for	   2	   hours	   (Figure	   5.25),	   18	   hours	   (results	   not	   shown)	   and	   24	   hours	  
(results	  not	   shown)	  prior	   to	  addition	  of	  B3Z	  hybridoma	  cells.	  After	   the	   stimulation	  
period,	  105	  B3Z	  cells	  were	  added,	  and	  co-­‐cultured	  in	  a	  total	  volume	  of	  200μl	  for	  24	  
hours.	  The	  addition	  of	  SIINFEKL	  peptide	  showed	  that	   the	  SIINFEKL-­‐mAb	  conjugates	  
were	  not	  having	  a	  detrimental	  effect	  on	  the	  splenocytes	  (Figure	  5.25).	  Once	  SIINFEKL	  
peptide	   was	   included	   a	   difference	   in	   the	   antigen-­‐presentation	   between	   the	  
SIINFEKLC-­‐CD40mAb	   and	   SIINFEKLC-­‐GL117	   conjugates	   was	   observed	   down	   to	   the	  
concentration	   of	   1.25µg/ml	   (p<0.01,	   unpaired	   two-­‐tailed	   Student	   t	   test).	   This	   was	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Figure	   5.24.	   Co-­‐culture	   of	   splenocytes	   stimulated	   with	   SIINFEKLC-­‐mAb	   conjugate	   or	  
SIINFEKL	  and	  mAb	  mixtures,	  and	  B3Z	  T	  cell	  hybridomas.	  The	  concentration	  of	  IL-­‐2	  produced	  
by	   B3Z	   after	   24	   hour	   co-­‐culture	   is	   shown.	   Splenocytes	   stimulated	   with	   2µg/ml	   (2µM)	  
SIINFEKL	  peptide	  (dashed	  red)	  served	  as	  a	  positive	  control.	  No	  stimulation	  or	  stimulation	  of	  
splenocytes	   with	   20µg/ml	   of	   CD40mAb	   only	   or	   GL117mAb	   only	   (black	   bars)	   served	   as	  
negative	  controls.	  Splenocytes	  were	  stimulated	  with	  four	  series	  of	  two-­‐fold	  dilutions	  starting	  
at	   20µg/ml	   CD40mAb	   and	   2µg/ml	   SIINFEKL	   peptide	   mixture	   (blue)	   or	   GL117mAb	   and	  
SIINFEKL	   peptide	   mixture	   (black	   with	   blue	   background).	   Splenocytes	   stimulated	   with	  
20µg/ml	  (1),	  10µg/ml	  (2),	  5µg/ml	  (3),	  2.5µg/ml	  (4)	  or	  1.25µg/ml	  (5)	  of	  SIINFEKLC-­‐CD40mAb	  
(red)	  and	  SIINFEKLC-­‐GL117	  (black	  with	  red	  background)	  conjugates	  are	  shown.	  Splenocytes	  
were	  stimulated	  with	  all	  stimulants	  for	  2	  hours	  prior	  to	  co-­‐culture	  with	  B3Z.	  	  Unpaired	  two-­‐
tailed	   Student’s	   t-­‐test	   was	   used	   to	   determine	   statistical	   significance	   (mean	   +/-­‐	   SD).	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Figure	   5.25.	   Co-­‐culture	   of	   splenocytes	   stimulated	   with	   different	   concentrations	   of	  
SIINFEKLC-­‐mAb	  conjugate	  in	  the	  absence	  or	  presence	  of	  SIINFEKL	  peptide,	  with	  B3Z	  T	  cell	  
hybridomas.	   The	   ability	   of	   B3Z	   to	   produce	   IL-­‐2	   after	   24	   hour	   co-­‐culture	   is	   shown.	  
Splenocytes	   stimulated	   with	   2µg/ml	   (2µM)	   SIINFEKL	   peptide	   (dashed	   red)	   served	   as	   a	  
positive	   control.	   No	   stimulation	   or	   stimulation	   of	   splenocytes	   with	   20µg/ml	   of	   CD40mAb	  
only	   or	   GL117	  mAb	   only	   (black	   bars)	   served	   as	   negative	   controls.	   Splenocytes	   stimulated	  
with	   20µg/ml	   (1),	   10µg/ml	   (2),	   5µg/ml	   (3),	   2.5µg/ml	   (4)	   or	   1.25µg/ml	   (5)	   of	   SIINFEKLC-­‐
CD40mAb	   (red)	   and	   SIINFEKLC-­‐GL117mAb	   (black	   with	   red	   background)	   conjugates	   are	  
shown.	   Splenocytes	   stimulated	  with	   the	   same	   concentrations	   of	   SIINFEKLC-­‐CD40mAb	   (red	  
dotted)	   and	   SIINFEKLC-­‐GL117mAb	   (blue	   dotted)	   conjugates	   each	   with	   the	   addition	   of	  
2µg/ml,	  1µg/ml,	  0.5µg/ml,	  0.25µg/ml	  or	  0.125µg/ml	  SIINFEKL	  peptide	  is	  shown.	  Splenocytes	  
were	  stimulated	  for	  2	  hours	  prior	  to	  the	  addition	  of	  B3Z.	   	  Unpaired	  two-­‐tailed	  Student’s	  t-­‐
test	   was	   used	   to	   determine	   statistical	   significance	   (mean	   +/-­‐	   SD).	   ****	   p<0.0001,	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As	   the	   CD40mAb	   and	   SIINFEKL	   mixtures,	   but	   not	   the	   SIINFEKLC-­‐CD40mAb	  
conjugates,	   enhanced	   antigen	   presentation	   to	   B3Z,	   the	   co-­‐culture	   experiment	  was	  
repeated	   and	   the	   SIINFEKL	   presentation	   on	   MHC	   class	   I	   was	   analysed	   by	   flow	  
cytometry	  (see	  Section	  2.2.6.8.2.).	  The	  highest	  concentrations	  of	  20µg/ml	  SIINFEKLC-­‐
mAb	  conjugates,	  or	  2µg/ml	   SIINFEKL	  and	  20µg/ml	  mAb	  mixture	  were	  used.	   In	   this	  
experiment	  the	  APCs	  relevant	  for	  this	  chapter	  were	  investigated	  by	  gating	  on	  CD19+	  
CD86+	  cells	  (Figure	  5.29A)	  and	  CD11c+	  CD86+	  cells	  (Figure	  5.29B),	  presenting	  SIINFEKL	  
bound	  to	  MHC	  class	  I	  (see	  gating	  strategy	  in	  Section	  2.2.6.8.2).	  The	  supernatants	  of	  
the	   co-­‐cultures	   used	   for	   the	   flow	   cytometry	   experiment	   were	   analysed	   for	   IL-­‐2	  
measured	   by	   ELISA.	   The	   results	   were	   consistent	   with	   the	   previous	   results	   (not	  
shown).	  
Consistent	  with	   results	   shown	   by	   IL-­‐2	   ELISA	   (Figure	   5.24),	   activated	   splenic	   B	   cells	  
(Figure	   5.26A)	   and	   DCs	   (Figure	   5.26B)	   stimulated	   with	   SIINFEKL	   and	   CD40mAb	  
mixture	   presented	   significantly	   more	   (**p<0.01,	   unpaired,	   two-­‐tailed	   Student’s	   t-­‐
test)	  SIINFEKL	  on	  their	  MHC	  class	   I	   than	   isotype	  control	  mAb	  mixture.	   Interestingly	  
however,	   in	   contrast	  with	   the	   results	   shown	   by	   IL-­‐2	   ELISA	   (Figure	   5.24),	   activated	  
splenic	   B	   cells	   and	   DCs	   stimulated	   with	   SIINFEKLC-­‐CD40mAb	   conjugate	   presented	  
significantly	  more	  (**p<0.01,	  unpaired,	  two-­‐tailed	  Student’s	  t-­‐test)	  SIINFEKL	  on	  their	  
MHC	   class	   I	   compared	   to	   the	   SIINFEKLC-­‐GL117mAb	   conjugate.	   Due	   to	   this	  
development,	   we	   considered	   the	   fact	   that	   the	   IL-­‐2	   ELISA	   used	   was	   not	   sensitive	  
enough	   to	   detect	   accurately	   low	   concentrations	   of	   IL-­‐2	   produced	   by	   B3Z	   cells.	  
Therefore,	   splenocytes,	   BM-­‐DCs	   and	   positively-­‐selected	   B	   cells	   stimulated	   with	  
SIINFEKLC-­‐CD40mAb	  conjugate	  concentrations	  as	  high	  as	  100μg/ml	  were	  co-­‐cultured	  
with	   B3Z	   (results	   not	   shown).	   Still,	   however	   there	   was	   no	   difference	   in	   the	   IL-­‐2	  
concentration	  in	  the	  supernatants	  of	  SIINFEKLC-­‐CD40mAb	  conjugate-­‐stimulated	  and	  












A.	   B.	   	  
Figure	   5.26.	   Flow	   cytometry	   analysis	   demonstrating	   the	   effect	   CD40mAb	   had	   on	   the	  
antigen-­‐presenting	  capacity	  of	  splenic	  CD19+	  and	  CD11c+	  cells.	  Splenocytes	  stimulated	  with	  
2µg/ml	   (2µM)	   SIINFEKL	   peptide	   (dashed	   red)	   served	   as	   a	   positive	   control.	   Stimulation	   of	  
splenocytes	   with	   20µg/ml	   of	   CD40mAb	   or	   GL117mAb	   only	   (grey	   bars)	   served	   as	   negative	  
controls.	   Splenocytes	   stimulated	   with	   2µg/ml	   SIINFEKL	   and	   20µg/ml	   CD40mAb	   (blue)	   or	  
GL117mAb	   (black	  with	   blue	   background)	  mixture	   are	   shown.	   Splenocytes	   stimulated	  with	  
20µg/ml	   SIINFEKL-­‐CD40mAb	   (red)	   and	   SIINFEKL-­‐GL117mAb	   (black	   with	   red	   background)	  
conjugates	   are	   shown.	   Splenocytes	   were	   stimulated	   for	   4	   hours.	   	   MFI	   of	   H-­‐2Kb/SIINFEKL	  
expression	   on	   CD86+	   CD19+	   cells	   (A)	   and	   the	  MFI	   of	   H-­‐2Kb/SIINFEKL	   expression	   on	   CD86+	  
CD11c+	   cells	   are	   shown.	   Unpaired	   two-­‐tailed	   Student’s	   t-­‐test	   was	   used	   to	   determine	  
statistical	   significance	   (mean	  +/-­‐	   SD).	   **	  p<0.01.	   This	   figure	   represents	   three	  experiments.	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5.6. Investigation	  into	  CD40mAb-­‐adjuvanted	  conjugate	  uptake	  
and	  activation	  of	  B	  cells	  and	  BM-­‐DCs	  in	  vivo	  
The	   in	   vitro	  work	   conducted	   in	   this	   chapter	   supported	   the	   hypothesis	   that	   both	  B	  
cells	  and	  DCs	  can	  potentially	  play	  a	  role	  in	  the	  adjuvant	  effect	  of	  antigen-­‐CD40mAb-­‐	  
conjugates.	  We	   therefore	  moved	  on	   to	   test	   the	  hypothesis	   in	   vivo	   by	   investigating	  
the	  effect	  SIINFEKLC-­‐CD40mAb	  had	  on	  the	  capacity	  of	  DCs	   to	   take	  up	  antigen	  and,	  
after	   activation,	  migrate	   to	   the	  draining	   lymph	  nodes.	   In	   addition,	  we	   investigated	  
whether	   lymph	   node-­‐resident	   B	   cells	   also	   become	   activated	   after	   subcutaneous	  
injection	   with	   the	   SIINFEKLC-­‐CD40mAb	   conjugate.	   This	   was	   investigated	   by	  
subcutaneously	  immunising	  C57Bl/6	  or	  BALB/c	  mice	  with	  10μg	  SIINFEKLC-­‐CD40mAb	  
conjugate	   on	   the	   right	   flank	   and	   10μg	   SIINFEKLC-­‐GL117mAb	   conjugate	   on	   the	   left	  
flank	   (Figure	   5.27,	   see	   Section	   2.2.7.6.1.).	   The	  draining	   inguinal	   lymph	  nodes	  were	  
harvested	  after	  24	  hours	  and	   the	   levels	  of	   the	   co-­‐stimulatory	  molecule	  CD86	  on	  B	  
cells	  and	  DCs	  was	  analysed	  by	  flow	  cytometry	  (see	  Section	  2.2.7.6.2.).	  The	  presence	  
of	  SIINFEKLC	  bound	  to	  H-­‐2Kb	  on	  non-­‐activated	  CD19+	  and	  CD11c+	  cells	  or	  on	  CD19+	  
and	  CD11c+	  cells	  with	  enhanced	  co-­‐stimulatory	  molecule	  expression	  in	  the	  draining	  
lymph	   node	   was	   analysed	   with	   an	   anti-­‐mouse	   H-­‐2Kb	   bound	   to	   SIINFEKL	   antibody	  
(Figure	  5.28).	  Results	  showed	  that	  there	  was	  no	  difference	  in	  SIINFEKLC	  presentation	  
on	  MHC	   class	   I	   of	   activated	   or	   non-­‐activated	   B	   cells	   or	   DCs	   between	   the	   draining	  
lymph	   nodes	   of	   right	   (SIINFEKLC-­‐CD40mAb	   conjugate	   immunised)	   or	   left	   flank	  
(SIINFEKLC-­‐GL117mAb	   conjugate	   immunised).	   Interestingly	   however,	   SIINFEKLC-­‐
CD40mAb	   conjugate	   significantly	   upregulated	   CD86	   expression	   on	   B	   cells	   in	   the	  
draining	  lymph	  node	  compared	  to	  the	  SIINFEKLC-­‐GL117	  control	  (Figure	  5.29A).	  This	  



















A.	   B.	   	  
C.	   	  D.	   	  
Figure	  5.28.	  The	  ability	  of	  SIINFEKL-­‐mAb	  conjugates	  to	  modulate	  antigen-­‐presentation	  of	  B	  
cells	   and	   DCs.	   C57Bl/6	   mice	   were	   subcutaneously	   immunised	   with	   10μg	   SIINFEKLC-­‐
CD40mAb	  conjugate	  on	  the	  right	  flank	  and	  SIINFEKLC-­‐GL117	  conjugate	  on	  the	  left	  flank.	  The	  
effect	   of	   SIINFEKLC-­‐CD40mAb	   (red)	   or	   SIINFEKLC-­‐GL117	   (blue)	   on	   lymph	   node:	   A.	   B	   cell	  
SIINFEKL	  presentation,	  B.	  DC	  SIINFEKL	  presentation,	  C.	  Activated	  B	  cell	  SIINFEKL	  presentation	  
and	  D.	  Activated	  DC	  SIINFEKL	  presentation,	  are	  shown.	  A	  paired	  two-­‐tailed	  student’s	  t-­‐test	  
was	  used	  to	  determine	  statistical	  significance	  (mean	  +/-­‐	  SD).	  ns=non-­‐significant.	  This	  figure	  
represents	   results	   from	   two	   separate	   experiments,	   and	   a	   total	   of	   5	   mice.	   Each	   dot	  





















































































































































A.	   	  
B.	  	   	  
Figure	  5.29.	  Effect	  of	  the	  SIINFEKL-­‐mAb	  conjugates	  on	  the	  activation	  status	  of	  B	  cells	  and	  
DCs.	   C57Bl/6	   or	   BALB/c	   mice	   were	   subcutaneously	   immunised	   with	   10μg	   SIINFEKLC-­‐
CD40mAb	  conjugate	  on	  the	  right	  flank	  and	  SIINFEKLC-­‐GL117mAb	  conjugate	  on	  the	  left	  flank.	  
The	  effect	   of	   SIINFEKLC-­‐CD40mAb	   (red)	   or	   SIINFEKLC-­‐GL117mAb	   (blue)	   on	   lymph	  node:	  A.	  
Activation	   status	  of	  B	   cells	   and	  B.	  Activation	   status	  of	  DCs	  are	   shown.	  A	  paired	   two-­‐tailed	  
Student’s	   t-­‐test	   was	   used	   to	   determine	   statistical	   significance	   (mean	   +/-­‐	   SD).	   **p<0.01.	  
ns=non-­‐significant.	   This	   figure	   represents	   results	   from	   three	   separate	   experiments,	   and	   a	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Discussion	  
The	  induction	  of	  a	  robust	  cytotoxic	  CD8+	  T	  cell	  response	  is	  critical	  for	  protective	  and	  
long-­‐lasting	  immunity	  against	  intracellular	  infections	  and	  cancers.	  This	  is	  the	  unmet	  
requirement	  of	   cancer	   vaccines	  under	  development.	   For	   the	  CD40mAb-­‐adjuvanted	  
vaccines	  to	  induce	  a	  CD8+	  T	  cell	  response,	  conjugated	  antigen	  has	  to	  be	  internalised	  
by	  phagocytosis	  or	  endocytosis	  and	  cross-­‐presented	  onto	  MHC	  class	  I.	  Other	  integral	  
qualities	  for	  an	  effective	  vaccine	  is	  the	  ability	  to	  co-­‐deliver	  antigens	  to	  professional	  
APCs	  with	  consequent	  APC	  activation	  and	  antigen	  presentation	  to	  T	  cells	  leading	  to	  
the	  initiation	  of	  an	  antigen-­‐specific	  immune	  response.	  In	  this	  chapter,	  these	  qualities	  
were	  investigated	  in	  the	  context	  of	  CD40mAb-­‐adjuvanted	  vaccines	  incorporating	  the	  
use	  of	  an	  OVA	  CD8+	  T	  cell	  epitope-­‐based	  vaccine,	  SIINFEKLC-­‐CD40mAb	  as	  a	  model.	  
Epitope-­‐based	  vaccines	  are	  considered	  as	  an	  ideal	  choice	  as	  a	  vaccine	  because	  they	  
allow	  the	  delivery	  of	  antigens	  to	  CD4+	  or	  CD8+	  T	  cells	   in	  the	  right	   immune	  context,	  
which	  results	   in	  a	  specific	   immune	  response.	   In	   fact,	  vaccines	  based	  on	  CD8+	  T	  cell	  
epitopes	   have	   induced	   both	   viral-­‐specific	   and	   tumour-­‐specific	   protective	   cytotoxic	  
immunity	   (Feltkamp	   et	   al.,	   1993,	   Aichele	   et	   al.,	   1995).	   However,	   immunisation	   of	  
exogenous	   or	   synthetic	   peptides	   admixed	   with	   an	   adjuvant	   to	   enhance	  
immunogenicity	   is	   suboptimal	   and	   inefficient,	   as	   the	  peptide	  and	   the	  adjuvant	   are	  
not	  directed	  to	  the	  same	  APC.	  This	  leads	  to	  the	  production	  of	  a	  mixed	  population	  of	  
APCs	   that	  are	   just	  activated	  or	   just	  antigen	  presenting	  with	  only	  a	   few	  being	  both.	  
Activated	   peptide-­‐loaded	   APCs	   are	   necessary	   for	   an	   efficient	   immune	   response	  
(Aichele	  et	  al.,	  1995,	  De	  Vries	  et	  al.,	  2003a,	  De	  Vries	  et	  al.,	  2003b,	  Heit	  et	  al.,	  2008),	  
whereas	  peptide-­‐loaded	  APCs	  that	  are	  not	  activated	  promote	  tolerance	  (Diehl	  et	  al.,	  
1999).	  To	  ensure	  that	  peptide-­‐loaded	  APCs	  in	  this	  study	  were	  activated	  the	  peptide	  
and	  the	  CD40mAb	  (acting	  as	  the	  adjuvant)	  were	  chemically	  conjugated.	  
Naive	  CD8+	  T	  cells	  are	  not	  able	  to	  directly	  kill	  infected	  cells	  or	  tumour	  cells.	  However,	  
on	   antigen-­‐encounter	   the	   naive	   CD8+	   T	   cells	   proliferate	   and	   differentiate	   into	  
antigen-­‐specific	  effector	  CD8+	  T	  cells.	  The	  effector	  CD8+	  T	  cells	  target	  and	  kill	  the	  cells	  
presenting	   the	   antigen	   (Barber	   et	   al.,	   2003).	   CD8+	   T	   cells	   were	   implicated	   as	   the	  
major	   effector	   cells	   in	   the	   immune	   response	   generated	   due	   to	   immunisation	  with	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CD40mAb	  conjugated	  to	  a	  lymphoma	  antigen	  in	  a	  murine	  tumour	  model	  (Carlring	  et	  
al.,	  2012).	  However,	  the	  CD8+	  T	  cell	  response	  was	  never	  directly	  assessed.	  This	  study	  
was	   the	   first	   that	   directly	   showed	   that	   CD40mAb	   conjugated	   to	   antigen	   vaccine	  
stimulated	  effector	  CD8+	  cytotoxic	  T	  cell	   responses	  against	   the	  conjugated	  antigen.	  
Immunisation	   with	   the	   SIINFEKLC-­‐CD40mAb	   conjugate	   induced	   the	   production	   of	  
effector	   CD8+	   T	   cells	   that	   directly	   targeted	   and	   killed	   51%	   of	   the	   SIINFEKL-­‐loaded	  
cells	   (Figure	   5.7).	   In	   contrast,	   immunisation	   with	   the	   control	   conjugate	   induced	  
negligible	  killing	  of	  SIINFEKL-­‐loaded	  cells	  (Figure	  5.7).	  This	  result	  was	  the	  impetus	  for	  
the	  work	  carried	  out	  in	  this	  chapter.	  	  
The	  mice	  were	  also	  immunised	  with	  SIINFEKLC	  and	  CD40mAb	  as	  a	  mixture	  in	  the	  in	  
vivo	  cytotoxicity	  experiment.	  The	  CD40mAb	  in	  the	  mixture	  also	  induced	  an	  antigen-­‐
specific	   effector	   CD8+	   T	   cell	   response	   against	   the	   SIINFEKLC	   peptide.	   This	   was	  
consistent	   with	   other	   studies	   that	   also	   demonstrated	   that	   triggering	   of	   CD40	  
receptor	  by	  CD40mAb	  significantly	  enhances	  epitope-­‐	  or	  peptide-­‐based	  anti-­‐tumour	  
vaccine	  efficacy	  due	  to	  priming	  of	  CD8+	  T	  cells	  (Diehl	  et	  al.,	  1999,	  Ito	  et	  al.,	  2000a,	  Ito	  
et	  al.,	   2000b,	  Ninomiya	  et	  al.,	   2002).	  However,	   in	   these	   studies,	   various	   important	  
differences	  to	  ours	  were	  noted,	  namely	  (i)	  high	  doses	  of	  peptides	  (100μg)	  were	  co-­‐
administered	   with	   CD40mAb	   per	   mouse,	   (ii)	   peptides	   were	   encapsulated	   in	  
liposomes	   which	   also	   induce	   cytotoxic	   CD8+	   T	   cell	   responses,	   (iii)	   peptides	   were	  
admixed	  with	  other	  adjuvants	  like	  Freund’s	  adjuvant	  and/or	  (iv)	  CD40mAb	  was	  used	  
in	  doses	  as	  high	  as	  250μg	  per	  mouse.	  Therefore,	  considering	  the	  mentioned	  studies,	  
effector	  CD8+	  T	  cell	  directed	  killing	  of	  SIINFEKL-­‐loaded	  cells	  induced	  by	  the	  CD40mAb	  
and	   SIINFEKLC	  mixture	   in	   our	   experiment	  was	   expected.	  What	  was	   surprising	  was	  
the	   fact	   that	   the	  CD40mAb-­‐SIINFEKLC	   conjugate	  did	  not	   induce	   significantly	  better	  
effector	   CD8+	   T	   cell	   responses	   against	   SIINFEKLC	   peptide	   than	   the	   CD40mAb	   and	  
SIINFEKLC	  mixture	   (Figure	  5.7).	  A	  similar	   response	  between	  the	  two	  vaccines	  could	  
be	  attributed	  to	  the	  relatively	  high	  dose	  administered.	  Each	  mouse	  in	  this	  work	  was	  
immunised	   with	   40μg	   CD40mAb	   and	   2μg	   peptide.	   Early	   studies	   with	   CD40mAb-­‐
adjuvanted	   conjugates	   showed	   that	   immunising	   with	   doses	   as	   low	   as	   1μg	  
significantly	   enhanced	   antigen-­‐specific	   antibody	   responses	   compared	   to	   CD40mAb	  
admixed	  with	  antigen,	  which	  also	  resulted	  in	  reduced	  side-­‐effects	  (Barr	  et	  al.,	  2003).	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This	   means	   that	   10μg	   or	   less	   peptide-­‐CD40mAb	   conjugates	   should	   be	   used	   for	  
subsequent	  in	  vivo	  studies.	  
Prior	   to	   proceeding	   to	   the	   targeting	   and	   uptake	   experiments,	   the	   SIINFEKLC-­‐
CD40mAb	  conjugates	  were	  also	  used	  to	  test	  their	  effect	  on	  the	  activation	  status	  of	  
DCs	  and	  B	  cells.	  Consistent	  with	  results	  in	  chapter	  4,	  SIINFEKL-­‐CD40mAb	  conjugates,	  
significantly	  enhanced	  co-­‐stimulatory	  molecule	  expression	  of	  both	  B	  cells	  (Figure	  5.9)	  
and	   DCs	   (Figure	   5.9,	   5.10)	   in	   vitro	   compared	   to	   the	   SIINFEKLC-­‐GL117mAb	   control	  
conjugate.	  	  
Conjugation	   of	   labelled	   peptide	   (SIINFEKLFAM)	   to	   labelled	   antibody	   (mAbDylight)	  
allowed	   testing	   of	   the	   hypothesis	   that	   conjugation	   enables	   co-­‐delivery	   of	   the	  
CD40mAb	  and	  the	  antigen	  to	  the	  same	  APC,	  by	  means	  of	  fluorescence	  microscopy.	  
The	  number	  of	  conjugates	  targeting	  B	  cells	  (Figure	  5.12)	  and	  DCs	  (Figure	  5.18)	  varied	  
according	  to	  the	  APC	  type.	  
DCs	   are	   very	   efficient	   at	   internalising	   numerous	   different	   antigens	   and	   presenting	  
them	  in	  a	  highly	  immunogenic	  format	  (Romani	  et	  al.,	  1989,	  Inaba	  et	  al.,	  1993,	  Caux	  
et	  al.,	  1994).	  The	  aforementioned	  properties	  including	  their	  ability	  to	  traffic	  antigens	  
from	  the	  periphery	   to	   the	  secondary	   lymphoid	  organs	  which	  are	  T	  cell	   rich,	   is	  why	  
DCs	  are	  so	  prominently	  investigated	  and	  targeted	  in	  adjuvant	  research.	  Different	  DC	  
receptors	   for	   example	   DEC205,	   and	   CD40	   have	   been	   targeted	   in	   vaccine	  
development	  (Bonifaz	  et	  al.,	  2004).	  When	  antigens	  bind	  to	  these	  receptors,	  they	  are	  
internalised	  by	  means	  of	  clathrin-­‐coated	  domains	  and	  both	  enhance	  presentation	  by	  
MHC	  class	  I	  and	  MHC	  class	  II	  (Bonifaz	  et	  al.,	  2004).	  A	  study	  targeting	  the	  DEC205	  and	  
CD40	  receptors	  on	  human	  DC	  subtypes	  using	  corresponding	  antibodies	  showed	  that	  
the	  antibodies	  were	  both	  internalised.	  However,	  anti-­‐DEC205	  antibodies	  localised	  in	  
the	   late	   endosome,	   whilst	   anti-­‐CD40	   antibodies	   localised	   mainly	   in	   the	   early	  
endosomes	   and	   only	   minimally	   in	   late	   endosomes	   after	   6	   hours	   of	   in	   vitro	  
stimulation	  (Chatterjee	  et	  al.,	  2012).	  Anti-­‐DEC205	  antibodies	  were	   internalised	  to	  a	  
greater	   extent	   than	   anti-­‐CD40	   antibodies	   but	   CD40	   receptor	   targeting	   was	   more	  
efficient	  for	  cross	  presentation	  (Chatterjee	  et	  al.,	  2012).	   In	  this	  study	  SIINFEKLCFAM-­‐
CD40mAbDylight	  and	  SIINFEKLCFAM-­‐GL117mAbDylight	  (Figure	  5.13,	  5.15)	  were	  incubated	  
with	  DCs	   for	   up	   to	   an	   hour,	   and	   high	   numbers	   of	   both	   SIINFEKLC-­‐mAb	   conjugates	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targeted	  BM-­‐DCs	  even	  after	  5	  minutes.	  This	  suggested	  that	  the	  different	  conjugates	  
were	  targeting	  different	  receptors	  and	  being	  internalised	  by	  separate	  mechanisms	  at	  
later	   time	   points.	   However,	   significantly	   more	   co-­‐localised	   SIINFEKLCFAM	   and	  
CD40mAbDylight	   was	   observed	   at	   the	   60	   minute	   time-­‐point,	   which	   is	   a	   possible	  
consequence	  of	  CD40	   ligation.	  The	   latter	  phenomenon	  could	  be	  shown	  by	  the	   fact	  
that	  the	  pH	  sensitive	  FAM	  (green)	  dye	  of	  the	  SIINFEKLCFAM-­‐CD40mAbDylight	  conjugate	  
decreased	  in	  brightness	  between	  5	  and	  60	  minutes.	  The	  decrease	  in	  brightness	  could	  
be	   attributed	   to	   the	   peptide	   being	   trafficked	   into	   an	   endosomal	   compartment	   of	  
lower	  pH,	  and	  is	  a	  marker	  of	   internalisation.	  Fluorescein-­‐derived	  dyes	  have	  been	  in	  
fact	  used	  as	  an	  indicator	  of	  the	  pH	  of	  endosomes	  (Murphy	  et	  al.,	  1984).	  	  
DCs	   can	   internalise	   antigens	   by	   three	   mechanisms	   namely	   clathrin-­‐mediated	  
endocytosis,	   phagocytosis	   and	  macropinocytosis	   (Blum	  et	   al.,	   2013).	   In	   contrast	   to	  
DCs,	   B	   cells	   are	   less	   efficient	   at	   taking	   up	   antigen	   non-­‐specifically,	   and	   are	   more	  
focused	   on	   antigen-­‐specific	   uptake	   (Lanzavecchia,	   1985),	   which	   could	   be	   clearly	  
observed	  by	  the	  low	  numbers	  of	  co-­‐localised	  SIINFEKLFAM	  and	  CD40mAbDylight	  present	  
after	  5	  and	  60	  minutes	   compared	   to	  DC	   (Figure	  5.21).	  B	   cells	   are	  most	  efficient	  at	  
internalising	  antigens	   through	   their	  BCR	   (Lanzavecchia,	  1985),	   and	  are	  better	  APCs	  
when	   the	   antigen	   load	   is	   limited	   (Malynn	   et	   al.,	   1985,	   Bouaziz	   et	   al.,	   2007).	   At	   5	  
minutes	   both	   SIINFEKLFAM-­‐CD40mAbDylight	   and	   SIINFEKLCFAM-­‐GL117mAbDylight	  
conjugates	  might	   be	   just	   localising	   on	   the	   B	   cell	   surface.	  However,	   at	   60	  minutes,	  
there	   is	   a	   significant	   difference	   between	   the	   two	   conjugates,	   probably	   because	   of	  
internalisation.	   Chatterjee	   and	   colleagues	   (2012)	   explain	   that	   once	   internalised	  
CD40-­‐targeted	   antigens	   are	   more	   stable	   than	   antigens	   targeting	   other	   receptors,	  
showing	   that	   antigens	   internalised	   into	   other	   compartments	   were	   degraded	   at	   a	  
higher	  rate.	  Although	  the	  latter	  study	  was	  conducted	  in	  DCs,	  this	  could	  be	  a	  reason	  
why	   less	   co-­‐localised	   SIINFEKLCFAM-­‐GL117mAbDylight	   was	   observed	   after	   60	  minutes	  
whilst	  the	  SIINFEKLFAM-­‐CD40mAbDylight	  persists.	  
Further	   to	   APC	   targeting	   and	   uptake,	   the	   ability	   of	   APCs	   to	   cross-­‐present	   the	  
CD40mAb-­‐adjuvanted	  vaccines	  to	  CD8+	  T	  cells	  was	  investigated	  in	  vitro.	  Even	  though	  
DCs	  are	  considered	  specialised	  at	  cross-­‐presenting	  exogenous	  antigens	  to	  MHC	  class	  
I	   (Maurer	   et	   al.,	   2002),	   B	   cells	   have	   also	   shown	   to	   have	   the	   capacity	   to	   do	   this	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(Shirota	  et	  al.,	  2002,	  Heit	  et	  al.,	  2004).	  Whether	  CD40mAb	  enhances	  B	  cell	  or	  BM-­‐DC	  
cross-­‐presentation	   of	   SIINFEKL	   to	   B3Z	   hybridoma	   T	   cells	   in	   co-­‐culture	   was	  
investigated	  by	  the	  use	  of	  both	  the	  CD40mAb	  admixed	  with	  SIINFEKL	  peptide	  as	  well	  
as	   by	   SIINFEKLC-­‐CD40mAb	   conjugates.	   The	   unconjugated	   CD40mAb	   enhanced	  
antigen	   presentation	   by	   BM-­‐DCs	   and	   B	   cells	   to	   B3Z	   compared	   to	   their	   respective	  
isotype	   antibodies	   (Figure	   5.24).	   This	   was	   concluded	   due	   to	   increased	   IL-­‐2	  
production,	   indicative	   of	   B3Z	   activation.	   However,	   the	   stimulation	   of	   APCs	   with	  
SIINFEKLC-­‐CD40mAb	  conjugates	  did	  not	  lead	  to	  B3Z	  activation.	  This	  might	  have	  been	  
due	   to	   the	   fact	   that	   the	   SIINFEKL	   peptide	   in	   the	  mixture	   with	   CD40mAb	  was	   just	  
loading	   onto	   the	   MHC	   class	   I	   of	   the	   APC,	   and	   not	   being	   processed,	   or	   the	   B3Z	  
hybridoma	   T	   cells	  were	   not	   producing	   detectable	   levels	   of	   IL-­‐2.	   The	   original	   study	  
using	  B3Z	  hybridoma	  T	  cells	  to	  research	  antigen	  presentation	  demonstrated	  that	  the	  
optimal	   activity	   of	   the	   B3Z	   cells	   depended	   upon	   the	   presentation	   of	   the	   exact	  
analogue	  of	  the	  naturally	  processed	  octamer,	  SIINFEKL	  (Shastri	  and	  Gonzalez,	  1993).	  
Another	  study	  showed	  that	  an	  extra	  residue	  at	  the	  N-­‐terminal	  or	  C-­‐terminal	  or	  both	  
termini	  of	  SIINFEKL	  reduces	  B3Z	  activity	  by	  30-­‐,	  1000-­‐,	  and	  30,000-­‐fold	  respectively	  
(Serwold	   and	   Shastri,	   1999).	   They	   also	   subsequently	   showed	   that	   the	   lack	   of	   B3Z	  
activity	  was	  due	   to	   the	  poor	   recognition	  by	   the	   TCR	   rather	   than	   the	   failure	  of	   the	  
peptides	   to	  bind	   to	   the	  MHC	  class	   I.	   This	   is	   consistent	  with	  our	   study	  because	   the	  
addition	  of	  a	  cysteine	  to	  the	  octamer	  terminal	  resulted	  in	  no	  detectable	  B3Z	  activity,	  
whilst	   SIINFEKL	   peptide	   (with	   no	   terminal	   cysteine)	   used	   admixed	   with	   CD40mAb	  
demonstrated	  detectable	  B3Z	  activation.	  	  
Published	   work	   showed	   that	   CD40mAb	   enhanced	   cross-­‐presentation	   of	   the	  
conjugated	  peptide	  (Chatterjee	  et	  al.,	  2012).	  However,	  in	  the	  aforementioned	  study,	  
human	   DC	   subtypes	   isolated	   from	   the	   blood	   and	   CD8+	   T	   cells	   isolated	   from	  
lymphocytes	   were	   utilised,	   different	   to	   the	   murine	   BM-­‐DCs	   and	   the	   B3Z	   CD8+	  
hybridoma	  T	  cells	  utilised	  in	  our	  study.	  To	  further	  investigate	  cross-­‐presentation,	  the	  
SIINFEKL/Kb	  complex	  presented	  by	  APCs	  was	  tested	  by	  flow	  cytometry	  using	  an	  anti-­‐
SIINFEKL/Kb	   complex	   antibody.	   Flow	   cytometry	   showed	   that	   significantly	   more	  
SIINFEKL	  was	  presented	  by	  both	  SIINFEKLC-­‐CD40mAb	  conjugate	  as	  well	  as	  CD40mAb	  
and	   SIINFEKL	   mixture	   stimulated	   cells,	   compared	   to	   the	   respective	   GL117mAb	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controls.	   This	   was	   observed	   on	   both	   activated	   splenic	   CD19+	   and	   CD11c+	   cells,	  
showing	   that	   CD40mAb	   adjuvant	   works	   and	   targets	   both	   these	   cell	   types	   and	  
enhances	  cross-­‐presentation	  of	  SIINFEKLC	  to	  the	  MHC	  class	  I.	  
An	  earlier	   study	   carried	  out	   in	  our	   laboratory	   showed	   that	   a	   fluorescently	   labelled	  
CD40mAb-­‐antigen	  conjugate	  immunised	  subcutaneously,	  was	  detected	  inside	  cells	  in	  
the	   draining	   inguinal	   lymph	   node	   (Carlring	   et	   al.,	   2012).	   We	   wanted	   to	   take	   this	  
experiment	  a	  step	  further	   in	  this	  study	  to	   investigate	  which	  APCs	  are	  taking	  up	  the	  
CD40mAb-­‐antigen	   conjugate	   and	   whether	   they	   become	   activated	   in	   the	   process.	  
Different	   adjuvants	   have	   different	   effects	   at	   the	   site	   of	   injection,	   which	   lead	   to	  
antigen	   transport	   to	   the	   lymph	   nodes	   by	   a	   number	   of	   different	   cell	   types.	   For	  
example,	  whilst	  alum	  adjuvants	  seem	  to	  act	  mainly	  on	  monocytes	  and	  macrophages	  
(Seubert	  et	  al.,	  2008),	  MF59	  adjuvant	  largely	  acts	  on	  granulocytes,	  in	  fact	  neutrophils	  
are	   the	   first	   cell	   type	   recruited	   to	   the	   injection	   site,	   followed	   by	   monocytes,	  
eosinophils,	  DCs	  and	  a	  very	  small	  numbers	  of	  B	  cells	  and	  T	  cells	  (Calabro	  et	  al.,	  2011).	  
However,	  both	  adjuvants	  have	  an	  impact	  on	  the	  differentiation	  of	  monocytes	  to	  DCs	  
(Rimaniol	  et	  al.,	  2004,	  Seubert	  et	  al.,	  2008).	  Even	  though	  the	  draining	  lymph	  nodes	  
harvested	   from	   mice	   injected	   intramuscularly	   with	   alum	   or	   MF59	   admixed	   with	  
antigen	   both	   contained	   antigen-­‐containing	   DCs	   and	   B	   cells	   after	   24	   hours,	   alum	  
unlike	   MF59	   only	   demonstrated	   slight	   enhanced	   numbers	   of	   antigen-­‐containing	  
APCs.	   Furthermore,	   draining	   lymph	   nodes	   of	   mice	   injected	   intramuscularly	   with	  
MF59	   admixed	   with	   antigen	   showed	   antigen-­‐containing	   neutrophils	   after	   just	   7	  
hours	  of	  injection,	  which	  were	  not	  detected	  after	  alum	  injection.	  This	  indicates	  that	  
neutrophils	  could	  also	  traffic	  antigens	  to	  secondary	  lymphoid	  organs	  (Calabro	  et	  al.,	  
2011).	  
Other	   adjuvants,	   like	   TLR-­‐agonists	   for	   example	   MPL	   (Ismaili	   et	   al.,	   2002,	  
Didierlaurent	  et	  al.,	  2009,	  Didierlaurent	  et	  al.,	  2014)	  directly	  activate	  DCs	  in	  vitro	  and	  
in	   vivo.	   A	  DC-­‐activating	   adjuvant	   is	   a	  necessary	   component	   for	   an	  effective	   cancer	  
vaccine.	  Intramuscular	  injection	  with	  TLR-­‐agonist	  MPL	  also	  lead	  to	  increased	  DC	  and	  
monocyte	   numbers	   compared	   to	   injection	  with	   alum	   adjuvant,	   at	   both	   24	   and	   72	  
hours.	  However,	  whilst	  lymph	  node	  DCs	  expressed	  higher	  levels	  of	  CD40	  and	  CD86,	  
only	  CD40	  was	  enhanced	  on	   lymph	  node	  monocytes	   (Didierlaurent	  et	  al.,	  2009).	   In	  
CHAPTER	  5	  
	   241	  
our	   study	   the	   DCs	   present	   in	   the	   inguinal	   draining	   lymph	   nodes	   24	   hours	   after	   a	  
subcutaneous	   injection	   did	   not	   present	   SIINFEKL	   and	   were	   not	   activated	   (Figure	  
5.28).	   This	   was	   surprising	   as	   in	   vitro	   work	   showed	   that	   the	   CD40mAb-­‐antigen	  
conjugate	   enhanced	   DC	   activation	   as	   well	   as	   SIINFEKL	   presentation	   by	   DCs.	   In	  
contrast,	  although	  activated	  and	  non-­‐activated	  B	  cells	  in	  the	  draining	  lymph	  node	  did	  
not	  present	  SIINFEKL,	  B	  cell	  activation	  status	  was	  enhanced	  in	  mice	  immunised	  with	  
SIINFEKLC-­‐CD40mAb	   compared	   to	   those	   immunised	   with	   SIINFEKLC-­‐GL117mAb	  
conjugate.	  B	  cells	  have	  recently	  been	  found	  to	  take	  up	  antigen	  from	  the	  surface	  of	  
follicular	  DCs	  and	  macrophages	   in	  vivo	   (Suzuki	  et	  al.,	  2009),	  however	   this	  still	  does	  
not	  explain	  why	  SIINFEKL	  is	  not	  presented	  on	  the	  B	  cell	  surface.	  One	  reason	  could	  be	  
that	  flow	  cytometry	  might	  not	  be	  sensitive	  enough	  to	  detect	  the	  presented	  SIINFEKL.	  
However,	  B	  cells	  might	  also	  be	  taking	  up	  CD40mAb	  from	  cell	  surface,	  which	  would	  be	  
an	  explanation	  of	  why	   they	  are	  activated.	   Studies	  have	  demonstrated	   that	   soluble	  
antigens	   smaller	   than	  70kDa	  gain	  direct	   access	   to	   the	   lymph	  nodes	   via	   fibroblastic	  
reticular	   cell	   conduits	   (Pape	   et	   al.,	   2007,	   Roozendaal	   et	   al.,	   2009).	   However,	   the	  
SIINFEKLC-­‐mAb	  conjugates	  are	  of	  higher	  MW,	  so	  it	  is	  unlikely	  that	  they	  gain	  access	  to	  
the	  lymph	  nodes	  directly.	  
Further	  experiments	  have	  to	  be	  performed	  to	  verify	  and	  reach	  conclusions	  over	  the	  
fate	   of	   CD40mAb-­‐antigen	   conjugates	   in	   vivo.	   The	   use	   of	   a	   fluorescently	   labelled	  
conjugate	  would	  give	  more	  detailed	  information	  on	  the	  APCs	  important	  at	  the	  site	  of	  
immunisation	  as	  well	  as	  the	  APCs	  migrating	   in	  high	  numbers	  to	  the	  draining	   lymph	  
nodes	   to	  present	   the	  conjugated	  antigen.	  A	  detail	   to	  be	   taken	   in	  consideration	   for	  
subsequent	  experiments	   is	   the	  differentiation	  between	  migratory	  DCs	  and	  resident	  
DCs	  in	  the	  lymph	  nodes.	  Other	  cell	  types	  such	  as	  for	  example	  neutrophils,	  monocytes	  
and	  macrophages,	  which	  have	  found	  to	  be	  play	  a	  role	  in	  trafficking	  of	  antigens	  from	  
the	  periphery	  to	  the	  secondary	  lymphoid	  organs	  (Abadie	  et	  al.,	  2005,	  Bonneau	  et	  al.,	  
2006,	  Calabro	  et	  al.,	  2011),	  were	  they	  deliver	  antigens	  to	  professional	  APCs	  should	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Conclusions 	  
Our	   results	   support	   the	   hypothesis	   that	   CD40mAb-­‐adjuvanted	   vaccines	   induce	  
effector	  CD8+	  T	   cell	   responses	   in	   vivo.	   CD40mAb	  co-­‐delivers	   conjugated	  antigen	   to	  
both	  B	  cells	  and	  DCs	   in	  vitro.	   In	  addition,	  even	  though	  further	  testing	  is	  required	   in	  
vivo,	   both	   B	   cells	   and	   DCs	   become	   activated	   on	   stimulation	   with	   the	   CD40mAb-­‐
adjuvanted	  vaccines,	  and	  play	  a	  role	  in	  enhancing	  CD40mAb-­‐antigen	  vaccine	  antigen	  
cross-­‐presentation	  to	  CD8+	  T	  cells	  in	  vitro.	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6.1.	  Overview	  
Our	  group	  has	  been	  investigating	  CD40mAb	  as	  an	  adjuvant	  for	  more	  than	  a	  decade.	  
Experimental	   progress	   so	   far	   has	   shown	   that	   immunisation	  with	  CD40mAb	  at	   high	  
doses	   (500μg)	   can	  enhance	  antibody	   responses	  against	   co-­‐inoculated	  TI-­‐1	  and	  TI-­‐2	  
antigens	  (Dullforce	  et	  al.,	  1998,	  Barr	  and	  Heath,	  1999).	  This	  adjuvant	  effect	  can	  also	  
be	  achieved	  when	  using	  50-­‐fold	  lower	  doses	  when	  chemically	  conjugated	  to	  antigen	  
(Barr	   et	   al.,	   2003),	   which	   also	   resulted	   in	   less	   side-­‐effects.	   Immunisation	   with	  
CD40mAb	   conjugated	   to	   antigen	   at	   low	   doses	   enhanced	   antigen-­‐specific	   antibody	  
titres	   up	   to	   a	   1000-­‐fold	   compared	   to	   immunisation	   with	   CD40mAb	   admixed	   with	  
antigen	   (Barr	   et	   al.,	   2003).	   Moreover,	   a	   more	   rapid	   antigen-­‐specific	   immune	  
response	   was	   observed	   in	   mice	   immunised	   with	   the	   CD40mAb-­‐antigen	   conjugate	  
compared	   to	   the	   licensed	   adjuvants,	   like	   MPL	   or	   alum,	   admixed	   with	   antigen	  
(Bhagawati-­‐Prasad	   et	   al.,	   2010).	   Early	   studies	   also	   demonstrated	   that	   CD40mAb	  
administered	  alone	  enhanced	  ex	  vivo	  lymphocyte	  responses	  to	  itself	  (Carlring	  et	  al.,	  
2004).	   In	   addition,	   CD40mAb	   conjugated	   to	   antigen	   enhanced	   lymphocyte	  
proliferation	  in	  response	  to	  the	  antigen	  ex	  vivo	  compared	  to	  the	  isotype	  mAb	  control	  
conjugate	   (Hatzifoti	   and	   Heath,	   2007).	   However,	   in	   the	   quoted	   study	   the	  
proliferating	  lymphocytes	  were	  only	  assumed	  to	  be	  CD4+	  T	  cells.	  	  
The	  most	  recent	  study	  by	  our	  group	  demonstrated	  that	  CD40mAb	  conjugated	  to	  the	  
A20	  murine	   B	   cell	   lymphoma	   Id	   (A20-­‐CD40mAb)	   showed	   synergy	  with	  MPL	   in	   the	  
murine	   A20	   lymphoma	  model,	   resulting	   in	   enhanced	   overall	   and	  median	   survival,	  
and	   also	   delayed	   tumour	   progression	   in	   response	   to	   A20	   tumour	   challenge	  
compared	  to	  control	  groups.	  Furthermore,	  effector	  CD8+	  T	  cells	  were	  highlighted	  as	  
the	   major	   mediators	   for	   tumour	   rejection	   by	   means	   of	   in	   vivo	   depletion	   studies,	  
although	   CD8+	   CTL	   responses	   were	   not	   directly	   measured.	   It	   is	   noteworthy	   that	  
immunisation	   with	   A20-­‐CD40mAb	   conjugate	   vaccine	   did	   not	   result	   in	   any	   tumour	  
protection	   when	   both	   CD4+	   and	   CD8+	   T	   cells	   were	   depleted	   prior	   to	   tumour	  
challenge,	  highlighting	  the	  importance	  of	  both	  cell	  types	  (Carlring	  et	  al.,	  2012).	  	  
Considerable	   progress	   has	   been	   made	   regarding	   the	   roles	   of	   CD40mAb	   as	   an	  
adjuvant	  but	  the	  mode	  of	  action	  is	  still	  unclear.	  Studies	  carried	  out	  to	  investigate	  the	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CD40-­‐CD154	   interaction	  have	  shown	  CD40	  expressing	  B	  cells	   (Hasbold	  et	  al.,	  1994,	  
Heath	  et	  al.,	  1994,	  Vallé	  et	  al.,	  1989)	  and	  DCs	  (Caux	  et	  al.,	  1994,	  Cella	  et	  al.,	  1996,	  
Björck	   et	   al.,	   1997,	   Mutini	   et	   al.,	   1999)	   are	   both	   candidates	   crucial	   in	   the	  
immunogenicity	   of	   CD40mAb	   as	   an	   adjuvant.	   A	   recent	   study	   showed	   that	   the	   co-­‐
engagement	  of	  both	  the	  inhibitory	  FcγRIIB	  receptor	  through	  the	  CD40mAb	  Fc	  region	  
and	  the	  CD40	  receptor	  is	  essential	  for	  CD40mAb	  to	  work	  as	  a	  T	  cell	  adjuvant	  through	  
APCs	   (Li	   and	   Ravetch,	   2011).	   In	   addition,	   Li	   and	   Ravetch	   (2011)	   also	   showed	   that	  
modulating	  the	  CD40mAb	  Fc	  domain	  to	  bind	  to	  FcγRIIB	  at	  a	  higher	  affinity,	  leads	  to	  
enhanced	  antigen-­‐specific	  CD8+	  T	  cell	  responses.	  This	   is	  an	  example	  showing	  that	  a	  
better	  understanding	  of	  how	  CD40mAb	  works	  will	   lead	  to	  improving	  the	  efficacy	  of	  
the	  current	  immunotherapies	  and	  its	  use	  as	  an	  adjuvant.	  
The	  main	  findings	  of	  this	  PhD	  work	  have	  already	  been	  discussed.	  The	  current	  chapter	  
aims	   to	   reconcile	   the	   results	   together	   and	   address	   their	   application	   in	   a	   clinical	  
context.	   In	   addition	   the	   limitations	   of	   certain	   methodologies	   are	   also	   discussed	  
together	   with	   possible	   future	   work.	   The	   first	   aim	   of	   this	   work	   was	   to	   refine	   the	  
conjugation	   strategy	   currently	  used	   in	  our	   laboratory	   to	  maximise	   the	  potential	   of	  
CD40mAb-­‐adjuvanted	   conjugates	   (Chapter	   3).	   The	   second	   aim	   was	   to	   bridge	   the	  
gaps	  in	  understanding	  certain	  roles	  of	  CD40mAb-­‐antigen	  conjugates	  and	  determine	  
which	  APC	  is	  crucial	  to	  the	  mechanism	  of	  action	  of	  CD40mAb	  conjugated	  to	  vaccine	  
antigen	  as	  a	  T	  cell	  adjuvant	  (Chapters	  4	  and	  5).	  For	  the	  purpose	  of	  the	  work	  in	  this	  
thesis,	  research	  was	  focused	  on	  B	  cells	  and	  DCs.	  
	  
6.2.	   Development	   of	   more	   refined	   CD40mAb-­‐adjuvanted	  
conjugate	  vaccines	  
In	   vitro	   cross-­‐linking	   of	   the	   CD40	   receptor	   on	   B	   cells	   by	   multimeric	   CD40mAb	  
positively	  correlates	  with	  B	  cell	  proliferation	  (Banchereau	  et	  al.,	  1991).	  In	  contrast,	  in	  
vivo	  CD40mAb	  as	  an	  adjuvant	  works	  best	  at	  a	  low	  MW	  (Heath	  and	  Laing,	  2004).	  The	  
previously	  mentioned	  observation	  was	  the	  impetus	  behind	  the	  hypothesis	  that	  a	  low	  
average	   MW	   CD40mAb-­‐antigen	   conjugate	   would	   maximise	   the	   potential	   of	  
CD40mAb	  as	  an	  adjuvant,	  leading	  to	  improved	  vaccines	  (Chapter	  3).	  The	  hypothesis	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was	  investigated	  using	  click	  chemistry	  together	  with	  size-­‐exclusion	  HPLC.	  These	  two	  
techniques	   allowed	   us	   to	   refine	   the	   method	   by	   which	   the	   CD40mAb-­‐antigen	  
conjugates	  were	  made.	  	  
The	   important	   property	   of	   click	   chemistry	   is	   that	   it	   involves	   specific	   reagent	  
components	  that	  have	  unique	  functional	  groups	  that	  are	  narrowly	  reactive	  towards	  
each	   other,	   and	   no	   side-­‐reactions	   occur	   (Kolb	   et	   al.,	   2001).	   This	   property	   allows	  
better	   control	   than	   the	   technique	   currently	   used	   in	   our	   laboratory,	   over	   the	  
formation	   of	   large	   complexes	   of	   CD40mAb-­‐antigen	   conjugate,	   resulting	   in	   the	  
development	  of	  vaccines	  with	  more	  consistent	  composition.	  The	  size-­‐exclusion	  HPLC	  
used	   together	   with	   copper	   free	   click	   chemistry	   allowed	   the	   isolation	   of	   the	   low	  
average	   MW	   conjugate	   containing	   minimal	   to	   no	   contaminating	   unconjugated	  
protein	  and	  the	  high	  average	  MW	  conjugate.	  
Our	  hypothesis	  was	  tested	  using	  CD40mAb	  conjugated	  to	  the	  A20	  murine	  lymphoma	  
Id	   as	   a	   prophylactic	   vaccine	   in	   the	   murine	   A20	   lymphoma	   model.	   The	  
immunogenicity	  and	  anti-­‐tumour	  effects	  of	  low	  average	  MW,	  high	  average	  MW	  and	  
heterogeneous	  A20-­‐CD40mAb	   conjugates	  made	  by	   click	   chemistry	  were	   compared	  
to	  the	  Standard	  A20-­‐CD40mAb	  conjugate	  (made	  by	  sulphydryl-­‐maleimide	  coupling).	  
Only	   immunisation	   with	   the	   CLICK	   A20-­‐CD40mAb	   conjugate	   of	   low	   average	   MW	  
significantly	   enhanced	   specific	   anti-­‐Id	   responses	   compared	   to	   the	   Standard	   A20-­‐
CD40mAb	   conjugate.	   In	   addition,	   the	   low	   average	   MW	   conjugate	   administered	  
prophylactically	   prior	   to	   A20	   tumour	   challenge,	   demonstrated	   the	   longest	  median	  
survival	   and	   best	   tumour	   rejection	   compared	   to	   the	   other	   CLICK	   and	   Standard	  
conjugates.	   These	   results	   were	   consistent	   with	   our	   hypothesis,	   showing	   that	  
increased	  CD40mAb	  accessibility	  leads	  to	  superior	  vaccines.	  
The	   increase	   in	   median	   and	   overall	   survival	   observed	   in	   tumour	   challenged	   mice	  
immunised	  with	  the	  low	  average	  MW	  conjugate	  compared	  to	  immunisation	  with	  the	  
Standard	  A20-­‐CD40mAb	  conjugate	  was	  not	  statistically	  significant,	  but	  a	  strong	  trend	  
was	  observed.	  The	  lack	  of	  significance	  could	  be	  attributed	  to	  a	  low	  number	  of	  mice	  
included	  in	  the	  study.	  Future	  work	  should	  involve	  repetition	  of	  the	  experiment	  using	  
larger	  numbers	  of	  mice	  making	  the	  results	  more	  robust.	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The	  effectiveness	  of	  conjugates	  made	  by	  click	  chemistry	  versus	  standard	  conjugation	  
strategy	  was	  also	  assessed	  using	  OVA	  as	  a	  model	  antigen	  conjugated	  to	  CD40mAb.	  
Low	   average	   MW,	   high	   average	   MW	   and	   heterogeneous	   CLICK	   OVA-­‐CD40mAb	  
conjugate	   immunised	   mice	   all	   showed	   significantly	   enhanced	   primary	   antibody	  
responses	  against	  OVA	  compared	  to	  the	  Standard	  OVA-­‐CD40mAb	  immunised	  mice.	  
However,	   it	   is	   important	   to	   note	   that	   the	   Standard	  OVA-­‐CD40mAb	   conjugate	  was	  
less	   immunogenic	   compared	   to	   previous	   studies	   (Barr	   et	   al.,	   2003).	   HPLC	  
chromatograms	  showed	  that	  the	  Standard	  OVA-­‐CD40mAb	  conjugate	  was	  composed	  
of	   largely	  high	  average	  MW	  protein	  together	  with	  unconjugated	  OVA	  or	  CD40mAb.	  
In	  vitro	  ELISA	  and	  flow	  cytometry	   investigations	  confirmed	  that	  a	  proportion	  of	  the	  
high	   average	   MW	   protein	   was	   OVA-­‐CD40mAb	   conjugate.	   The	   presence	   of	   high	  
average	  MW	  complexes	   formed	  due	   to	  unspecific	   interactions	   could	  have	   reduced	  
CD40mAb	  accessibility.	  This	  could	  have	  been	  a	  reason	  why	  Standard	  OVA-­‐CD40mAb	  
conjugate	  used	  for	  this	  study	  was	  found	  to	  be	  less	  immunogenic.	  
Click	  chemistry	  has	  shown	  success	   in	  other	  studies	  since	   its	  discovery	  slightly	  more	  
than	   a	   decade	   ago.	   One	   example	   is,	   that	   click	   chemistry	   allowed	   the	   controlled	  
coupling	   of	   different	   numbers	   of	  MUC1	   glycopeptides	   to	   TLR2	   lipopeptide	   ligands	  
forming	   oligovalent	   glycopeptide-­‐lipopeptide	   conjugates	   (Cai	   et	   al.,	   2011).	   MUC1	  
glycoprotein	   is	   one	   of	   the	   most	   characterized	   tumour	   antigens,	   and	   vaccines	  
previously	   made	   by	   this	   group	   involved	   the	   conjugation	   of	   MUC1	   to	   the	   protein	  
carrier	   BSA,	  which	   led	   to	   non-­‐specific	   immune	   responses	   towards	   the	  BSA	   in	   vivo.	  
MUC1	   complex	   conjugates	   produced	   by	   click	   chemistry	   were	   immunogenic	  
producing	  IgG1	  and	  IgG2a-­‐type	  antibodies.	  Furthermore,	  the	  vaccine	  containing	  four	  
MUC1	   glycopeptides	   conjugated	   to	   TLR2	   lipopeptides	   produced	   IgG2a-­‐type	  
antibodies	  which	  bound	  to	  and	   initiated	  killing	  of	  MCF-­‐7	  breast	  tumor	  cells	   in	  vitro	  
(Cai	   et	   al.,	   2014).	   Cai	   and	   colleagues	   (2014)	   stated	   that	   the	   response	  by	   the	  more	  
defined	   synthetic	   vaccines	   was	   stronger	   than	   that	   elicited	   by	   previously	   used	  
vaccines	  of	  MUC1	  conjugated	  to	  BSA.	  
In	   conclusion,	   the	   results	   from	   our	   work	   demonstrated	   that	   the	   development	   of	  
more	  refined,	  low	  average	  MW	  conjugates	  maximises	  the	  potential	  of	  CD40mAb	  as	  
an	   adjuvant	   and	   enhances	   vaccine	   efficacy	   satisfying	   our	   hypothesis.	   Further	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investigation	  of	  OVA-­‐CD40mAb	  conjugates	  made	  by	  click	  chemistry	  and	  the	  standard	  
method	   in	   Chapter	   4	   showed	   that	  OVA	  was	   contaminated	  with	   endotoxin.	  Due	   to	  
this	  development,	   further	  studies	   in	  Chapters	  4	  and	  5	  were	  carried	  out	  using	  OVA-­‐
immunodominant	   epitopes	   conjugated	   to	   CD40mAb	   vaccines	   instead	   of	   OVA.	   The	  
OVA-­‐peptides	  were	  synthesised	  with	  a	  cysteine	  terminal	  on	  their	  carboxyl-­‐end.	  This	  
allowed	   efficient	   conjugation	   of	   maleimide-­‐activated	   mAbs	   to	   the	   OVA-­‐peptides.	  
Sulphydryl-­‐maleimide	   coupling	   was	   the	   conjugation	   of	   choice	   for	   two	   reasons;	   (i)	  
only	  one	  sulphydryl-­‐containing	  cysteine	  group	  was	  present	  on	  the	  peptide	  therefore	  
cross-­‐linking	  was	  minimised	  and	  (ii)	  the	  amino-­‐terminal	  of	  the	  peptide	  was	  free	  for	  
labelling	  with	  fluorescent	  compounds	  or	  biotin.	  
	  
6.3.	   Mode	   of	   action	   of	   CD40mAb-­‐adjuvanted	   conjugate	  
vaccines	  
The	  choice	  of	  adjuvant	   in	  modern	  vaccine	  development	  must	  be	  justified	  and	  must	  
fulfill	  an	  unmet	  requirement	  of	  the	  vaccine.	  A	  better	  understanding	  of	  the	  mode	  of	  
action	   of	   adjuvants	   will	   lead	   to	   vaccine	   formulations	   that	   directly	   influence	   the	  
immune	   effectors	   crucial	   for	   vaccine-­‐mediated	   protection.	   CD40mAb-­‐adjuvanted	  
conjugates	   in	   the	   presented	   work	   were	   shown	   in	   the	   clinical	   context	   of	   B	   cell	  
lymphoma	  (Chapter	  3).	  The	  most	  suitable	  candidates	  for	  the	  application	  of	  Id-­‐based	  
vaccines	   are	   patients	   affected	   with	   follicular	   lymphoma,	   a	   type	   of	   non-­‐Hodgkin’s	  
lymphoma,	  in	  first	  remission	  (Bendandi,	  2009).	  The	  current	  standard	  treatment	  for	  B	  
cell	   non-­‐Hodgkin’s	   lymphoma	   includes	   the	   use	   of	   the	   monoclonal	   antibody	   anti-­‐
CD20	  (RituxanTM	  or	  rituximab;	  Genentech)	  (Marcus	  et	  al.,	  2005,	  Schulz	  et	  al.,	  2007).	  
The	   addition	   of	   rituximab	   together	   with	   chemotherapy,	   was	   found	   to	   improve	  
overall	   survival,	   disease	   control	   and	   response	   rates	   in	   patients	   with	   follicular	  
lymphoma	  (Schulz	  et	  al.,	  2007).	  However,	  advanced	  stage	  follicular	  lymphoma	  is	  still	  
considered	   incurable,	   this	   is	   why	   novel	   therapeutic	   strategies	   are	   crucial	   for	   the	  
elimination	  of	  the	  residual	  disease	  after	  chemotherapy	  and	  immunotherapy.	  
Therapeutic	   Id-­‐based	   vaccines	   aim	   to	   improve	   passive	   immunotherapies,	   like	  
rituximab,	  by	  inducing	  long-­‐lasting	  antibody,	  CD4+	  and	  CD8+	  T	  cell	  responses	  against	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the	  tumour.	  Furthermore,	  vaccine-­‐mediated	  immune	  responses	  tend	  to	  be	  directed	  
towards	  different	  tumour	  epitopes	  creating	  immunological	  memory,	  diminishing	  the	  
risk	  of	  the	  tumour	  escaping	  the	  immune	  system	  (Park	  and	  Neelapu,	  2008).	  Id-­‐based	  
vaccine-­‐mediated	   immune	   responses	   are	   assumed	   to	   have	   better	   outcomes	  when	  
the	   tumour	   burden	   is	  minimal	   (Park	   and	  Neelapu,	   2008),	   therefore	   chemotherapy	  
with	  or	  without	  rituximab	  is	  usually	  administered.	  In	  fact,	  the	  most	  recent	  phase	  III	  
clinical	   trial	   using	   Id-­‐based	   vaccines	   showed	   clinical	   benefit	   against	   follicular	  
lymphoma	   patients	   because	   the	   treatment	   was	   restricted	   only	   to	   patients	   who	  
achieved	   complete	   response	   after	   first-­‐line	   chemotherapy	   (Schuster	   et	   al.,	   2011,	  
Melero	  et	  al.,	  2014).	  
It	   is	  noteworthy	  that	  chemotherapy	  also	  affects	  normal	  tissues	  and	  targets	  dividing	  
lymphocytes,	  which	   are	   required	   for	   the	   immune	   response,	  whilst	   treatment	  with	  
rituximab	   leads	   to	  depletion	  of	  both	  malignant	  and	  normal	  B	  cells	   (Maloney	  et	  al.,	  
1994,	  Anolik	  et	  al.,	  2007).	  As	  a	  consequence,	  some	  time	  for	  immunological	  recovery	  
has	  to	  be	  allowed	  prior	  to	  administration	  of	  the	  Id-­‐based	  vaccine.	   In	  fact,	  timing	  of	  
post-­‐treatment	   vaccination	   is	   critical,	   and	   possibly	   a	   reason	   why	   two	   from	   three	  
substantial	  phase	   III	   clinical	   trials	   in	  which	   lymphoma	   Id-­‐based	  vaccines	  were	  used	  
were	  unsuccessful	   (Levy	  et	  al.,	  2008,	  Freedman	  et	  al.,	  2009,	  Schuster	  et	  al.,	  2009).	  
Better	  study	  design	  and	  understanding	  of	  treatment	  would	  lead	  to	  better	  outcomes	  
(Bendandi,	  2009).	  
Vaccination	   used	   as	   an	   adjunct	   to	   or	   after	   rituximab	   therapy	   needs	   to	   be	   able	   to	  
activate	   APCs	   other	   than	   B	   cells	   to	   be	   successful.	   Otherwise	   some	   time	   for	   B	   cell	  
recovery	   needs	   to	   be	   allowed.	   Ascertaining	   which	   APC	   plays	   a	   crucial	   role	   in	   the	  
adjuvant	   effect	   of	   the	   CD40mAb-­‐adjuvanted	   conjugates	   will	   give	   valuable	  
information	   regarding	   whether	   their	   use	   will	   be	   successful	   after	   treatment	   with	  
immunotherapies.	  The	  work	  presented	  in	  this	  thesis	  (Chapters	  4	  and	  5)	  was	  heavily	  
focused	   on	   determining	   which	   APCs	   play	   a	   crucial	   role	   in	   the	   adjuvant	   effect	   of	  
CD40mAb	   conjugated	   to	   antigen,	   and	   their	   roles	   leading	   to	   CD4+	   or	   CD8+	   T	   cell	  
responses.	  This	  information	  would	  be	  valuable	  for	  the	  optimal	  timing	  of	  CD40mAb-­‐Id	  
therapy	  relative	  to	  other	  therapies	  such	  as	  rituximab.	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The	   CD4	   and	   CD8	   OVA	   immunodominant	   epitopes,	   ISQAVHAAHAEINAGR	   and	  
SIINFEKL	   (respectively)	   conjugated	   to	   CD40mAb	  were	   used	   to	   investigate	  whether	  
CD40mAb-­‐adjuvanted	  conjugates	  work	  via	  B	  cells,	  DCs	  or	  both.	  The	  work	  shown	   in	  
this	   thesis	   demonstrates	   that	   both	   aforementioned	   conjugates	   upregulated	   CD80	  
and	   CD86	   co-­‐stimulatory	   molecules	   on	   splenic	   B	   cells	   and	   immature	   BM-­‐DCs	  
indicating	  that	  both	  cell	  types	  were	  activated	  in	  vitro.	  Surprisingly	  in	  vivo,	  B	  cells	  but	  
not	   DCs	   in	   the	   draining	   inguinal	   lymph	   node	   had	   up-­‐regulated	   their	   surface	   co-­‐
stimulatory	   molecules	   after	   subcutaneous	   immunisation	   with	   the	   SIINFEKLC-­‐
CD40mAb	   vaccine	   compared	   to	   the	   isotype	   control	  mAb	   conjugate.	   However,	   the	  
activated	   B	   cells	   were	   not	   presenting	   SIINFEKL	   on	   MHC	   class	   I.	   The	   SIINFEKLC-­‐
CD40mAb	   conjugate	   could	   have	   gained	   access	   to	   the	   lymph	   node	   indirectly	   by	  
means	  of	  other	  APCs	  like	  peripheral	  monocytes,	  macrophages	  or	  follicular	  DCs.	  We	  
have	   assumed	   that	   the	   B	   cells	   have	   taken-­‐up	   antigen	   from	   the	   surface	   of	   the	  
mentioned	  cell	  types,	  but	  the	  work	  in	  this	  thesis	  did	  not	  extend	  to	  investigate	  this.	  	  
A	   very	   recent	   study	  monitored	   the	  distribution	  of	   labelled	  QS-­‐21	  and	  antigen	  with	  
different	   fluorochromes	   at	   the	   site	   of	   injection	   (muscle)	   and	   tracked	   these	  
conjugates	  to	  the	  draining	  lymph	  nodes	  (Didierlaurent	  et	  al.,	  2014).	  Results	  showed	  
that	  both	  QS-­‐21	  and	  antigen	  were	  detected	  in	  the	  lymph	  node	  within	  just	  30	  minutes	  
of	   injection,	   showing	   that	   they	   had	   drained	   directly	   to	   the	   lymph	   node.	   It	   was	  
interesting	   to	   note	   that	   within	   24	   hours,	   the	   QS-­‐21	   and	   the	   antigen	   could	   be	  
observed	  in	  different	  areas	  of	  the	  lymph	  node.	  Another	  study	  used	  fluorescent	  OVA	  
to	  show	  that	  OVA-­‐loaded	  DCs	  and	  monocytes	  migrate	  to	  the	  draining	  lymph	  nodes	  in	  
higher	   numbers	   and	   enhance	   their	   co-­‐stimulatory	   molecule	   expression	   on	  
intramuscular	   co-­‐injection	  with	  MPL	  but	   not	   alum	   (Didierlaurent	   et	   al.,	   2009).	   The	  
use	   of	   fluorescently-­‐labelled	   conjugates	   would	   therefore	   possibly	   enable	   better	  
tracking	  of	  the	  conjugates	  in	  vivo	  in	  order	  to	  verify	  our	  results	  and	  reach	  conclusions	  
regarding	   the	   effects	   of	   CD40mAb-­‐antigen	   conjugates	   on	   B	   cells,	   DCs	   as	   well	   as	  
monocytes	  or	  macrophages.	  
CD40mAb	  fluorescently	  labelled	  with	  Dylight650	  conjugated	  to	  SIINFEKL	  fluorescently	  
labelled	   with	   FAM,	   allowed	   the	   investigation	   of	   whether	   CD40mAb-­‐adjuvanted	  
conjugates	  co-­‐deliver	  the	  antigen	  and	  CD40mAb	  signal	  to	  the	  same	  APC.	  The	  results	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showed	  that	  CD40mAb	  co-­‐delivered	  antigen	  to	  both	  B	  cells	  and	  BM-­‐DCs	  in	  vitro.	  The	  
difference	   observed	   between	   the	   two	   APCs	   was	   that	   BM-­‐DCs	   uptake	   more	  
SIINFEKLC-­‐CD40mAb	  conjugates	  and	  at	  a	  much	  quicker	  rate	  than	  B	  cells	  compared	  to	  
the	  respective	   isotype	  mAb	  control	  conjugates.	  This	  was	  attributed	  to	  the	  fact	  that	  
immature	  DCs	  are	  more	  efficient	  at	  the	  uptake	  of	  antigen	  by	  different	  mechanisms	  
(Romani	   et	   al.,	   1989,	   Inaba	   et	   al.,	   1993,	   Caux	   et	   al.,	   1994),	  whilst	   B	   cells	   focus	   on	  
antigen-­‐specific	  uptake	  (Lanzavecchia,	  1985).	  	  	  
B	  cells	  and	  BM-­‐DCs	  targeted	  by	  the	  CD40mAb-­‐SIINFEKLC	  conjugates	  also	  enhanced	  
cross-­‐presentation	  of	  SIINFEKL	  on	  MHC	  class	  I	  compared	  to	  the	  isotype	  mAb	  control	  
conjugate	   in	   vitro.	   Due	   to	   limitations	   in	   the	   technique	   used,	   it	   could	   not	   be	  
concluded	  whether	  CD40mAb-­‐antigen	  conjugates	  enhances	  B	  cell	  or	  BM-­‐DC	  antigen	  
presentation	  on	  MHC	  class	   II.	  As	  discussed	   in	  Chapter	  4,	  alternative	  cells	  should	  be	  
utilized	  instead	  of	  DO11.10	  hybridoma	  T	  cells	  in	  order	  to	  achieve	  a	  more	  conclusive	  
result	   in	   future	  experiments.	  Examples	  of	  such	  alternatives	   include	  CD4+	  cells	   from	  
DO11.10	   BALB/c,	   specific	   to	   H-­‐2d	   (Son	   et	   al.,	   2002,	   Aubin	   et	   al.,	   2010),	   or	   OT-­‐II	  
C57Bl/6,	  specific	  to	  H-­‐2b	  (Kool	  et	  al.,	  2011)	  transgenic	  mice	  having	  an	  OVA-­‐reactive	  T	  
cell	  receptor.	  
Generally,	  it	  is	  still	  unclear	  whether	  an	  Id-­‐specific	  humoral	  or	  cell-­‐mediated	  immune	  
response	  is	  the	  main	  mechanism	  by	  which	  tumour	  protection	  is	  achieved.	  A	  specific	  
anti-­‐Id	  response	  was	  found	  crucial	  in	  protection	  against	  tumours	  (Cesco-­‐Gaspere	  et	  
al.,	   2005,	   Inogès	   et	   al.,	   2006,	   Cesco-­‐Gaspere	   et	   al.,	   2008)	   in	   murine	   models	   and	  
clinically	  correlated	  with	  overall	  survival	  (Ai	  et	  al.,	  2009).	  However,	  T	  cell	  responses	  
were	   also	   associated	   with	   pre-­‐clinical	   benefit	   experimentally	   in	   murine	   models	  
(Biragyn	   et	   al.,	   1999,	   Carlring	   et	   al.,	   2012)	   and	   in	   humans	   (Bendandi	   et	   al.,	   1999,	  
Inogès	   et	   al.,	   2006).	   Both	   humoral	   and	   cell-­‐mediated	   responses	   contribute	   to	   the	  
therapeutic	  effects	  of	  the	  Id-­‐vaccines,	  however	  their	  relative	  effect	  has	  not	  yet	  been	  
fully	   confirmed.	  Until	   a	  better	  understanding	  of	   the	  mechanism	   leading	   to	   tumour	  
protection	   is	   better	   ascertained,	   Bendandi	   (2009)	   suggests	   that	   Id-­‐based	   vaccines	  
should	  aim	  to	  induce	  both	  humoral	  and	  cell-­‐mediated	  immune	  responses.	  
Results	   from	  the	  work	  discussed	   in	  Section	  6.2,	   show	   that	  CD40mAb-­‐Id	  conjugates	  
are	   able	   to	   induce	   specific	   anti-­‐Id	   antibody	   responses	   in	   the	   A20	   murine	   B	   cell	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lymphoma	  model.	  SIINFEKLC	  and	  ISQAVHAAHAEINAGRC	  (referred	  to	  as	   ISQC	  in	  this	  
work)	   peptides	   conjugated	   to	   CD40mAb	   were	   used	   in	   this	   work	   as	   models	   to	  
investigate	  the	  impact	  of	  CD40mAb-­‐adjuvanted	  epitope-­‐based	  vaccine	  on	  CD8+	  and	  
CD4+	   T	   cell	   responses	   respectively.	   Disappointingly,	   in	   my	   hands	   using	   ISQC-­‐
CD40mAb	   conjugates,	   whether	   CD4+	   T	   cell	   responses	   are	   enhanced	   after	   ex	   vivo	  
stimulation	   could	   not	   be	   fully	   ascertained.	   However,	   our	   work	   showed	   the	   novel	  
discovery	   that	   CD40mAb	   conjugated	   to	   SIINFEKLC	   peptide	   induced	   a	   peptide-­‐
targeted	  CD8	  cytotoxic	  response.	  This	  is	  a	  valuable	  finding	  because	  the	  induction	  of	  a	  
robust	   effective	   CD8	   T	   cell	   response	   is	   one	   of	   the	   shortcomings	   of	   most	   novel	  
adjuvants.	   Some	   adjuvants	   have	   shown	   the	   ability	   to	   induce	   strong	   CD8	   T	   cell	  
responses	   like	  TLR-­‐agonists,	  but	  most	  TLR-­‐agonists	  except	  for	  the	   licensed	  MPL	  are	  
not	  safe	  for	  use	  in	  humans.	  The	  fact	  that	  CD40mAb	  currently	  tested	  in	  phase	  I	  clinical	  
trials	  as	   immunotherapy	  is	  well	  tolerated	  and	  safe	  for	  use	  in	  humans	  (Vonderheide	  
et	  al.,	  2007,	  Johnson	  et	  al.,	  2010,	  Vonderheide	  and	  Glennie,	  2013,	  Beatty	  et	  al.,	  2013,	  
Fanale	  et	  al.,	  2014),	  shows	  that	  the	  use	  of	  CD40mAb	  as	  an	  adjuvant	  is	  a	  step	  in	  the	  




The	   main	   novel	   finding	   in	   this	   work	   is	   the	   fact	   that	   epitope-­‐based	   CD40mAb	  
conjugate	  vaccine	  induced	  an	  antigen-­‐specific	  CD8	  T	  cell	  response,	  consolidating	  the	  
potential	   of	   CD40mAb	   as	   an	   adjuvant	   in	   cancer	   vaccines.	   Furthermore,	   the	   use	   of	  
low	  average	  MW	  CD40mAb-­‐adjuvanted	  conjugate	  vaccines	  maximised	  the	  adjuvant	  
properties	  of	  CD40mAb,	  and	  showed	  to	  be	  superior	  to	  heterogeneous	  vaccines.	  
The	   experimental	   progress	   on	   CD40mAb-­‐adjuvanted	   conjugates	   presented	   in	   this	  
work	   is	   summarised	   in	   Figure	   6.1,	   which	   bridges	   some	   of	   the	   gaps	   in	   the	  
understanding	   of	   the	   mechanism	   of	   the	   vaccines.	   However,	   some	   questions	   still	  
remain	  unanswered,	  for	  example	  the	  role	  of	  DCs	  contributing	  to	  the	  adjuvant	  effect	  
of	   the	   conjugate	   still	   needs	   to	   be	   fully	   ascertained	   in	   vivo.	   Another	   example	   is	  
whether	  CD4+	  T	  cell	  responses	  are	  enhanced	  and	  if	  so	  whether	  TH1	  or	  TH2	  responses	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are	  predominant.	   Information	  regarding	  CD4+	  T	  cell	   responses	  will	  allow	   justify	   the	  
application	   of	   CD40mAb-­‐adjuvanted	   vaccines	   either	   alone	   or	   in	   combination	   with	  
other	   adjuvants	   in	   clinical	   contexts	   not	   exclusive	   to	   B	   cell	   lymphoma	   for	   example	  



















Figure	  6.1.	   Some	  of	   the	  answered	  questions	   regarding	   the	  mechanism	  of	   action	  of	  
CD40mAb-­‐adjuvanted	  conjugate.	   	  Vaccine	  antigen	  and	  CD40mAb	  are	  co-­‐delivered	  to	  
the	  same	  B	  cell	  or	  DC.	  CD40mAb	  stimulation	  leads	  to	  B	  cell	  or	  DC	  activation	  by	  means	  
of	   upregulation	   of	   surface	   co-­‐stimulatory	   molecules	   CD80	   and	   CD86.	   CD40mAb	  
conjugated	   to	   antigen	   enhances	   B	   cell	   or	   DC	   antigen-­‐presentation	   to	   CD8+	   T	   cells	  
leading	   to	  a	  CTL	   response	  against	  vaccine	  antigen.	  Whether	  CD40mAb	  conjugated	  to	  
antigen	  enhances	  presentation	  to	  CD4+	  T	  cells	  and	  leads	  to	  either	  TH1	  or	  TH2	  (or	  both)	  
response	   still	   needs	   to	   be	   ascertained.	  All	   results	  with	   CD40mAb-­‐antigen	   conjugates	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